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Abstract 
 
 
Nociceptin/orphanin FQ (N/OFQ) is an opioid-like neuropeptide which activates the 
NOP receptor. N/OFQ exerts an inhibitory control on locomotion through inhibition of 
dopamine (DA) neurons located in the substantia nigra (SN), which degenerate in 
Parkinson’s disease (PD). In the present study, we demonstrated that NOP receptor 
antagonists facilitated and inhibited motor behavior in 1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine (MPTP)-treated mice and nonhuman primates depending on dose. In 
naïve mice, we found that dual response to NOP receptor antagonists was DA-
dependent and mediated by D2 postsynaptic (facilitation) and D2 presynaptic receptors 
(inhibition). Consistently, inhibition induced by high doses of NOP receptor antagonists 
in MPTP-treated mice was reversed by D2 receptor blockade, leading to a widening of 
their therapeutic window. Evidence that endogenous N/OFQ not only sustains 
symptoms but also contributes to neurodegeneration in PD was also provided. In fact, 
NOP receptor knockout mice were found to be partially resistant against MPTP-induced 
loss of nigral DA cells. In order to understand the mechanisms underlying motor effects 
of endogenous N/OFQ, we investigated the role of nigral NOP receptors in the control 
of motor cortex (M1) output. Motor inhibition induced by exogenous N/OFQ was 
associated with reduction in M1 excitability while the opposite was true for motor 
facilitation induced by NOP receptor antagonists. Finally, we investigated M1 
reorganization in parkinsonian conditions and found that M1 excitability was decreased 
after 6-OHDA lesioning in rats. We concluded that endogenous N/OFQ controls motor 
activity via NOP receptors located in SN and through modulation of DA transmission, 
leading to changes in activity of the basal ganglia-thalamo-cortical pathway and M1 
output. Moreover, we provide evidence that NOP receptor antagonists may represent a 
novel approach for symptomatic and neuroprotective therapy of PD. 
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Introduction 
 
 
Parkinson’s disease 
 
Classified as the second most common neurodegenerative disorder, Parkinson’s disease 
(PD) is a disabling motor disease that affects approximately 0.1% of the world 
population and 1% of the population over 60 years of age. Clinical symptoms of PD are 
related to impairment of motor function such as akinesia (absence of movement or 
temporary paralysis), bradykinesia (abnormal slowness of movement execution), resting 
tremor, rigidity an abnormalities in gait and posture. Many parkinsonian patients also 
display non motor symptoms such as sleep disturbance, depression, anxiety, cognitive 
impairment and autonomic dysfunctions. 
 
Neuropathology 
Postmortem analysis of brains from PD patients demonstrated that the key pathological 
characteristics are loss of melanin-pigmented cells in the substantia nigra pars compacta 
(SNc) and presence of insoluble proteinaceous cytoplasmic inclusions termed Lewy 
bodies in the remaining cells (Irizarry et al., 1998). SNc, a nucleus located in the ventral 
mesencephalon, contains DA-producing neurons that project to the striatum, where they 
form synaptic connections with the GABAergic medium spiny neurons. Nevertheless, 
motor symptoms appear only when the level of degeneration exceeds the critical 
threshold of ~70% of nerve terminals and ~50% of midbrain DA neurons. However, 
neurodegeneration in PD extends beyond DA neurons; it is also detected in 
noradrenergic locus coeruleus, serotonergic raphe nuclei, cholinergic nucleus basalis of 
Meynert, cerebral cortex, olfactory bulb and autonomic nervous system. In recent times, 
a new concept has emerged in the understanding of PD pathology (Braak et al., 2003) 
proposing that PD neurodegeneration progresses from lower brainstem nuclei to 
cerebral cortical areas. The first appearance of disease-related symptoms correlates with 
functional deficits in the lower brainstem and olfactory bulb, then dysfunction impacts 
the brainstem to produce classical PD motor symptoms (Braak et al., 2003). Changes in 
other nuclei are observed and are thought to be secondary to the primary disease 
(Henderson et al., 2005). The disease progresses until cortical and cognitive changes 
develop. 
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Etiology 
The cause of PD is poorly understood. Epidemiological studies have shown that while 
sporadic PD usually occurs at an average of 60 years of age, familial onset tends to 
develop at a younger age (<50 years) and occurs in approximately 1% of all PD cases 
(Polymeropoulos et al., 1996). Pathogenic mutations in specific genes (PARK loci) 
were observed in familial PD giving emphasis to the genetics of parkinsonism. 
Mutations in the alpha-synuclein (α-syn), Parkin, PTEN-Induced putative Kinase 1 
(PINK1), DJ-1, Leucine-rich repeat kinase 2 (LRRK2), UCH-L1 and ATP13A2 genes 
have all been shown to be associated with familial PD (George et al., 2009). Although 
mutations in LRRK2 have also been detected in sporadic PD, genetic mutations alone 
cannot explain the majority of disease cases. The discovery of 1-methyl-4-phenyl—
1,2,3,6-tetrahydropyridine (MPTP; Langston, 1983) which causes DA neuron 
degeneration and parkinsonism in humans, suggested that environmental factors may 
play a pivotal role, most likely through toxicity pathways involving oxidative stress, 
mitochondrial dysfunction and inflammation (Przedborski et al., 2000). Various 
environmental toxins such as drugs of abuse (amphetamine, ecstasy, cocaine), 
agricultural chemicals (paraquat, rotenone), transition metals (iron, copper, manganese, 
aluminium) are known to cause the disease (George et al., 2009). In addition, 
proteasome dysfunction has been observed in DA neurons in PD patients, suggesting 
that the failure to clear damaged and cytotoxic protein aggregates contributes to 
neurodegeneration (Olanow and McNaught, 2006). 
 
 
Motor circuitry 
 
Motor information is generated in the cerebral cortex, processed in the basal ganglia and 
transmitted back to the motor cortex via the thalamic relay. This forms a functional loop 
which regulates movement initiation and execution (i.e. the so-called “cortico-basal 
ganglia-thalamo-cortical” loop; Albin et al, 1989; Alexander and Crutcher, 1990). The 
disruption of coherent information flow, (mediated by different neurotransmitters), 
between these structures results in disturbed motor activity. Primary neurotransmitters 
in the CNS are γ-amino butyric acid (GABA), glutamate (GLU) and dopamine (DA). 
GABA is the main inhibitory amino acid neurotransmitter, GLU is the main excitatory 
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one and DA, depending on the receptor subtype activated, causes inhibitory (D2-like) or 
excitatory (D1-like) responses. 
 
The basal ganglia 
The basal ganglia are a subcortical interconnected group of nuclei, comprised of the 
striatum, the globus pallidus (GP), the subthalamic nucleus (STN) and the substantia 
nigra (SN). Basal ganglia are involved in motor, cognitive and limbic functions 
(Alexander et al., 1986; Albin et al., 1989; DeLong, 1990; Obeso et al., 2000). In 
primates, the striatum is further divided into the caudate and the putamen, while in 
rodents these two structures are not separated from each other. In primates, also the GP 
is divided an external (GPe) and an internal (GPi) portion, which are referred to as the 
GP and the entopeduncolar nucleus, respectively, in rodents. At last, SN is separated in 
the SNc and the SNr. The striatum is the major input nucleus and receives excitatory 
(glutamatergic) afferents mainly from the cerebral cortex and the thalamus. The striatum 
also receives a dopaminergic input from the SNc. DA exerts a modulatory effect on 
GABAergic striatal medium spiny neurons which, in turn, regulate the BG output 
structures (GPi and SNr) via two distinct neuronal pathway: the so-called direct and 
indirect pathways. The neuronal populations originating the two pathways can be 
identified based on distinctive patterns of DA receptor subtypes and opioid co-
transmitters. Neurons of the direct pathway predominantly express excitatory D1 
receptors and prodynorphin mRNA, while neurons of the indirect pathway mainly 
express inhibitory D2 receptors and preproenkephalins mRNA (Gerfen et al., 1990). The 
direct pathway makes monosynaptic contacts with GPi/SNr neurons, whereas the 
indirect pathway connects to the GPi/SNr via GPe and STN. Both GPi and SNr send 
inhibitory projections to the thalamus which, in turn, sends excitatory projections back 
to the cortex. Activation of the direct pathway inhibits GPi/SNr neurons, leading to 
disinhibition of thalamo-cortical glutamatergic projections and facilitation of movement 
initiation and execution. Conversely, activation of the indirect pathway, causes GPe 
inhibition and STN disinhibition. This will excite GPi/SNr neurons leading to thalamic 
inhibition and movement suppression, In PD, the lack of DA leads to an imbalance 
between the two pathways (Wichmann and DeLong, 1996). The lack of D1 receptor 
stimulation leads to hypoactivation of the direct pathway while the lack of D2 receptor 
stimulation leads to hyperactivation of the indirect pathway. This imbalance eventually 
 11
causes hyperactivation of the inhibitory GPi/SNr neurons, which leads to thalamic 
inhibition and motor impairment (Obeso et al., 2000). 
 
Motor cortex 
In mammals, the hierarchical organization among the cortical motor areas is under 
investiagtion. The primary motor cortex (M1) was identified based on its agranular 
cytoarchitectonic (Brecht et al., 2004). The division between M1 and premotor cortex is 
notoriously fuzzy: it may be more of a gradient than a border (Graziano et al., 2002). 
Premotor cortex projects to and controls M1, which in turn projects to and controls the 
spinal cord. Damage to M1 does not cause a general loss of the ability to move; instead, 
it results in a specific deficit in fine manual coordination. Many new motor areas have 
been described, including the supplementary motor area, the cingulated motor areas and 
many subdivisions of the premotor cortex. However, M1 is the most important region 
for movement control. It contains a somatotopic representation of the major 
subdivisions of the body musculature and predominantly controls the limb muscles on 
the contralateral side of the body albeit only at the level of head, limbs and trunk. 
Within representations of body parts, M1 map appears to be organized in mostly 
distributed and overlapping patches (Schieber, 2001). The cortical map of movements is 
thought to be an emergent property of distributed, horizontal, modifiable network within 
the cortex (Donoghue, 1995). In recent years, evidence has been provided that PD is a 
complex network disorder in which abnormal activity of BG neurons strongly affects 
the excitability, oscillatory activity, synchrony responses of those areas of the cerebral 
cortex involved in planning and execution of movement (Galvan and Wichmann, 2008). 
However, the nature and the time at which these abnormalities appear are unknown. 
Previous studies indicate that M1 activity is reduced (Buhmann et al. 2003; Escola et al. 
2002, 2003; Parr-Brownlie and Hyland, 2005; Lefaucheur, 2005; Brown et al., 2009), 
increased (Sabatini et al., 2000; Pelled et al., 2002; Seiss and Praamstra, 2004, 
Lefaucheur, 2005) or normal (Dick et al., 1984; Metz et al., 2004) under parkinsonian 
conditions in animals and humans. This variability could be attributed to precise 
experimental factors (i.e. methods, time and region of interest) since more recent studies 
performed in PD patients (Thickbroom et al., 2006; Huang et al., 2007) indicate a 
biphasic reorganization into M1 (i.e. increase and decrease of excitability). Indeed, 
these findings indicate that there is a dynamic reorganisation of the corticomotor 
representation even at a relatively early stage of the disease and suggest a dynamic 
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process of M1 reorganisation with progressive increases and decreases in regional 
metabolism at key nodes of the motor and cognitive networks. 
 
 
Treatment options for PD 
 
PD is presently incurable. Alleviation of parkinsonian symptoms to improve the quality 
of life for patients is the principal goal of PD management in clinical practice. Most 
patients in early stages of PD will improve in response to medications that are directed 
at correcting DA biochemical deficit and enhancing DA transmission with the DA 
precursor L-3,4-dihydroxyphenylalanine (L-dopa) or with DA receptor agonists. 
 
L-dopa 
Administration of the immediate DA precursor, L-dopa, is the gold standard of PD 
therapy (Carlsson, 2002). L-dopa is a small neutral molecule (3,4-
dihydroxyphenylalanine) that crosses the blood brain barrier using the large aminoacid 
transporter and can be converted to DA in (spared) DA (and also serotonergic) neurons. 
Indeed, these neurons contain the enzyme that convert L-dopa to DA, the L-aromatic 
aminoacid decarboxylase (AADC). In order to avoid peripheral decarboxylation of L-
dopa, the drug is combined with a decarboxylase inhibitor that does not significantly 
cross the blood brain barrier, such as carbidopa or benserazide (Hornykiewicz, 2002). 
L-dopa effectively alleviates PD symptoms in the early stages of disease. The current 
“storage hypothesis” holds that at this stage of PD the available DA neurons and pre-
synaptic DA terminals maintain the capacity to process exogenous L-dopa and carry out 
physiological handling of synthesized DA (Obeso et al., 2004). It has been suggested 
that the benefits of L-dopa wear off with disease progression and ongoing death of DA 
neurons (Lee et al., 2008) This view may be misleading due to the inability to 
discriminate between treatment effects and natural progression of the disease. 
According to the “storage hypothesis”, in the absence of DA neurons, L-dopa is 
metabolized to DA by neural cells that lack “dopaminergic machinery” (George et al., 
2009). As a result, DA release becomes pulsatile rather than continuous, and eventually 
leads to changes in post-synaptic receptor signalling and development of motor 
complications (Agid et al., 1985). Therefore, as the disease progresses, leading to fewer 
and fewer functional DA terminals in the striatum that can convert the L-dopa to DA 
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and store it, higher and more frequent doses are required to obtain the same efficacy as 
in the early phases of the disease. Inevitably, the long-term use of high doses and the 
increased frequency of administration, leads, in the majority of the PD patients, to the 
development of debilitating motor effects such as motor fluctuations and abnormal 
involuntary movements (dyskinesias) and non motor effects such as hallucinations and 
psychosis (due to overdosing of “normosensitive” DA receptors). 
 
DA receptors agonists 
The rationale for using direct DA receptor agonists was the delivery of continuous 
stimulation of DA receptors, thought to be necessary to prevent development of motor 
fluctuations in long-term (Radad et al., 2005). This approach was put forward as an 
alternative to L-dopa treatment, based on the hypothesis that L-dopa treatment set 
pulsatile stimulation of postsynaptic DA receptors, promoting the development of motor 
fluctuations (Obeso et al., 2000). DA agonists such as pramipexole (PPX), ropinirole 
and rotigotine bypass the degenerating neurons and directly stimulate the intact, 
although denervated, postsynaptic receptors in the striatum (Factor et al., 2008). These 
agonists are not as effective as L-dopa in relieving PD motor symptoms, however, their 
addition to L-dopa therapy can significantly reduce dyskinesias (Calne, 1993). 
Numerous in vitro and in vivo pre-clinical studies have established the neuroprotective 
potential of DA agonists, that can be mediated via several mechanisms including free 
radical scavenging and anti-oxidative properties (George et al., 2009). However, data 
from human trials are still not conclusive in this respect. 
 
Other therapeutic options 
Alternative treatments have been used with varying degrees of success such as GLU 
antagonists (Kornhuber et al., 1991), monoamine oxidase inhibitors (Birkmayer et al., 
1975), catechol-O-methytransferase inhibitors (Ruottinen and Rinne, 1998), A2A 
receptor antagonists (Jenner et al., 2009) and cholinergic antagonists (Duvoisin, 1967). 
Beside pharmacological treatment, some surgical procedures have been performed on 
PD patients, among which ablative surgery (i.e. pallidotomy or thalamotomy) or deep 
brain stimulation (DBS) of the thalamus, GPi or STN. The aim of pallidotomy and DBS 
is to reduce the excessive inhibitory output from GPi and SNr (Ashkan et al., 2004). 
Taken together, it is clear that the currently available treatments for PD are lacking in 
some key areas such as therapeutic longevity and side effect profiles. For these reasons, 
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investigators continue to search for alternative therapies with an emphasis on 
neuroprotective agents to slow or halt the progression of the disease. However, the 
majority of PD patients will gradually deteriorate. It is thought that an ongoing 
apoptotic death of DA neurons in SN underpins this relentless natural history of PD. 
Novel restorative therapies for PD under investigation are transplantation of fetal DA 
neurons or stem cells, and gene therapy based on viral-mediated delivery of enzymes 
critical for DA metabolism or neurotrophic factors. 
 
 
Animal models of Parkinson’s disease 
 
Until now, very little is known about why and how the PD neurodegenerative process 
begins and progresses. Consequently, investigators still rely heavily on animal models 
to obtain greater insights into PD pathogenesis, and, in particular, to predict the clinical 
efficacy of new treatments. Whereas recent genetic discoveries have led to a number of 
genetic models of PD, none of these shows the typical degeneration of DA neurons. 
Therefore, neurotoxins such as 6-OHDA and MPTP still remain the most popular tools 
to produce selective neuronal death both in in vitro and in vivo systems. 
 
MPTP 
The protoxin MPTP, which is structurally similar to a number of commonly used 
herbicides and pesticides, can induce specific loss of substantia nigra neurons in many 
vertebrate species, from human to mouse. After systemic administration, MPTP rapidly 
enters the brain where it is processed into glial cells. MPTP first is metabolized by the 
enzyme MAO-B to 1-methyl-4-phenyl-2, 3-dihydropyridium (MPDP+) that then 
deprotonates to generate the corresponding pyridium species (MPP+). MPP+ enters in 
DA cells and accumulates in the mitochondria, where it inhibits cellular respiration 
through the blockade of the electron transport enzyme NADH:ubiquinone 
oxidoreductase (complex I). Blockade of this complex inhibits ATP production and 
stimulates superoxide radical formation (Przedborski et al., 2000). The produced 
superoxide radicals react with nitric oxide (NO) to produce peroxynitrite, a highly 
reactive tissue-damaging species that damages proteins by oxidation and nitration. 
Among these proteins is found tyrosine hydroxylase (TH), the rate limiting enzyme in 
DA synthesis. The process of nitration inactivates TH and, consequently DA 
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production. Peroxynitrite also nicks DNA, which, in turn, activates poly(ADP-ribose) 
polymerase (PARP). PARP activation consumes ATP, and thus acutely depletes cell 
energy stores. This latter event aggravates the preexisting energy failure due to MPP+-
induced mitochondrial respiration blockade and precipitates cell death (Smeyne and 
Jackson-Lewis, 2005). Studies using MPTP have led to the development of useful 
animal models of PD. MPTP-treated mouse is commonly used to investigate the 
neurotoxicity pathways underlying PD and test the neuroprotective potential of 
antiparkinsonian drugs. Nonetheless, this model has failed to reproduce the motor 
impairment seen in PD patients or consistently replicate the phenotype observed in 
other parkinsonism models. Indeed, mice treated with MPTP can display no change in 
motor behavior (Miller et al., 1991; Itzhak et al., 1999), transient (Nishi et al., 1991; 
Sedelis et al., 2000) or sustained (Fredriksson et al., 1994; Haobam et al., 2005) motor 
impairment, and even hyperlocomotion (Colotla et al., 1990; Chia et al., 1996). Though 
this variability could be attributed to precise experimental factors (Sedelis et al., 2001; 
Jackson-Lewis and Przedborski, 2007), it has prevented the MPTP mouse model from 
being used to screen for symptomatic antiparkinsonian drugs, essentially limiting its 
applications to neurotoxicity studies. Nonhuman primate models of Parkinson's disease 
are a key tool to unravel PD pathophysiology and evaluate therapeutic strategies for the 
disease. The motor and cognitive skills of nonhuman primates as well as their 
neuroanatomical complexity closely resemble those of humans and thus can provide 
insight on issues that have clinical impact (Emborg, 2007). MPTP-treated monkeys 
develop a parkinsonian motor syndrome that replicates key PD features such as rigidity, 
bradykinesia and postural instability and that is responsive to conventional DA 
replacement treatments (Stephenson et al., 2005). Similar to PD patients, MPTP-treated 
monkeys may also present nonmotor signs, including frontostriatal cognitive deficits 
(Taylor et al. 1999) and changes in sleep pattern (Barcia et al., 2003). Researchers have 
also documented temporary autonomic disturbances affecting noradrenergic cardiac 
innervation (Goldstein et al. 2003). Biochemical analysis of striatal DA in PD monkeys 
reveals differences depending on the method of administration and, to a lesser degree, 
the individual (Emborg, 2007). Intramuscular, subcutaneous or intravenous injections 
are appropriate methods of systemic administration in monkeys. Intraperitoneal 
injections are not advisable as they increase the risk of infection or gastrointestinal 
complications. Intracarotid administration of MPTP is an appealing model because it 
decreases the risks to animals and investigators as well as the variability associated with 
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the systemic model. Administration of the neurotoxin continues as needed to develop 
the desired level of disability, for this reason, it is important to evaluate animals after 
each dosing for PD signs and general effects of MPTP intoxication in order to stop 
administration if necessary. 
 
6-OHDA 
The most extensively used animal model of PD is the 6-OHDA rat (Ungerstedt, 1968). 
6-OHDA is a toxin that enters DA neurons through the high affinity DA transporter 
(DAT) and accumulates in the cytosol. It then inhibits the mitochondrial complexes I 
and IV (Glinka and Youdim, 1995; Glinka et al., 1996) and simultaneously forms free 
radicals causing oxidative stress (Olanow, 1993), which synergistically leads to 
degeneration of DA neurons (Glinka et al., 1997). The toxin does not cross the blood 
barrier brain and, therefore, has to be injected directly into the brain, in an area 
containing DA fibers. Following 6-OHDA-induced DA degeneration, the rat exhibits 
many of the disease-related symptoms observed in PD, including motor deficits and 
development of L-dopa-induced dyskinesias. In order to obtain an almost complete 
destruction of the nigrostriatal DA pathway, 6-OHDA is injected into the medial 
forebrain bundle (MFB), in close vicinity to the SNc DA cell bodies (Ungerstedt, 1968). 
Following the injection, a rapid loss of DA neurons occurs within the first days, leading 
to a severe depletion (>97%) of striatal DA content and loss of SNc DA neurons 
(Ungerstedt, 1968; Kirik et al., 1998). The MFB lesion also depletes the VTA by up to 
80% (Kirik et al., 1998). This lesion is most commonly performed unilaterally. Indeed, 
animals receiving bilateral injections develop aphagia and adipsia, requiring extensive 
monitoring and care to be kept alive (Ungerstedt, 1971; Zigmod and Stricker, 1972). In 
addition, the unilateral model has the advantage that behavioural deficit affects muscles 
at the body side contralateral to the lesion. The intact side can therefore be used as an 
internal control. 
 
 
The nociceptin/orphanin FQ neuropeptide 
 
The identification of nociceptin/orphanin FQ (N/OFQ; Meunier et al., 1995; Reinscheid 
et al., 1995) represented the first successful use of reverse pharmacology, and led to 
deorphanization of a particular G-protein coupled receptor, namely opioid receptor like 
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1 (ORL-1; Mollereau et al., 1994) or, more recently, N/OFQ peptide receptor (NOP; 
Cox et al., 2000). 
 
The N/OFQ-NOP receptor system 
NOP receptor activation inhibits the formation of cyclic AMP, closes voltage-gated 
Ca2+ channels and opens inwardly rectifying K+ channels. The net effect at cellular level 
is the reduction of neuronal excitability and neurotransmitter release (Mogil and 
Pasternak, 2001). Although the N/OFQ-NOP receptor system shares considerable 
structural and localization features with the classical opioid system, N/OFQ does not 
bind classical opioid receptors, and NOP receptor activity is insensitive to the opioid 
antagonist naloxone, an important property used (especially when selective antagonists 
were not available) to discriminate N/OFQ actions with those of classical opioids . For 
these reasons, the N/OFQ-NOP receptor system is considered as “a nonopioid branch of 
the opioid family” (Cox et al., 2000). The N/OFQ-NOP receptor system is widely 
expressed in cortical and subcortical areas (Darland et al, 1998; Neal et al, 1999) and is 
involved in a wide range of physiological responses, with effects noted in the nervous 
system (central and peripheral), the cardiovascular system, the airways, the 
gastrointestinal tract, the urogenital tract and the immune system (Lambert, 2008). A 
wide range of neurotransmitter systems, including glutamate, catecholamines and 
tachykinins, are modulated by N/OFQ (Lambert, 2008). Understanding of the complex 
biological roles played by endogenous N/OFQ was dependent upon the generation of 
useful research tools, particularly transgenic animals and selective ligands, especially 
antagonists. Knockout mice for the N/OFQ precursor (ppN/OFQ-/-; Köster et al., 1999) 
or the NOP receptor (NOP-/-; Nishi et al., 1997) gene are available. Recently, NOP-/- rats 
were also generated (Homberg et al., 2009). From an experimental point of view, basic 
pharmacological properties of selective NOP receptor ligands have been characterized. 
From a clinical perspective, NOP receptor agonists can be developed as an innovative 
drug class for the treatment of pain, water-retaining disease, anxiety, urinary 
incontinence, drug addiction and cough while NOP receptor antagonist may represent a 
novel approach for memory loss, depression, movement disorders and sepsis (Calo’ et 
al., 2010). For all this reason, the NOP receptor is an emerging target with broad 
therapeutic potential. 
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N/OFQ and motor activity 
Endogenous N/OFQ exerts a physiologically inhibitory control over motor function 
(Marti et al., 2004a; 2008). Indeed, NOP receptor selective antagonists such as the 
peptide [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101; Calo’ et al., 2002) and nonpeptide 
1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H 
benzimidazol-2-one (J-113397 or Compound B; Kawamoto et al., 1999) and its achiral 
analogue 1-[1-(cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-
ethyl-1,3-dihydro-2H-benzimidazol-2-one (Trap-101; Trapella et al., 2006) increased 
stepping activity, run speed and rotarod performance in naïve rats (Marti et al., 2004a; 
2008, 2009). J-113397 and Trap-101 also elevated motor performance in naïve mice 
(Viaro et al., 2008; Marti et al., 2008), while J-113397 increased arm movement speed 
in nonhuman primates (Viaro et al., 2008). The view of N/OFQ as a physiological 
constraint over motor activity was also corroborated by the finding that NOP-/- mice had 
greater stepping activity and rotarod performance than wild-type mice (Marti et al., 
2004a, 2005; Viaro et al., 2008). Recent data, however, suggested that endogenous 
N/OFQ may play a more complex role in motor control. Indeed, J-113397 and Trap-101 
facilitated motor activity at low doses and impaired it at higher ones through NOP 
receptor blockade in naïve rodents (Viaro et al., 2008; Marti et al., 2008). A similar dual 
response was also reported after i.c.v. administration of N/OFQ, low doses facilitating 
(Florin et al., 1996; Jenck et al., 1997; Higgins et al., 2001; Kuzmin et al., 2004, Marti 
et al., 2009) and higher ones inhibiting (Reinscheid et al., 1995; Devine et al., 1996; 
Rizzi et al., 2001; Higgins et al., 2001; Kuzmin et al., 2004; Marti et al., 2009) 
spontaneous locomotion. Importantly, we found that N/OFQ-induced motor facilitation 
was a true motor response (Marti et al., 2009) and not a result of an anxiolytic effect of 
N/OFQ as previously thought (Florin et al., 1996; Jenck et al., 1997). In fact, motor 
improvement induced by low N/OFQ doses given i.c.v. or injected into SNr was 
associated with enhanced motor cortex excitability and motor output, while motor 
impairment induced by higher N/OFQ doses was accompanied by opposite 
electrophysiological changes (Marti et al., 2009). Interestingly, NOP receptor 
antagonists replicated the electrophysiological and behavioral changes induced by low 
N/OFQ doses, overall suggesting that dual motor responses to NOP receptor ligands are 
mediated by NOP receptors in SNr and NOP receptor antagonists and N/OFQ (at low 
doses) activate common pathways. Evidence that mesencephalic DA neurons transduce 
motor actions of NOP receptor ligands has been presented. Indeed, N/OFQ and NOP 
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receptor antagonists, given systemically or into SNr, inhibited and facilitated DA 
release in dorsal striatum, respectively (Marti et al., 2004a). Moreover, N/OFQ inhibited 
DA release in limbic striatum (Murphy et al., 1999; Narayanan et al., 2004) while J-
113397 elevated it, although via NOP-unrelated mechanisms (Koizumi et al., 2004). 
Finally, even the hyperlocomotive response to N/OFQ was reported to be DA-
dependent (Florin et al., 1996; Kuzmin et al., 2004). 
 
NOP receptor antagonists and PD 
Endogenous N/OFQ also seems to play an important inhibitory role on motor behaviour 
in pathological conditions. Indeed, we collected evidence that N/OFQ sustains 
symptoms and neurodegeneration associated with PD (Marti et al., 2005). Thus, NOP 
receptor antagonists attenuated motor impairment in rats made hypokinetic with 
haloperidol (Marti et al., 2004b) or 6-OHDA lesioning (Marti et al., 2005, 2007, 2008) 
as well as in mice and nonhuman primates treated with MPTP (Viaro et al., 2008; 
Visanji et al., 2008). NOP receptor antagonists act via blockade of NOP receptors in 
SNr causing reduction of glutamate and increase of GABA release in SNr and, 
consequently, overinhibition of the nigro-thalamic pathway. To support 
pharmacological studies, genetic deletion of the NOP receptor (NOP-/- mice) conferred 
partial protection from haloperidol-induced akinesia (Marti et al., 2005), a phenomenon 
linked to the reduced ability of haloperidol to elevate nigral GLU release in NOP-/- mice 
(Mabrouk et al., 2010). Interestingly, DA depletion causes up-regulation of N/OFQ 
synthesis (Marti et al., 2005; Brown et al., 2006; Di Benedetto et al., 2009) and release 
(Marti et al., 2005) in SNr, thereby exacerbating negative influence of N/OFQ on DA 
cells and motor output. The role of N/OFQ in parkinsonism, however, may go beyond 
phenotype modulation. Indeed, mice with deletion of the N/OFQ precursor (ppN/OFQ) 
were found to be partially resistant to MPTP toxicity as shown by the reduced loss of 
nigral DA cells and striatal DA terminals observed following MPTP treatment in 
comparison with wild-type controls (Marti et al.,. 2005; Brown et al., 2006). However, 
different peptides (i.e. N/OFQ, N/OFQ II and nocistatin) are generated by cleavage of 
the ppN/OFQ precursor (Okuda-Ashitaka and Ito, 2000), questioning the view that 
endogenous N/OFQ modulates MPTP-induced neurotoxicity. 
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Purpose 
 
 
The overall goal of this interdisciplinary study was to investigate the involvement of 
N/OFQergic transmission in motor activity under physiological and pathological 
conditions, in particularly PD. Specific aims of the study were as follows: 
1) In order to dissect out the role of endogenous DA and the contribution of specific DA 
receptor subtypes to motor responses to NOP receptor antagonists, subtype-selective 
DA receptor antagonists were challenged against motor facilitating and inhibitory doses 
of N/OFQ and NOP receptor antagonists. This behavioural and neurochemical study 
was performed in naïve mice. 
2) In order to prove the concept that blockade of nociceptinergic transmission is a new 
approach for symptomatic therapy of PD, we tested the effectiveness of NOP receptor 
antagonists in mice intoxicated with MPTP. This behavioural study was performed by 
testing NOP receptor antagonists alone or in combination with classical 
antiparkinsonian compounds. 
3) In order to confirmed the efficacy of NOP receptor antagonists also in animals 
models that showed symptoms that closely resemble those observed in parkinsonian 
patients, we tested drugs in nonhuman primates. This behavioural study was performed 
in naïve and then in MPTP-treated macaques. 
4) In order to demonstrate that endogenous N/OFQ sustains not only symptoms but also 
neurodegeneration associated with PD, we tested the impact of MPTP in NOP-/- mice by 
using behavioural tests and stereological counting. 
5) In order to investigate whether N/OFQ controls motor behaviour through NOP 
receptors located in SNr and modulation of motor cortex output, we used behavioral 
testing and intracortical microstimulation technique. NOP receptor ligands were locally 
injected in SNr (and M1, for a comparison) of naïve rats. 
6) In order to study the progressive reorganization of motor cortex under parkinsonian 
conditions, the intracortical microstimulation technique was used in rats made 
hemiparkinsonians with 6-OHDA at different time points after lesion. 
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Materials and methods 
 
 
Animals 
 
All animals used in the study were housed with free access to food and water and kept 
under environmentally controlled conditions (12-h light/dark cycle with light on 
between 07:00 and 19:00). The experimental protocols were approved by the Italian 
Ministry of Health (licenses n. 94/2007B and 194/2008B) and Ethical Committee of the 
University of Ferrara. Adequate measures were taken to minimize animal pain and 
discomfort. After surgery, the skin was closed using surgical sutures and the wound was 
cleansed with an antibiotic solution (Rifamicina SV, Lepetit, Milano). 
 
Mice 
Young adult male (20-25 g; 10-12 weeks old) Swiss, C57BL/6J, NOP+/+ and NOP-/-
mice were used in this study. Swiss and C57BL/6J mice were purchased from Harlan 
Italy (S. Pietro al Natisone, Italy), while NOP-/- and NOP+/+ mice (Nishi et al., 1997) 
were raised at the vivarium of the Section of Pharmacology of the University of Ferrara. 
NOP-/- mice were grown on a C57BL/6J background. 
 
Rats 
Young adult male (150-300 g; 12-16 weeks old) Sprague-Dawley and Wistar rats were 
used in this study. Sprague-Dawley rats were purchased from Harlan Italy (S. Pietro al 
Natisone, Italy), while Wistar rats were generated at the vivarium of the Section of 
Human Physiology of the University of Ferrara. 
 
Nonhuman primates 
Young adult male macaques (Macaca fascicularis) were included in the study. Animals 
were housed individually at the New England Primate Research Center. All the studies 
were done following NIH guidelines and were approved by the IACUC at Harvard 
Medical Area and the New England Regional Primate Research Center. 
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Lesion of the DA system 
 
In order to obtain a destruction of the DAergic system, different protocols were used, 
depending on the type of lesion to obtain (partial or total, unilateral or bilateral) and the 
species of animal to be treated. 
 
6-OHDA lesion in rats 
Unilateral lesion of DA neurons was induced in isoflurane-anaesthetised rats (Marti et 
al., 2005). Eight micrograms of 6-OHDA (in 4 µl of saline containing 0.02% ascorbic 
acid) were stereotaxically injected in the right MFB according to the following 
coordinates from bregma: AP= -4.4 mm, ML= -1.2 mm, VD= -7.8 mm below dura 
(Paxinos and Watson, 1982). 
 
MPTP lesion in mice 
Bilateral lesion of DA neurons was induced in C57BL/6J mice using an acute protocol 
for MPTP administration (4 x 20 mg/Kg, 90 min apart; Marti et al., 2005; Viaro et al., 
2008, 2010). 
 
MPTP lesion in nonhuman primates 
Bilateral lesion of DA neurons was induced in nonhuman primates by subcrhonic 
administration of MPTP (0.3 mg/kg/week, i.v. for 7.5 ± 2.5 weeks) as described by 
Jenkins et al. (2004) and Sanchez-Pernaute et al. (2007). 
 
 
Pharmacological treatments 
 
For systemic administration (i.p.), the volume injected was 10 µl/g body weight. For 
local (central) administration, different methods are used in according to stereotaxic 
coordinates of rat brain (Paxinos and Watson, 1982) and mouse brain (Paxinos and 
Franklin, 2003). 
 
Microinjection technique in mice 
The injections in the lateral cerebral ventricle (LCV) of mice were given according to 
the procedure described by Laursen and Belknap (1986). Briefly, the syringe was held 
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at an approximate 45° angle to the skull. Bregma was found by lightly rubbing the point 
of the needle over the skull until the suture was felt. Once found, care was taken to 
maintain the approximate 45° angle and the needle was inserted about 2 mm lateral to 
the midline. The skull is relatively thin at this point, so only mild pressure was required 
to insert and remove the needle. Drugs were slowly injected (0.5 µl in about 5 sec) and 
to prevent the substance from refluxing, the needle was withdrawn from the skull 5 sec 
later. 
 
Microinjection technique in awake rats 
A guide cannula (outer diameter 0.55 mm, inner diameter 0.35 mm) was stereotaxically 
implanted under isoflurane anesthesia (1.4 % in air delivered at 1.2 ml/min) 1 mm 
above the right or left LCV, M1 or SNr, according to the following coordinates from 
bregma: LCV, AP -0.9, ML ±1.4, VD -2; M1, AP +2, ML ±2, VD -0.5; SNr, AP -5.5, 
ML ±2.2, VD -7.3. The cannula was secured to the skull by acrylic dental cement and 
metallic screws. A stainless steel obturator (outer diameter 0.30 mm) was left in place 
inside the guide. After a 7 day recovery period, each rat was opportunely handled and 
trained before behavioral tests. The day of the experiment, the obturator was removed 
and drugs were injected (volume 0.5 µl) through a stainless-steel injector (outer 
diameter 0.30 mm; inner diameter 0.15 mm) protruding 1 mm from the cannula tip. 
 
Microinjection technique in anaesthetized rats 
The animal was anaesthetized (ketamine hydrochloride, 50 mg/kg, i.p.) and placed in a 
Kopf stereotaxic apparatus and a large craniotomy was performed over the frontal 
cortex. The dura remained intact, and was kept moist with a 0.9 % saline solution. Drug 
injections were performed using a Hamilton syringe connected to the injection cannula 
with polyethylene tubing, in the left or right LCV (AP= -0.8 mm; ML= ±1.5 mm; VD= -
3.5 mm below the pial surface), layer V of central M1 (AP= 2-3 mm and ML= 2.5-3 
mm; VD= -1.5 mm) and SNr (AP= -5.5 mm; ML= ±2.2 mm; VD= -7.6 mm). Drugs 
were slowly injected and, to prevent the substance from refluxing, the needle was 
withdrawn from the cortex 120 sec later. 
 
Lidocaine injection 
For performed the lidocaine injection in M1, a total of 12 µl of 3% lidocaine injected at 
three sites within the forelimb motor cortex (Maggiolini et al., 2008), according to the 
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following coordinates from bregma (AP= 1 ML= 3; AP= 2 ML= 3; AP= 3 ML= 3). The 
cannula was lowered into the selected site 1 mm below the pial surface and the 
lidocaine was slowly injected (4 µl/min) and, to prevent the substance from refluxing, 
the needle was withdrawn from the cortex 120 sec later. For the duration of the 
experiment, cortical inactivation was maintained by supplementary injections of 
lidocaine (1-2 times for each animal) at the same sites when the forelimb movement at 
these sites was ICMS-evoked at the highest current used under the present experimental 
condition (60µA). The injected sites were remapped every 30 minutes to confirm that 
sites were inactivated. 
 
Cortical bicuculline application 
Under surgical stereomicroscopy, the dura on the M1 was removed and a 30 µl solution 
of 50 µM bicuculline was applied to the cortical surface (Stojic et al., 2008), by using a 
Gilson micropipette. The temperature of the solution was 35-37°C and the volume was 
maintained by supplementary application (1-2 times for each animal). 
 
 
Behavioural studies in rodents 
 
Motor activity in rodents was evaluated by means of different behavioural tests specific 
for different motor abilities, as previously described (Marti et al., 2004a, 2004b, 2005, 
2007, 2008, 2009; Viaro et al., 2008, 2010). The different tests are useful to evaluate 
motor functions under static conditions or dynamic conditions, as an integration of 
coordination, gait, balance, muscle tone and motivation to run, and wre performed in a 
fixed sequence In the case of evaluation of pharmacological treatment, tests were 
performed 10 min before drug injection (control session) and 10 and 60 min after drug 
injection. With this protocol, both facilitatory/inhibitory and short/long term effects can 
be detected (Marti et al., 2004a). 
 
Drug-induced rotation 
The rotational model (Ungerstedt and Arbuthnott, 1970) was used to select the rats 
which had been successfully lesioned with 6-OHDA. Two weeks after lesion, rats were 
injected with amphetamine (5 mg/Kg i.p., dissolved in saline) and only those rats 
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performing >7 ipsilateral turns/min were enrolled in the study. This behaviour has been 
associated with >95% loss of striatal extracellular DA levels (Marti et al., 2002). 
 
Bar test 
This test, also known as the catalepsy test (Sandberg et al., 1988), measures the ability 
of the animal to respond to an externally imposed static posture. Each rodent was placed 
gently on a table and the right and left forepaws were placed alternatively on blocks of 
increasing heights (1.5, 3 and 6 cm for mice and 3, 6 and 9 cm for rats). The immobility 
time (in sec) of each forepaw on the block was recorded (cut-off time 20 sec per step, 60 
sec maximum). Akinesia was calculated as total time spent on the blocks (mean 
between the two forepaws). 
 
Reaction time test 
This test measures motor reactivity of the animal in a open field. Mice were allowed to 
habituate to the center of a square arena (150x150 cm) for 5 min, then elevated 3 cm 
above the surface (lifting from the tail), and finally left to fall. When the animal touched 
the floor, the latency time for the first forelimb movement was recorded. 
 
Drag test 
This test (modification of the ”whelbarrow” test; Schallert et al., 1979), measures the 
ability of the animal to balance its body posture using forelimbs in response to an 
externally imposed dynamic stimulus (backward dragging; Marti et al., 2005). Each 
rodent was gently lifted from the tail (allowing the forepaws on the table) and dragged 
backwards at a constant speed (about 20 cm/sec) for a fixed distance (100 cm). The 
number of touches made by each forepaw was counted by two separate observers (mean 
between the two forepaws). 
 
Elevated body swing test 
The test was conducted in a dark plastic box (40×40×50 cm). Initially, each rat was 
allowed to habituate in the box for 5 min then it was elevated 3 cm above the ground by 
holding its tail. When the animal turned with its body (i.e. head and trunk) more than 
30° to either side of the vertical axis a swing was counted. The direction and the number 
of swings carried out in 60 sec were recorded. 
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Speed test 
This tests essentially measure animal speed in an open field. The rodent was allowed to 
habituate in a square arena (150x150 cm) for 5 min then elevated 3 cm about the ground 
(by holding its tail) and finally positioned in the centre of the arena. When the animal 
touched the floor it started running. Behavior was scored online using the “correct 
walking” criteria (see Bouwman et al, 2005). Data acquisition was stopped when the rat 
changed its acceleration, velocity or direction. Run speed was calculated as distance 
traveled (cm/sec). 
 
Stair climbing test 
This test (modification of the SCA test; Kumar and Sehgal, 2007) analyzed the 
motivation and the motor skill during a climb-walk. Each mouse was positioned on the 
first step (2 cm height, 2 cm long, 5 cm wide) of a 45°-sloping staircase. At the top of 
the staircase a food pellet was lodged in a small dark goal box. The speed needed for 
climbing 20 consecutive steps (50 cm) was recorded. Steps made at the beginning and 
the end of the climb were excluded because of velocity changes or obvious 
acceleration/deceleration. 
 
Grip test 
This test was used to evaluate the skeletal muscular strength in mice (Meyer et al., 
1979). The grip-strength apparatus (ZP-50N, IMADA, Japan) is comprised of a wire 
grid (5 × 5 cm) connected to an isometric force transducer (dynamometer). In the grip-
strength test mice were held by their tails and allowed to grasp the grid with their 
forepaws. The mice were then gently pulled backward by the tail until the grid was 
released. The maximal and the average force exerted by the mouse before losing grip 
was recorded. The mean of 10 measurements for each animal was calculated and the 
maximal and mean force was determined. The skeletal muscular strength in mice was 
expressed in grams force (gf) and was recorded and processed by IMADA ZP-Recorder 
software. 
 
Rotarod test 
This test analyzes the ability of the rodents to run on a rotating cylinder (diameter 8 cm) 
and provides information on different motor parameters such as coordination, gait, 
balance, muscle tone and motivation to run (Rozas et al., 1997). The fixed-speed rotarod 
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test was employed according to a previously described protocol (Marti et al., 2004a; 
Viaro et al., 2008, 2010). Briefly, animals were tested at stepwise increasing speeds 
(180 sec each) and time spent on the rod calculated (in sec). Drug effect was calculated 
by monitoring motor activity within a limited speed range (four speed) causing a 
progressive decrement of performance to ~40% of the maximal response. 
 
Footprinting test 
This test provides information on gait patterns (Klapdor et al., 1997). Mice paws were 
marked with ink and gait patterns (stride length and width, foot angle, overlap, speed) 
analyzed after walking over a sheet of paper (Fig. 2F). The apparatus was composed of 
a white runway (5 cm wide, 70 cm long, with borders of 10 cm height) arranged to lead 
out into a dark goal box (20 x 20 x 30 cm). The parameters were measured by wetting 
forepaws and hindpaws with commercially available pencil nontoxic ink (the paws were 
painted with different colored inks) and allowing the mice to trot on a strip of paper (5 
cm wide, 70 cm long) onto the runway. Pawprints made at the beginning and the end of 
the run were excluded because of velocity changes or obvious acceleration/deceleration. 
Stride length is the average distance (in mm) of forward movement between each 
forepaw and hindpaw footprint. Stride width is the average lateral distance (in mm) 
between opposite left and right forepaw and opposite left and right hindpaw. It has been 
calculated by measuring the perpendicular distance of a given step to a line connecting 
its opposite preceding and succeeding steps. Foot angle is the angle of hindpaw (in 
degree) with respect to main direction. It has been calculated by measuring the 
amplitude of angle between the direction of run and each direction of the hindpaw (line 
starting at center of paw to the third finger). Placement of paws is the footprint overlap 
(in mm) and is calculated by measuring the distance between the center of the forepaw 
footprint and the ipsilateral hindpaw footprint, taken from successive steps. Speed of 
run (in cm/sec), was calculated by the ratio between the length of runway and time spent 
along the runway. After the run, animals were placed in a cage filled with 0.5 cm warm 
water for 1 min in order to wash off the dye. 
 
Spontaneous activity 
Spontaneous motor activity and step parameters were detected in a freely-moving 
mouse by videotape recording (Canon Camcorder HG21) and off-line analysis. The 
animal was placed in a square box (50 x 50 cm) and the recorded video was then 
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analysed by two separate observers. Global, horizontal and fine movements were 
quantified together with immobility (i.e. freezing) time. Step parameters such as time 
for movement preparation and initiation, step speed and length were also evaluated. 
Activity measurements were conducted between 11:00 and 15:00 during the light phase. 
 
 
Behavioural studies in nonhuman primates 
 
In order to monitor parkinsonian phenotype and the effectiveness of drug treatments, 
motor activity in nonhuman primates were analysed by the movement analysis panel 
(MAP) test and neurologist evaluation. 
 
Movement analysis panel (MAP) 
Animals were trained to perform a computerized timed reaching task that measures the 
speed of arm movements (Jenkins et al., 2004). Training was carried out for an average 
of 6 days for the platform task and 8-12 days for the straight rod task, until the 
performance (time to retrieve the treats) was stable. For pharmacological evaluation, 
animals were tested 30 min after the administration of vehicle (saline) for two days and 
then with either saline or the active drugs. In addition, global motor activity data was 
obtained using activity monitors (Actiwatch) for a week at the naïve and parkinsonian 
stages (Table 1). These tests provide objective measures of bradykinesia and 
hypokinesia, respectively. 
 
Parkinsonian rate scale (PRS) 
For motor evaluation, animals were transferred to a Plexiglas observation cage where 
they were videotaped. Motor behavior was rated according to a scale based on the motor 
subscale of the UPDRS (Unified Parkinson Disease Rating Scale), as described (Jenkins 
et al., 2004; Sanchez-Pernaute et al., 2007). The following signs were scored from 0 to 
3: bradykinesia in the left and right arms (L/R), tremor L/R, rigidity L/R, hypokinesia, 
posture/balance (for a total score from 0 to 24). Scores were obtained at 30-45 min after 
each drug or vehicle administration. 
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Intracortical microstimulation in rats 
 
The intracortical microstimulation (ICMS) technique is commonly used to 
quantitatively evaluate plastic changes in the motor cortex following motor output 
disconnection because it is useful in evaluating the strength of functional connection 
between the motor cortex and the target motoneuron pool (Sanes et al., 1990). It 
presumes that after motor output disconnection/manipulation, the motor cortical 
changes in the types of evoked movements and in the minimal level of current necessary 
to evoke movements, reflect the adapting changes of cortical circuits. If so, the 
difference changes in cortical evoked movements and in their current threshold over 
time could reveal different underlying mechanisms in adaptive remodeling of 
disconnected/manipulated cortical circuits. In each animal, the movements evoked by 
ICMS in the frontal agranular cortex were mapped. 
 
Surgical procedure 
The anaesthetized animal was placed in a Kopf stereotaxic apparatus and a large 
craniotomy was performed over the frontal cortex of both hemispheres. The dura 
remained intact and was kept moist with an 0.9% saline solution. The electrode 
penetrations were regularly spaced out over a 500µm grid. Alteration in the coordinate 
grid, up to 50µm, was sometimes necessary to prevent the electrode from penetrating 
the surface blood vessels. These adjustments in the coordinate grid were not reported in 
the reconstructing maps. When the adjustment was over 50µm, the penetration at this 
site was not performed. Glass insulated tungsten electrodes (0.6-1MΩ impedance at 
1kHz) were used for stimulation. The electrode was lowered perpendicularly into the 
cortex to a depth of 1.5 mm below the cortical surface and adjusted ±200 µm so as to 
evoke movement at the lowest threshold. In preliminary experiments this depth was 
found to correspond to layer V of the frontal agranular cortex (Franchi, 2000). 
 
Mapping procedure 
The mapping procedure was similar to the one described by Donoghue and Wise(1982) 
and Sanes et al. (1990), and detailed elsewhere (Franchi, 2000). Briefly, monophasic 
cathodal pulses (30ms train duration at 300Hz, 200µs pulse duration) of a maximum of 
60 µA were passed through the electrode with a minimum interval of 2.5 s. Two 
observers were required to detect movement and determine threshold. One observed the 
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movement without knowledge of the actual current intensity and was unaware of which 
group the particular rat belonged to. The other observer changed the level of current. 
Starting with a 60µA current, intensity was decreased in 5µA steps until the movement 
was no longer evoked; then the intensity was increased to a level at which 
approximately 50% of the stimulations elicited movement. This level defined the 
current threshold. If no movements or twitches were evoked with 60µA, the site was 
recorded as negative (ineffective site). Mapping was initiated at a high current because 
the initial polysynaptic recruitment of remote neurons optimizes the detection of 
movements in this 500µm step grid mapping. Body parts activated by ICMS were 
identified by visual inspection and/or muscle palpation. When eye movement was 
observed, the current threshold was determined under optical microscope.  A normal 
component of the output organization of rat M1 is the presence of some sites along the 
border region between two movement representations from which movement of both 
body parts can be evoked simultaneously. At such sites, both movements were recorded 
for that position regardless of the individual thresholds (which were determined 
separately for each). Hereafter such movements are identified as ‘threshold-movement’ 
and ‘over-threshold movement’, respectively, according to value of the individual 
threshold. In some sites along the border region between two movement representations, 
both movements can be evoked simultaneously at the current threshold level (dual 
movement site). Forelimb movements evoked by threshold current typically consisted 
of brief twitches of the elbow or shoulder (proximal limb movement), wrist and digit 
(distal limb movement), or simultaneous twitches of both muscles groups. Forelimbs 
and hindlimbs were approximately half-way between flexion and extension and were 
alternately flexed and extended, particularly at the representational borders. 
 
 
Neurotransmitter release 
 
The pharmacological profiles of presynaptic DA receptors modulating monoamine 
release from mice striatal synaptosomes were studied and compared using different 
dopaminergic ligand. 
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Synaptosome preparation 
To minimize pain and discomfort, mice were decapitated under light ether anesthesia 
and the striatum was quickly excised to prepare synaptosomes, as previously described 
(Morari et al., 1998). Briefly, striata were homogenized in ice-cold 0.32 M sucrose 
buffer at pH 7.4 then centrifuged for 10 min at 2,500 gmax (4°C). The supernatant was 
then centrifuged for 20 min at 9,500 gmax (4°C) with the synaptosomal pellet being 
resuspended in oxygenated (95% O2, 5% CO2) Krebs solution (mM: NaCl 118.5, KCl 
4.7, CaCl2 1.2, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 10) containing ascorbic 
acid (0.05 mM) and disodium EDTA (0.03 mM). Synaptosomes were pre-loaded with 
[3H]-DA by incubation in medium containing 50 nM [3H]-DA (specific activity 27.8 
Ci/mmol, NEN DuPont, Boston, MA, USA.) for 25 min. One milliliter aliquots of the 
suspension (~0.35 mg protein) were slowly injected into nylon syringe filters (outer 
diameter 13 mm, 0.45 µM pore size, internal volume of about 100 µl; MSI, Westporo, 
MA, USA) which were then connected to a peristaltic pump. Filters were maintained at 
36.5 °C in a thermostatic bath and superfused at a flow rate of 0.4 ml/min with a pre-
oxygenated Krebs solution. Under these experimental conditions, spontaneous [3H]-DA 
efflux was essentially unaffected by reuptake. Sample collection (every 3 min) was 
initiated after a 20 min period of filter washout. The effect of drugs was evaluated on 
both spontaneous and K+-stimulated neurotransmitter outflow. In this case, drugs were 
added to the perfusion medium 6 (agonist) or 9 (antagonist) min before a 10 mM KCl 
pulse (120 sec) and maintained until the end of the experiment. 
 
[3H]-DA analysis 
[3H]-DA levels in the samples were measured by liquid scintillation spectrophotometry. 
Sample superfusate (1.2 ml/sample) and filter retained (dissolved with 1 ml of 1 M 
NaOH followed by 1 M HCl) were opportunely mixed with Ultima Gold XR 
scintillation fluid (Packard Instruments B.V., Groningen, The Netherlands) and 
radioactivity was determined by a Beckman LS 1800 β-spectrophotometer. 
 
 
Histological analysis 
 
After in vivo experiments, the animals were sacrificed for the histological evaluations.  
All neurons contain Nissl substance, which is primarily composed of granular 
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endoplasmic reticulum and ribosomes, and occurring in nerve cells body and dendrites. 
Because of the RNA content, Nissl substance is very basophilic and will be very sharply 
stained with cresyl violet acetate. This aspecific staining was used for check the 
placement of the probes or electrode. The tracks was verified by microscopic 
examination and the animals in which the tracks were not correctly positioned were 
discarded from the study. On contrary, tyrosine hydroxylase (TH; tyrosine 3-
monooxygenase) is a selective marker, because this enzyme is content only in the 
cytoplasme of dopaminergic cells. TH is responsible for catalyzing the conversion of 
the amino acid L-tyrosine to dihydroxyphenylalanine (dopa). Dopa is a precursor for 
dopamine which in turn is a precursor for norepinephrine (noradrenaline) and 
epinephrine (adrenaline). 
 
Tissue processing 
Mice were deeply anesthetized with ketamine and xylazine (85+15 mg/Kg; i.p.) and rats 
were deeply anaesthetised with Zoletil 100® (10 mg/Kg, i.m.; Virbac Laboratories, 
Carros, France), transcardially perfused at room temperature with phosphate-buffered 
saline (PBS; 20 mM, pH 7.4) and fixed with cold 4% paraformaldheyde in PBS. Brains 
were removed, post-fixed overnight, transferred to 20% sucrose solution in PBS for 
cryoprotection (until they sunk) and stored at -80°C. We used a cryostat at −18°C to cut 
40 µm coronal sections, which were collected free floating (in PBS) for all analysis. 
 
Nissl staining 
Sections at levels of cortex and SNc were mounted on gelatine-coated slides, stained 
with cresyl violet, dried in escalating alcohol concentration (50-70-90-95-100%), 
cleared in xylene and coverslipped with mounting medium. 
 
TH immunohistochemistry 
Sections at levels of striatum and SNc, were rinsed 3 times in PBS and incubated for 15 
min in 3% H2O2 and 10% methanol in PBS to block the endogenous peroxidase activity. 
After washing in PBS, the sections were preincubated in blocking serum (5% normal 
horse serum and 0.3% Triton x100 in PBS) for 60 min, followed by incubation in anti-
TH mouse monoclonal antibody solution (1:2000, Chemicon, Temcula, CA) for 16 hr at 
room temperature. The sections were then rinsed in PBS and incubated for 1 hr in 
biotinylated horse anti-mouse IgG secondary antibody (1:200; Vector Laboratories, 
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Burlingame, CA). After rinsing, sections were incubated with avidin-biotin-peroxidase 
complex (Vector Laboratories) for 30 min at room temperature. After rinsing with PBS, 
immunoreactivity was visualized by incubating the sections in a solution containing 
0.05% 3,3-diaminobenzidine (DAB) in 0.013% H2O2 in PBS for about 1 min. The 
sections were rinsed in PBS, mounted on chrome-alum-coated slides, eventually 
counterstained with cresyl violet, dried with escalating alcohol concentration, cleared in 
xylene and coverslipped with mounting medium. 
 
Optical density evaluation 
The sections were viewed with a Zeiss Axioskop (Carl Zeiss, Germany). Sections were 
acquired (AxioCam ICc3, Carl Zeiss, Germany) and TH-immunoreactive fiber density 
analyzed using ImageJ software (Wayne Rasband; NIH, USA). For each animal, optical 
density was calculated as the mean of the 5 striatal levels and corrected for non-specific 
background, measured in the corpus callosum. 
 
Stereological cell counting 
For counting of TH-immunoreactive neurons (phenotypic marker) and cresyl violet 
stained cells (structural marker) in SNc, an unbiased stereological sampling method was 
used (West and Gundersen, 1990), based on optical dissector stereological probe 
(Bezard et al., 2003; Gross et al., 2003). Stereological analysis was performed using an 
Leica DMRE microscope with a motorized Z and X-Y stage encoders linked to a 
computer-assisted stereological system (Mercator Digital Imaging System, Explora 
Nova, La Rochelle, France). For each animal, SNc boundaries were delimited at low 
magnification (2.5×) by examining the size and shape of the different groups of TH-
immunoreactive neurons and their axonal projections, as well as nearby fibre bundles 
according to the mouse brain atlas. SNc boundaries were drawn on every fourth section 
and the first was randomly chosen. SNc volume was calculated using the formula V(SNc) 
=∑S td; where ∑S is the sum of surface areas (µm2), t the average section thickness and 
d the distance between the sections (Theoret et al., 1999). The average section thickness 
(t) was estimated to 12 µm after immunohistochemistry processing and guard zones of 2 
µm were used to ensure that top and bottom of sections are never included in the 
analysis. Eight sections were used for each animal. From a random start position, a 
computer-generated sampling grid placed the counting frames. The counting frame size 
was 50 µm length and 50 µm width. We left a distance of 100 µm (x) and 100 µm (y) 
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between each counting frame. Within each frame, all cell nuclei which came into focus 
(40× immersion oil objective; Gundersen et al., 1988) were counted. A neuron was 
counted if more than half the cell body was inside the two consecutive boundaries taken 
into account. To estimate the number of TH-immunoreactive neurons we used: N= 
V(SNc) (∑Q−/∑V(dis)); where N is the estimation of the number of TH-immunoreactive 
neurons, V the volume of SNc, ∑Q− the number of cells counted in the frames and 
∑V(dis) is the total volume of frames (Theoret et al., 1999). 
 
 
Data presentation and statistical analysis 
 
Data are expressed as means ± SEM of n determinations per group. Different statistical 
analysis was performed, as appropriate: Student’s t-test, χ2 test presented in a two-way 
contingency table, one-way ANOVA followed by the Newman-Keuls or PLSD test, and 
two-way repeated measure (RM) ANOVA followed by contrast analysis and the 
sequentially rejective Bonferroni test. P values <0.05 were considered to be statistically 
significant. In order to facilitate the readership, we reported the results of statistics 
performed on data in a separate section (appendix I). 
 
 
Materials 
 
6-OHDA bromide, amphetamine methylester, benserazide hydrochloride, bicuculline 
methochloride, L-dopa methyl ester and MPTP hydrochloride were purchased from 
Sigma (St. Louis, MO, USA). Amisulpride, domperidone, GBR12783, raclopride and 
SCH23390 were purchased from Tocris (Bristol, UK). PPX was purchased from 
McTony Bio&Chem (Vancouver, Canada). S33084 was provided by Institut de 
Recherches Servier (Croissy-sur-Seine, France). Lidocaine hydrochloride was 
purchased from S.Anna Hospital (Ferrara, Italy). N/OFQ, J-113397, Trap-101 and UFP-
101 were synthesized in the laboratories of the Department of Pharmaceutical 
Chemistry at the University of Ferrara. All drugs were freshly dissolved in the vehicle 
just prior to use. 
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Results 
 
 
Part I Different subpopulations of D2 receptors mediate dual motor responses of 
NOP receptor antagonists in mice 
 
 
Dose-response curves of NOP receptor antagonists 
 
The motor profiles of three NOP receptor antagonists were investigated in C57BL/6J 
mice by using static and dynamic tests providing complementary information on motor 
parameters: the bar, drag and rotarod tests. The non peptide antagonist J-113397 and its 
achiral analogue Trap-101 were administered systemically while the peptide antagonist 
UFP-101 was given i.c.v. Basal activity in absolute values was 0.8 ± 0.1 sec 
(immobility time in the bar test), 16.5 ± 0.9 steps (drag test) and 937.9 ± 62.1 sec (time 
on rod). Motor activity was not different at the right and left paw so data were pooled 
together. 
 
J-113397 
J-113397 caused long lasting inhibition of the immobility time in the bar test at 10 
mg/Kg, lower doses being ineffective (Fig. 1A). J-113397 caused a dual regulation of 
stepping activity in the drag test (Fig. 1B) and rotarod performance (Fig. 1C). In both 
tests, facilitation was observed at 0.3 and 1 mg/Kg and reduction at 10 mg/Kg. 
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Figure 1. J-113397 dually modulated motor activity in C57BL/6J mice. Systemic administration of J-
113397 (0.1-10 mg/Kg, i.p.) affected motor performance in the bar (A), drag (B) and rotarod (C) test. All 
tests were performed before (control session) and after (10 and 60 min) drug injection. Data are means ± 
SEM of 6 determinations per group and were expressed as percentage of the control session. *p<0.05, 
**p<0.01 different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferrroni’s test). 
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Trap-101 
Trap-101 did not affect the immobility time at any of the doses tested (Fig. 2A). 
However, Trap-101 dually modulated motor activity in the drag and rotarod test, 
increasing the number of steps (Fig. 2B) and time on rod (Fig. 2C) at 10 mg/Kg and 
reducing them at 30 mg/Kg. administration. These effects were observed only at 10 min 
after drug administration. 
 
UFP-101 
UFP-101 increased the immobility time at 30 nmol (Fig. 2D) and caused dual responses 
in the drag (Fig. 2E) and rotarod test (Fig. 2F), namely facilitation at 1 and 3 nmol and 
marked inhibition at 30 nmol. Differently from non peptide antagonists, the effects of 
UFP-101 were detected also at 60 min after injection. 
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Figure 2. Trap-101 and UFP-101 dually modulated motor activity in C57BL/6J mice. Systemic 
administration of Trap-101 (0.1-30 mg/Kg, i.p.), or i.c.v. injection of UFP-101 (0.1-30 nmol) affected 
motor performance in the bar (A, D), drag (B, E) and rotarod (C, F) test. All tests were performed before 
(control session) and after (10 and 60 min) drug injection. Data are means ± SEM of 6 determinations per 
group and were expressed as percentage of the control session. *p<0.05, **p<0.01 different from saline 
(RM ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
 
DA receptor subtypes differentially modulate motor actions of NOP receptor 
antagonists 
 
We previously reported that NOP receptor antagonists elevate striatal DA release in 
rats, suggesting that endogenous N/OFQ tonically inhibits nigro-striatal DA 
transmission (Marti et al., 2004a). We therefore employed selective DA receptor 
antagonists to unravel the contribution of endogenous DA to motor actions of NOP 
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receptor antagonists. The D1/D5 receptor antagonist SCH23390, the D2/D3 receptor 
antagonists raclopride and amisulpride, and the D3 selective receptor antagonist S33084 
were tested alone and in combination with motor facilitating or inhibiting doses of NOP 
receptor antagonists. 
 
Effects of DA receptor antagonists 
Raclopride dose-dependently inhibited motor performance, as shown by an increase in 
immobility time (Fig. 3A) and a reduction in both the number of steps (Fig. 3B) and 
time on rod (Fig. 3C). These effects were evoked at 0.1 and 0.3 mg/Kg and observed 
both 30 and 80 min after administration. Amisulpride partially replicated motor 
inhibiting action of raclopride, causing a prolonged increase in immobility time (Fig. 
3D) and inhibition of rotarod performance (Fig. 3F) at the highest dose tested (15 
mg/Kg). Delayed impairment of rotarod performance was observed also at 5 mg/Kg. 
Different from raclopride, amisulpiride did not affect stepping activity in the drag test 
(Fig. 3E). 
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Figure 3. D2/D3 receptor antagonists decreased motor activity in C57BL/6J mice. Systemic administration 
of raclopride (0.03-0.3 mg/Kg, i.p.) and amisulpride (0.5-15 mg/Kg, i.p.) affected motor performance in 
the bar (A, D), drag (B, E) and rotarod (C, F) test. All tests were performed before (control session) and 
after (30 and 80 min) drug injection. Data are means ± SEM of 6 determinations per group and were 
calculated as percentage of the control session. *p<0.05, **p<0.01 different from saline (RM ANOVA 
followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
SCH23390 produced consistent motor inhibition in the three tests (Fig. 4). Increased 
immobility time (Fig. 4A), reduced stepping activity (Fig. 4B) and rotarod performance 
(Fig. 4C) were observed at 0.01 and 0.03 mg/Kg. The effects in the bar and drag tests 
were prolonged, while those in the rotarod were detected only 30 min after injection. 
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S33084 did not produce marked changes in motor activity (Fig. 4D-F), the only effect 
observed being mild inhibition of stepping at 0.64 mg/Kg (Fig. 4E). 
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Figure 4. D1/D5 and D3 receptor antagonists differentially affected motor activity in C57BL/6J mice. 
Systemic administration of the D1/D5 antagonist SCH23390 (0.003-0.03 mg/Kg, i.p.) affected motor 
performance in the bar (A), drag (B) and rotarod (C) test. Systemic administration of the D3 receptor 
selective antagonist S33084 (0.04-0.64 mg/Kg, i.p.) affected motor performance in the drag (E) but not in 
the bar (D) and rotarod (F) test. All tests were performed before (control session) and after (30 and 80 
min) drug injection. Data are means ± SEM of 6 determinations per group and were calculated as 
percentage of the control session. *p<0.05, **p<0.01 different from saline (RM ANOVA followed by 
contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
Interaction between DA receptor antagonists and NOP receptor antagonists 
To disclose the role of endogenous DA, we challenged motor facilitating or inhibiting 
doses of NOP receptor antagonists with doses of DA receptor antagonists per se 
ineffective on motor activity. Motor facilitating doses were first investigated. 
Raclopride (0.03 mg/Kg) prevented the increase in stepping activity (Fig. 5B) and 
rotarod performance (Fig. 5C) induced by J-113397 (0.3 mg/Kg), Trap-101 (0.3 mg/Kg) 
and UFP-101 (3 nmol). Conversely, amisulpride (0.5 mg/Kg), SCH23390 (0.003 
mg/Kg) and S33084 (0.16 mg/Kg) were ineffective (Fig. 5E-F). 
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Figure 5. Facilitation of motor activity induced by NOP receptor antagonists in C57BL/6J mice was 
selectively prevented by the D2/D3 selective antagonist raclopride. Pretreatment (20 min in advance) with 
raclopride (0.03 mg/Kg, i.p.) prevented motor facilitation induced by low doses of J-113397 (0.3 mg/Kg, 
i.p.), Trap-101 (10 mg/Kg, i.p.) and UFP-101 (3 nmol, i.c.v.) in the drag (B) and rotarod (C) test. 
Raclopride and NOP receptor antagonists did not affect motor performance in the bar test (A). 
Pretreatment with amisulpride (0.5 mg/Kg, i.p.), S33084 (0.16 mg/Kg, i.p.) and SCH23390 (0.003 
mg/Kg, i.p.) did not affect motor facilitation induced by J-113397 (0.3 mg/Kg, i.p.) in the drag (E) and 
rotarod (F) test. Amisulpride, S33084, SCH23390 and J-113397 (alone or in combination) did not affect 
motor performance in the bar test (D). All tests were performed before (control session) and after (10 and 
60 min) NOP receptor antagonist administration. When DA receptor antagonists were tested alone, 
behavioral testing was performed 30 and 80 min after drug injection. Data are means ± SEM of 6 
determinations per group and were calculated as percentage of the control session. *p<0.05, **p<0.01 
different from saline; °p<0.05, °°p<0.01 different from the same group in the absence of raclopride or J-
113397 (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
Differently from facilitation, motor inhibition caused by J-113397 (10 mg/Kg), Trap-
101 (30 mg/Kg) and UFP-101 (30 nmol) in the bar (Fig. 6A), drag (Fig. 6B) and rotarod 
(Fig. 6C) test was prevented by amisulpride, raclopride being ineffective (Fig. 6D-F). It 
is noteworthy that individual doses of J-113397 and Trap-101 which caused inhibition 
of stepping activity in the drag test induced significant stimulation in the presence of 
amisulpride (Fig. 6B). A similar reversal of action was observed for J-113397 on 
rotarod performance (Fig. 6C). 
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Figure 6. Inhibition of motor activity induced in C57BL/6J mice by NOP receptor antagonists was 
selectively prevented by the D2/D3 selective antagonist amisulpride. Pretreatment (20 min in advance) 
with amisulpride (0.5 mg/Kg, i.p.) reduced motor inhibition caused by high doses of J-113397 (10 
mg/Kg, i.p.), Trap-101 (30 mg/Kg, i.p.) and UFP-101 (30 nmol, i.c.v) in the bar (A), drag (B) and rotarod 
(C) test. Conversely, pretreatment with raclopride (0.03 mg/Kg, i.p.) was ineffective (D-F). All tests were 
performed before (control session) and after (10 and 60 min) NOP receptor antagonist injection. When 
DA receptor antagonists were tested alone, behavioral testing was performed 30 and 80 min after drug 
administration. Data are means ± SEM of 6 determinations per group and were expressed as percentage of 
the control session. *p<0.05, **p<0.01 different from saline; °p<0.05, °°p<0.01 different from the same 
group in the absence of amisulpride (RM ANOVA followed by contrast analysis and the sequentially 
rejective Bonferrroni’s test). 
 
Raclopride prevented motor facilitation induced by N/OFQ 
The data collected thus far indicate that the dual action profile of NOP antagonists is 
mediated by endogenous DA acting on populations of D2 receptors differently sensitive 
to amisulpride and raclopride. Previous studies in mice have reported that N/OFQ given 
i.c.v. stimulates spontaneous locomotion through DA-dependent mechanisms (Florin et 
al., 1996; Kuzmin et al., 2004). We therefore investigated the role of D2 receptors in 
motor facilitation induced by N/OFQ in the bar, drag and rotarod tests. N/OFQ 
produced different effects on motor activity depending on the dose and motor task used. 
In particular, N/OFQ monotonically increased immobility time (Fig. 7A) and dually 
regulated both stepping activity (Fig. 7B) and rotarod performance (Fig. 7C). The 
effects were also detected after 60 min from administration. Motor facilitation in the 
drag and rotarod tests was observed at 0.01 nmol while motor inhibition predominated 
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at higher doses (0.1-10 nmol) in all tests. Increases in stepping activity and rotarod 
performance induced by 0.01 nmol N/OFQ were prevented by raclopride (Fig. 7E-F). 
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Figure 7. N/OFQ dually modulated motor activity in C57BL/6J mice. I.c.v. injections of N/OFQ (0.1-30 
nmol) affected motor performance in the bar (A), drag (B) and rotarod (C) test. Pretreatment (20 min in 
advance) with raclopride (0.03 mg/Kg, i.p.) prevented motor facilitation induced by low doses of N/OFQ 
(0.01 nmol, i.c.v.) in the drag (E) and rotarod test (F). Low doses of N/OFQ, alone or in combination with 
raclopride, did not affect motor performance in the bar test (D). All tests were performed before (control 
session) and after (10 and 60 min) N/OFQ injection. When DA receptor antagonists were tested alone, 
behavioral testing was performed 30 and 80 min after drug injection. Data are means ± SEM of 6 
determinations per group and were calculated as percentage of the control session. *p<0.05, **p<0.01 
different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferrroni’s test). 
 
Selectivity of NOP receptor ligands 
To test the specificity of NOP receptor ligands, motor facilitating and inhibitory doses 
of J-113397, UFP-101 and N/OFQ were challenged in NOP+/+ and NOP-/- mice.  
In NOP+/+ mice (Fig. 8A), J-113397 facilitated rotarod performance at 0.1 and 1 mg/Kg 
and inhibited it at 10 mg/Kg. No major difference was observed between Swiss and 
NOP+/+ mice in terms of sensitivity to J-113397 or duration of the response. Conversely, 
J-113397 was not effective in NOP-/- mice at any of the doses tested (Fig. 8B), 
suggesting that both the facilitation and the inhibition observed in NOP+/+ mice were 
due to NOP receptor blockade. 
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Figure 8. Selectivity of J-113397. Systemic administration of J-113397 (0.03-10 mg/Kg, i.p.) affected 
motor performance in the rotarod test in NOP+/+ mice (A) but was ineffective in NOP-/- mice (B). The test 
was performed before (control session) and after (10 and 60 min) drug injection. Data are means ± SEM 
of 8-10 determinations per group and were calculated as percentage of the control session. *p<0.05 
different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferroni’s test). 
 
Low doses of UFP-101 (3 nmol) and N/OFQ (0.01 nmol) did not affect immobility time 
(Fig 9A) but facilitated stepping activity (Fig. 9B) and rotarod performance (Fig. 9C) in 
NOP+/+ mice. Higher doses of UFP-101 (30 nmol) and N/OFQ (10 nmol) elevated 
immobility time and inhibited stepping and rotarod performance (Fig. 10A-C). These 
effects were detectable also at 60 min after treatment. No major difference was observed 
between C57BL/6J and NOP+/+ mice in terms of sensitivity to N/OFQ or duration of the 
response. Conversely, UFP-101 and N/OFQ were not effective in NOP-/- mice at any of 
the doses tested, suggesting that the dual responses they evoked in NOP+/+ mice relied 
on the interaction (blockade and stimulation, respectively) with NOP receptors. 
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Figure 9. Selectivity of UFP-101 and N/OFQ. I.c.v. injections of motor facilitating and inhibiting doses 
of UFP-101 (3 and 30 nmol, respectively) and N/OFQ (0.01 and 10 nmol, respectively) affected motor 
performance in the bar (A), drag (B) and rotarod (C) test in NOP+/+ mice, being ineffective in NOP-/- 
mice. All tests were performed before (control session) and 10 min and 60 min after drug injection. Data 
are means ± SEM of 6 determinations per group and were calculated as percentage of the control session. 
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**p<0.01 different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferrroni’s test). 
 
 
DA receptor antagonists prevented motor inhibition induced by L-dopa and PPX 
 
To strengthen the role of D2 receptors in motor control, we first analyzed motor 
responses to the DA precursor, L-dopa (in combination with benserazide), and the 
D3/D2 agonist PPX. These compounds were tested alone or in combination with 
different classes of DA receptor antagonists. 
 
L-dopa 
L-dopa inhibited motor activity at the highest dose tested (100 mg/Kg), elevating 
immobility time (Fig. 10A) and reducing both stepping activity (Fig. 10B) and rotarod 
performance (Fig. 10C). Impaired rotarod performance was also detected at the lower 
10 mg/Kg dose. 
 
PPX 
Similar to L-dopa, PPX evoked a marked increase in immobility time (Fig. 10D) and 
rotarod performance (Fig. 10F) at 0.1 and 1 mg/Kg. Stepping activity, however, was 
minimally and transiently reduced only at the highest PPX dose tested (1 mg/Kg; Fig. 
10E). These effects were also observed at 60 min post-injections time. 
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Figure 10. DA receptor agonists decreased motor activity in C57BL/6J mice. Systemic administration of 
L-dopa (1-100 mg/Kg plus benserazide 4:1 ratio, i.p.) and PPX (0.0001-1 mg/Kg, i.p.) affected motor 
performance in the bar (A, D), drag (B, E) and rotarod (C, F) test. All tests were performed before 
(control session) and after (10 and 60 min) drug administration. Data are means ± SEM of 6 
determinations per group and were calculated as percentage of the control session. *p<0.05, **p<0.01 
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different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferrroni’s test). 
 
Interaction between DA receptor antagonists and agonists 
Since motor inhibition was the only effect detected following DA agonists, amisulpride 
and raclopride were used to demonstrate the involvement of D2/D3 receptors. 
Amisulpride consistently prevented motor inhibition induced by high doses of L-dopa 
(100 mg/Kg) in the bar, drag and rotarod tests (Fig. 11A-C). Conversely, it modulated 
the effects of PPX depending on the test and agonist dose used. Thus, amisulpride 
prevented the increase in immobility time induced by 0.1 mg/Kg PPX (Fig. 11A) but 
failed to attenuate the impairment in rotarod performance induced by the same dose 
(Fig. 11C). Amisulpride also did not affect motor inhibition induced by the higher PPX 
dose (1 mg/Kg) in the bar and drag tests (Fig. 11A-B) but slightly attenuated 
impairment in rotarod performance (Fig. 11C). On the other hand, raclopride did not 
prevent motor inhibition induced by PPX on the rotarod (Fig. 11F) and even worsened 
the inhibition of immobility time (Fig. 11D) and stepping activity (Fig. 11E) induced by 
PPX in the bar and drag tests, respectively. 
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Figure 11. Motor inhibition induced by L-dopa in C57BL/6J mice was inhibited by the D2/D3 receptor 
selective antagonist amisulpride. Pretreatment (20 min in advance) with amisulpride (0.5 mg/Kg, i.p.) 
differentially affected motor inhibition induced by L-dopa (100 mg/Kg plus benserazide 25 mg/Kg, i.p.) 
and PPX (0.1 and 1 mg/Kg, i.p.) in the bar (A), drag (B) and rotarod (C) test. Amisulpiride prevented the 
inhibition induced by L-dopa but was ineffective against that induced by PPX (1 mg/Kg). Amisulpiride 
only prevented the inhibition induced by PPX 0.1 mg/Kg in the bar test (A). Pretreatment with raclopride 
(0.03 mg/Kg, i.p.) did not attenuate motor inhibition induced by L-dopa and PPX and even worsened it 
(D-F). All tests were performed before (control session) and after (10 and 60 min) L-dopa and PPX 
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administration. When DA receptor antagonists were tested alone, behavioral testing was performed 30 
and 80 min after drug injection. Data are means ± SEM of 6 determinations per group and were calculated 
as percentage of the control session. *p<0.05, **p<0.01 different from saline; °p<0.05, °°p<0.01 different 
from the same group in the absence of amisulpride or raclopride (RM ANOVA followed by contrast 
analysis and the sequentially rejective Bonferrroni’s test). 
 
Since PPX is a potent D3 receptor agonist, we investigated whether motor inhibition 
could be mediated by D3 receptors (Fig. 12). Not only did S33084 not prevent motor 
inhibition induced by both doses of PPX in the three tests (Fig. 12A-C) but it even 
worsened impairment of stepping activity induced by PPX 1 mg/Kg in the drag test 
(Fig. 12B). Likewise, S33084 enhanced inhibition of stepping activity induced by 100 
mg/Kg L-dopa (Fig. 12B) leaving unaffected its motor responses in the bar (Fig. 12A) 
and rotarod (Fig. 12C) tests. A combination of S33084, amisulpride and raclopride 
failed to attenuate PPX-induced inhibition (data not shown). We finally investigated 
whether peripheral D2-like receptors could contribute to motor inhibition induced by 
PPX, e.g. by inducing hypotension. The peripheral non selective D2 receptor antagonist 
domperidone (5 mg/Kg; Fig. 12D-F) did not affect motor activity alone and also failed 
to prevent the effect of 0.1 mg/Kg PPX. 
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Figure 12. Motor inhibition induced by DA agonists in C57BL/6J mice was insensitive to the D3 
selective receptor antagonist S33084 or the peripheral non selective DA receptor antagonist domperidone. 
Pretreatment (20 min in advance) with S33084 (0.16 mg/Kg, i.p.) or domperidone (5 mg/Kg, i.p.) did not 
attenuate motor inhibition caused by L-dopa (100 mg/Kg plus benserazide 25 mg/Kg; i.p.) and PPX (0.1 
and 1 mg/Kg) in the bar (A, D), drag (B, E) and rotarod (C, F) test. S33084 alone even increased the 
inhibition induced by both DA receptor agonists in the drag test (B). All tests were performed before 
(control session) and after (10 and 60 min) DA receptor agonist administration. When DA receptor 
antagonists were tested alone, behavioral testing was performed 30 and 80 min after drug injection. Data 
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are means ± SEM of 6 determinations per group and were calculated as percentage of the control session. 
*p<0.05, **p<0.01 different from saline; °p<0.05, °°p<0.01 different from the same group in the absence 
of S33084; #p<0.05 different from PPX 1 mg/Kg (RM ANOVA followed by contrast analysis and the 
sequentially rejective Bonferrroni’s test). 
 
L-dopa and PPX oppositely modulated [3H]-DA release in striatal synaptosomes 
Previous in vivo data suggest that motor inhibitory actions of L-dopa and PPX rely on 
an interaction with presynaptic D2 autoreceptors. We therefore analyzed the effects of 
L-dopa (free-base) and PPX in a preparation of striatal synaptosomes preloaded with 
[3H]-DA (Figs 13-14). This would also demonstrate whether L-dopa might have 
biological activity per se or if its effects are due to its conversion to DA. Basal 
synaptosomal [3H]-DA efflux was 0.021 ± 0.001 pmol mg prot-1 min-1 (n=68) and 
corresponded to a fractional release of 6.79 ± 0.15 %. A 2 minute pulse of KCl 10 mM 
evoked a tritium overflow of 0.006 ± 0.001 pmol mg prot-1 min-1 (n=24) which was 
attenuated by ~70 % in the absence of Ca++ (Fig. 14). PPX (100 nM) decreases [3H]-DA 
overflow (~51 %) and this effects was prevented by pre-treatment with amisulpride (100 
nM), ineffective per se (Fig. 13A). Conversely, L-dopa (1 µM) doubled [3H]-DA 
overflow (Fig. 13B). This effect was prevented by SCH23390 (100 nM) but not by the 
DA transporter blocker GBR12783 (300 nM; Fig 13B). Neither compound affected the 
K+-evoked tritium overflow. 
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Figure 13. PPX and L-dopa oppositely modulated K+-evoked DA release from synaptosomes. PPX (100 
nM) inhibited (A) while L-dopa (1 µM) elevated (B) the [3H]-DA overflow evoked by a 2 min pulse of 10 
mM KCl from a preparation of striatal synaptosomes in superfusion. The inhibition induced by PPX was 
prevented by the D2-like receptor antagonist amisulpride (A) while the stimulation induced by L-dopa 
was prevented by the D1-like receptor antagonist SCH23390 (B). PPX and L-dopa were administered 6 
min KCl whereas antagonists 3 min before agonists. Data are means ± SEM of 6 determinations per 
group and were expressed as percentage of control (i.e. the K+-evoked tritium overflow). *p<0.05, 
**p<0.01 different from control (ANOVA followed by the Newman-Keuls test). 
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L-dopa (1-100 µM) also increased in a dose-dependent manner tritium efflux (Fig. 
14A). GBR12783 (300 nM) prevented the response to 10 µM L-dopa (Fig. 14B) and 
attenuated that of 100 µM L-dopa (Fig. 14C), while SCH23390 (1 µM) was ineffective. 
GBR12783 and SCH23390 did not affect spontaneous tritium efflux at the doses tested. 
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Figure 14. L-dopa increased spontaneous tritium efflux from synaptosomes. L-dopa (1-100 µM) elevated 
spontaneous tritium efflux from a preparation of striatal synaptosomes in superfusion pre-loaded with 
[3H]-DA (A). The DA transporter blocker GBR12783 but not the D1-like selective antagonist SCH23390 
prevented the elevation induced by L-dopa (10 µM; B) and attenuated that induced by L-dopa (100 µM; 
C). GBR12783 and SCH23390 were given 3 min before L-dopa and maintained until the end of 
experiments. Data are means ± SEM of 6 determinations per group and were expressed as percentage of 
basal tritium efflux (calculated as the mean between the two samples before L-dopa). *p<0.05, **p<0.01 
different from washout; °°p<0.01 different from L-dopa alone (ANOVA followed by the Newman-Keuls 
test performed on AUC values). 
 
 
Part II. NOP receptor antagonists attenuate parkinsonism in MPTP-treated mice 
 
 
Characterisation of the experimental model 
 
In C57BL/6J mice, MPTP administration induced a variety of acute behavioral changes 
observed unsystematically, such as muscular hypotonia, piloerection, elevated bowed 
stiff tail (i.e. Straub tail), increased respiration (i.e. hyperpnea). These phenomena 
appeared immediately after the first injection and vanished within 16 hours. About 30% 
of MPTP-treated mice died within 24 hr after toxin administration. Body weight of 
surviving MPTP-treated mice did not change with respect to vehicle-injected mice over 
time (data not shown). 
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MPTP induced loss of TH staining in the striatum 
Seven days after treatment, MPTP-treated mice displayed partial (~60%) bilateral loss 
of TH-immunoreactive DA terminals compared to vehicle-injected mice (Fig. 15A-C). 
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Figure 15. MPTP-treatment reduced the TH-immunoreactive fibre density in the C57BL/6J mouse 
striatum. Photomicrographs of TH-immunoreactive fibres in the striatum of a saline (A) and MPTP-
treated (B) mouse. C, Optical density of TH-immunoreactive fibres in the striatum. Data are means ± 
SEM of 10 determinations per group. ***p<0.001 different from saline (Student’s t-test). 
 
MPTP treatment caused akinesia and bradykinesia 
MPTP increased the immobility time. The effect was maximal at D1 after injection and 
subsided from D4 onward (Fig. 16A). At 6 days after MPTP, mice were still akinetic. 
MPTP caused a marked loss of reactivity (Fig. 16B), that was substantially unchanged 
from D1 through D6, and a decrease in stepping activity(Fig. 16C), that was maximal at 
D1 and D2 (~60%) and still detectable, albeit attenuated (~15%), at D6. MPTP  caused 
a marked impairment of climbing speed (Fig. 16D) at D1 (~70%) which tended to revert 
back over time (~40% at D6), and a maximal reduction of pulling force (Fig. 16E) in the 
D1-D4 range. After 6 days, however, the pulling force was normalized. Finally, MPTP 
caused a maximal ~65% impairment of the rotarod performance (Fig. 16F) at D1. In the 
following days, attenuation of motor impairment settled to ~30%. 
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Figure 16. MPTP-treatment induced akinesia and bradykinesia in C57BL/6J mice. Systemic 
administration of MPTP (4x20 mg/Kg) increased the immobility time (bar test; in sec, A) and reaction 
time (reaction time test; in sec; B) and decreased the number of steps (drag test; C), the climbing speed 
(stair climbing test; cm/sec; D), the pulling force (grip test; gram force; E) and the time spent on the rod 
(in sec, rotarod test; F). All tests were performed before and after (daily for 6 days) MPTP-treatment. 
Data are means ± SEM of 10 determinations per group. *p<0.05, **p<0.01 different from saline (RM 
ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
MPTP treatment caused abnormalities in gait and posture 
MPTP caused a slight reduction (~16%) of hindpaw stride length (Fig. 17A). A parallel 
impairment was detectable by measuring forepaw stride length (data not shown). MPTP 
caused a long lasting increase (~20%) of hindpaw stride width (Fig. 17B) and caused a 
mismatch in the overlap of the ipsilateral paw that showed a tendency to recover over 
time (Fig. 17C). Moreover, MPTP caused a stable increase in the angle amplitude 
between hindpaws and the main direction (Fig. 17D). Finally, MPTP caused an marked 
decrease of running speed (Fig. 17E), which was almost halved with respect to saline-
treated animals. 
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Figure 17. MPTP-treatment induced abnormalities of gait and posture in C57BL/6J mice. Systemic 
administration of MPTP reduced the stride length of hindlimbs (in mm; A), increased the stride width of 
hindlimbs (in mm; B), the distance of matching (in mm; C) and the angle of hindpaws (in degrees; D), 
and reduced the run speed (in cm/sec; E). F. Complete set of parameters in footprints of a saline (left) and 
MPTP-treated mouse (right). All tests were performed before and after (daily for 6 days) MPTP-
treatment. Data are means ± SEM of 10 determinations per group. *p<0.05, **p<0.01 different from 
saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
 
Responsiveness to classical antiparkinsonian compounds 
 
To investigate whether the MPTP-induced phenotype was generated by DA deficiency, 
the ability of DA receptor agonists (i.e. L-dopa and PPX) to attenuate motor deficit was 
investigated. Animals were challenged in the bar, drag and rotarod test, performed 7 
days after MPTP intoxication, when mice displayed increased immobility time (Fig 
18A), reduced number of steps (Fig 18B) and impaired rotarod performance (Fig. 18C) 
compared to pre-treatment values. 
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Figure 18. Motor impairment in C57BL/6J mice at 7 days after MPTP treatment. Systemic administation 
of MPTP (4x20 mg/Kg, i.p.) affected motor performance in the bar (in sec; A), drag (B) and rotarod test 
(in sec; C). All tests were performed before (pre-MPTP, control session) and 7 days after (post-MPTP) 
MPTP. Data are means ± SEM of 10 determinations per group. *p<0.05, different from saline (ANOVA 
followed by the Newman-Keuls test). 
 
L-dopa 
L-dopa caused dual and prolonged changes of immobility time (Fig. 19A), namely a 
reduction at 10 mg/Kg and an increase at 100 mg/Kg. L-dopa elevated the number of 
steps (Fig. 19B) at 1 and 10 mg/Kg, being ineffective at higher doses. The effect of 1 
mg/Kg was transient whereas that produced by 10 mg/Kg was detected also 60 min 
after injection. Finally, L-dopa increased rotarod performance (Fig. 19C) at 10 mg/Kg 
and reduced it at 100 mg/Kg. These effects were long lasting. Since L-dopa was 
administered in combination with benserazide (ratio 4:1), benserazide alone was tested 
at the highest does (25 mg/Kg). Benserazide did not affect motor performance with 
respect to saline (data not shown). 
 
PPX 
PPX 0.01 and 0.1 mg/Kg increased the immobility time (Fig. 19D), although the effect 
of the lower dose appeared only 60 min after injection. Lower PPX doses were 
ineffective. PPX elevated the number of steps (Fig. 19E) in the 0.0001-0.01 mg/Kg dose 
range but was ineffective at higher doses (0.1 mg/Kg). Only the facilitation induced by 
0.001 mg/Kg was long lasting. Finally, PPX failed to modulate rotarod performance up 
to 0.001 mg/Kg while impairing it at 0.01 and 0.1 mg/Kg (Fig. 19F). 
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Figure 19. DA receptor agonists attenuated parkinsonian symptoms in MPTP-treated C57BL/6J mice. 
Systemic administration of L-Dopa (0.1-100 mg/Kg, i.p.) or PPX (0.0001-0.1 mg/Kg, i.p.) affected motor 
performance in the bar (A,D), drag (B,E) and rotarod test (C,F). All tests were performed at 7 days after 
MPTP administration, before (control session) and after (10 and 60 min) drug injection. Data are means ± 
SEM of 7-8 determinations per group and were calculated as percentage of the control session. *p<0.05, 
**p<0.01 different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferroni’s test). 
 
 
Responsiveness to NOP receptors antagonists 
 
Seven days after MPTP treatment, NOP receptor antagonists J-113397 and Trap-101 
were also tested since these compounds were found effective in promoting movement in 
rats treated with 6-OHDA (Marti et al., 2005, 2007, 2008). 
 
J-113397 
J-113397 (0.01-0.03 mg/Kg) reduced the immobility time (Fig. 20A) the number of 
steps (Fig 20B) and the rotarod performance (Fig. 20C). However, higher doses of J-
113397 exerted opposite effects. In fact, J-113397 (1 mg/Kg) increased the immobility 
time and reduced rotarod performance, being ineffective in the drag test.  
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Figure 20. J-113397 attenuated parkinsonian symptoms in MPTP-treated C57BL/6J mice. Systemic 
administration of J-113397 (0.01-1 mg/Kg, i.p.) affected motor performance in the bar (A), drag (B) and 
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rotarod test (C). All tests were performed at 7 days after MPTP administration, before (control session) 
and after (10 and 60 min) drug injection. Data are means ± SEM of 8-10 determinations per group and 
were calculated as percentage of the control session. *p<0.05 different from saline (RM ANOVA 
followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
Trap-101 
Trap-101 caused a transient reduction of immobility time (Fig. 21A) at 0.01 and 0.1 
mg/Kg but was ineffective at 1 mg/Kg. Moreover, Trap-101 elevated the number of 
steps (Fig. 21B) in the 0.001-0.1 mg/Kg dose range, being ineffective at 1 mg/Kg. Only 
the facilitation induced by Trap-101 0.1 mg/Kg was detected at 60 min after injection. 
Trap-101 failed to modulate the rotarod performance up to 0.1 mg/Kg and transiently 
reduced it at 1 mg/Kg (Fig. 21C). 
0
100
200
300
400
500 10 min 60 min
A
**
Im
m
ob
ili
ty
 ti
m
e (
%
 o
f c
on
tr
ol
)
0
20
40
60
80
100
120
140
160
10 min 60 minB
*
** ****
St
ep
s (
%
 o
f c
on
tr
ol
)
0
20
40
60
80
100
120
140
160
10 min 60 min
Trap-101  0.001 mg/Kg
saline
Trap-101  0.01 mg/Kg
Trap-101  1 mg/Kg
C
Trap-101  0.1 mg/Kg
*
Ti
m
e o
n 
ro
d 
(%
 o
f c
on
tr
ol
)
Figure 21. Trap-101 attenuated parkinsonian symptoms in MPTP-treated C57BL/6J mice. Systemic 
administration of Trap-101 (0.001-1 mg/Kg, i.p.) affected motor performance in the bar (A), drag (B) and 
rotarod test (C). All tests were performed at 7 days after MPTP administration, before (control session) 
and after (10 and 60 min) drug injection. Data are means ± SEM of 7-8 determinations per group and 
were calculated as percentage of the control session. *p<0.05, **p<0.01 different from saline (RM 
ANOVA followed by contrast analysis and the sequentially rejective Bonferroni’s test). 
 
 
Interaction between DA receptor agonists and NOP receptor antagonists 
 
We previously demonstrated (Marti et al., 2007, 2008) that co-administration of L-dopa 
and J-113397 or Trap-101 produced additive attenuation of parkinsonism in 6-OHDA 
hemilesioned rats. Therefore, we first tested whether subthreshold doses (at least in two 
of three tests) of L-dopa (1 mg/Kg) and Trap-101 (0.001 mg/Kg) could synergize in 
attenuating parkinsonism in MPTP-treated mice. We then tested whether subthreshold 
doses of PPX (0.0001 mg/Kg) could produce additive effects with Trap-101 (0.001 
mg/Kg). 
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L-dopa and Trap-101 
L-dopa and Trap-101 alone were ineffective whereas their combination reduced the 
immobility time (Fig. 22A). This effect was observed only at 10 min after injection. L-
dopa and Trap-101 slightly increased the number of steps in the drag test (Fig. 22B) and 
their combination produced an additive effect. The combination effect was even more 
evident at 60 min, since both compounds were ineffective alone. No change in rotarod 
performance (Fig. 22C) was observed after administration of subthreshold doses of L-
dopa and Trap-101, either alone or in combination. 
 
PPX and Trap-101 
No change in immobility time (Fig. 22D) or in rotarod performance (Fig. 22F) was 
observed after administration of subthreshold doses of PPX and Trap-101, either alone 
or in combination. Conversly, PPX and Trap-101 transiently elevated number of steps 
(Fig. 22E) while their combination produced a greater (additive) and sustained 
improvement. 
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Figure 22. Combination of L-dopa and PPX with Trap-101 synergistically or additively attenuated 
parkinsonian symptoms in MPTP-treated C57BL/6J mice. Combined administration of L-dopa (1 mg/Kg, 
i.p.) and Trap-101 (0.001 mg/Kg, i.p.) affected motor performance in the bar (A) and drag (B) test but not 
in the rotarod test (C). Combined administration of PPX (0.0001 mg/Kg, i.p.) and Trap-101 (0.001 
mg/Kg, i.p.) affected motor activity only in the drag test (E), but not in the bar (D) and rotarod (F) test. 
All tests were performed at 7 days after MPTP administration, before (control session) and after (10 and 
60 min) drug injection. Data are means ± SEM of 7-8 determinations per group and were calculated as 
percentage of the control session. *p<0.05, **p<0.01 different from saline; °p<0.05 different from L-
dopa; #p<0.05 different from Trap-101 (RM ANOVA followed by contrast analysis and the sequentially 
rejective Bonferroni’s test). 
 
 
 55
D2 receptor blockade prevented paradoxical inhibition induced by DA receptor 
agonists and NOP receptor antagonists 
 
PPX is known to depress motor activity (Mierau and Schingnitz, 1992; Maj et al., 1998; 
Siuciak and Fujiwara, 2004), likely via stimulation of presynaptic D2S (short isoform) 
autoreceptors (Usiello et al., 2000; Vallone et al., 2000). We therefore tested the 
hypothesis that motor inhibition induced by L-dopa and PPX could be reversed by the 
D2/D3 receptor antagonist amisulpride. Indeed, this antagonist preferentially bind to D2 
autoreceptors at low doses (Scatton et al., 1997; Perrault et al., 1997; Schoemaker et al., 
1997). To investigate the DA-dependence of the motor inhibitory produced by NOP 
receptor blockade, we used J-113397. Differently from Trap-101, J-113397 caused 
marked motor inhibition also in the bar test (Viaro et al., 2008). The effect of 
amisulpride alone was first assessed in a dose-finding study. 
 
Amisulpride 
Amisulpride caused a prolonged increase of immobility time (Fig. 23A) and a 
prolonged reduction in stepping activity (Fig. 23B) at the highest dose tested (5 mg/Kg). 
Moreover, amisulpride caused sustained motor impairment on the rotarod at 0.5 and 5 
mg/Kg (Fig. 23C), which could be detected also at 60 min after injection. 
 
Interaction between amisulpride and DA receptor agonists and NOP receptor 
antagonists 
Based on these preliminary findings we selected an ineffective dose of amisulpride (0.1 
mg/Kg) and challenged it with motor inhibiting doses of L-Dopa (100 mg/Kg), PPX 
(0.1 mg/Kg) or J-113397 (1 mg/Kg). Motor inhibition caused by L-dopa (100 mg/Kg) 
and J-113397 (1 mg/Kg) in the bar test (Fig. 23D) was reversed into facilitation in the 
presence of amisulpride. Conversely, amisulpride did not prevent the effect of PPX. In 
the drag test (Fig. 23E), L-Dopa and PPX were ineffective either alone or in 
combination with amisulpride. However, J-113397, ineffective alone, caused a 
prolonged increase in stepping activity in the presence of amisulpride. Finally, motor 
impairment on rotarod (Fig. 23F) caused by L-dopa and J-113397 was prevented by 
amisulpride. However, amisulpride failed to attenuate the effect of PPX. 
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Figure 23. The D2/D3 receptor selective antagonist amisulpride prevented motor inhibition induced by 
high doses of L-dopa and J-113397 but not PPX in MPTP-treated C57BL/6J mice. Systemic 
administration of amisulpride alone (0.1-5 mg/Kg, i.p.) inhibited motor performance in the bar (A), drag 
(B) and rotarod (C) test. Twenty min pretreatment with amisulpride (0.5 mg/Kg, i.p.) differentially 
affected motor inhibition induced by L-dopa (100 mg/Kg, i.p.) and J-113397 (1 mg/Kg, i.p.) in the bar 
(D), drag (E) and rotarod test (F) but was ineffective against hypomotility induced by PPX (0.1 mg/Kg; 
i.p.). All tests were performed at 7 days after MPTP administration, before (control session) and after (10 
and 60 min) L-dopa, PPX and J-113397 injection. When amisulpride were tested alone, behavioral testing 
was performed 30 and 80 min after injection. Data are means ± SEM of 6 determinations per group and 
were calculated as percentage of the control session. *p<0.05, **p<0.01 different from saline; °p<0.05, 
°°p<0.01 different from amisulpride alone (RM ANOVA followed by contrast analysis and the 
sequentially rejective Bonferroni’s test). 
 
Interaction between domperidone and PPX 
We finally tested whether the PPX-induced hypolocomotion had a peripheral origin. 
The peripheral DA receptor antagonist domperidone (5 mg/Kg) alone failed to affect the 
immobility time (Fig. 24A), number of steps (Fig. 24B) or rotarod performance (Fig. 
24C) and was not able to counteract the inhibitory effect of PPX. 
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Figure 24. Motor inhibition induced by PPX was insensitive to peripheral DA antagonist domperidone in 
MPTP-treated mice. Twenty min pretreatment with domperidone (5 mg/Kg, i.p.) did not attenuate motor 
inhibition caused by PPX (0.1 mg/Kg, i.p.) in the bar (A), drag (B) and rotarod (C) test. All tests were 
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performed at 7 days after MPTP administration, before (control session) and after (10 and 60 min) PPX 
injection. When domperidone was tested alone, behavioral testing was performed 30 and 80 min after 
injection. Data are means ± SEM of 6 determinations per group and were calculated as percentage of the 
control session. *p<0.05, **p<0.01 different from saline (RM ANOVA followed by contrast analysis and 
the sequentially rejective Bonferroni’s test). 
 
 
Part III. NOP receptor antagonists attenuate MPTP-induced parkinsonism in 
nonhuman primates 
 
 
J-113397 in naïve macaques 
 
Similarly to previous experiments in mice, we first tested the efficacy of J-113397 in 
untreated (naïve) macaques, for an evaluation of the effective dose range. J-11397 did 
not affect motor performance in naïve macaques at 0.1 and 1 mg/kg (Fig. 25). At a 
higher dose (3 mg/kg) J-113397 induced a faster performance in the straight rod test in 
two of the animals (Fig. 25A), although the other two did not perform the test. 
Therefore we tested these animals on a simpler task (i.e. the platform task) but at this 
dose animals were inattentive and performance was slightly slower than normal (Fig 
25B). 
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Figure 25. J-113397 modulated motor activity in nonhuman primates. Systemic administration of J-
113397 (0.1-3 mg/Kg, i.m.) affected motor performance in the MAP test. Average time to retrieve a treat 
in the straight rod test (in sec; A) was significantly improved in 2 animals at the higher dose tested, but at 
this dose the other 2 animals showed side effects (distractibility, scratching and “wet dog” shakes) and 
failed to perform. These 2 animals were subsequently tested in the platform task of the MAP test (in sec; 
B) in which they performed significantly worse at the higher dose. *p<0.05 different from saline 
(ANOVA followed by PLSD test). 
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J-113397 in MPTP-treated macaques 
 
After the study in naïve macaques, we tested the effectiveness of J-113397 in MPTP-
treated-macaques. L-dopa was used as a positive control. Pharmacological tests were 
performed in nonhuman primates at least 3 months after the last MPTP dose (Tab. 1). 
Animal Weight (Kg) PRS score after MPTP
PRS score 3 
months 
after MPTP
Activity d/n 
(% from 
baseline) 
Mf23 4.4 17 18.3 -76/-60 
Mf25 5.4 19 21.5 -77/-62 
Mf30 6.1 21 20.0 -68/-32 
Mf34 5.3 18 18.5 -5/-60 
 
Table 1. Individual characteristics of MPTP-lesioned primates. 
 
We first examined the response to four doses of J-113397 (0.01, 0.03, 0.1 and 1 mg/kg) 
in two stable parkinsonian animals (data not shown). From 0.03 to 1 mg/kg we did not 
observe any beneficial effect on either parkinsonian score or MAP platform 
performance; at 1 mg/kg both animals displayed long episodes of akinesia (freezing) 
similar to the effect of high doses of J-113397 observed in 6-OHDA rats (30 mg/Kg, 
Morari and Marti, unpublished observation) and did not perform the reaching test. No 
major side effects were observed at 0.03 mg/kg but one animal did not test and the other 
did not show any improvement in the reaching task. With the lower dose (0.01 mg/kg) 
both animals showed an improvement in the MAP platform reaching task and therefore 
we selected this dose for the rest of the experiments. Both J-113397 (0.01 mg/kg) and 
L-dopa (30 mg/kg) induced a significant benefit in parkinsonian scores in the 4 animals 
(Fig 26A). The overall improvement after J-113397 administration (19±3%) was more 
moderate than that achieved with L-dopa (46±3%). Although as a group, the difference 
between L-dopa and J-113397 improvement in global PRS score did not reach 
significance, only in one animal (Mf25) was the response to both drugs not significantly 
different (Fig 26A). There was no significant effect of the baseline PRS score (i.e. 
severity of the parkinsonian signs) on the response to either drug. We further analyzed 
the therapeutic effect on parkinsonian symptoms (Fig 26B). The largest improvement 
induced by J-113397 (~30%) was observed on hypokinesia and the L-dopa effect on 
this particular symptom was not significantly different from J-113397. Other symptoms 
(rigidity, tremor and bradykinesia) improved significantly more with L-dopa (Fig 26B). 
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Figure 26. J-113397 attenuated parkinsonian symptoms in MPTP-treated primates. Systemic 
administration of J-113397 (0.01 mg/kg, i.p.) and L-dopa (30 mg/kg, i.p.) affected the global PRS score. 
The average improvement over the baseline score (n= 2-3 pharmacological tests for each compound) is 
shown for each animal (A). The improvement after J-113397 administration was more moderate than that 
achieved with L-dopa (Fisher PLSD). Comparative analysis of the pharmacological effects of L-dopa and 
J-113397 on parkinsonian symptoms (B) showed that all symptoms improved more with L-dopa except 
for hypokinesia. All tests were performed at least 3 months after the last MPTP dose. 
 
Finally, we evaluated the performance of the parkinsonian animals in the MAP test (Fig 
27). MPTP induced a significant increase in the time needed to complete the platform 
task in 3 out of 4 animals (Mf23, Mf25 and Mf30). These animals showed a significant 
improvement in the time to retrieve treats from the platform with L-dopa and one of 
them had also a significant improvement in performance after J-113397. 
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Figure 27. J-113397 attenuated parkinsonian symptoms in MPTP-treated primates. Systemic 
administration of J-113397 (0.01 mg/kg, i.p.) affected motor performance on the MAP test. MPTP 
induced a significant increase in the time needed to complete the platform task (animals were unable to 
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perform the straight rod task) in 3 out of 4 animals (Mf23, Mf25 and Mf30). In these animals, L-dopa 
improvement on task performance was significant. Only one of them (Mf23) showed a significant 
improvement in response to J-113397. All tests were performed at least 3 months after the last MPTP 
dose. *p<0.05, different from post-MPTP performance; #p<0.05, different from J-113397 (ANOVA 
followed by PLSD test). 
 
 
Part IV. Deletion of the NOP receptor confers resistance to MPTP-induced toxicity 
 
 
NOP-/- mice are partially resistant to MPTP-induced motor deficits 
 
MPTP treatment caused greater fatalities in NOP+/+ (58%) than NOP-/- mice (11%) at 24 
hr after administration. Body weight of MPTP-treated mice did not change over time 
with respect to vehicle-injected mice. Treatment with saline did not change motor 
performance in both NOP-/- and NOP+/+ mice. 
 
Physiological motor activity in NOP+/+ and NOP-/- mice 
NOP-/- mice exhibited a different basal motor activity with respect to NOP+/+ mice (Tab. 
2). In particular, NOP-/- mice displayed greater number of steps, speed run, time on rod 
and horizontal locomotion, showing less fine movements. NOP-/- mice also displayed a 
faster preparation and iniziation time of movement and execution speed. Finally, NOP-/- 
displayed a greater average force than NOP+/+ mice. 
NOP+/+ NOP-/- 
 Immobility time (sec) 0.3±0.1 0.1±0.1 
 Number of steps 10.8±0.2 13.2±0.7 ** 
 Run speed (cm/sec) 48.4±2.4 63.7±4.5 ** 
Exercise-
driven 
activity 
 Time on rod (sec) 1517.8±54.6 1926.6±50.6 *** 
 Movement time (sec)  119.0±1.0 119.7±0.3 
 Horizontal locomotion time (sec) 48.9±2.5 111.9±6.6 *** 
 Fine movements time (sec) 71.1.1±2.5 8.1±6.6 *** 
Spontaneous 
activity 
 Freezing time (sec) 0.8±0.8 0.3±0.3 
 Preparation time (sec) 0.056±0.002 0.041±0.001 *** 
 Initiation time (sec) 0.266±0.032 0.121±0.006 *** 
 Air time (sec) 0.920±0.068 0.981±0.068 
 Execution speed (cm/sec) 0.478±0.030 0.579±0.019 * 
Step 
parameters 
 Step length (cm) 6.720±0.169 6.259±0.177 
 Maximal force (gf/cm) 123.0±10.1 130.2±5.5 Muscle 
strength  Average force (gf/cm) 20.2±1.5 28.2±1.5 ** 
 
Table 2. NOP-/- mice perform better than NOP+/+ mice. Basal motor activity was measured by analyzing 
spontaneous or exercise-driven motor activity, step parameters and muscle strength. Data are means ± 
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SEM of 10 determinations per group. *p<0.05, **p<0.01, ***p<0.001 different from NOP+/+ mice 
(Student’s t-test). 
 
Exercise-driven activity in MPTP-treated NOP+/+ and NOP-/- mice 
MPTP increased immobiliy time in both genotypes (Fig. 28A). However, NOP-/- mice 
displayed a lower impairment with respect to NOP+/+ mice, which was significant from 
D3 onward (D6: 6.4±1.4 vs 13.1±2.8 sec). MPTP reduced the number of steps (Fig. 
28B) in both genotypes at D1 and D2, although the effect was milder in NOP-/- mice. In 
the following days, motor impairment was significant only in NOP+/+ mice, Likewise, 
MPTP reduced the speed of run (Fig. 28C) in both genotypes from D1 through D3. 
However, while speed impairment was long lasting in NOP+/+ mice, NOP-/- mice were 
normal from D4 (D6: 95.6±7.5% vs 62.9±7.1%). Finally, MPTP decreased the rotarod 
performance (Fig. 28D) in both genotypes. Nevertheless, NOP-/- mice showed lesser 
impairment than NOP+/+ mice (95.6±7.5% vs 62.9±7.1%) at D1. 
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Figure 28. NOP-/- mice are more resistant than NOP+/+ mice to MPTP-induced hypokinesia. Systemic 
administration of MPTP (4x20 mg/Kg, i.p.) affected exercise-driven activity in the bar (A), drag (B), 
speed (C) and rotarod test (D). All tests were performed before (control session) and after (daily for 6 
days) MPTP-treatment. Data are means ± SEM of 10 determinations per group and were calculated as 
percentage of the control session. *p<0.05, **p<0.01 different from NOP+/+ mice; °p<0.05, °°p<0.01 
different from pre-MPTP values (day 0) (RM ANOVA followed by contrast analysis and the sequentially 
rejective Bonferrroni’s test). 
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Spontaneous activity in MPTP-treated NOP+/+ and NOP-/- mice 
MPTP reduced global movements (Fig. 29A) in both genotypes at 6 days after 
treatment. This reduction was greater in NOP+/+ than NOP-/- mice. MPTP also reduced 
horizontal movements to a greater extent in NOP+/+ mice (Fig. 29B) . This reduction 
was inversely correlated to an increase in fine movements. Hypolocomotion was also 
related to an increase in freezing episodes that were more frequent in NOP+/+ mice. 
0
20
40
60
80
100
120
NOP+/+
NOP-/-
A
day 6
***
° °°
° °°
day 0
M
ov
em
en
t t
im
e
(%
 o
f o
bs
er
va
tio
n 
w
in
do
w
)
0
20
40
60
80
100
120
NOP+/+
NOP-/-
B
day 6
Horizontal Fine Freezing Horizontal Fine Freezing
day 0
***
° °°
° °°
° °°
***
° °°
° °°***
**
*
°
M
ov
em
en
t t
im
e
(%
 o
f o
bs
er
va
tio
n 
w
in
do
w
)
Figure 29. NOP-/- mice are more resistant than NOP+/+ mice to MPTP-induced impairment of 
spontaneous activity. Systemic administration of MPTP (4x20 mg/Kg, i.p.) reduced total movements (A), 
horizontal locomotion and fine movements, and freezing time (B) All tests were performed before 
(control session) and 6 days after MPTP-treatment. Data are means ± SEM of 8 determinations per group 
and were calculated as percentage of pre-MPTP values. *p<0.05, **p<0.01, ***p<0.001 different from 
NOP+/+ mice; °p<0.05, °°°p<0.001 different from day 0 (RM ANOVA followed by contrast analysis and 
the sequentially rejective Bonferrroni’s test). 
 
Step parameters in MPTP-treated NOP+/+ and NOP-/- mice 
Analysis of various step parameters(Fig. 30), performed 6 days after treatment, showed 
that only NOP+/+ mice had an impairment in preparation and iniziation time, air time, 
execution time and step length. 
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Figure 30. NOP-/- mice are more resistant than NOP+/+ mice to MPTP-induced changes in step 
parameters. Systemic administration of MPTP (4x20 mg/Kg, i.p.) reduced preparation, iniziation and air 
time, execution speed and step length. Data were collected before (control session) and 6 days after 
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MPTP-treatment. Data are means ± SEM of 5-8 determinations per group and were calculated as 
percentage of the control session (pre-MPTP values). *p<0.05 different from NOP+/+ mice (Student’s t-
test). 
 
Muscle strength in MPTP-treated NOP+/+ and NOP-/- mice 
MPTP reduced the force peak and average force values (Fig. 31) at 6 days after 
treatment, both in NOP-/- and NOP+/+ mice. In this case, no difference was observed 
between genotypes. 
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Figure 31. NOP-/- mice are more resistant than NOP+/+ mice to MPTP-induced inhibition of muscle 
strength. Systemic administration of MPTP (4x20 mg/Kg, i.p.) reduced maximal and average force. The 
tests were performed before (control session) and 6 days after MPTP-treatment. Data are means ± SEM of 
5-8 determinations per group and were calculated as percentage of the control session (pre-MPTP values). 
 
 
NOP-/- mice are partially resistant to MPTP-induced neurodegeneration 
 
Under control conditions (saline treatment Fig. 32A-D) both NOP-/- and NOP+/+ mice 
showed similar numbers of TH-immunoreactive neurons in SNc (3973.03±426.29 vs 
3917.03±403.51). MPTP treatment caused a marked loss of the number of TH-
immunoreactive cells (Fig. 32E). However, the number of TH-immunoreactive cells 
surviving MPTP treatment was significantly higher in NOP-/- mice than NOP+/+ 
(2347.99±304.93 vs 1044.15±152.81). 
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Figure 32. NOP receptor deletion partially attenuated MPTP-induced loss of DA cells in SNc. 
Representative microphotographs of TH-positive neurons in SNc, 7 days after saline or MPTP treatment 
(80 mg/Kg) in NOP+/+ (A, C) and NOP-/- (B, D) mice. Stereological quantification of DA neurons (E). 
Data are means ± SEM of 5-10 determinations. **p<0.01, different from NOP+/+ mice; °°p<0.01, 
°°°p<0.001 different from saline (ANOVA followed by the Newman-Keuls test). 
 
 
Part V. N/OFQ modulates cortical output and motor activity in rats through nigral 
NOP receptors 
 
 
I.c.v. injections of NOP receptor ligands affect motor activity 
 
To investigate the role of central NOP receptors in modulation of motor activity, 
N/OFQ was injected i.c.v. (in LCV). UFP-101 was also administered to test the 
specificity of N/OFQ action and to investigate the role of endogenous N/OFQ. Saline 
injections did not affect motor activity. Indeed, immobility time, number of steps, speed 
and rotarod performance were similar in saline-injected (0.6 ± 0.2 sec, 13.2 ± 0.3, 67.4 
± 2.1 cm/sec and 1021 ± 27 sec, respectively) and control (0.8 ± 0.3 sec, 12.9 ± 0.8, 
68.6 ± 6.3 cm/sec and 1064 ± 18 sec, respectively) rats. Since i.c.v. injection of saline, 
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N/OFQ and UFP-101 did not induce forepaw motor asymmetry, results obtained at the 
contralateral and the ipsilateral forepaw in the bar and drag test were pooled together. 
 
N/OFQ 
N/OFQ 0.1 nmol evoked a modest and transient elevation of immobility time compared 
to saline (Fig. 33A) while 1 and 10 nmol N/OFQ evoked a more robust and prolonged 
response, detectable 60 min after injection. No change in immobility time was elicited 
by 0.01 nmol. N/OFQ evoked a biphasic response in the drag test (Fig. 33B), namely 
facilitation at 0.01 nmol and inhibition at higher doses (0.1-10 nmol). Both facilitation 
and inhibition were detected after 60 min. A biphasic response was showed also in the 
speed test (Fig. 33C), where N/OFQ improved speed at 0.01 nmol and inhibited it at 
higher doses (0.1-10 nmol). Both effects were long-lasting. Finally, N/OFQ improved 
rotarod performance (Fig. 33D) at 0.01 nmol and impaired it at higher doses. 
 
UFP-101 
UFP-101 caused prolonged reduction of immobility time (Fig. 33E) and elevation of 
number of steps (Fig. 33F), speed (Fig. 33G) and rotarod performance (Fig. 33H) at 10 
nmol. UFP-101 also improved rotarod performance at 1, although the effect was 
transient. 
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Figure 33. N/OFQ and UFP-101 modulated motor activity in naїve rats. I.c.v. injection of N/OFQ (0.01-
10 nmol) or UFP-101 (0.1-10 nmol) affected motor performance in the bar (A, E), drag (B, F), speed (C, 
G) and rotarod (D, H) test. All tests were performed before (control session) and after (10 and 60 min) 
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drug injection. Data are means ± SEM of 7-9 determinations per group. *p<0.05, **p<0.01 different from 
saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
Co-injection of N/OFQ and UFP-101 
To investigate the selectivity of N/OFQ action, co-injections of low and high N/OFQ 
and UFP-101 doses (1:10 ratio) were performed. LCV injection of N/OFQ or UFP-101 
did not induce turning behavior in the range of doses tested. We first tested the 
specificity of 0.01 nmol N/OFQ by challenging it with 0.1 nmol UFP-101 (Fig. 34). 
N/OFQ elevations of number of steps (Fig. 34A), speed (Fig. 34B) and rotarod 
performance (Fig. 34C) were prevented by UFP-101 which was ineffective alone. 
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Figure 34. Motor facilitation induced by i.c.v. N/OFQ in naїve rats is NOP receptor dependent. Low 
doses of N/OFQ (0.01 nmol) and UFP-101 (0.1 nmol) were co-injected in the lateral cerebral ventricle 
and motor performance was evaluated in the drag (A), speed (B) and rotarod (C) test. All tests were 
performed before (control session) and after (10 and 60 min) drug injection. In the drag and speed test 
data are expressed as absolute values (steps, and cm/sec, respectively) whereas in the rotarod test as 
percentage of the control session  Data are means ± SEM of 7 determinations per group. **p<0.01 
different from saline; §§p<0.01 different from N/OFQ (RM ANOVA followed by contrast analysis and the 
sequentially rejective Bonferrroni’s test). 
 
We then tested the specificity of high N/OFQ doses by challenging 1 nmol N/OFQ with 
10 nmol UFP-101 (Fig. 35). N/OFQ elevated immobility time (Fig. 35A) while UFP-
101, ineffective alone, prevented this effect. In the drag test (Fig. 35B), N/OFQ reduced 
the number of steps while UFP-101 increased it. The combination of the two was the 
sum of their effects, i.e. no change with respect to saline-treated animals. In the speed 
test (Fig. 35C), N/OFQ reduced, whereas UFP-101 increased speed. Again, combination 
of the two caused no change in speed when compared to saline-treated animals. Finally, 
N/OFQ reduced rotarod performance (Fig. 35D) and UFP-101 improved it. Co-
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application of N/OFQ and UFP-101 caused a slight increase in performance compared 
to saline-treated rats. 
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Figure 35. Motor inhibition induced by i.c.v. N/OFQ in naїve rats is NOP receptor dependent. High 
doses of N/OFQ (1 nmol) and UFP-101 (10 nmol) were co-injected in the lateral cerebral ventricle and 
motor performance evaluated in the bar (A), drag (B), speed (C) and rotarod (D) test. All tests were 
performed before (control session) and after (10 and 60 min) drug injection. In the bar, drag and speed 
test data are expressed as absolute values (sec, steps, and cm/sec, respectively) whereas in the rotarod test 
as percentage of the control session. Data are means ± SEM of 7 determinations per group. *p<0.05, 
**p<0.01 different from saline. §p<0.05, §§p<0.01 different from N/OFQ. #p<0.05, ##p<0.01 different from 
UFP-101 (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
 
M1 injections of NOP receptor ligands did not affect motor activity 
 
To investigate the localization of NOP receptors involved in motor actions elicited by 
i.c.v. N/OFQ and UFP-101, intracortical injections (layer V of M1) were first made. 
Saline, N/OFQ (0.01-10 nmol) or UFP-101 (10 nmol) failed to affect rat performance in 
the bar, drag, speed and rotarod test (Fig. 36A-C). 
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Figure 36. Intracortical injections of N/OFQ or UFP-101 did not affect motor activity. N/OFQ (0.01-10 
nmol) or UFP-101 (0.1-10 nmol) were injected in M1 and motor performance evaluated in the bar (A), 
drag (B), speed (C) and rotarod (D) test. Motor performance in the bar and drag test was evaluated 
separately at the paws ipsilateral and contralateral to the injection side. All tests were performed before 
(control session) and after (10 and 60 min) drug injection. In the bar, drag and speed test data are 
expressed as absolute values (sec, steps, and cm/sec, respectively) whereas in the rotarod test as 
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percentages of motor activity in the control session. Data are means ± SEM of 7 determinations per 
group. 
 
 
SNr injections of NOP receptor ligands affect motor activity 
 
Based on our previous finding that NOP receptors located in the SNr modulate rotarod 
performance in rats (Marti et al, 2004a) we investigated whether motor effects induced 
by i.c.v. N/OFQ and UFP-101 could be reproduced by SNr injections. Since injections 
were made unilaterally, motor activity was evaluated separately at the ipsilateral and 
contralateral paw. Saline did not affect motor parameters at the contralateral and 
ipsilateral forepaw compared to control rats. 
 
N/OFQ 
Analysis of the immobility time at the contralateral paw in the bar test (Fig. 37A-B) 
showed that N/OFQ increased the immobility time dose-dependently and in a prolonged 
way, being active yet at 0.1 nmol. Qualitatively similar data were obtained at the 
ipsilateral paw. In the drag test (Fig. 37C-D), N/OFQ elevated the number of steps at 
the contralateral paw at 0.01 nmol but reduced them in the 0.1-10 nmol range. 
Conversely, N/OFQ dose-dependently reduced the number of steps at the ipsilateral 
paw,, the threshold inhibitory dose being 1 nmol. N/OFQ biphasically modulated rat 
speed (Fig. 37E), low doses (0.01 nmol) being facilitatory and higher ones (0.1–10 
nmol) inhibitory. 
 
UFP-101 
Analysis of the immobility time did not reveal significant effects of UFP-101 at the 
contralateral and ipsilateral paws. UFP-101 (1 and 10 nmol) elevated the number of 
steps at the contralateral paw in the drag test (Fig. 37F-G) both at 10 and 60 min post 
injection time. Conversely, no changes were observed on stepping activity at the 
ipsilateral paw. Finally, UFP-101 (1 and 10 nmol) consistently elevated speed at 10 and 
60 min after injection. (Fig. 37H). 
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Figure 37. Intranigral injections of N/OFQ or UFP-101 modulated motor activity in naїve rats. N/OFQ 
(0.01-10 nmol) or UFP-101 (0.1-10 nmol) were injected in SNr and motor performance evaluated in the 
bar (A-B), drag (C-D, F-G) and speed (E-H) test. Motor performance in the bar and drag test was 
evaluated separately at the paws ipsilateral and contralateral to the injection side. All tests were 
performed before (control session) and after (10 and 60 min) drug injection. In the bar, drag and speed 
test data are expressed as absolute values (sec, steps, and cm/sec, respectively) whereas in the rotarod test 
as percentages of motor activity in the control session. Data are means ± SEM of 7 determinations per 
group.  *p<0.05 and **p<0.01 different from saline (RM ANOVA followed by contrast analysis and the 
sequentially rejective Bonferrroni’s test). 
 
Co-injection of N/OFQ and UFP-101 
To investigate the selectivity of N/OFQ action in SNr, co-injections of low and high 
N/OFQ and UFP-101 doses (1:10 ratio) were performed (Fig. 38). UFP-101 (0.1 nmol), 
ineffective alone, prevented the increase in the number of steps (Fig. 38A) and speed 
(Fig. 38B) induced by N/OFQ (0.01 nmol). Likewise, UFP-101 (10 nmol) ineffective 
alone, prevented the increase in immobility time induced by N/OFQ (1 nmol) both at 
the contralateral and ipsilateral (Fig. 38C) paw. In the drag test (Fig. 38D), N/OFQ 
reduced the number of steps made by the contralateral paw while UFP-101 increased it. 
The combination of the two did not result in significant changes compared to saline-
treated animals. At the ipsilateral paw, N/OFQ reduced the number of steps and UFP-
101, ineffective alone, prevented this effect. Finally, N/OFQ reduced speed (Fig. 38E), 
UFP-101 increased it and their combination resulted in a stimulation not different from 
that evoked by UFP-101 alone. 
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Figure 38. Motor changes induced by intranigral N/OFQ in naїve rats were NOP receptor dependent. 
N/OFQ and UFP-101 were co-injected at low (0.01 and 0.1 nmol, respectively; A-B) and high (1 and 10 
nmol, respectively; C-E) doses in SNr and motor performance evaluated in the drag (A, D), speed (B, E) 
and bar (C) test. Motor performance in the bar and drag test was evaluated separately at the paws 
ipsilateral and contralateral to the injection side. All tests were performed 10 min after drug injection. In 
the bar, drag and speed test data are expressed as absolute values (sec, steps, and cm/sec, respectively) 
and are means ± SEM of 7 determinations per group. *p<0.05, **p<0.01 different from saline. §§p<0.01 
different from N/OFQ (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferrroni’s test). 
 
 
Effects of NOP receptor ligands on M1 output 
 
Since NOP receptor stimulation or blockade affected motor activity, the hypothesis was 
tested that manipulation of central NOP receptors could change output from M1. 
 
I.c.v. injections of NOP receptor ligands 
Examination of M1 maps (examples are given in Fig. 39) revealed several changes in 
movement representation in the 10 nmol N/OFQ group (Fig. 39E). Contiguous 
unresponsive sites were consistently observed within M1 after i.c.v. injection of 10 
nmol N/OFQ. 
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Figure 39. Effect of i.c.v. injection of N/OFQ and UFP-101 on M1 output in naїve rats. Representative 
M1 maps of movements evoked at threshold current levels in the vibrissa and forelimb areas. A schematic 
of rat brain is represented (A), which shows vibrissa and forelimb areas (right) and reports a coordinate 
grid (left). The maps relative to control rats (B) and rats injected with saline (C), N/OFQ (0.01 nmol; D), 
N/OFQ (10 nmol; E) and UFP-101 (10 nmol; F) in the lateral cerebral ventricle are also shown. The 
microelectrode was sequentially introduced to a depth of 1500 µm. Interpenetration distances were 500 
µm. In these mapping schemes, frontal poles are at the bottom. Zero corresponds to bregma; numbers 
indicate rostral or caudal distance from the bregma or lateral distance from the mid-line. Movement 
evoked at one point is indicated by symbols and threshold range by the different grey scale. Absence of 
symbol (within or at the border of the maps) indicates that penetration was not performed due to presence 
of a large vessel. 
 
To quantitatively assess these changes, the percentage of both unresponsive and 
responsive sites (movement sites in the vibrissa and forelimb areas) was calculated 
within the total site population (Fig. 40A). Analysis revealed changes in movement 
representation after injection of NOP receptor ligands. N/OFQ 10 nmol doubled the 
percentage of unresponsive sites. This effect was associated with a significant decrease 
(~49 %) in movement sites in the vibrissa representation and no change in excitable 
sites in forelimb representation. NOP receptor ligands significantly affected movement 
thresholds (Fig. 40B). N/OFQ (10 nmol) increased threshold currents in both vibrissa 
and forelimb representations (~55% and ~47%, respectively) whereas both N/OFQ 
(0.01 nmol) and UFP-101 (10 nmol) reduced them (~17 and ~33 %), although only in 
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forelimb representation. The differences in excitability appeared in more detail by 
looking at the distribution of vibrissa and forelimb movement thresholds. N/OFQ (10 
nmol) caused a significant increase in the percentage of those sites where higher 
currents were necessary to evoke vibrissa (Fig. 40C) and forelimb (Fig. 40D) 
movements. Conversely, N/OFQ (0.01 nmol) and UFP-101 (10 nmol) did not change 
the distribution of thresholds in the vibrissa but caused a significant leftward shift of the 
distribution curve in the forelimb representation. In ~40 % of sites, currents lower than 
20 µA were usually necessary to evoke forelimb movement. 
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Figure 40. Effect of i.c.v. injection of N/OFQ and UFP-101 on M1 output in naїve rats. N/OFQ (0.01 and 
10 nmol) and UFP-101 (10 nmol) were injected in the lateral cerebral ventricle, and the percentage of 
unresponsive and excitable sites in the vibrissa and forelimb areas (A) or average thresholds currents 
required to evoke vibrissa and forelimb movements (B) were measured. Threshold current distribution is 
also shown (C-D). The percentage of other movements sites (neck, jaw, eye and hindlimb) are not shown 
because these movements were not extensively explored. Data are means ± SEM of 5 determinations per 
group. *p<0.05, **p<0.01 different from control (ANOVA followed by the Newman-Keuls test). 
 
Cortical injection of NOP receptor ligands 
To investigate whether NOP receptors located in M1 modulated local excitability, 
injections of NOP receptor ligands in the layer V of M1 were made (examples are given 
in Fig. 41). 
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Figure 41. Intracortical injections of N/OFQ and UFP-101 in naїve rats. Examples of cross-shaped grids 
showing injection and stimulation sites in control rats (B) or rats injected with saline (C), N/OFQ (0.01 
and 10 nmol; D, E), and UFP-101 (10 nmol; F) in M1. A schematic of rat brain showing vibrissa and 
forelimb areas (right) and reporting a coordinate grid (left) is also represented (A). For each stimulation 
site, a letter indicates the type of ICMS-evoked movement and the corresponding number the threshold 
current (in µA) required to evoke it. 
 
No significant changes were observed in all treated group compared to saline at each 
level away from the injection site (Fig. 42). 
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Figure 42. M1 injections of N/OFQ and UFP-101 had no effects on M1 output in naive rats. N/OFQ 
(0.01 and 10 nmol) and UFP-101 (10 nmol) were injected in the central M1 and the average thresholds 
currents required to evoke vibrissa and forelimb movements (A) were measured. Threshold current 
distribution of vibrissa (B) and forelimb (C) is also shown. The percentage of other movements sites 
(neck, jaw, eye and hindlimb) are not shown because these movements were not extensively explored. 
Data are means ± SEM of 5 determinations per group (ANOVA followed the Newman-Keuls test). 
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SNr injections of NOP receptor ligands 
Intranigral injections of NOP receptor ligands were performed to investigate whether 
NOP receptors located in SNr affected motor excitability (representative examples 
given in Fig. 43). 
 
Figure 43. Effect of intranigral injection of N/OFQ and UFP-101 on M1 output in naive rats. 
Representative M1 maps of movements evoked at threshold current levels in the vibrissa and forelimb 
areas. A schematic of rat brain showing vibrissa and forelimb areas (right) and reporting a coordinate grid 
(left) is represented (A). The maps relative to control rats (B) and rats injected with saline (C), N/OFQ 
(0.01 nmol; D), N/OFQ (10 nmol; E) and UFP-101 (10 nmol; F) in substantia nigra reticulata are also 
shown. The microelectrode was sequentially introduced to a depth of 1500 µm. Interpenetration distances 
were 500 µm. In these mapping schemes, frontal poles are at the bottom. Zero corresponds to bregma; 
numbers indicate rostral or caudal distance from the bregma or lateral distance from the mid-line. 
Movement evoked at one point is indicated by symbols and threshold range by the different grey scale. 
Absence of symbol (within or at the border of the maps) indicates that penetration was not performed due 
to presence of a large vessel. 
 
M1 maps derived in SNr revealed that NOP receptor ligands modulated the number of 
responsive and unresponsive sites (Fig. 44A). N/OFQ (10 nmol) was ineffective in the 
vibrissa area but increased (~121 %) the number of unresponsive sites and 
simultaneously reduced (~60 %) the number of excitable sites in the forelimb 
representation. NOP receptor ligands modulated threshold currents (Fig. 44B). N/OFQ 
(10 nmol) enhanced the mean threshold values in the vibrissa (~29 %) and forelimb 
(~58 %) areas. Moreover, UFP-101 (10 nmol) reduced (~44 %) threshold currents 
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selectively in the forelimb. A slight inhibition (~15 %) was also observed with 0.01 
nmol N/OFQ in the forelimb area which, however, did not reach the level of 
significance. Threshold distribution showed that N/OFQ 10 nmol shifted to the right the 
distribution in both vibrissa (Fig. 44C) and forelimb (Fig. 44D) evoked movements. 
Conversely, N/OFQ (0.01 nmol) and UFP-101 (10 nmol) caused a significant leftward 
shift in the threshold distribution in forelimb representation. 
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Figure 44. Effect of intranigral injection of N/OFQ and UFP-101 on M1 output in naive rats. N/OFQ 
(0.01 and 10 nmol) and UFP-101 (10 nmol) were injected in SNr, and the percentage of unresponsive and 
excitable sites in the vibrissa and forelimb areas (A) or the thresholds currents required to evoke vibrissa 
and forelimb movements (B) were measured. Threshold current distribution is also shown (C-D). The 
percentage of other movements sites (neck, jaw, eye and hindlimb) are not shown because these 
movements were not extensively explored. Data are means ± SEM of 5 determinations per group. 
*p<0.05, **p<0.01 significantly different from control (ANOVA followed by the Newman-Keuls test). 
 
 
Part VI. Cortical progressive changes in 6-OHDA-treated rats 
 
 
Time-course of the M1 reorganization in 6-OHDA-treated rats 
 
6-OHDA treatment induced progressive loss of DA terminals 
Unilateral 6-OHDA injection caused a marked loss of striatal DA terminals in the 
hemisphere ipsilateral to the lesion (Fig. 45A-C)., The denervation was significant in 
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the ventral but not dorsolateral striatum at 3 days after lesion. At later stages, both 
regions were almost totally denervated (Fig. 45D). 
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Figure 45. Unilateral 6-OHDA injection in rats destroyed TH-immunoreactive DA terminals in the 
ipsilateral striatum. Representative microphotographs of TH-immunoreactive fibers in the ipsilateral 
striatum before (A) and 3 (B) and 15 days (C) after 6-OHDA treatment. (E) Optical density of TH-
immunoreactive fibers in the striatum. Data are means ± SEM of 5 determinations per group and are 
expressed as ratio between optical density in the denervated (ipsilateral) and intact (contralateral) side. 
**p<0.01 different from control; °°p<0.01 different from dorsolateral striatum (RM ANOVA followed by 
contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
6-OHDA treatment affected motor activity 
6-OHDA caused a marked and bilateral increase of immobility time in bar test (Fig. 
46A), which was almost maximal already from 3 days after lesion. 6-OHDA caused a 
severe and prolonged decrease in stepping activity at the contralateral limb (Fig. 46B). 
The ipsilateral limb was quantitatively less affected, showing full recovery after 120 
days. Finally, 6-OHDA caused a prolonged decrease of number of swings which 
selectively affected the contralateral side (Fig. 46C). 
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Figure 46. 6-OHDA injection affected motor activity in rats. Motor activity was evaluated in the bar (A), 
drag (B) and elevated body swing (C) test. All tests were performed before as well as 3, 15, 30, 60 and 
120 days after lesion. No effect was observed after vehicle injection. Data are means ± SEM of 5 
determinations per group and are expressed as absolute values (sec, steps and swings, respectively). 
*p<0.05, **p<0.01 different from control; °p<0.05, °°p<0.01 different from the ipsilateral side (RM 
ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
6-OHDA treatment altered M1 excitability 
In parallel with behavioural testing, ICMS was performed in 6-OHDA-lesioned rats at 
different time points after lesion (3, 15, 30, 60 and 120 days). Examination of M1 maps 
(examples are given in Fig. 47) revealed several progressive changes in movement 
representation. An incresase of unresponsive sites were consistently observed within 
M1 after 6-OHDA injection. 
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Figure 47. 6-OHDA injection in rats affected M1 output. Representative bilateral M1 maps of 
movements evoked at threshold current levels relative to control (A) and vehicle-injected (B) rats as well 
as rats at 3 (C), 15 (D), 30 (E), 60 (F), 120 (G) days after unilateral 6-OHDA injection. The 
microelectrode was sequentially introduced to a depth of 1500 µm. Interpenetration distances were 500 
µm. In these mapping schemes, frontal poles are at the bottom. Zero corresponds to bregma; numbers 
indicate rostral or caudal distance from the bregma or lateral distance from the mid-line. Movement 
evoked at one point is indicated by symbols and movement type by the different grey scale. Absence of 
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symbol (within or at the border of the maps) indicates that penetration was not performed due to presence 
of a large vessel. 
 
6-OHDA rats exhibited a marked increase in total size of not excitable area in M1 (Fig. 
48A). The effect was maximal at 15 days for both the lesioned and unlesioned side and 
it was still evident, albeit attenuated, within the 30-120 days range. The size of 
unexcitable area was greater in the lesioned than unlesioned side in all groups of rats, 
although the difference reached significance only within the 3-15 days range. To 
quantitatively assess the difference in movement representation between control and 6-
OHDA rats, we compared the cortical areas where vibrissa and forelimb movement 
were represented at threshold current. Other cortical areas (e.g. those evoking eye and 
neck movements) were too small, so these values were not considered for quantitative 
analysis. 6-OHDA caused a bilateral transient decrease in the size of the vibrissa area 
(Fig. 48B) both at 3 and 15 days after treatment, although only at 15 days the size of 
vibrissa area in the lesioned side was significantly smaller than in the unlesioned side. 
For the forelimb area, analysis was performed separately for the caudal and rostral 
regions. 6-OHDA decreased the size of caudal forelimb area (Fig. 48C) selectively in 
the lesioned side from 15 days onward (at 30 days only a trend to inhibition was 
observed, though). MPTP treatment significantly decreased the size of rostral forelimb 
area in the lesioned side (Fig. 48D) from 15 days on. Surprisingly, in the unlesioned 
side, there was a strong and transient increase in the area size at 3 days. However, area 
size dropped below control values at 15 days and normalized at later times. 6-OHDA 
treatment caused an increase of threshold currents in both the ipsilateral and 
contralateral vibrissa area within the 3-15 days range (Fig. 48E). The increase was 
significantly greater in the lesioned than unlesioned side. The ipsilateral vibrissa area 
displayed a slight increase of threshold values also within the 60-120 days range. An 
increase of threshold currents in both ipsilateral and contralateral forelimb area (Fig. 
48F) was found from 15 days after 6-OHDA lesion. At this time-point, threshold values 
were strongly higher in the lesioned than unlesioned side. Conversely, at later points no 
difference was detected between hemispheres. No differences were also observed in the 
threshold current intensities required to elicit forelimb movements in caudal vs rostral 
forelimb area (data not shown). 
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Figure 48. 6-OHDA lesion in rats changed M1 excitability. 6-OHDA treatment affected the size (in mm) 
of not excitable (A), vibrissa (B), caudal (C) and rostral forelimb (D) areas as well as threshold currents 
(in µA) in vibrissa (E) and forelimb (F) areas. All measures were performed in control and vehicle-
injected rats as well as in rats at 3, 15, 30, 60 and 120 days after 6-OHDA lesion. No effect was observed 
after vehicle treatment. Data are means ± SEM of 5 determinations per group. *p<0.05, **p<0.01 
different from control; °p<0.05, °°p<0.01 significantly different from the ipsilateral side (RM ANOVA 
followed by contrast analysis and the sequentially rejective Bonferrroni’s test). 
 
6-OHDA treatment affected evoked movement 
To evaluate the status of the interhemispheric connections, the percentage of ipsilateral 
vs contralateral movements elicited by stimulation in the M1 of lesioned and unlesioned 
hemisperes was investigated. Under control conditions (i.e. before 6-OHDA lesion), 
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unilateral stimulation of M1 elicited movement only in the contralateral vibrissa. After 
lesion, however, the percentage of ipsilateral (mono or bilateral) movements increased 
to equal contralateral movements at days 30 and 60 (Fig. 49A). Stimulation in the 
unlesioned side resulted in a different pattern of changes. Indeed, the percentage of ipsi-
bilateral vibrissa movement significantly increased only at 30 days (Fig. 49B). For 
forelimb movement in the lesioned side, the percent of total forelimb area eliciting ipsi-
bilateral movement in all 6-OHDA rats was greater compared to control rats (Fig. 49C). 
This increase was significant only in the 30-day rat group, almost approaching 70% of 
the forelimb area value. For forelimb movements in the unlesioned side, the percentage 
of total forelimb area eliciting ipsi-bilateral and contralateral forelimb movements did 
not differ between 6-OHDA and control rats (Fig. 49D). Finally, we evaluated the 
changes in the typology and amplitude of forelimb movements, Under control 
conditions, unilateral M1stimulation elicited distal movements (~90%). In the lesioned 
side, distal movements in 6-OHDA rats were significantly less compared to control rats 
(Fig. 49E). Decrease in distal movements was greater in the 30-day group rats. In the 
unlesioned side, the percent of distal movements was smaller in 6-OHDA rats compared 
to control rats, though the decrease was significant only within the 3-30 days range (Fig. 
49F). 
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Figure 49. 6-OHDA treatment changed the type of evoked-movements in rats. In both the lesioned and 
unlesioned sides, 6-OHDA treatment affected the the percentage of ipsi-bilateral and contralateral vibrissa 
(A, B) and forelimb (C-D) movements as well as the percentage of distal and proximal forelimb 
movements. All measures were performed in control, vehicle-injected and 6-OHDA hemilesioned rats at 
3, 15, 30, 60 and 120 days after lesion. No effect was observed after vehicle treatment. Data are means ± 
SEM of 5 determinations per group. *p<0.05, **p<0.01 different from control; °p<0.05, °°p<0.01 
different from ipsilateral side (RM ANOVA followed by contrast analysis and the sequentially rejective 
Bonferrroni’s test). 
 
 
Biochemical mechanisms underlying M1 changes in 6-OHDA-treated rats 
 
Mechanisms underling the short- and long-term M1 changes (evaluated at 15 and 60 
days, respectively) were determined by means of three pharmacological treatments 
aimed at different targets: the local anesthetic lidocaine, to measure the effect of 
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interhemispheric (i.e. transcallosal) activity, the DA precursor L-dopa to restore the 
DAergic transmission, and the GABAA antagonist bicuculline to remove endogenous 
inhibitory activity of cortical circuits. Studies began 10 minutes after drug treatments. 
 
Lidocaine restored lateralization of movements 
To investigate if the increase of ipsi-bilateral forelimb movements in the lesioned side 
of 30-day rats was due to the activity in the unlesioned side (i.e. homotopic contralateral 
cortex), we injected lidocaine (3%) into the forelimb area of the unlesioned side (Fig. 
50A). Saline injections did not produce changes. In 6-OHDA rats, the percent of total 
map area eliciting ipsi-bilateral and contralateral vibrissa movement (Fig. 50B) did not 
differ between saline and lidocaine treatment. The percentage of total map area eliciting 
ipsi-bilateral and contralateral forelimb movements (Fig. 50C) did not differ between 
control and 6-OHDA rats treated with lidocaine. We conclude that lidocaine injections 
into the homotopic M1 of the unlesioned side normalized the ratio between contalateral 
and ipsi-bilateral forelimb movements in the forelimb area of the lesioned side. 
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Figure 50. Lidocaine restored the type of evoked-movements in 6-OHDA-treated rats. Representative 
bilateral M1 maps of movements evoked at threshold current levels after intracortical injection of 
lidocaine (3%) at 30 days after unilateral 6-OHDA treatment (A). The microelectrode was sequentially 
introduced to a depth of 1500 µm. Interpenetration distances were 500 µm. In these mapping schemes, 
frontal poles are at the bottom. Zero corresponds to bregma; numbers indicate rostral or caudal distance 
from the bregma or lateral distance from the mid-line. Movement evoked at one point is indicated by 
symbols and movement type by the different grey scale. Absence of symbol (within or at the border of the 
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maps) indicates that penetration was not performed due to presence of a large vessel. Lidocaine, injected 
in forelimb area of homotopic cortex (injected sites are marked with circles), restored output in the 
forelimb (C) but not vibrissa (B) area. *p<0.05, **p<0.01 different from control; ##p<0.01 different from 
contralateral movement (RM ANOVA followed by the Newman-Keuls test). 
 
L-dopa partially restored M1 output 
To investigate if the 6-OHDA-induced effects were due to DA loss, the ability of L-
dopa (6 mg/Kg; with benserazide 15 mg/Kg) to reverse 6-OHDA-induced effects on M1 
was investigated at 15 and 60 days after lesion. Vehicle administration had no effect in 
both control and 6-OHDA rats (data not shown). Treatment with L-dopa had no effect 
in control rats. Conversely,, L-dopa partially reversed 6-OHDA-induced effects on 
ipsilateral M1 at both 15 and 60 days (Fig. 51). 
 
Figure 51. L-dopa treatment affected M1 output in 6-OHDA-treated rats. Representative unilateral M1 
maps of movements evoked at threshold current levels after L-dopa injection (6 mg/Kg plus benserazide 
15 mg/Kg, i.p) in control rats (A) and 6-OHDA hemilesioned rats at 15 (B) and 60 (C) days after lesion. 
The microelectrode was sequentially introduced to a depth of 1500 µm. Interpenetration distances were 
500 µm. In these mapping schemes, frontal poles are at the bottom. Zero corresponds to bregma; numbers 
indicate rostral or caudal distance from the bregma or lateral distance from the mid-line. Movement 
evoked at one point is indicated by symbols and movement type by the different grey scale. Absence of 
symbol (within or at the border of maps) indicates that penetration was not performed due to presence of 
a large vessel. 
 
In particular, L-dopa attenuated the increase of not excitable area induced by 6-OHDA 
(Fig. 52A); the effect of L-dopa was stronger at 15 than 30 days though the size 
remained significantly higher compared to control in both groups. L-dopa restored the 
size of vibrissa area in the 15-days rat group (Fig. 52B). Consistently, L-dopa restored 
the size of the caudal forelimb movement representation at both 15 and 60 days (Fig. 
52C) although it failed to do so in the rostral forelimb area (Fig. 52D). L-dopa also 
normalized the number of both distal (Fig. 52E) and proximal (Fig. 52F) forelimb 
movements. Finally, L-dopa failed to restore the normal threshold current values in both 
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the vibrissa and forelimb areas(Fig. 52G) although it attenuated the increase in threshold 
current values in the vibrissa area at 15 days (Fig. 52H). 
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Figure 52. L-dopa treatment partially restored M1 output in 6-OHDA-treated rats. L-dopa (6 mg/Kg plus 
benserazide 15 mg/Kg, i.p.) affected the size (in mm) of not excitable area (A), vibrissa area (B), caudal 
(C) and rostral forelimb area (D) the percentage of distal (E) and proximal (F) forelimb movements and 
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the threshold current (in µA) of vibrissa (G) and forelimb area (H). All measures were performed on the 
cortex ipsilateral to the 6-OHDA injection in control, sham and 6-OHDA hemilesioned rats at 15 and 60 
days after lesion. No effect was observed after vehicle treatment. Data are means ± SEM of 5 
determinations per group. *p<0.05, **p<0.01 different from control; °p<0.05 and °°p<0.01 significantly 
different from vehicle (“without L-dopa”; RM ANOVA followed by contrast analysis and the 
sequentially rejective Bonferrroni’s test). 
 
Bicuculline partially restored M1 output 
To investigate if the 6-OHDA-induced changes in M1 output are due to an increased 
influence of inhibitory pathways, mediated by cortical GABAA receptor activation), the 
ability of bicuculline (50 µM) to attenuate cortical depression was investigated. 
Treatment with vehicle did not produce changes in both control and 6-OHDA treated 
rats (Fig. 53). 
 
Figure 53. Bicuculline treatment affected M1 output in 6-OHDA-treated rats. Representative unilateral 
motor cortex maps of movements evoked at threshold current levels after cortical application of 
bicuculline (50µM) in control (A) and 6-OHDA hemilesioned rats at 15 (B) and 60 (C) days after lesion. 
The microelectrode was sequentially introduced to a depth of 1500 µm. Interpenetration distances were 
500 µm. In these mapping schemes, frontal poles are at the bottom. Zero corresponds to bregma; numbers 
indicate rostral or caudal distance from the bregma or lateral distance from the mid-line. Movement 
evoked at one point is indicated by symbols and movement type by the different grey scale. Absence of 
symbol (within or at the border of the maps) indicates that penetration was not performed due to presence 
of a large vessel. 
 
Bicuculline decreased not excitable area in both control and 6-OHDA-treated rats (Fig. 
54A). Consistently, bicuculline increased the size of vibrissa area in control rats and 6-
OHDA lesioned rats (Fig. 54B). In these animals, the area size was normalized 
compared to control animals (without bicuculline). Analysis on caudal forelimb area 
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values (Fig. 54C) showed that bicuculline caused a marked decrease in control rats, 
without changing the effects of 6-OHDA. Conversely, bicuculline restores the size of 
rostral forelimb area both at 15 and 60 days after 6-OHDA (Fig. 54D). Bicuculline 
decreased the number of distal forelimb movements (Fig. 54E) and increased the 
number of proximal forelimb movements (Fig. 54F) in control rats, although it failed to 
modulate movements in 6-OHDA-treated rats. Finally, bicuculline produced a mild 
reduction of vibrissa (Fig. 54G) and forelimb (Fig. 54H) threshold currents in control 
rats, without changing them in 6-OHDA. It is worthy of mention, however, that 60 days 
after 6-OHDA lesion, threshold currents after bicuculline did not differ from pre-
bicuculline levels. 
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Figure 54. Bicuculline partially restored M1 output in 6-OHDA-treated rats. Cortical application of 
bicuculline (50 µM) affected the size (in mm) of not excitable area (A), vibrissa area (B), caudal (C) and 
rostral forelimb area (D), the percentage of distal (E) and proximal (F) forelimb movements and the 
threshold current (in µA) of vibrissa (G) and forelimb area (H). All measures were performed in the 
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cortex of control, sham and 6-OHDA hemilesioned rats (ipsilateral M1) at 15 and 60 days after lesion. No 
effect was observed after vehicle treatment. Data are means ± SEM of 5 determinations per group. 
*p<0.05, **p<0.01 from control; °p<0.05 and °°p<0.01 different from pre-bicuculline; #p<0.05 and 
##p<0.01 different from control pre-bicuculline (RM ANOVA followed by contrast analysis and the 
sequentially rejective Bonferrroni’s test). 
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General discussion 
 
 
Part I. Endogenous DA mediates motor responses of NOP receptor antagonists 
 
The role of endogenous DA in the modulation of motor activity has been largely 
investigated using DA selective antagonists, DA lesioning techniques and DA receptor 
knockout mice (Clark and White, 1997; Millan et al., 2004; Scatton et al., 1997; Vallone 
et al., 2000). In keeping with these studies, raclopride and amisulpride dose-dependently 
increased akinesia (bar test) and bradykinesia (drag test), and impaired overall gait 
abilities (rotarod test), likely through the blockade of striatal D2L (long isoform) 
postsynaptic receptors (Wang et al., 2000). D3 receptors appear to be minimally 
involved in tonic regulation of motor activity since S33084 alone did not produce 
marked changes in motor performance. Mimicking D2/D3 receptor antagonists, 
SCH23390 induced dose-dependent motor impairment (Clark and White, 1997). L-dopa 
and PPX caused monotonic motor inhibition. Hypomotility is mediated by central 
(domperidone-insensitive) DA receptors, possibly presynaptic D2S (short isoform) 
receptors, via reduced striatal DA release (Carter and Müller, 1991). Indeed, L-dopa and 
PPX-induced motor inhibition was counteracted by amisulpride supporting the role of 
D2 autoreceptors (Scatton et al., 1997). However, PPX effects appeared poorly sensitive 
to amisulpride. This may be due to the different levels of DA receptor occupancy 
required to induce the biological response and/or to the different spectrum of DA 
receptors activated by the two agonists. Additional mechanisms not involving classical 
D2 receptors may also be recruited by PPX to inhibit motor performance. Interestingly, 
although D3 receptors appear not to be tonically activated, they markedly contributed to 
motor responses to PPX and L-dopa. Indeed, S33084 worsened inhibition of stepping 
activity induced by both agonists in the drag test, suggesting that D3 receptors play a 
specific role in facilitation of movement initiation and execution. The worsening of 
PPX-induced motor inhibition observed in the presence of raclopride may also rely on 
the high affinity of this compound for the D3 receptor. Alternatively, the opposite 
modulation of the PPX response exerted by raclopride (enhancement) and amisulpride 
(attenuation) may be due to blockade of different D2 receptor subpopulations, namely 
post- and presynaptic. In fact, amisulpride given systemically was reported to inhibit D2 
autoreceptors at low doses and block postsynaptic D2 receptors, thereby causing 
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akinesia and catalepsy, at higher ones (Scatton et al., 1997). UFP-101 microinjections in 
SNr or systemic administrations of J-113397 and Trap-101 in mice facilitated motor 
activity at low doses and inhibited it at higher ones. Motor facilitation induced by NOP 
receptor antagonists was raclopride-sensitive but amisulpride-insensitive, suggesting 
that NOP receptor blockade can ultimately lead to postsynaptic D2L receptor activation. 
Motor facilitation induced by low N/OFQ doses was also raclopride-sensitive. This 
extends previous findings that N/OFQ-induced facilitation was prevented by haloperidol 
(Florin et al., 1996) or by lesioning the DA system (Kuzmin et al., 2004), further 
suggesting that low doses of N/OFQ and NOP antagonists activate common pathways. 
Contrary to facilitation, motor inhibition induced by NOP antagonists was amisulpride-
sensitive and raclopride-insensitive, suggesting that high doses of NOP receptor 
antagonists cause excessive DA release leading to stimulation of negative feedback 
mechanisms via D2 autoreceptors. Indeed, motor inhibition was reversed into 
facilitation in the presence of amisulpride. D1/D5 and D3 receptors do not contribute to 
motor responses to NOP receptor ligands. An important finding of the release studies, is 
that D1/D5 receptors mediate presynaptic facilitatory actions of L-dopa on DA release 
occurring prior to its conversion to DA. This finding may be clinically relevant as D1/D5 
receptor stimulation underlie L-dopa-induced dyskinesia during PD therapy (Obeso et 
al., 2000). 
For a more detailed discussion, see original paper VI reported in appendix II. 
 
 
Part II. NOP receptor blockade attenuates parkinsonism in mice 
 
The use of a broad range of motor tasks allowed for the collection of information on 
different motor parameters in MPTP-treated mice such as the time required to initiate 
(akinesia) and execute (bradykinesia) a movement, muscle strength, gait patterns and 
coordinated motor performance in freely moving or exercise-driven conditions. These 
tests showed that the MPTP-induced bilateral partial (~60%) lesions of striatal DA 
terminals was associated with an increase of immobility and reaction time, a reduction 
of stepping activity, climbing speed, time on rod and muscle strength, as well as gait 
abnormalities such as reduced stride length and increased stride width. Motor deficits 
were maximal the day following MPTP administration and subsided 3-4 days afterward, 
being still detectable a week later. The evidence of a parkinsonian-like phenotype at 7 
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days after intoxication was further confirmed by positive response to DA agonists. L-
dopa (1-10 mg/Kg) attenuated MPTP-induced motor impairment in the bar, drag and 
rotarod tests. Motor testing however disclosed a paradoxical effects of L-dopa, high 
doses causing exacerbation of parkinsonism. Reports that L-dopa can exacerbate 
symptoms in patients have been published (Wiener et al., 1978; Jenkins and Pearce, 
1992; Merello and Lees, 1992; Cicarelli et al., 2002), but this is the first evidence for a 
dual motor response to L-dopa in a model of parkinsonism. PPX exerted symptomatic 
antiparkinsonian effects in MPTP-treated mice by promoting stepping in the drag test. 
This effect was observed at very low doses but vanished at higher ones. In fact, overt 
motor inhibition in the bar and rotarod tests emerged at this dose. As for L-dopa, this 
dual response has not been previously reported for PPX. J-113397 and Trap-101 
attenuated parkinsonism in MPTP-treated mice. In addition, Trap-101 synergistically or 
additively (depending on test) attenuated MPTP-induced akinesia/bradykinesia when 
combined with L-dopa and PPX. Both antiparkinsonian and pro-akinetic actions of 
NOP receptor antagonists appeared at much lower doses than those effective in 
promoting movement naïve mice. This leftward shift of the dose-response curve may be 
related to up-regulation of N/OFQ transmission following DA depletion (Marti et al., 
2005; Di Benedetto et al., 2009). A possible explanation of the dual motor responses of 
tested drugs calls for a different contribution of D2 pre- and postsynaptic receptors. The 
main result of the present study suggests that low doses of a D2/D3 receptor antagonist, 
possibly acting on D2 (auto)receptors, can reverse it. Indeed, under parkinsonian 
conditions, DA deafferentation causes compensatory supersensitvity in striatal 
postsynaptic D2 receptors, which allows DA agonists to promote movement (Seeman, 
2007) outweighing the negative contribution of D2 autoreceptors. This possibility may 
be further underpinned by experiments with amisulpride that inhibit D2 autoreceptors at 
low doses and block postsynaptic D2 receptors at higher ones (Scatton et al., 1997; 
Perrault et al., 1997; Schoemaker et al., 1997). High L-dopa doses not only activate D2 
postsynaptic receptors but also D2 autoreceptors, leading to a reduction of 
neurosecretion and firing activity at DA pathways. In this context, reversal of L-dopa 
motor inhibition into facilitation (bar test) by amisulpride may be explained on the basis 
of a removal of D2 autoreceptor inhibition leading to disclosure of a D2 postsynaptic 
facilitation. D3 receptors have been shown to inhibit locomotion (Sautel et al., 1995; 
Pritchard et al., 2007; Mela et al., 2010). The failure of amisulpride in preventing PPX-
induced hypolocomotion remains puzzling. One possible reason could be a suboptimal 
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antagonist/agonist dose ratio, in view of the poor brain penetrability of amisulpride 
(Assiè et al., 2006) and the different mechanisms of action of L-dopa and PPX. A major 
concern regarding possible clinical use of NOP receptor antagonists was that high doses 
of these compounds caused motor inhibition in MPTP-treated mice. As for L-dopa, 
amisulpride reversed the pro-akinetic effect of J-113397 and prevented its inhibition of 
rotarod performance. In addition, it disclosed a J-113397-mediated facilitation in the 
drag test. This suggests that motor inhibition induced by NOP receptor antagonists is 
mediated by endogenous DA. 
For a more detailed discussion, see original paper V reported in appendix II. 
 
 
Part III. NOP receptor blockade attenuates parkinsonism in nonhuman primates 
 
The most important finding of the present study is that the NOP receptor antagonist J-
113397 reversed motor disabilities in MPTP-treated nonhuman primates. In line with a 
previous study (Ko et al, 2006), J-113397 did not exert motor effects in naïve macaques 
up to 1 mg/Kg. However, higher doses (3 mg/Kg) improved arm speed (straight rod 
test) in two animals while the remaining two could not perform the test, looking 
distracted and slightly “hallucinated”. Although the inconsistency of response prevents 
from drawing firm conclusions on the role of endogenous N/OFQ, the data obtained in 
two animals are in line with the view that the peptide plays an inhibitory role on motor 
activity. Nevertheless, high doses of J-113397 may also activate sigma receptors (Chiou 
et al., 2007), causing loss of attention and hallucinations (Okuyama et al., 1994). The 
MPTP-lesioned nonhuman primate (macaque) model reproduces many PD motor 
symptoms faithfully and is used to assess the therapeutic potential of novel 
antiparkinsonian drugs (Dauer and Przedborski, 2003). J-113397 was effective, not only 
in the rodents models of PD, but also in the parkinsonian macaques, overall suggesting 
that endogenous N/OFQ plays a role in experimental parkinsonism independent of the 
species and models used. Interestingly, not only did DA loss not prevent the 
antiparkinsonian action of J-113397 but it also enhanced sensitivity to J-113397, 
resulting in a leftward shift of the dose-response curve. In parkinsonian macaques, J-
113397 was less effective than L-dopa, although it improved hypokinesia comparably to 
L-dopa, indicating a general depressive effect of endogenous N/OFQ on movement. 
From a clinical perspective, however, the narrow therapeutic range is quite 
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disappointing, as the antiparkinsonian effects of 0.01 mg/Kg J-113397 vanished at 
higher doses, turning into motor inhibition at 1 mg/Kg. It can be proposed that the 
antiparkinsonian action of J-113397 is mediated by blockade of inhibitory NOP 
receptors expressed on residual nigral DA cells resulting in increased DA transmission. 
However, NOP receptor antagonists are effective also under conditions of DA depletion 
and DA receptor blockade (Marti et al., 2004b; Marti et al., 2005) suggesting that 
endogenous N/OFQ causes motor depressant responses also via non-DA mechanisms. 
our data reinforce the view that endogenous N/OFQ plays a role in motor symptoms in 
parkinsonism across species. Moreover, the efficacy of J-113397 in some MPTP-treated 
primates raises the possibility of a therapeutic effect of NOP receptor antagonists in PD 
patients, although the dual action of J-113397 in parkinsonian primates needs to be 
further characterized (i.e. presynaptic D2 blockade). 
For a more detailed discussion, see original paper II reported in appendix II. 
 
 
Part IV. NOP receptor deletion protects against MPTP-induced toxicity. 
 
NOP-/- mice had a different motor phenotype than NOP+/+ mice. Indeed, at variance with 
previous studies (Nishi et al., 1997; Murphy et al., 2002; Gavioli et al., 2003; Koizumi 
et al., 2004), we found that NOP-/- mice had greater exploratory activity, involving 
movement of the limbs, head and other body muscles. Moreover, NOP-/- mice displayed 
an increased speed of movement execution and muscle strength. Therefore, NOP 
receptors tonically activated by endogenous N/OFQ appear to inhibit both spontaneous 
and exercise-driven motor activity. Endogenous N/OFQ also contributes to symptoms 
associated with experimental parkinsonism. In fact deletion of the NOP receptor 
attenuates the MPTP-induced motor impairment. This protective effect was observed in 
a dynamic context (exercise-driven motor activity) as well as by analyzing spontaneous 
activity and steps parameters. In these last years, we collected compelling 
pharmacological (Marti et al., 2004, 2005, 2007, 2008; Viaro et al., 2008, 2010; 
Mabrouk et al. 2010) and genetic (Marti et al., 2005; Mabrouk et al., 2010) evidence 
that N/OFQ sustains motor deficit associated with experimental parkinsonism. The role 
of N/OFQ in parkinsonism, however, may go beyond phenotype modulation. Mice with 
deletion of the N/OFQ precursor (ppN/OFQ) were found to be partially resistant to 
MPTP toxicity as shown by less severe loss of nigral DA cells and striatal DA terminals 
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observed following MPTP in comparison with wild-type controls (Marti et al.,. 2005; 
Brown et al., 2006). However, different peptides (i.e. N/OFQ, N/OFQ II and nocistatin) 
are generated by cleavage of the ppN/OFQ precursor (Okuda-Ashitaka and Ito, 2000). 
These peptides do not bind to the NOP receptor but exert biological activity (Reinscheid 
et al., 2000), questioning the view that endogenous N/OFQ is the culprit for MPTP-
induced neurotoxicity. The stereological cell counting technique has unequivocally 
demonstrated that endogenous N/OFQ contributes to MPTP toxicity because the 
deletion of the NOP receptor conferred (partial) resistance to MPTP-induced cells loss. 
This finding suggests that N/OFQ is involved in the MPTP-induced neurodegeneration, 
possibly playing a pathogenic role in PD. Therefore, NOP receptor antagonists may be 
used not only in the symptomatic but also in the neuroprotective treatment of PD. 
 
 
Part V. Nigral NOP receptors modulate M1 excitability and motor activity 
 
Exogenous N/OFQ produced a dose-dependent, biphasic regulation of motor 
performance in rats. Inhibition was predominant since it was quantitatively larger and 
detected in a wider dose-range than facilitation. Conversely, UFP-101 monotonically 
facilitated motor activity suggesting an inhibitory role for endogenous N/OFQ in motor 
control. NOP receptor ligands produced changes in M1 output which were consistent 
with their motor effects. ICMS in layer V of M1 elicits movement via direct stimulation 
of corticofugal and/or intracortical neurons (Jankowska et al, 1975), resulting in 
summation of excitatory synaptic potentials in motoneurons and muscle activity. Thus, 
exogenous N/OFQ biphasically regulated motor cortex excitability, low doses being 
facilitatory and higher ones inhibitory. Conversely, UFP-101 increased motor cortex 
excitability (in the forelimb area), suggesting that endogenous N/OFQ tonically inhibits 
forelimb movement. Both behavioral and electrophysiological effects were evoked by 
i.c.v. and intranigral, but not intracortical, drug injections, overall suggesting that 
subcortical NOP receptors regulate motor behavior and motor cortex output via 
modulation of cortical afferents. Indeed, neither motor output nor behavior was affected 
by M1 injections of NOP receptor ligands. This indicates that cortical NOP receptors 
were not involved in local modulation of cortico-fugal neurons and motor activity. 
Motor impairment has been consistently reported as one of the main biological effects 
induced by central NOP receptor stimulation in rodents (Nishi et al., 1997; Noda et al., 
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1998; Higgins et al., 2001). This study reveals that motor inhibition is associated with a 
reduction in cortical activity. Inhibition of locomotion was not the only effect induced 
by central NOP receptor stimulation since very low doses of N/OFQ (0.01 nmol) 
produced mild but significant facilitation. This facilitation was previously related to the 
well-known anxiolytic effect of NOP receptor agonists (Jenck et al, 1997). However, 
the present study points out that the 0.01 nmol N/OFQ-induced facilitation is a specific 
motor effect. Indeed, i.c.v. N/OFQ enhanced not only motor performance, but also M1 
excitability. Moreover, both facilitation in motor performance and increase in M1 
excitability was replicated by stimulation of NOP receptors in the SNr, suggesting 
activation of motor pathways. Despite the fact that exogenous N/OFQ evoked both 
motor facilitation and inhibition, the latter effect appeared predominant. This is in line 
with the finding that endogenous N/OFQ physiologically inhibits movement. Indeed, 
UFP-101, given i.c.v. or injected in SNr, facilitated motor performance and increased 
M1 excitability. Therefore, the present study suggests that changes in cortical output 
and behavior are mainly operated by subcortical NOP receptors located in SNr, possibly 
through modulation of the “cortico-basal ganglia-thalamo-cortical” loop. 
For a more detailed discussion, see original paper IV reported in appendix II. 
 
 
Part VI. Cortical progressive changes in parkinsonian conditions 
 
In recent years, many works have attempted to investigate the relationship between the 
activity of motor cortex and the progression of PD, although the results have been 
controversial. The purpose of the present study was to investigate the time-course of 
changes in the motor cortex following DA depletion induced by unilateral MFB 6-
OHDA injection. Knowledge of the rate of M1 changes, particularly during the early 
phases, is essential for the understanding of the neurobiological mechanisms as well as 
for the design of experimental trials to evaluate potential treatment strategies. 
Histological evaluation showed that, beginning 15 days after 6-OHDA lesion, DA loss 
was complete and stable. Detection of behavioral impairment in hemiparkinsonian rats 
revealed an important and bilateral akinesia at rest (bar test). Forelimb, trunk and neck 
were impaired prevalently at the contralateral side (drag and elevated body swings test). 
To study the short and long term motor cortex reorganization in hemiparkinsonian rats 
we performed bilateral mapping of M1. ICMS-derived maps of movement 
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representation in M1 are essentially static and reflect the strength of corticospinal 
connections. In hemiparkinsonian rats, global cortical excitability was decreased after 6-
OHDA lesioning. M1 changes were evident in both the ipsilateral and contralateral 
hemispheres. M1 reorganization was time-dependent but not in a linear fashion.  We 
found an initial progressive depression (3-15 days) followed by a compensation with a 
transient increase of excitability (30 days) and a stabilization phase (60-120 days). 
Moreover, 6-OHDA treatment increased the number of proximal limb movements, 
demonstrating that M1 loses the ability to evoke fine movements (paw, finger). Several 
mechanisms may account for the reduction in excitability and movement representations 
in the motor cortex. First, an altered pattern of neuronal discharge in the basal ganglia 
may led to abnormalities in M1 preventing the facilitation of cortical excitability 
required to induce ICMS-evoked movements. Since lidocaine normalized the ratio 
between contralateral and ipsi-bilateral forelimb movements in the lesioned side, we can 
conclude that the increase of ipsi-bilateral forelimb movements in the lesioned side is 
due to a transcallosal activity. This aspect underpinned the importance of the 
compensatory role of the homotopic contralateral cortex (Maggiolini et al., 2008). In 
humans, interhemispheric connections are thought to play a crucial role in motor control 
by ensuring a spatially and temporally coordinated recruitment of a set of muscles 
(Devanne et al, 2006). Under parkinsonian conditions the role of interhemispheric 
connections may thus be altered. Response to L-dopa revealed that cortical changes 
induced by 6-OHDA lesioning were, at least partially, generated by DA deficiency. 
Indeed, systemic L-dopa totally restored the size in the vibrissa and caudal forelimb 
area, but was ineffective in promoting similar changes at the rostral forelimb area. 
Previous studies (Marti et al., 2005, 2007) demonstrated that 6 mg/Kg L-dopa was 
effective in increasing the motor performance in 6-OHDA-treated rats. Consistently, a 
recent study revealed a modulatory role for DA upon the rostral forelimb region 
excitability (Hosp et al., 2009). Pyramidal neurons of the motor areas are considered to 
be under the control of thalamo-cortical afferents (Kuramoto et al., 2009). After DA 
depletion, a loss of the normal thalamic modulation on pyramidal cells is observed due 
to an increase in nigro-thalamic GABAergic pathway discharge. This may the 
probability of pyramidal cells to reach ICMS-induced activity. In the present model of 
PD, 6-OHDA injection may also affect DA tegmental neurons causing a reduction of 
the facilitatory action of DA on M1 pyramidal neurons. Indeed, the motor cortex 
receives DA projections arising from the ventral tegmental region (i.e. the mesocortical 
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pathway; Seamans and Yang, 2004). Finally, experiments with bicuculline showed that 
M1 changes are also due to an increase in intracortical GABAergic inhibition. In fact,  
intracortical application of bicuculline at a subconvulsive concentration ensuring full 
GABA receptor blockade (Stojic et al., 2008), increased the number of excitable sites in 
the rostral forelimb area, a region were L-dopa was ineffective. In normal conditions, 
endogenous cortical GABA is critically placed to maintain the form of motor 
representations (Benali et al., 2008). In 6-OHDA rats, endogenous GABAergic 
transmission in this area gets stronger than in other regions of M1 and this cortical 
GABAergic influence may account for dysruptions of cortical activity. Overall, this 
study provides evidence that dynamic remodelling of movement representation occurs 
in the motor cortex of hemi-parkinsonian rats. For the first time, ICMS technique could 
be proved useful to predict the effectiveness of classical and potential antiparkinsonian 
therapeutics. 
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Appendix I. Statistical analysis 
 
 
Tab. 1 
Analysis not required. 
 
Tab. 2 
Stimulated activity (immobility time, p=0.07; number of steps, p=0.0012; run speed, 
p=0.0080, time on rod, p<0.0001). 
Spontaneous activity (movement time, p=0.44; horizontal locomotion time, p<0.0001; 
fine movements time, p<0.0001; freezing time, p=0.44). 
Step parameters (preparation time; p<0.0001; iniziation time, p=0.0002; air time, 
p=0.56; execution speed p=0.0121; step length, p=0.11). 
Muscular activity (maximal force, p=0.55; average force, p=0.0044). 
 
Fig. 1 
A) Effect of treatment (F4,20=23.95, p<0.0001), time (F1,4=0.16, p=0.68) and time x 
treatment interaction (F4,25=0.13, p=0.97). 
B) Effect of treatment (F4,20=31.97, p<0.0001), time (F1,4=16.33, p=0.0004) and time x 
treatment interaction (F4,25=12.88, p<0.0001). 
C) Effect of treatment (F4,20=11.62, p<0.0001) time (F1,4=20.64, p=0.0001) and time x 
treatment interaction (F4,25=17.15, p<0.0001). 
 
Fig. 2 
A) Effects of treatment (F4,20=0.79, p=0.54), time (F1,4=0.23, p=0.63) and time x 
treatment interaction (F4,25=0.26, p=0.89). 
B) Effect of treatment (F4,20=12.27, p<0.0001), time (F1,4=0.51, p=0.48) and time x 
treatment interaction (F4,25=4.81, p=0.0051). 
C) Effect of treatment (F4,20=11.39, p<0.0001), time (F1,4=0.15, p=0.70) and time x 
treatment interaction (F4,25=1.44, p=0.25). 
D) Effect of treatment (F5,25=2918.82, p<0.0001), time (F1,5=4.03, p=0.05) and time x 
treatment interaction (F5,30=3.45, p=0.0139). 
E) Effect of treatment (F5,25=68.00, p<0.0001), time (F1,5=0.22, p=0.63) and time x 
treatment interaction (F5,30=7.15, p=0.0002). 
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F) Effect of treatment (F5,25=182.58, p<0.0001), time (F1,5=1.57, p=0.22) and time x 
treatment interaction (F5,30=3.67, p=0.0103). 
 
Fig. 3 
A) Effect of treatment (F3,15=42.92, p<0.0001), time (F1,3=1.19, p=0.29) and time x 
treatment interaction (F3,20=0.49, p=0.70). 
B) Effect of treatment (F3,15=28.19, p<0.0001), time (F1,3=0.83, p=0.37) and time x 
treatment interaction (F3,20=0.12, p=0.95). 
C) Effect of treatment (F3,15=14.53, p=0.0001), time (F1,3=1.10, p=0.31) and time x 
treatment interaction (F3,20=0.91, p=0.45). 
D) Effect of treatment (F3,15=17.26, p<0.0001), time (F1,3=12.43, p=0.0021) and time x 
treatment interaction (F3,20=8.83, p=0.0006). 
E) Effect of treatment (F3,15=2.66, p=0.06), time (F1,3=1.40, p=0.25) and time x 
treatment interaction (F3,20=0.43, p=0.74). 
F) Effect of treatment (F3,15=11.83, p=0.0003), time (F1,3=3.94, p=0.06) and time x 
treatment interaction (F3,20=2.95, p=0.06). 
 
Fig. 4 
A) Effect of treatment (F3,15=29.84, p<0.0001), time (F1,3=12.28, p=0.0022) and time x 
treatment interaction (F3,20=13.08, p=0.0001). 
B) Effect of treatment (F3,15=14.15, p=0.0001), time (F1,3=15.56, p=0.0008) and time x 
treatment interaction (F3,20=6.21, p=0.0037). 
C) Effect of treatment (F3,15=6.68, p=0.0044), time (F1,3=9.59, p=0.0057) and time x 
treatment interaction (F3,20=8.96, p=0.0006). 
D) Effect of treatment (F3,15=0.08, p=0.97), time (F1,3=0.02, p0.89) and time x treatment 
interaction (F3,20=0.09, p=0.96). 
E) Effect of treatment (F3,15=3.99, p=0.0283), time (F1,3=0.59, p=0.45) and time x 
treatment interaction (F3,20=9.36, p=0.0005). 
F) Effect of treatment (F3,15=0.22, p=0.87), time (F1,3=0.05, p=0.83) and time x 
treatment interaction (F3,20=0.69, p=0.57). 
 
Fig. 5 
A) Effect of treatment (F7,35=1.32, p=0.27), time (F1,7=0.01, p=1.00) and time x 
treatment interaction (F7,40=0.54, p=0.80). 
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B) Effect of treatment (F7,35=26.79, p<0.0001), time (F1,7=13.89, p=0.0006) and time x 
treatment interaction (F7,40=12.61, p<0.0001). 
C) Effect of treatment (F7,35=34.90, p<0.0001), time (F1,7=2.97, p=0.09) and time x 
treatment interaction (F7,40=2.62, p=0.0252). 
D) Effect of treatment (F7,35=0.90, p=0.52), time (F1,7=1.27, p=0.27) and time x 
treatment interaction (F7,40=0.45, p=0.87). 
E) Effect of treatment (F7,35=12.42, p<0.0001), time (F1,7=91.79, p<0.0001) and time x 
treatment interaction (F7,40=11.75, p<0.0001). 
F) Effect of treatment (F7,35=5.65, p=0.0002), time (F1,7=59.43, p<0.0001) and time x 
treatment interaction (F7,40=6.07, p=0.0001). 
 
Fig. 6 
A) Effect of treatment (F7,35=514.87, p<0.0001), time (F1,7=12.34, p=0.0011) and time x 
treatment interaction (F7,40=9.39, p<0.0001). 
B) Effect of treatment (F7,35=42.86, p<0.0001), time (F1,7=13.50, p=0.0007) and time x 
treatment interaction (F7,40=3.12, p=0.0101). 
C) Effect of treatment (F7,35=34.92, p<0.0001), time (F1,7=6.05, p=0.0183) and time x 
treatment interaction (F7,40=8.26, p<0.0001). 
D) Effect of treatment (F3,15=34.80, p<0.0001), time (F1,3=1.20, p=0.29) and time x 
treatment interaction (F3,20=1.52, p=0.24). 
E) Effect of treatment (F3,15=57.83, p<0.0001), time (F1,3=23.35, p=0.0001) and time x 
treatment interaction (F3,20=9.37, p=0.0005). 
F) Effect of treatment (F3,15=4.59, p=0.0180), time (F1,3=30.16, p<0.0001) and time x 
treatment interaction (F3,20=9.10, p=0.0005). 
 
Fig. 7 
A) Effect of treatment (F4,20=490.48, p<0.0001), time (F1,4=13.44, p=0.0012) and time x 
treatment interaction (F4,25=4.57, p=0.0066). 
B) Effect of treatment (F4,20=220.49, p<0.0001), time (F1,4=1.71, p=0.20) and time x 
treatment interaction (F4,25=3.34, p=0.0253). 
C) Effect of treatment (F4,20=170.50, p<0.0001), time (F1,4=7.66, p=0.0105) and time x 
treatment interaction (F4,25=0.36, p=0.83). 
D) Effect of treatment (F3,15=0.41, p=0.75), time (F1,3=0.16, p=0.70) and time x 
treatment interaction (F3,20=0.34, p=0.80). 
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E) Effect of treatment (F3,15=57.83, p<0.0001), time (F1,3=2.51, p=0.13) and time x 
treatment interaction (F3,20=1.44, p=0.26). 
F) Effect of treatment (F3,15=18.92, p<0.0001), time (F1,3=0.77, p=0.39) and time x 
treatment interaction (F3,20=0.36, p=0.78). 
 
Fig. 8 
See original paper II reported on appendix II. 
 
Fig. 9 
A) Effect of treatment (F4,20=2194.47, p<0.0001), time (F1,4=4.82, p=0.0376) and time x 
treatment interaction (F4,25=2.27, p=0.09). 
B) Effect of treatment (F4,20=200.43, p<0.0001), time (F1,4=1.42, p=0.24) and time x 
treatment interaction (F4,25=1.67, p=0.19). 
C) Effect of treatment (F4,20=393.10, p<0.0001), time (F1,4=5.88, p=0.0229) and time x 
treatment interaction (F4,25=1.92, p=0.14). 
 
Fig. 10 
A) Effect of treatment (F3,15=28.28, p<0.0001), time (F1,3=2.80, p=0.11) and time x 
treatment interaction (F3,20=2.07, p=0.14). 
B) Effect of treatment (F3,15=32.23, p<0.0001), time (F1,3=0.85, p=0.37) and time x 
treatment interaction (F3,20=1.08, p=0.38). 
C) Effect of treatment (F3,15=36.80, p<0.0001), time (F1,3=0.65, p=0.43) and time x 
treatment interaction (F3,20=0.45, p=0.72). 
D) Effect of treatment (F5,25=11.59, p<0.0001), time (F1,5=1.47, p=0.26) and time x 
treatment interaction (F5,30=4.84, p=0.0023). 
E) Effect of treatment (F5,25=8.22, p=0.0001), time (F1,5=4.54, p=0.0414) and time x 
treatment interaction (F5,30=2.77, p=0.0360). 
F) Effect of treatment (F5,25=27.42, p<0.0001), time (F1,5=0.76, p=0.39) and time x 
treatment interaction (F5,30=3.02, p=0.0251). 
 
Fig. 11 
A) Effect of treatment (F7,35=18.96, p<0.0001), time (F1,7=0.04, p=0.84) and time x 
treatment interaction (F7,40=3.15, p=0.0095). 
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B) Effect of treatment (F7,35=26.39, p<0.0001), time (F1,7=0.96, p=0.33) and time x 
treatment interaction (F7,40=2.99, p=0.0128). 
C) Effect of treatment (F7,35=48.11, p<0.0001), time (F1,7=5.19, p=0.0281) and time x 
treatment interaction (F7,40=2.05, p=0.07). 
D) Effect of treatment (F5,25=16.19, p<0.0001), time (F1,5=0.44, p=0.51) and time x 
treatment interaction (F5,30=2.48, p=0.05). 
E) Effect of treatment (F5,25=44.81, p<0.0001), time (F1,5=2.93, p=0.10) and time x 
treatment interaction (F5,30=1.70, p=0.17). 
F) Effect of treatment (F5,25=64.86, p<0.0001), time (F1,5=20.52, p=0.0001) and time x 
treatment interaction (F5,30=3.72, p=0.0098). 
 
Fig. 12 
A) Effect of treatment (F7,35=16.12, p<0.0001), time (F1,7=9.16, p=0.0043) and time x 
treatment interaction (F7,40=5.03, p=0.0004). 
B) Effect of treatment (F7,35=41.59, p<0.0001), time (F1,7=0.01, p=0.91) and time x 
treatment interaction (F7,40=5.72, p=0.0001). 
C) Effect of treatment (F7,35=59.90, p<0.0001), time (F1,7=29.81, p<0.0001) and time x 
treatment interaction (F7,40=3.55, p=0.0046). 
D) Effect of treatment (F3,15=23.27, p<0.0001), time (F1,3=16.54, p=0.0006) and time x 
treatment interaction (F3,20=5.52, p=0.0063). 
E) Effect of treatment (F3,15=3.13, p00.06), time (F1,3=0.32, p=0.58) and time x 
treatment interaction (F3,20=1.51, p=0.24). 
F) Effect of treatment (F3,15=64.81, p<0.0001), time (F1,3=13.39, p=0.0016) and time x 
treatment interaction (F3,20=3.44, p=0.0365). 
 
Fig. 13 
A) Effect of treatment (F4,35=44.24, p<0.0001). 
B) Effect of treatment (F5,43=14.80, p<0.0001). 
 
Fig. 14 
A) Effect of treatment (F3,22=19.62, p<0.0001). 
B) Effect of treatment (F5,32=13.73, p<0.0001). 
C) Effect of treatment (F3,22=18.57, p<0.0001). 
 
 120
Figs. 15–17 
See original paper V reported on appendix II. 
 
Fig. 18 
A) Effect of treatment (F3,35=24.52, p<0.0001). 
B) Effect of treatment (F3,35=7.21, p=0.0008). 
C) Treatment (F3,35=7.54, p=0.0002). 
 
Fig. 19 
See original paper V reported on appendix II. 
 
Fig. 20 
See original paper II reported on appendix II. 
 
Figs. 21–24 
See original paper V reported on appendix II. 
 
Figs. 25–27 
See original paper II reported on appendix II. 
 
Fig. 28 
A) Effect of genotype (F1,9=6.21, p=0.0343), time (F6,6=34.51, p=0.00002) and time x 
genotype interaction (F6,108=1.31, p=0.3760). 
B) Effect of genotype (F1,9=13.35, p=0.0053), time (F6,6=20.73, p=0.0009) and time x 
genotype interaction (F6,108=2.07, p=0.20). 
C) Effect of genotype (F1,9=13.22, p=0.0054), time (F6,6=7.04, p=0.0158) and time x 
genotype interaction (F6,108=2.47, p=0.15). 
D) Effect of genotype (F1,9=0.94, p=0.3573), time (F6,6=15.41, p=0.0021) and time x 
genotype interaction (F6,108=2.23, p=0.18). 
 
Fig. 29 
A) Effect of genotype (F1,7=165.41, p<0.0001), time (F1,1=3.12, p=0.08) and time x 
genotype interaction (F1,14=82.59, p=0.07). 
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B) Effect of genotype (F5,35=16.43, p=0.0009), time (F1,42=0.19, p=0.68) and time x 
genotype interaction (F5,42=50.16, p=0.0003). 
 
Fig. 30 
Effect of treatment (preparation time, p=0.0166; iniziation time, p=0.0256; air time, 
p=0.0416; execution speed, p=0.0442; step length, p=0.0211). 
 
Fig. 31 
A) Effect of genotype (F1,7=0.02, p=0.88), time (F1,1=12281.25, p=0.0057) and time x 
genotype interaction (F1,14=0.01, p=0.97). 
B) Effect of genotype (F1,7=0.06, p=0.82), time (F1,1=199.19, p=0.0450) and time x 
genotype interaction (F1,14=0.19, p=0.74). 
 
Fig. 32 
Effect of treatment (F3,26=16.84, p<0.0001). 
 
Figs. 33–44 
See original paper IV reported on appendix II. 
 
Fig 45 
Effect of striatal region (F1,6=12.29, p=0.0016), time (F6,24=106.86, p<0.0001) and time 
x striatal region interaction (F6,28=10.45, p<0.0001). 
 
Fig. 46 
A) Effect of treatment (F1,6=17.87, p=0.0002), time (F6,24=25.83, p<0.0001) and time x 
treatment interaction (F6,28=3.18, p=0.0166). 
B) Effect of treatment (F1,6=138.28, p<0.0001), time (F6,24=25.56, p<0.0001) and time x 
treatment interaction (F6,28=20.12, p<0.0001). 
C) Effect of treatment (F1,6=50.11, p<0.0001), time (F6,24=10.28, p<0.0001) and time x 
treatment interaction (F6,28=4.59, p=0.0023). 
 
Fig. 47 
Analysis not required. 
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Fig. 48 
A) Effect of treatment (F1,6=23.99, p<0.0001), time (F6,24=25.83, p<0.0001) and time x 
treatment interaction (F6,28=4.43, p=0.003). 
B) Effect of treatment (F1,6=1.12, p=0.30), time (F6,24=15.04, p<0.0001), and time x 
treatment interaction (F6,28=1.46, p=0.23). 
C) Effect of treatment (F1,6=29.64, p<0.0001), time (F6,24=4.29, p=0.0045) and time x 
treatment interaction (F6,28=3.54, p=0.0099). 
D) Effect of treatment (F1,6=25.06, p<0.0001), time (F6,24=9.27, p<0.0001) and time x 
treatment interaction (F6,28=4.56, p=0.0024). 
E) Effect of treatment (F1,6=12.38, p=0.0015), time (F6,24=10.70, p<0.0001) and time x 
treatment interaction (F6,28=2.15, p=0.08). 
F) Effect of treatment (F1,6=3.67, p=0.06), time (F6,24=18.02, p<0.0001) and time x 
treatment interaction (F6,28=3.19, p=0.0162). 
 
Fig. 49 
A) Effect of movement (F1,6=133.53, p<0.0001), time (F6,24=1.00, p=0.45) and time x 
movement interaction (F6,28=6.29, p=0.0002). 
B) Effect of movement (F1,6=1368.37, p<0.0001), time (F6,24=1.00, p=0.45) and time x 
movement interaction (F6,28=9.56, p<0.0001). 
C) Effect of movement (F1,6=202.13, p<0.0001), time (F6,24=1.00, p=0.45) and time x 
movement interaction (F6,28=13.85, p<0.0001). 
D) Effect of movement (F1,6=855.11, p<0.0001), time (F6,24=1.00, p=0.45) and time x 
movement interaction (F6,28=0.36, p=0.90). 
E) Effect of movement (F1,6=93.38, p<0.0001), time (F6,24=1.10, p=0.39) and time x 
movement interaction (F6,28=15.69, p<0.0001). 
F) Effect of movement (F1,6=24.98, p<0.0001), time (F6,24=1.00, p=0.49) and time x 
movement interaction (F6,28=7.25, p<0.0001). 
 
Fig. 50 
A) Analysis not required. 
B) Effect of treatment (F5,29=34.02, p<0.0001). 
C) Effect of treatment (F5,29=62.15, p<0.0001). 
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Fig. 51 
Analysis not required. 
 
Fig. 52 
A) Effect of treatment (F1,4=28.34, p=0.0060), time (F2,2=53.07, p<0.0001) and time x 
treatment interaction (F2,16=19.61, p<0.0001). 
B) Effect of treatment (F1,4=11.88, p=0.0261), time (F2,2=11.42, p=0.0008) and time x 
treatment interaction (F2,16=9.56, p<0.0019). 
C) Effect of treatment (F1,4=7.89, p=0.0483), time (F2,2=7.57, p<0.0049) and time x 
treatment interaction (F2,16=4.58, p=0.0267). 
D) Effect of treatment (F1,4=2.57, p=0.18), time (F2,2=46.81, p<0.0001) and time x 
treatment interaction (F2,16=0.85, p=0.45). 
E) Effect of treatment (F1,4=36.05, p=0.0039), time (F2,2=9.65, p<0.0018) and time x 
treatment interaction (F2,16=1.85, p=0.19). 
F) Effect of treatment (F1,4=36.06, p=0.0039), time (F2,2=9.64, p<0.0018) and time x 
treatment interaction (F2,16=1.85, p=0.19). 
G) Effect of treatment (F1,4=5.34, p=0.08), time (F2,2=33.35, p<0.0001) and time x 
treatment interaction (F2,16=3.26, p=0.06). 
H) Effect of treatment (F1,4=1.67, p=0.27), time (F2,2=28.16, p<0.0001) and time x 
treatment interaction (F2,16=3.53, p=0.05). 
 
Fig. 53 
Analysis not required. 
 
Fig. 54 
A) Effect of treatment (F1,4=27.23, p=0.0064), time (F2,2=27.97, p<0.0001) and time x 
treatment interaction (F2,16=0.99, p=0.39). 
B) Effect of treatment (F1,4=45.90, p=0.0025), time (F2,2=18.17, p=0.0001) and time x 
treatment interaction (F2,16=3.07, p=0.07). 
C) Effect of treatment (F1,4=0.31, p=0.61), time (F2,2=8.01, p=0.0039) and time x 
treatment interaction (F2,16=2.71, p=0.10). 
D) Effect of treatment (F1,4=4.09, p=0.11), time (F2,2=1.71, p=0.21) and time x 
treatment interaction (F2,16=4.16, p=0.0351). 
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E) Effect of treatment (F1,4=2.55, p=0.19), time (F2,2=9.49, p<0.0019) and time x 
treatment interaction (F2,16=1.62, p=0.23). 
F) Effect of treatment (F1,4=2.55, p=0.19), time (F2,2=9.49, p<0.0019) and time x 
treatment interaction (F2,16=1.62, p=0.23). 
G) Effect of treatment (F1,4=25.21, p=0.0074), time (F2,2=15.02, p=0.0002) and time x 
treatment interaction (F2,16=0.09, p=0.92). 
H) Effect of treatment (F1,4=37.69, p=0.0036), time (F2,2=15.18, p=0.0002) and time x 
treatment interaction (F2,16=0.07, p=0.93). 
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The Nociceptin/Orphanin FQ Receptor Antagonist J-113397
and L-DOPA Additively Attenuate Experimental
Parkinsonism through Overinhibition of the
Nigrothalamic Pathway
Matteo Marti,1 Claudio Trapella,2 Riccardo Viaro,1 andMichele Morari1
1Department of Experimental and Clinical Medicine, Section of Pharmacology, and Neuroscience Center, and 2Department of Pharmaceutical Sciences and
Biotechnology Center, University of Ferrara, 44100 Ferrara, Italy
By using a battery of behavioral tests, we showed that nociceptin/orphanin FQ receptor (NOP receptor) antagonists attenuated
parkinsonian-like symptoms in 6-hydroxydopamine hemilesioned rats (Marti et al., 2005).We now present evidence that coadministra-
tion of the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H
benzimidazol-2-one (J-113397) and L-DOPA to 6-hydroxydopamine hemilesioned rats produced an additive attenuation of parkinson-
ism. To investigate the neurobiological substrates underlying this interaction, in vivo microdialysis was used in combination with
behavioral measurements (bar test). J-113397 and L-DOPA alone reduced the time on bars (i.e., attenuated akinesia) and elevated GABA
release selectively in the lesioned substantia nigra reticulata. J-113397 also reduced nigral glutamate levels, whereas L-DOPA was inef-
fective. J-113397 and L-DOPA coadministration produced additive antiakinetic effect, which was associated with additive increase in
nigral GABA release but no additional reductions in glutamate levels. To investigate whether the increase in nigral GABA release could
translate to changes in nigrothalamic transmission, GABA release was monitored in the ventromedial thalamus (one of the main target
areas of the nigrothalamic projections). J-113397 and L-DOPA decreased thalamic GABA release and attenuated akinesia, their combi-
nation resulting in a more profound effect. These actions were prevented by perfusing the voltage-dependent Na channel blocker
tetrodotoxin or the GABAA receptor antagonist bicuculline in the substantia nigra reticulata. These data demonstrate that J-113397 and
L-DOPA exert their antiparkinsonian action through overinhibition of nigrothalamic transmission and suggest that NOP receptor antag-
onists may be useful as an adjunct to L-DOPA therapy for Parkinson’s disease.
Key words: J-113397; L-DOPA; microdialysis; nociceptin; 6-OHDA; Parkinson’s disease
Introduction
Nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are
expressed in cortical and subcortical motor areas and, particu-
larly, in the substantia nigra (SN), which contains dopamine
(DA) neurons that degenerate in Parkinson’s disease (PD).
N/OFQ inhibits the activity of DA neurons located in the SN
compacta (SNc) (Marti et al., 2004a) and impairs spontaneous
(Reinscheid et al., 1995; Devine et al., 1996) and exercise-induced
locomotion (Marti et al., 2004a). More recently, we presented
evidence that endogenous N/OFQ sustains symptoms and neu-
rodegeneration associated with PD. Indeed, upregulation of
N/OFQergic transmission was found in the DA-depleted SN re-
ticulata (SNr) of 6-hydroxydopamine (6-OHDA) hemilesioned
(hemiparkinsonian) rats (Marti et al., 2005). Moreover, systemic
or intranigral injections of NOP receptor antagonists attenuated
akinesia both in hemiparkinsonian and haloperidol-treated rats
(Marti et al., 2004b, 2005). Finally, deletion of the NOP receptor
or the preproN/OFQgene conferredmice partial resistance to the
cataleptic action of haloperidol and protection against MPTP-
induced loss of SNcDA neurons, respectively (Marti et al., 2005).
Reduction of glutamate (GLU) release in the SNr may represent
the mechanism by which NOP receptor antagonists reverse par-
kinsonism, because this class of compounds normalized
haloperidol-evoked GLU levels in the SNr, an effect that corre-
lated with attenuation of akinesia (Marti et al., 2004b, 2005). To
further strengthen the view that NOP receptor antagonists may
be useful in PD therapy, we undertook the present study to in-
vestigate the ability of the nonpeptide NOP receptor antagonist
1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-
3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397)
(Kawamoto et al., 1999) to synergize with L-DOPA. L-DOPA still
represents the most effective treatment of PD, although chronic
treatment almost invariably produces motor fluctuations and
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dyskinesias (Obeso et al., 2000) that cause reduction in the clin-
ical response over time. From a clinical point of view, combining
L-DOPA with other antiparkinsonian drugs may allow a reduc-
tion in L-DOPA dosage, thereby delaying the onset of L-DOPA
side effects.
In the present study, we evaluated L-DOPA action in a full
dose range (experiment 1), further testing whether subthreshold
(experiment 2) and submaximal (experiment 3) doses of
J-113397 and L-DOPA produced additive antiparkinsonian ef-
fects. To investigate the mechanisms underlying this interaction,
GLU and GABA release was analyzed by microdialysis in the SNr
of rats undergoing behavioral testing (bar test; experiment 4). To
determine whether changes in SNr neurotransmitter release cor-
related with changes of activity of nigrothalamic GABAergic neu-
rons (i.e., the basal gangliamotor output), GABA release was also
measured in the ventromedial thalamus (VMTh) (experiment 5),
one of the main targets of nigrothalamic GABAergic neurons (Di
Chiara et al., 1979; MacLeod et al., 1980). Finally, to confirm that
both antiakinetic action and the changes in thalamic GABA re-
lease after J-113397 and L-DOPA coadministration were attrib-
utable to inhibition of nigrothalamic GABAergic transmission,
neurochemical and behavioral analysis were performed during
reverse dialysis of the voltage-dependent Na channel blocker
tetrodotoxin (TTX) (experiment 6) or the GABAA receptor an-
tagonist bicuculline (experiment 7) in the SNr.
Materials andMethods
Rats used in the study (see below) were kept under regular lighting con-
ditions (12 h light/dark cycle) and given food and water ad libitum. The
experimental protocols performed in the present studywere approved by
the Italian Ministry of Health (license number 71-2004-B) and by the
Ethics Committee of the University of Ferrara.
Measurement of antiakinetic effects of levodopa and J-113397
in hemiparkinsonian rats
6-OHDA lesion
Unilateral lesion of DA neurons (Marti et al., 2005) was induced in
isoflurane-anesthetizedmale Sprague Dawley rats (150 g; Harlan Italy, S.
Pietro al Natisone, Italy). Eightmicrograms of 6-OHDA (in 4l of saline
containing 0.02% ascorbic acid) were stereotaxically injected according
to the following coordinates from bregma: anteroposterior (AP), 4.4
mm; mediolateral (ML),1.2 mm; ventrodorsal (VD),7.8 mm below
dura (Paxinos andWatson, 1982). The rotationalmodel (Ungerstedt and
Arbuthnott, 1970) was used to select the rats that had been successfully
lesioned. Two weeks after surgery, rats were injected with amphetamine
(5 mg/kg, i.p., dissolved in saline) and only those rats performing more
than seven ipsilateral turns per minute were enrolled in the study. This
behavior has been associated with95% loss of striatal extracellular DA
levels (Marti et al., 2002b). Experiments were performed 6–8 weeks after
lesion.
Histological evaluation
The animals were deeply anesthetized with Zoletil 100 (10 mg/kg, i.m.;
Virbac Laboratories, Carros, France), transcardially perfusedwith 20mM
potassium PBS (KPBS) and fixed with 4% paraformaldehyde in KPBS,
pH 7.4. The brains were removed, fixed in the fixative overnight, and
transferred to 25% sucrose solution in KPBS for cryoprotection. Serial
coronal sections of 40 m thickness were made using a freezing mic-
rotome. Every second section in the striatum was selected from the re-
gion spanning from bregma 0.5 to 1.5 and processed for tyrosine
hydroxylase (TH) immunohistochemistry.
Sections were rinsed three times in KPBS and incubated for 15 min in
3% H2O2 and 10% methanol in KPBS to block the endogenous peroxi-
dase activity. After washing in KPBS, the sections were preincubated in
blocking serum (5% normal horse serum and 0.3% Triton X-100 in
KPBS) for 60min, followed by incubation in anti-THmousemonoclonal
antibody solution (1:2000; Millipore, Billerica, MA) for 16 h at room
temperature. The sections were then rinsed in KPBS and incubated for
1 h in biotinylated horse anti-mouse IgG secondary antibody (1:200;
Vector Laboratories, Burlingame, CA). After rinsing, sections were incu-
bated with avidin–biotin peroxidase complex (Vector Laboratories) for
30min at room temperature. After rinsingwith KPBS, immunoreactivity
was visualized by incubating the sections in a solution containing 0.05%
3,3-diaminobenzidine (DAB) in 0.013%H2O2 in KPBS for1min. The
sections were rinsed in KPBS, mounted on gelatin-coated slides, dried
with ethanol and xylene, and coverslipped with mounting medium. Ev-
ery section was viewed with a Zeiss Axioskop (Zeiss, Oberkochen, Ger-
many), acquired with Polaroid (Waltham, MA) DMC camera and TH-
immunoreactive fiber density analyzed using ImageJ software (Wayne
Rasband, National Institutes of Health, Bethesda, MD). To estimate the
TH-density staining, the optical densities were corrected for nonspecific
background density, which was measured in the corpus callosum. TH-
positive fiber density was calculated as the ratio between optical density
in the denervated (ipsilateral) and intact (contralateral) side (Fig. 1).
Behavioral studies in rats
Motor activity in rats was evaluated by means of three behavioral tests
specific for different motor abilities, as previously described (Marti et al.,
2005): (1) the bar test (Sanberg et al., 1988), whichmeasures rat ability to
respond to an externally imposed static posture; (2) the drag test [mod-
ification of the postural adjustment test (Lindner et al., 1999)], which
measures rat ability to balance body posture using forelimbs in response
to an externally imposed dynamic stimulus (backward dragging); and (3)
the rotarod test, which measures rat ability to run on a rotating cylinder
(Rozas et al., 1997). The different tests are useful to evaluate akinesia and
motor asymmetry under static conditions (bar test), akinesia, bradyki-
nesia, and asymmetry under dynamic conditions (drag test), and overall
motor performance (rotarod test) as an integration of coordination, gait,
balance, muscle tone, and motivation to run. The bar and the drag tests
were performed 10 min after intraperitoneal injections of J-113397,
L-DOPA, or their combination, whereas the rotarod test was performed
10 and 60 min after drug injection.
Bar test.Each rat was placed gently on a table, and the contralateral and
ipsilateral forepaws were placed alternatively on blocks of increasing
heights (3, 6, and 9 cm). Total time (in seconds) spent by each paw on the
blocks was recorded (cutoff time, 20 s).
Drag test. Each rat was gently lifted from the tail (allowing forepaws on
the table) and dragged backwards at a constant speed (20 cm/s) for a
fixed distance (100 cm). The number of steps made by each paw was
counted by two separate observers.
Rotarod test. The fixed-speed rotarod test (Rozas et al., 1997) was used
according to a previously described protocol (Marti et al., 2004a). Briefly,
rats were trained for 10 d to a specific motor task on the rotarod until
their motor performance became reproducible. Rats were tested in a
control session at four increasing speeds (10, 15, 20, 25 rpm for hemipar-
kinsonian rats and 30, 35, 40, and 45 rpm for sham-operated rats; 180 s
each), causing a progressive decrement of performance to40% of the
maximal response (i.e., the experimental cutoff time). Such a protocol
Figure 1. Effect of 6-OHDA injections on the TH-positive fiber density in the striatum. Pho-
tomicrograph of TH-positive fibers in the striata of a hemiparkinsonian rat.
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was set to detect both facilitatory and inhibitory drug effects. Two other
sessions were repeated 10 and 60min after drug injection, and drug effect
was expressed as total time spent on the rod.
Measurement of GLU and GABA levels in hemiparkinsonian
rats by microdialysis
Two microdialysis probes (1 mm dialyzing membrane; AN69; Hospal,
Bologna, Italy) were implanted bilaterally in the lesioned and unlesioned
SNr (AP, 5.5; ML,  2.2; VD, 8.3) or ipsilateral and contralateral
VMTh (AP, 2.3; ML,  1.4; VD, 7.4) of isoflurane-anesthetized
hemiparkinsonsian rats. Twenty-four hours after implantation, probes
were perfused (3 l/min) with a modified Ringer’s solution (in mM: 1.2
CaCl2, 2.7 KCl, 148 NaCl, and 0.85 MgCl2) and sample collection (every
15 min) started after a 6–7 h washout. L-DOPA and J-113397 were ad-
ministered systemically (intraperitoneally) alone or in combination, and
GLU and GABA levels were monitored every 15 min up to 3 h. In a
separate set of experiments, two microdialysis probes were implanted in
the lesioned SNr and ipsilateral VMTh, and GABA was measured in the
VMTh. In these experiments, to correlate changes of amino acid dialysate
levels withmotor activity, rats undergoingmicrodialysis were challenged
in the bar test every 15 min (Marti et al., 2004b, 2005). Routinely, exper-
iments were repeated for 3 d after surgery, and treatments were random-
ized between groups, because preliminary testing showed that drug effect
did not change depending on the day of experiment or treatment re-
ceived in the preceding days. A notable exception was, however, repre-
sented by experiments using TTX because the toxin produced long-
lasting effects that prevented additional testing. At the end of the
experiments, rats were killed and probe location verified by microscopic
examination (Fig. 2).
GLU and GABA levels in the dialysate were measured by HPLC cou-
pled to fluorimetric detection, with minor modifications of the method
described previously (Marti et al., 2003). Briefly, 40 l samples were
pipetted into glass microvials and placed in a thermostated (4°C) Tria-
thlon autosampler (Spark Holland, Emmen, The Netherlands). Thirty-
five microliters of o-pthaldialdheyde/boric acid solution were added to
each sample, and 50 l of the solution was injected onto a Chromsep
analytical column (3 mm inner diameter, 10 cm length; Chrompack,
Middelburg, The Netherlands). The column was eluted at a flow rate of
0.48 ml/min with a mobile phase containing 0.1 M sodium acetate, 10%
ethanol, and 2.5% tetrahydrofuran, pH 6.5; to achieve a good separation,
a two-step linear gradient of methanol in aqueous sodium acetate buffer
was provided by a Beckman 125 pump (Beckman Instruments, Fuller-
ton, CA). GLU and GABA were detected by means of a fluorescence
spectrophotometer RF-551 (Shimadzu, Kyoto,
Japan). GLU and GABA retention times were
4 and 17 min, respectively, and the sensi-
tivity of the method for both amino acids was
150 fmol/sample.
Data presentation and
statistical analysis
Motor performance has been expressed as time
on bar or on rod (in seconds) and number of
steps (drag test). In microdialysis studies, GLU
and GABA release has been expressed as per-
centage  SEM of basal values (calculated as
mean of the two samples before the treatment).
In Figure legends (and in Results), amino acid
dialysate levels for each group of rats are also
given in absolute values (in nanomolar
concentration).
To analyze behavior, statistical analysis was
performed (CoStat 6.3; CoHort Software,
Monterey, CA) on absolute data by one-way or
two-way ANOVA followed by the Newman–
Keuls test for multiple comparisons. Drug in-
teractionwas studied experimentally according
to a 2  2 factorial design, and data were ana-
lyzed with conventional two-way ANOVA, fac-
tor one being L-DOPA and factor two being J-113397. Whenever behav-
ior was analyzed at different time points (e.g., during the rotarod test),
repeated-measure ANOVA was performed on absolute data, “within”
factor being time and “between” factor being treatment. In the case that
ANOVA yielded to a significant F score, post hoc analysis was performed
in contrast analysis to determine group differences. In the case that a
significant time treatment interaction was found, the sequentially re-
jective Bonferroni test was used (implemented on an Excel spreadsheet)
to determine specific differences (i.e., at the single time-point level) be-
tween groups. Two-way ANOVA with repeated measures on percentage
data was used in neurochemical experiments, within factor being time
and between factor being treatment. For each group, two pretreatment
and six post-treatment samples were considered. Contrast post hoc anal-
ysis was used to determine group differences, and the sequentially rejec-
tive Bonferroni test was used to determine differences at the single time-
point level, as described above. p values 0.05 were considered to be
statistically significant.
Materials
Amphetamine, 6-OHDA bromide, methyl L-DOPA hydrochloride, and
benserazide were purchased from Sigma (St. Louis, MO), TTX from
Alomone Labs (Jerusalem, Israel), and bicuculline from Tocris
Neuramin (Bristol, UK). J-113397 was synthesized in our laboratories as
reported previously (Marti et al., 2004a). All drugs were freshly dissolved
in isoosmotic saline solution just before use.
Results
L-DOPA relieved akinesia in hemiparkinsonian rats
(experiment 1)
Hemiparkinsonian rats displayed severe (98%) loss of TH-
positive DA terminals in the striatum ipsilateral to the 6-OHDA
injection side (0.02  0.03 ipsilateral/contralateral ratio, n  6)
(Fig. 1), whereas sham-operated rats showed no depletion at all
(0.99 0.02 ipsilateral/contralateral ratio, n 5). Hemiparkin-
sonian rats also displayed overall marked akinesia/bradykinesia
and motor asymmetry compared with vehicle-injected sham-
operated rats (Table 1). L-DOPA (in combination with 15 mg/kg
benserazide, i.p.) attenuated akinesia/bradykinesia and normal-
ized motor asymmetry within the 0.1–6 mg/kg dose range, in-
ducing a clear contralateral bias at higher doses (25 mg/kg) (Fig.
3). Lower L-DOPA doses reduced the time spent on the blocks
Figure 2. Schematic representation of coronal sections indicating microdialysis probe location in the SNr (AP5.30,5.60,
and5.80 frombregma) and VMTh (AP2.30,2.56, and2.80 frombregma). The filled circles represent the location of the
tip of the probe (data obtained from 45 animals).
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(F(9,64)  54.74; p  0.001) (Fig. 3A), in-
creased the number of steps (F(9,72) 
45.96; p  0.001) (Fig. 3B), and affected
rotarod performance (Fig. 3C). In this re-
spect, repeated-measureANOVA revealed
a significant effect of treatment (F(5,22) 
11.25; p  0.001), time (F(2,68)  6.59;
p  0.002), and time  treatment
(F(10,68) 50.81; p 0.001). Post hoc anal-
ysis revealed that L-DOPA stimulatedmo-
tor performance in the 0.3–6 mg/kg dose
range and inhibited it at 25 mg/kg. Over-
all, the most sensitive test was the bar test,
with L-DOPA significantly attenuating
akinesia at 0.1 mg/kg and normalizing
motor asymmetry at 6 mg/kg. When
L-DOPA was injected at high doses (25
mg/kg), it induced contralateral turning
and reversal ofmotor asymmetry, the con-
tralateral side of the body being more ac-
tive than the ipsilateral one. Contralateral
turning was, however, associated with
hampered rotarod performance (see also
Rozas et al., 1997; Marti et al., 2004a).
Combination of L-DOPA and J-113397
attenuated parkinsonian-like symptoms
in an additiveway (experiments 2 and 3)
By using the bar, drag, and rotarod tests,
we reported previously (Marti et al., 2005)
that systemic (intraperitoneal) injections
of J-113397 attenuated akinesia/bradyki-
nesia and attenuated motor asymmetry in
hemiparkinsonian rats. Its action fully de-
veloped within the 0.1–3 mg/kg range,
with 0.1 and 1mg/kg being the subthresh-
old and submaximal doses in two of three
tests, respectively. We therefore selected
subthreshold (0.1 mg/kg) and submaxi-
mal (1 mg/kg) doses of J-113397 and
L-DOPA to test whether their combina-
tion could produce additive effects.
Interaction between subthreshold doses (experiment 2)
In the bar test (Fig. 4A), two-way ANOVA revealed the main
effect of L-DOPA (F(1,32) 11.89; p 0.0016), but not J-113397
(F(1,32) 0.71; p 0.40), and a significant L-DOPA J-113397
interaction (F(1,32) 14.08; p 0.0007) at the ipsilateral side. At
the contralateral side, two-way ANOVA revealed the main effect
of L-DOPA (F(1,30) 26.06; p 0.0001) and J-113397 (F(1,30)
26.06; p 0.057) and a significant L-DOPA J-113397 interac-
tion (F(1,30)  5.41; p  0.0269). Post hoc analysis revealed that
L-DOPA and J-113397 reduced the time spent on the bar at both
forepaws, the effect of the combination being no greater than that
evoked by each compound alone. In the drag test (Fig. 4B), no
effect was detected, either when compounds were administered
alone or together. In the rotarod test (Fig. 4C), no main effect of
treatment was found (F(3,15)  1.84; p  0.18). Instead, a main
effect of time (F(2,42)  8.0; p  0.001) and a significant time 
treatment interaction (F(6,42) 9.28; p 0.001) was evident. Post
hoc analysis revealed that L-DOPA and J-113397 were ineffective,
whereas their combination elevated rotarod performance at 60
min after injection.
Table 1. Characterization of motor activity in vehicle-injected (sham-operated) and 6-OHDA-injected (hemiparkinsonian) rats
Sham-operated Hemiparkinsonian
Ipsilateral Contralateral Ipsilateral Contralateral
Bar test (s) 0.7 0.2 (n 12) 0.8 0.2 (n 12) 41.6 2.0* (n 22) 50.0 1.5*,** (n 22)
Drag test (steps) 12.3 0.3 (n 12) 12.4 0.5 (n 12) 10.4 0.4 (n 17) 3.8 0.3*,** (n 17)
Rotarod (s) 1044 93 (n 11) 428 30* (n 19)
Hemiparkinsonian rats displayed an increase in the total time spent on the blocks in the bar test, reduction in the number of steps made by the contralateral forepaw in the drag test, and reduced rotarod performance, compared with
sham-operated animals. Data (mean SEM)havebeenobtained from11 vehicle-injected and19hemiparkinsonian rats. *p0.05 versus sham-operated rats (Student’s t test or ANOVA followedby theNewman–Keulspost hoc test,when
appropriate). **p 0.05 versus the ipsilateral forepaw.
Figure 3. L-DOPA relieved akinesia/bradykinesia in hemiparkinsonian rats. A–D, Systemic administration (intraperitoneal;
arrow) of L-DOPA (0.1–25mg/kg, in combinationwith 15mg/kg benserazide) reduced the time spent on the blocks in the bar test
(A), increased the number of steps of the contralateral forepaw in the drag test (B), improved overall motor performance in the
rotarod test (C), and induced contralateral rotations (D). The bar and drag testswere performed 10min after injection; the rotarod
test was performed 10 and 60 min after injection. Motor asymmetry was evaluated by separately measuring activity of the paws
ipsilateral and contralateral (parkinsonian) to the lesioned side. Turning behavior (D) was assessed by counting the number of
rotations in the direction opposite to the injection side (i.e., contralateral) in 90min. Data aremean SEM (6–14 rats per group).
Statistical analysis was performed by one-way ANOVA followed by the Newman–Keuls test (A, B) or ANOVA with repeated
measures followed by contrast analysis and the sequentially rejective Bonferroni test (C). *p 0.05 versus saline-treated rats.
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Interaction between submaximal doses (experiment 3)
In the bar test (Fig. 5A), the main effect of L-DOPA (F(1,26) 
29.00; p  0.0001) and J-113397 (F(1,26)  26.77; p  0.0001)
were found together with a significant L-DOPA  J-113397 in-
teraction (F(1,26) 15.03; p 0.0006) at the ipsilateral paw.Main
effects of L-DOPA (F(1,23)  43.30; p  0.0001) and J-113397
(F(1,23)  21.33; p  0.0001) and a significant L-DOPA 
J-113397 interaction (F(1,23)  17.42; p  0.0004) were also ob-
served at the contralateral paw. At both forepaws, the effects of
each compound alone did not differ from that induced by their
coadministration.
In the drag test (Fig. 5B), neither compound affected motor
activity at the side of the body ipsilateral to the lesion. Conversely,
two-way ANOVA revealed the main effect of L-DOPA (F(1,29)
23.70; p  0.0001) and J-113397 (F(1,29)  13.25; p  0.0011),
although not a significant L-DOPA  J-113397 interaction
(F(1,29)  0.09; p  0.76), at the contralateral forepaw. Post hoc
analysis showed that the coapplication induced a greater effect
than each compound alone, leading to restoration of motor ac-
tivity at the parkinsonian forepaw.
In the rotarod test (Fig. 5C), main effects of treatment
(F(3,16) 9.53; p 0.0007) and time (F(2,57) 32.24; p 0.0001)
and a significant time  treatment interaction (F(10,57)  6.91;
p 0.0001)were found.Post hoc analysis at 10min after injection
revealed that L-DOPA and J-113397 elevated rotarod perfor-
mance, and the coapplication produced greater (additive)
improvement.
L-DOPA and J-113397 differentially modulated GLU and
GABA release in the SNr (experiment 4)
In previous studies, we showed that NOP receptor antagonists
inhibited spontaneous (Marti et al., 2002a, 2005) and
haloperidol-evoked (Marti et al., 2004b, 2005) GLU release in the
SNr and that this effect correlated with relief from akinesia. We
Figure4. Combinationof low (subthreshold) doses of J-113397and L-DOPA relievedakinesia/hypokinesia inhemiparkinsonian rats.A, Systemic (intraperitoneal) administrationof J-113397 (0.1
mg/kg), L-DOPA (0.1 mg/kg plus 15mg/kg benserazide), or their combination reduced the time spent on the blocks in the bar test. B, No effect was observed in the drag test. C, In the rotarod test,
improvement ofmotor performancewas detected onlywhen J-113397 and L-DOPAwere combined.Motor asymmetrywas evaluated by separatemeasures at the paws ipsilateral and contralateral
(parkinsonian) to the lesioned side. The bar and drag tests were performed 10 min after injection; the rotarod test was performed 10 and 60 min after injection. Data are mean SEM (6–14 rats
per group). Statistical analysis was performed by conventional two-way ANOVA followed by the Newman–Keuls test (A, B) or by two-way ANOVA with repeated measures followed in contrast
analysis and the sequentially rejective Bonferroni test (C). *p 0.05 versus saline-treated rats.
Figure 5. Combination of high (submaximal) doses of J-113397 and L-DOPA relieved akinesia/hypokinesia in hemiparkinsonian rats.A–C, Systemic (intraperitoneal) administration of J-113397
(1mg/kg), L-DOPA (1mg/kg plus 15mg/kg benserazide), or their combination reduced the time spent on the blocks in the bar test (A), increased the number of stepsmade by the contralateral paw
in thedrag test (B), and improvedoverallmotor performance in the rotarod test (C). In thedrag and rotarod tests, a greater effect (additive)was detectedwhen J-113397 and L-DOPAwere combined
together. Motor activity was evaluated by separate measures at the paws ipsilateral and contralateral (parkinsonian) to the lesioned side. The bar and drag tests were performed 10 min after
injection; the rotarod test was performed 10 and 60min after injection. Data aremean SEM (6–10 rats per group). Statistical analysis was performed by conventional two-way ANOVA followed
by theNewman–Keuls test (A,B) or by two-wayANOVAwith repeatedmeasures followedby contrast analysis and the sequentially rejectiveBonferroni test (C). *p0.05 versus saline-treated rats.
#p 0.05 versus L-DOPA alone. §p 0.05 versus J-113397 alone.
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therefore first investigated whether addi-
tive antiparkinsonian effects produced by
coadministration of submaximal L-DOPA
and J-113397 doses were associated with
greater reduction of SNr GLU release (Fig.
6A,B). GLU levels did not differ in the un-
lesioned (96.1  6.9 nM, n  30) and le-
sioned (94.4 6.9 nM, n 30) SNr. Nei-
ther compounds affected GLU outflow in
the unlesioned SNr (Fig. 6A). However,
repeated-measure ANOVA revealed a
main effect of treatment (F(3,18)  33.15;
p  0.0001) and time (F(7,168)  9.53;
p0.0001), as well as a significant
time  treatment interaction (F(21,168) 
3.27; p 0.0045) in the lesioned SNr (Fig.
6B). Post hoc analysis showed that
L-DOPA did not affect GLU levels,
whereas J-113397 reduced them, the com-
bination of the two being no more effec-
tive than J-113397 alone. Because these
findings did not indicate that changes in
GLU levels underlie the additive effect on
behavior, we nextmeasured GABA release
in the same area (Fig. 6C,D). GABA levels
did not differ in the unlesioned (10.5 0.4
nM, n 26) and lesioned (10.0 0.5 nM,
n 26) SNr. Neither compounds affected
GABA outflow in the unlesioned SNr (Fig.
6C). Conversely, repeated-measure
ANOVA showedmain effects of treatment
(F(3,15)  26.46; p  0.0001) and time
(F(7,147) 23.42; p 0.0001) and a signif-
icant time  treatment interaction in the
lesioned SNr (Fig. 6D). Post hoc analysis
revealed that L-DOPA and J-113397 ele-
vated GABA levels compared with saline,
the effect of the combination being greater
than that of each compound alone (Fig.
6D).
L-DOPA and J-113397 reduced GABA
release in the VMTh (experiment 5)
SNr is known to send GABAergic projections to the VMTh (Di
Chiara et al., 1979; MacLeod et al., 1980), which represents the
motor output of the basal ganglia. Thus, we hypothesized that the
attenuation of motor disabilities could be associated with inhibi-
tion of nigrothalamic transmission. To this purpose, we first in-
vestigated whether J-113397 and L-DOPA administration evoked
changes in thalamic GABA release (Fig. 7A,B). GABA levels in
the dialysate from the VMTh ipsilateral to the lesioned SNr
(18.9 1.0 nM; n 27) were23% higher compared with those
collected from the contralateral one (14.6 1.0 nM; n 25; p
0.05, Student’s t test). Neither L-DOPA or J-113397 affected
GABA release in the VMTh contralateral to the lesioned SNr (Fig.
7A). However, repeated-measure ANOVA revealed main effects
of treatment (F(3,15)  18.48; p  0.0001) and time (F(7,132) 
13.55; p 0.0001) and a significant time treatment interaction
(F(21,132)  2.24; p  0.003) in the VMTh ipsilateral to the le-
sioned SNr (Fig. 7B). Post hoc analysis revealed that L-DOPA and
J-113397 inhibited thalamic GABA release compared with saline,
and the combination produced greater inhibition comparedwith
that evoked by each compound alone.
Simultaneous behavioral testing was performed in animals
subjected to microdialysis, and motor activity was assessed sepa-
rately at the contralateral and ipsilateral forepaw by using the bar
test (Fig. 7C,D). At the contralateral paw, the main effects of
treatment (F(3,32) 34.23; p 0.0001) and time (F(7,300) 95.22;
p  0.0001) and a significant time  treatment interaction
(F(21,300)  14.06; p  0.0001) were found (Fig. 7C). The main
effects of treatment (F(3,32)  8.44; p  0.0001) and time
(F(7,300) 51.07; p 0.0001) and a significant time treatment
interaction (F(21,300) 8.50; p 0.0001)were also observed at the
ipsilateral paw (Fig. 7D). Post hoc analysis showed that L-DOPA
and J-113397 reduced to the same extent the time spent on the
blocks at both the contralateral and ipsilateral forepaw, although
only at the contralateral paw the combined administration of
L-DOPA and J-113397 produced greater effect than each com-
pound alone.
Reverse dialysis of TTX in the SNr prevented changes in
thalamic GABA release andmotor behavior by L-DOPA and
J-113397 combination (experiment 6)
To demonstrate that ongoing neuronal activity in the SNr was
essential for both the reduction of GABA release in the VMTh
Figure 6. J-113397 and L-DOPA regulated GLU and GABA release in the lesioned SNr. A–D, Two microdialysis probes were
bilaterally implanted in the unlesioned (A, C) and lesioned (B, D) SNr of hemiparkinsonian rats. Rats were treated systemically
(intraperitoneally; arrow)with J-113397 (1mg/kg), L-DOPA (1mg/kg plus benserazide 15mg/kg), or their combination. Data are
expressed asmeans SEM of n experiments. Basal GLU levels (in nanomolar concentration) in the dialysate from the unlesioned
and lesioned SNr were, respectively, as follows: 100.2 15.8, 103.7 19.5 (saline, n 6 both); 76.8 15.2, 73.2 14.7
(L-DOPA, n 6 both); 112.4 12.4, 100.9 12.1 (J-113397, n 11 and 12, respectively); 83.4 9.5, 94.7 9.9 (L-DOPA
J-113397, n 7 both). Basal GABA levels (in nanomolar concentration) in the dialysate from the unlesioned and lesioned SNr
were, respectively, as follows: 9.4 0.6, 9.2 0.9 (saline,n 6both); 10.9 0.9, 9.5 1.0 (L-DOPA,n 6both); 10.5 1.2,
11.6 0.9 (J-113397, n 7 both); 11.0 0.7, 9.6 1.3 (L-DOPA J-113397, n 7 both). Statistical analysis was performed
by two-way ANOVA with repeated measures followed by contrast analysis and the sequentially rejective Bonferroni test. *p
0.05 versus saline-treated rats. §p 0.05 versus J-113397 alone. #p 0.05 versus L-DOPA alone.
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and the antiakinetic action, L-DOPA and J-113397 were coad-
ministered systemically while perfusing the voltage-operated
Na channel blocker TTX in the lesioned SNr (Fig. 8).
Repeated-measure ANOVA on GABA levels in the lesioned
SNr (Fig. 8A) revealed amain effect of treatment (F(3,14) 46.40;
p 0.0001) and time (F(7,125) 9.50; p 0.0001) and a signifi-
cant time treatment interaction (F(21,125) 7.52; p 0.0001).
Post hoc analysis showed that SNr perfusion with TTX did not
affect spontaneous SNr GABA levels and prevented the elevation
of GABA release induced by combined administration of
J-113397 and L-DOPA. Repeated-measure ANOVAon ipsilateral
VMTh GABA levels (Fig. 8B) revealed main effect of treatment
(F(3,14) 77.50; p 0.0001) and time (F(7,125) 2.55; p 0.017)
and a significant time  treatment interaction (F(21,125)  4.63;
p  0.0001). Post hoc analysis showed that SNr perfusion with
TTX reduced VMTh GABA release and prevented the inhibitory
effect induced by coapplication of J-113397 and L-DOPA.
From a behavioral point of view,
repeated-measure ANOVA analysis at the
contralateral paw revealed a main effect of
treatment (F(3,12)  15.40; p  0.0002)
and time (F(7,120) 13.61; p 0.0001), as
well as a significant time  treatment in-
teraction (F(21,120)  6.92; p  0.0001)
(Fig. 8C). A similar response was observed
at the ipsilateral paw (Fig. 8D). Post hoc
analysis showed that TTX significantly re-
duced the time spent on the bar and pre-
vented the inhibition induced by coappli-
cation of J-113397 and L-DOPA.
Reverse dialysis of bicuculline in the
SNr prevented changes in thalamic
GABA release andmotor behavior by
L-DOPA and J-113397 combination
(experiment 7)
To demonstrate that activation of GABAA
receptors in the SNr was responsible for
overinhibition of nigrothalamic neurons
and antiparkinsonian action associated
with it, L-DOPA and J-113397 were coad-
ministered systemically while perfusing
the GABAA receptor blocker bicuculline
in the lesioned SNr (Fig. 9).
Repeated-measure ANOVA on GABA
levels in the lesioned SNr (Fig. 9A) re-
vealed amain effect of treatment (F(3,14)
27.75; p  0.0001) and time (F(7,125) 
11.05; p  0.0001) and a significant
time  treatment interaction (F(21,125) 
5.17; p 0.0001).Post hoc analysis showed
that perfusion with bicuculline in the SNr
did not affect basal GABA levels and left
unchanged the elevation of GABA release
induced by combined administration of
J-113397 and L-DOPA. In the VMTh (Fig.
9B), main effects of treatment (F(3,14) 
10.10; p 0.0008), but not time (F(7,125)
1.58; p  0.14), and a significant time 
treatment interaction (F(21,125)  2.29;
p 0.0025) were found. Post hoc analysis
revealed that bicuculline did not affect
spontaneous GABA release and prevented
the inhibitory influence induced by J-113397 and L-DOPA
combination.
From a behavioral point of view, repeated-measure ANOVA
at the contralateral paw (Fig. 9C) revealed a main effect of treat-
ment (F(3,12) 36.33; p 0.0001) and time (F(7,112) 8.12; p
0.0001), as well as a significant time  treatment interaction
(F(21,112)  8.93; p  0.0001). At the ipsilateral paw (Fig. 9D),
repeated-measure ANOVA revealed a main effect of treatment
(F(3,12)  4.51; p  0.024) and time (F(7,112)  2.16; p  0.043)
and a significant time  treatment interaction (F(7,112)  2.82;
p  0.0001). Post hoc analysis revealed that bicuculline did not
affect the time spent on the bar but prevented the inhibitory effect
induced by J-113397 and L-DOPA combination.
To study the relevance of GLU release inhibition in the anti-
akinetic response to combined application of L-DOPA and
J-113397, GLU levels were analyzed in the lesioned SNr during
perfusion of bicuculline (Fig. 10). Repeated-measure ANOVA
Figure7. J-113397 and L-DOPAproduced inhibition of GABA release in theVMThand reduction of the time spent on the blocks.
A, B, Twomicrodialysis probes were bilaterally implanted in the VMTh contralateral (unlesioned side; A) and ipsilateral (lesioned
side; B) to the lesioned SNr of hemiparkinsonian rats. Rats were treated systemically (intraperitoneally; arrow) with J-113397 (1
mg/kg), L-DOPA (1 mg/kg plus 15 mg/kg benserazide), or their combination. Data are expressed as means SEM of n experi-
ments. Basal GABA levels (in nanomolar concentration) in the dialysate from the VMTh at the unlesioned and lesioned side were,
respectively, as follows: 12.5 1.0, 15.8 2.3 (saline, n 6 both); 16.4 1.9, 20.4 0.4 (L-DOPA, n 6 both); 15.4 1.2,
20.9 1.7 (J-113397, n 6 both); 15.3 3.2, 22.7 1.4 (L-DOPA J-113397, n 6 both). C, D, Hemiparkinsonian rats
implanted in the SNr (Fig. 6) or VMTh were challenged in the bar test. Akinesia was evaluated (every 15 min for up to 90 min) by
using the bar test separately at the contralateral (C) and ipsilateral (D) paws (described in Materials and Methods). L-DOPA and
J-113397 attenuated akinesia at both paws although greater effectwas observed at the contralateral pawwhen both compounds
were applied together. Data aremeans SEMofn experiments (8–12per group). Statistical analysiswas performedby two-way
ANOVA with repeated measures followed by contrast analysis and the sequentially rejective Bonferroni test. *p 0.05 versus
saline-treated rats. #p 0.05 versus L-DOPA alone. §p 0.05 versus J-113397 alone.
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revealed amain effect of treatment (F(3,14)
18.80; p  0.0001) and time (F(7,125) 
15.46; p 0.0001) and a significant time
treatment interaction (F(21,125) 5.47; p
0.0001). Post hoc analysis showed that per-
fusion with bicuculline in the SNr did not
affect basal GLU levels. However, it de-
layed the reduction in GLU release in-
duced by combined administration of
J-113397 and L-DOPA.
Discussion
Systemic administration of anNOP recep-
tor antagonist (J-113397) or L-DOPA
alone dose-dependently attenuated
parkinsonian-like symptoms in hemipar-
kinsonian rats, whereas their combination
evoked additive effects depending on the
dose and the test used. Both compounds
exerted their antiakinetic actions through
a common “effector” as they produced ad-
ditive elevation of SNr GABA and inhibi-
tion of VMTh GABA release. This effect
was dependent on ongoing neuronal ac-
tivity in the SNr (TTX sensitive) and acti-
vation of SNr GABAA receptors (bicucul-
line sensitive), suggesting that J-113397
and L-DOPA acted through overinhibi-
tion of nigrothalamic GABAergic
neurons.
J-113397/L-DOPA interaction
on behavior
Unilateral lesion of SNc DA neurons
caused dramatic bilateral increase in the
immobility time, with the contralateral
(“parkinsonian”) forepaw being more se-
verely affected than the ipsilateral
(“good”) one. Although puzzling, this ob-
servation is consistent with reports that
unilateral DA depletion also affected pos-
ture (Whishaw et al., 2003), stepping time,
and stepping length (Olsson et al., 1995) at
the ipsilateral paw. Interestingly, when the
animal was forced to move (drag test), motor activity at the ipsi-
lateral pawwas only slightly impaired, suggesting that the bar and
drag test provide information on different aspects of motor pro-
gram. The bar test essentially measures the time to initiate a
movement (akinesia), whereas the drag test measures both the
time to initiate and to execute it (bradykinesia). The degree of
motor asymmetry in the drag test (65%) was consistent with
that reported by Wessell et al. (2004) (75%) and in line with
that found with the stepping [90% (Olsson et al., 1995); 80–
90% (Winkler et al., 2002);70% (Tillerson et al., 2001);75%
(Tseng et al., 2005); 50–90% (Kelsey et al., 2004)] or the postural
adjustment [75% (Lindner et al., 1996); 95% (Chang et al.,
1999)] tests. Powerful, dose-dependent attenuation of parkin-
sonism was produced by increasing L-DOPA doses: reduction of
akinesia at both the ipsilateral and the contralateral forepaw (0.1
mg/kg), improvement of exercise-induced motor performance
(0.3mg/kg), and reversal ofmotor asymmetry both under resting
(bar test) and dynamic (drag test) conditions (6 mg/kg). Similar
findings were reported by using the stepping (Olsson et al., 1995;
Chang et al., 1999; Winkler et al., 2002; Kelsey et al., 2004), pos-
tural adjustment (Lindner et al., 1996), and “wheelbarrow” [i.e.,
forward dragging (Schallert et al., 1979)] tests. It is noteworthy
that L-DOPA exerted an antiparkinsonian action at doses (0.1–6
mg/kg) lower than those eliciting contralateral rotations (25 mg/
kg), strengthening the view that ethological tests may be more
sensitive than analysis of pharmacologically induced (e.g., by do-
pamine agonists) turning behavior in screening for antiparkinso-
nian drugs.
The NOP receptor antagonist J-113397 reproduced L-DOPA
action, although less effectively because it did not reverse fully
motor asymmetry in the drag test (Marti et al., 2005). However,
combination of subthreshold doses (0.1 mg/kg) of J-113397 and
L-DOPA (ineffective per se) stimulated rotarod performance to
the same extent as L-DOPA 0.3 mg/kg, whereas combination of
submaximal doses (1 mg/kg) was as effective as L-DOPA 6mg/kg
in the drag test (i.e., it fully reversed asymmetry) and evoked a
sustained antiakinetic response in the bar test (see Results). Most
interestingly, combination of submaximal doses evoked supra-
maximal rotarod performance, suggesting that L-DOPA and
Figure 8. TTX prevented the reduction in VMTh GABA release and immobility time induced by L-DOPA and J-113397 coadmin-
istration. Two microdialysis probes were implanted in the lesioned SNr and ipsilateral VMTh of hemiparkinsonian rats. Perfusion
with TTX (1M; open bar) in the SNr started 90 min before systemic (intraperitoneal) coadministration (arrow) of J-113397 (1
mg/kg) and L-DOPA (1 mg/kg plus 15 mg/kg benserazide) and continued until the end of experiment. C, D, In the same rats,
akinesia was evaluated (every 15min for up to 180min) by using the bar test separately at the contralateral (C) and ipsilateral (D)
paws (described in Materials and Methods). Statistical analysis was performed by two-way ANOVA with repeated measures
followed by contrast analysis and the sequentially rejective Bonferroni test. Data are means SEM of n experiments. A, B, Basal
GABA levels (in nanomolar concentration) in the dialysate from the lesioned SNr (A) and ipsilateral VMTh (B)were, respectively, as
follows: 9.1 0.6 and 9.7 1.1 (washout/saline, n 5); 7.0 0.5 and 11.6 0.8 (TTX/saline, n 6); 7.3 0.7 and 13.5
0.9 (washout/J-113397 L-DOPA, n 5); 9.0 0.5 and 10.9 2.1 (TTX/J-113397 L-DOPA, n 5). *p 0.05 versus
saline-treated rats.
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J-113397 activated independent neuronal pathways rather than a
common, “saturable” mechanism. These data suggest that an
NOP receptor antagonist may be a good candidate for a combi-
nation therapy. From a clinical point of view, combination ther-
apy may benefit early PD patients by lowering L-DOPA dosage
and delaying dyskinesia onset, or it may benefit advanced PD
patients who require more than one medication to adequately
control PD symptoms.
Neurobiological substrates underlying
J-113397/L-DOPA interaction
Massive GLUergic innervation to the SNr is provided by the sub-
thalamic nucleus, which becomes overactive under parkinsonian
conditions (DeLong, 1990). Consistently, haloperidol evoked
catalepsy and elevated SNr GLU release (Marti et al., 2004b,
2005). NOP receptor antagonists attenuated haloperidol-
induced akinesia and normalized SNr GLU levels (Marti et al.,
2004b, 2005), prompting us to suggest that inhibition of SNr
GLU release underlies their antiparkinsonian action. SNr injec-
tions of UFP-101 [[Nphe1,Arg14,Lys15]N/OFQ-NH2] (Marti et
al., 2004b) reproduced the effects of sys-
temic injections of J-113397 (Marti et al.,
2005), further pointing to the SNr as their
site of action. Reverse dialysis ofN/OFQ in
the SNr elevated local GLU release via
GABA- and DA-mediated mechanisms
(Marti et al., 2002a). Thus, NOP receptor
antagonists may reduce SNr GLU release
in the DA-depleted SNr by blocking tonic
inhibition of DA and GABA neurons by
endogenous N/OFQ. Indeed, N/OFQ in-
hibits DA andGABA transmission inmes-
encephalic areas (Zheng et al., 2002; Marti
et al., 2004a), whereas NOP receptor an-
tagonists elevate SNr GABA release
(present study) and nigrostriatal DA
transmission (Marti et al., 2004a). How-
ever, bicuculline did not affect the increase
in SNr GABA and only delayed the reduc-
tion in GLU release evoked by L-DOPA
and J-113397, suggesting that GABAergic
inhibition is minimally involved in this
phenomenon. In the same animals, bicu-
culline prevented the motor effects of
combined L-DOPA and J-113397, further
indicating that inhibition of GLU release
may not be sufficient to explain the anti-
akinetic action of J-113397. In this respect,
J-113397 also increased GABA release in
the lesioned SNr and lowered GABA re-
lease in the ipsilateral VMTh. L-DOPA
shared this action, although it did not af-
fect SNr GLU levels. This suggests that DA
receptor stimulation and NOP receptor
blockade activated independent neuronal
pathways, converging on a common “ef-
fector”. According to the currentmodel of
basal ganglia functional organization (De-
Long et al., 1990), reduction of the sub-
thalamonigral GLUergic excitatory drive
and/or increase of the GABAergic inhibi-
tory influence on nigrothalamic GABAer-
gic neurons leads to disinhibition of
thalamocortical GLUergic projections and movement initiation
(Deniau and Chevalier, 1985). Thus, this “effector” is likely rep-
resented by nigrothalamic GABAergic neurons. More evidence
endorses this view. TTX perfusion in the SNr produced per se a
rapid decline in VMTh GABA release. This indicates that spon-
taneous VMTh GABA release partly reflects impulse-dependent
neuronal activity and is consistent with the fact that nigrotha-
lamicGABAneurons provide a tonic input to the thalamus (Guy-
enet and Aghajanian 1978; Waszczak et al., 1980). This input is
enhanced after DA lesion (Burbaud et al., 1995), which may ex-
plain whyGABA levels were higher in the VMTh ipsilateral to the
lesioned side. Interestingly, reduction of VMTh GABA release
induced by TTXwas associated with attenuation of akinesia. This
is consistent with our previous finding that SNr perfusion of
higher TTX concentrations (10 M) evoked contralateral rota-
tions in naive rats (Morari et al., 1996) and strengthens the view
that inhibition of nigrothalamic GABAergic neurons results in
disinhibition of locomotion (Starr et al., 1983; Deniau and Chev-
alier, 1985). Nigrothalamic GABAergic neurons express GABAA
receptors (Nicholson et al., 1995), which drive both tonic (Rick
Figure 9. Bicuculline (BIC) prevented the reduction in VMTh GABA release and immobility time induced by L-DOPA and
J-113397 coadministration. Two microdialysis probes were implanted in the lesioned SNr and ipsilateral VMTh of hemiparkinso-
nian rats. Perfusion with BIC (10 M; open bar) in the SNr started 90 min before systemic (intraperitoneal) coadministration
(arrow) of J-113397 (1mg/kg) and L-DOPA (1mg/kg plus 15mg/kg benserazide) and continued until the end of experiment. C,D,
In the same rats, akinesia was evaluated (every 15 min for up to 180 min) by using the bar test separately at the contralateral (C)
and ipsilateral (D) paws (described in Materials and Methods). Statistical analysis was performed by two-way ANOVA with
repeated measures followed by contrast analysis and the sequentially rejective Bonferroni test. Data are means SEM of n
experiments.A,B, Basal GABA levels (in nanomolar concentration) in the dialysate from the lesioned SNr (A) and ipsilateral VMTh
(B) were, respectively, as follows: 9.1 0.6 and 9.7 1.1 (washout/saline, n 5); 7.8 0.9 and 11.9 1.8 (BIC/saline, n
5); 7.3 0.7 and 13.5 0.9 (washout/J-113397 L-DOPA, n 5); 9.2 1.5 and 12.1 2.3 (BIC/J-113397 L-DOPA, n
5). *p 0.05 versus saline-treated rats.
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and Lacey, 1994) and phasic (in vivo) (Deniau and Chevalier,
1985) inhibition. Thus, bicuculline may prevent both the atten-
uation of akinesia and the decrease in VMTh GABA release by
blocking those postsynaptic GABAA receptors. Likewise, bicucul-
line prevented the reduction in VMTh GABA release induced by
systemic methamphetamine (Mark et al., 2004). Alternatively,
blockade of inhibitory GABAA receptors on (residual) nigral DA
cellsmay lead to increasedDA release (Westerink et al., 1992) and
attenuation of the inhibitory control driven by GABAA receptors
onto nigrothalamic GABAergic neurons (Waszczak andWalters,
1986), which may also result in attenuation of the antiakinetic
effect of L-DOPA.
The mechanisms through which systemic L-DOPA increased
SNr GABA release also remain to be investigated. L-DOPA could
stimulate D1 receptors on striatonigral neurons (Gerfen et al.,
1990), so to activate the “direct” pathway (Robertson and Rob-
ertson, 1989; Carta et al., 2005), or D1 receptors on striatonigral
nerve terminals (Starr, 1987; Aceves et al., 1991). The fact that
TTX prevented the L-DOPA effect rules out this latter hypothesis,
although it does not exclude an intranigral action of L-DOPA
because this agent could stimulate GABAergic interneurons
[dendritic location of D1 receptors has been detected in the SNr
(Huang et al., 1992)]. Finally, the possibility that L-DOPA in-
creases SNr GABA release by modulating the subthalamonigral
GLUergic projection cannot be discarded because L-DOPA ele-
vated SNr GLU levels. However, this possibility appears remote
in view of the mismatch between the dynamics of GABA and
GLU levels.
Concluding remarks
Combined administration of an NOP receptor antagonist (J-
113397) and L-DOPA produced additive attenuation of
parkinsonian-like symptoms through an increase in SNr GABA
release and consequent overinhibition of SNr GABAergic neu-
rons projecting to the VMTh. These data strengthen the role of
the VMTh in the modulation of parkinsonism (Wolfarth et al.,
1985; Kolasiewicz et al., 1988), emphasizing its role as a relay
nucleus for impulses ascending from the SNr to the cortex
(Klockgether et al., 1986). This appears relevant also in humans,
in whichmotor improvement induced by deep brain stimulation
in the subthalamic nucleus was associated with lowered GABA
release in the motor thalamus (Stefani et al., 2006). Overall, the
present study provides novel insights into the mechanisms un-
derlying the antiparkinsonian action of J-113397 and L-DOPA
and suggests that an NOP receptor antagonist may be used alone
or as an adjunct to L-DOPA in the therapy of PD.
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Available online 8 March 2008Endogenous nociceptin/orphanin FQ (N/OFQ) inhibits the activity of
dopamine neurons in the substantia nigra and affects motor behavior.
In this study we investigated whether a N/OFQ receptor (NOP) anta-
gonist, J-113397, can modify movement in naive mice and nonhuman
primates and attenuate motor deficits in MPTP-treated parkinsonian
animals. J-113397 facilitated motor activity in naïve mice at low doses
(0.1–1 mg/kg) and inhibited it at higher ones (10 mg/kg). Likewise, in
MPTP-treated mice, J-113397 reversed motor deficit at 0.01 mg/kg but
worsened hypokinesia at higher doses (1 mg/kg). In naïve nonhuman
primates, J-113397, ineffective up to 1 mg/kg, produced inconsistent
motor improvements at 3 mg/kg. Conversely, in parkinsonian primates
J-113397 (0.01 mg/kg) reversed parkinsonism, being most effective
against hypokinesia. We conclude that endogenous N/OFQ modulates
motor activity in mice and nonhuman primates and contributes to
parkinsonian symptoms in MPTP-treated animals. NOP receptor anta-
gonists may represent a novel approach to Parkinson's disease.
© 2008 Elsevier Inc. All rights reserved.
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Introduction
Nociceptin/orphanin FQ (N/OFQ) is an opioid-like neuro-
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doi:10.1016/j.nbd.2008.02.011activates the NOP receptor (Cox et al., 2000). The N/OFQ-NOP
receptor system is expressed in motor areas of the rodent (Neal
et al., 2001) and primate brain (Bridge et al., 2003) and, particu-
larly, in the substantia nigra (SN), which contains dopamine (DA)
neurons that degenerate in Parkinson3s disease (PD). N/OFQ
inhibits the activity of DA neurons located in the SN compacta
(SNc; Marti et al., 2004a) and impairs spontaneous (Reinscheid
et al., 1995; Devine et al., 1996) and exercise-induced locomotion
(Marti et al., 2004a) in rodents. Conversely, selective NOP re-
ceptor antagonists, such as [Nphe1, Arg14, Lys15]N/OFQ-NH2
(UFP-101; Calò et al., 2002) and 1-[(3R,4R)-1-cyclooctylmethyl-
3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimida-
zol-2-one (J-113397 or compound B; Kawamoto et al., 1999)
increase striatal DA release and rotarod performance (Marti et al.,
2004a), indicating that endogenous N/OFQ exerts an inhibitory
control on physiologically-stimulated locomotion. We have pro-
posed that endogenous N/OFQ plays a pathogenic role in PD
(Marti et al., 2005). Indeed, N/OFQ transmission was found
to be up-regulated in the DA-depleted SN of 6-hydroxydopamine
(6-OHDA) hemi-lesioned rats (Marti et al., 2005). Moreover, NOP
receptor antagonists alleviated akinesia/bradykinesia induced by
haloperidol administration (Marti et al., 2004b) and 6-OHDA
lesion (Marti et al., 2005), and enhanced the antiparkinsonian
effect of L-DOPA when co-administered to rats (Marti et al.,
2007). Finally, NOP receptor and ppN/OFQ knockout mice were
found to be more resistant than wild-type to haloperidol-induced
akinesia and 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine
(MPTP) induced toxicity, respectively (Marti et al., 2005). Here
we explored the hypothesis that the NOP antagonist J-113397
alleviates motor deficit in MPTP-treated mice and nonhuman
primates. The advantage of the MPTP models is that systemic
administration produces a bilateral DA denervation and, in
nonhuman primates, MPTP induces symptoms that closely resem-
ble those observed in parkinsonian patients. We used NOP receptor
Table 1
Individual characteristics of MPTP-lesioned primates
Animal # Weight
(kg)
PRS score
after MPTP
PRS score 3rd
month post-MPTP
Activity d/n
(% from baseline)
Mf23 4.4 17 18.25 −76/−60
Mf25 5.4 19 21.5 −77/−62
Mf30 6.1 21 20 −68/−32
Mf34 5.3 18 18.5 −5/−60
431R. Viaro et al. / Neurobiology of Disease 30 (2008) 430–438knockout (NOP−/−) mice to confirm the specificity of the in vivo
action of J-113397.
Materials and methods
Subjects
Mice
Male Swiss, C57BL/6J (20–25 g; 12 week old, Harlan Italy, S.
Pietro al Natisone, Italy), CD1/C57BL6J/129NOP+/+ andNOP−/−mice
(20–25 g; 12–15 week old; Nishi et al., 1997) were used. Mice were
kept under standard conditions (12 h dark:12 h light cycle, free access to
food and water) and the experimental protocols were approved by the
Italian Ministry of Health (licence n° 71-2004-B).
Mice were trained for a week in order to obtain a stable per-
formance in the three behavioral tests used to assess motor perfor-
mance. Mice were then treated acutely with MPTP (4×20 mg/kg,
90 min apart). Pharmacological tests were performed 7 days after
MPTP treatment, i.e. when DA cell loss stabilizes (Jackson-Lewis
and Przedborski, 2007). Mice were later sacrificed for tyrosine
hydroxylase (TH) immunohistochemistry (7th day post-MPTP).Fig. 1. J-113397 (0.03–10 mg/kg, i.p.) dually modulated rotarod performance in na
their motor performance was reproducible (see Materials and methods). On the day
session) and after (10 and 60 min) drug administration. The time spent on the rod wa
the control session and represent the mean±SEM of 8–10 determinations for each
analysis and the sequentially rejective Bonferroni's test).Nonhuman primates
Four young adult male macaques (Macaca fascicularis) were
included in the study. Animals were housed individually at the
New England Primate Research Center. All the studies were done
following NIH guidelines for animal welfare and were approved by
the IACUC at Harvard Medical Area and the New England Re-
gional Primate Research Center. After completion of experiments
in the naïve state, animals were rendered parkinsonian by systemic
administration of MPTP (0.3 mg/kg/week i.v. for 7.5±2.5 weeks)
as described (Jenkins et al., 2004; Sanchez-Pernaute et al., 2007).
Pharmacological tests were performed at least 3 months after the
last MPTP dose.
Behavioral assessment
Mice
Motor activity was evaluated blindly using a battery of previ-
ously validated behavioral tests specific for different motor abilities
under static (bar test; Sanberg et al., 1988) and dynamic (drag test
and fixed-speed rotarod test; Rozas et al., 1997; Marti et al., 2004a,
2005) conditions. On the day of experiment, the tests were per-
formed before (control session) and 10 and 60 min after drug or
vehicle injection. Each animal was taken as its own control.
Bar test. Each mouse was placed on a table and the contralateral
and ipsilateral forepaws were placed alternatively on blocks of in-
creasing heights (1.5, 3 and 6 cm). Total time (in seconds) spent by
each paw on the blocks was recorded (cut-off time of 20 s).
Drag test. Each mouse was lifted by the tail (allowing forepaws
on the table) and dragged backwards at a constant speed (∼20 cm/s)ïve Swiss and C57BL/6J mice. Mice were trained daily on the rotarod until
of the experiment, three behavioral sessions were carried out, before (control
s calculated (in seconds). Data are expressed as percent of the performance in
group. ⁎pb0.05; different from saline (RM ANOVA followed by contrast
432 R. Viaro et al. / Neurobiology of Disease 30 (2008) 430–438for a fixed distance (100 cm). The number of stepsmade by each paw
was counted by two separate observers.
Rotarod test. A protocol that allowed to detect both facilitatory
and inhibitory drug effects was used (Marti et al., 2004a). Mice were
tested at increasing speeds (usually from 5 to 45 rpm for naïve and
from 5 to 35 rpm for MPTP-treated mice; 180 s each) and motor
activity was calculated by comparing the performance over a speed
range (usually 30–45 rpm for naïve and 20–35 rpm for MPTP-
treated mice) causing a progressive decrement of performance to
∼40% of the maximal response (i.e. the experimental cut-off time).Fig. 2. Motor effects of J-113397were dependent on NOP receptor. J-113397
(0.03–10 mg/kg, i.p.) dually modulated rotarod performance in wild-type
mice (NOP+/+; panel A) but was ineffective in NOP receptor knockout mice
(NOP−/−; panel B). Mice were trained daily on the rotarod until their motor
performancewas reproducible (seeMaterials andmethods). On the day of the
experiment, three behavioral sessions were carried out, before (control
session) and after (10 and 60 min) drug administration. The time (in seconds)
spent on the rod was calculated. Data are expressed as percent of the
performance in the control session and are mean±SEM of 8–10 determina-
tions for each group. ⁎pb0.05; different from saline (RM ANOVA followed
by contrast analysis and the sequentially rejective Bonferroni's test).Nonhuman primates
Animals were trained to perform a computerized timed reaching
task that measures the speed of arm movements (MAP test; Jenkins
et al., 2004). Training was carried out for an average of 6 days for the
platform task and 8–12 days for the straight rod task, until the per-
formance (time to retrieve the treats) was stable. For pharmacological
evaluation, animals were tested 30 min after the administration of
vehicle (saline) for 2 days and then with either saline or the active
drugs. In addition, global motor activity data was obtained using
activitymonitors (Actiwatch) for aweek at the naïve and parkinsonian
stages (Table 1). These tests provide objective measures of brady-
kinesia and hypokinesia, respectively. For motor evaluation, animals
were transferred to a Plexiglas observation cage where they were
videotaped. Motor behavior was rated according to a scale based on
the motor subscale of the UPDRS (Unified Parkinson3s Disease
Rating Scale), as described (Jenkins et al., 2004; Sanchez-Pernaute
et al., 2007). The following signs were scored from 0 to 3: brady-
kinesia in the left and right arms (L/R), tremor L/R, rigidity L/R,
hypokinesia, posture/balance (for a total score from 0 to 24). Scores
were obtained at 30–45min after each drug or vehicle administration.
Histological evaluation in mice
Mice were anaesthetised with ketamine 85 mg/kg and xylazine
15 mg/kg (i.p.), transcardially perfused with 20 mM phosphate-
buffered saline (PBS) and fixed with 4% paraformaldehyde in PBS at
pH 7.4. The brains were removed, post-fixed overnight and cryopro-
tected in 20% sucrose (solution in PBS). Serial coronal sections of
30 µm thickness were made in the striatum (−0.8 to +1.3 from
bregma) and every second section processed for TH immunohisto-
chemistry, as described (Marti et al., 2007). Briefly, sections were
preincubated in blocking serum (5% normal horse serum and 0.3%
Triton X 100 in PBS), incubated overnight in anti-TH mouse mono-
clonal antibody solution (1:2000, Chemicon, Temcula, CA), then in
biotinylated horse anti-mouse IgG secondary antibody (1:200; Vector
Laboratories, Burlingame, CA) for 1 h and finally treatedwith avidin–
biotin-peroxidase complex (Vector Laboratories). Immunoreactivity
was visualized by incubating the sections in a solution containing
0.05% 3,3-diaminobenzidine (DAB) in 0.013% H2O2. Images from
every section were acquired with a Polaroid DMC camera mounted in
a Zeiss Axioskop (Carl Zeiss, Oberkochen, Germany) and the optical
density of TH-immunoreactive fibres in the striatum was analysed at
five AP levels for each animal (−0.10,+ 0.20,+ 0.50,+ 0.80,+ 1.10)
using ImageJ software (WayneRasband;NIH,USA).Region of interest
for estimation of optical density was performed in the dorsolateral area
of the caudate-putamen. Optical density (corrected for non-specific
background measured in the corpus callosum) was first calculated for
each animal as the mean of the 5 striatal levels. Group means(as presented in figure) were then obtained by averaging each indi-
vidual value.
Data presentation and statistical analysis
Mice
Motor performance was calculated as time on bar or on rod (in
seconds) and number of steps (drag test). Data are expressed as a
percent±SEMof the control session. Statistical analysiswas performed
(CoStat 6.3, CoHort Software,Monterey, CA,USA) on percent data by
repeated measure (RM) analysis of variance (ANOVA) followed by
contrast analysis and the sequentially rejective Bonferroni3s test.
Nonhuman primates
Statistical analysis was performed (StatView Software, SAS, CA),
using t tests and ANOVA (followed by the PLSD test) to determine
Fig. 3. MPTP administration produced motor impairment and loss of striatal DA terminals in C57BL/6J mice. Motor activity was evaluated by three behavioral
tests: the bar (panel A), drag (panel B) and rotarod (panel C) test. Mice were trained daily for a week until their motor activity was reproducible (see Materials and
methods). Before MPTP (20 mg/kg) or saline administration (4 injections, 90 min apart), motor activity was evaluated, and the time spent (seconds) on the blocks
(bar test), the number of steps made by the forelimbs (drag test) and the time spent on the rod (rotarod test) were calculated. Another session was repeated 7 days
after MPTP administration. Tyrosine hydroxylase (TH) immunohistochemistry was then performed in striatal slices (panels D–F). Photomicrograph of TH-positive
fibres in the striata of saline (panel D) and MPTP-injected (panel E) mice. Optical density of TH-positive fibres in the striatum (panel F). Values are presented as
means±SEM, obtained from 4 saline- and 6 MPTP-treated mice. Data are expressed in absolute values and are mean±SEM of 9 determinations for each group.
⁎pb0.05; different from saline-injected mice (panels A–C, ANOVA followed by the Newman–Keuls test; panel F, Student's t-test).
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Data are shown as mean values±SEM.Materials
L-DOPA methylester, benserazide and MPTP were purchased
from SigmaChemical Company (St Louis,MO, USA). J-113397 was
synthesized as a racemic mixture in our laboratories (Marti et al.,
2004a). All drugs were freshly dissolved in isoosmotic saline solution
prior to use.
Results
Studies in mice
Naïve Swiss and C57BL/6J mice
To investigate the role of endogenous N/OFQ in the regulation of
motor activity, J-113397 was administered systemically in Swiss mice
(Fig. 1A). RMANOVAshowed a significant effect of treatment (F5,40 =
20.90, pb0.0001), time (F1,5 = 4.80, p = 0.033) and a significant
time×treatment interaction (F5,48 = 3.51, p= 0.0087). Post-hoc analysis
showed that J-113397 facilitated rotarod performance in the 0.1–1 mg/
kg dose range (maximal increase ~34%) while inhibited it at 10 mg/kg(~29%). Both effects were evident up to 60 min after administration.
The complete battery of behavioral tests was then used to characterize
J-113397 action inC57BL/6Jmice (Figs. 1B–D). RMANOVAon the
immobility time as in the bar test (Fig. 1B), revealed a main effect of
treatment (F4,28 = 12.49, pb0.0001) but not time (F1,4 = 0.04, p=0.85)
and a non significant time×treatment interaction (F4,39 = 0.09, p =
0.98). J-113397 increased the immobility time at 10 mg/kg, lower
doses being ineffective. RM ANOVA on the number of steps as in the
drag test (Fig. 1C) revealed a main effect of treatment (F4,28 = 23.81,
pb0.0001), time (F1,4 = 27.65,pb0.0001) and a significant time×treat-
ment interaction (F4,39 = 14.00, pb0.0001). Likewise, RMANOVAon
the rotarod performance (Fig. 1D) showed a main effect of treatment
(F4,28 = 9.81, pb0.0001), time (F1,4 = 9.02, p = 0.0046) and a
significant time×treatment interaction (F4,39 = 15.23, pb0.0001). Post-
hoc analysis revealed that J-113397 enhanced the number of steps
(Fig. 1C) and the exercise-stimulated locomotion (Fig. 1D) at 0.3 and
1 mg/kg while reducing them at 10 mg/kg. No effects were observed
60 min after drug administration.Naïve NOP−/− mice
Since high doses of J-113397 (10 mg/kg) have been reported to
exert effects independent of NOP receptors (Koizumi et al., 2004), we
investigated the specificity of the J-113397 action (Fig. 2). RM
Fig. 4. J-113397 attenuated motor deficits in MPTP-treated C57BL/6J mice. Motor activity was evaluated by three behavioral tests: the bar (panel A), drag (panel
B) and rotarod (panel C) test. Mice were trained daily until their motor activity was reproducible (see Materials and methods), then they were treated with MPTP.
Seven days afterMPTPmicewere challengedwith saline, J-113397 (0.01–1mg/kg, i.p.) or L-DOPA (10mg/kg plus benserazide 2.5mg/kg, i.p.). Three behavioral
sessions were carried out, before (control session) and after (10 and 60 min) drug or saline administration. The time spent (seconds) on the blocks (bar test), the
number of steps made by the forelimbs (drag test) and the time spent on the rod (rotarod test) were calculated. Data are expressed as percent of the performance in
the control session and aremean±SEMof 8–10 determinations for each group. ⁎pb0.05; different from saline (RMANOVA followed by contrast analysis and the
sequentially rejective Bonferroni's test).
434 R. Viaro et al. / Neurobiology of Disease 30 (2008) 430–438ANOVA in NOP+/+ mice (Fig. 2A) revealed a significant effect of
treatment (F4,28 = 72.24, pb0.0001), time (F1,4 = 15.66, p = 0.0003)
and a significant time×treatment interaction (F4,39 = 7.42, p= 0.0002).
J-113397 facilitated rotarod performance at 0.1 and 1 mg/kg and
inhibited it at 10 mg/kg. No major difference was observed between
Swiss and NOP+/+ mice in terms of sensitivity to J-113397 or duration
of the response. Conversely, J-113397 was not effective in NOP−/−
mice at any of the doses tested (Fig. 2B), suggesting that both the
facilitation and the inhibition observed in NOP+/+ mice were due to
NOP receptor blockade.MPTP-treated C57BL/6J mice
Seven days after MPTP intoxication, mice displayed increased
immobility time (Fig. 3A), reduced number of steps (Fig. 3B) and
impaired rotarod performance (Fig. 3C) compared to pre-treatment
values. This behavior was associated with a ~60% loss of striatal
TH-positive nerve terminals (Figs. 3D–F). Motor deficit induced by
MPTP was reversed by L-DOPA and J-113397 (Fig. 4). Thus, RM
ANOVA on immobility time (Fig. 4A) revealed a significant effect
of treatment (F5,40 = 19.92, pb0.0001) but not time (F1,5 = 0.01, p =
0.92), and a significant time× treatment interaction (F5,48 = 4.15, p =
0.0032). L-DOPA (10 mg/kg) and J-113397 (0.01–0.03 mg/kg)
reduced the immobility time. However, J-113397 increased it at
1 mg/kg. RM ANOVA on the number of steps (Fig. 4B) revealed a
significant effect of treatment (F5,40 = 13.32, pb0.0001) but not time
(F1,5 = 0.12, p = 0.73), and a significant time×treatment interaction(F5,48 = 3.73, p = 0.0062). L-DOPA and J-113397 (0.01–0.03 mg/kg)
increased the number of steps. Higher doses of J-113397 (1 mg/kg)
were found ineffective. Finally, RM ANOVA on the rotarod perfor-
mance (Fig. 4C) showed a significant effect of treatment (F5,40 = 13.07,
pb0.0001) but not time (F1,5 = 2.54, p = 0.11), and a time×treatment
interaction at the limit of significance (F5,48 = 2.40, p = 0.05). L-DOPA
and J-113397 (0.01 mg/kg) increased the rotarod performance.
However, J-113397 (1 mg/kg) inhibited it. Differently from L-DOPA,
J-113397 was no longer effective after 60 min in all tests.Studies in nonhuman primates
Naïve macaques
The NOP receptor antagonist, J-113397 did not affect motor per-
formance in naïve macaques at 0.1 and 1 mg/kg (Fig. 5). At a higher
dose (3 mg/kg) J-113397 induced a faster performance in the straight
rod test in two of the animals (Fig. 5A), although the other two did not
perform the test. Therefore we tested these animals on a simpler task
(i.e. the platform task) but at this dose animals were inattentive and
performance was slightly slower than normal (Fig. 5B).
MPTP-treated macaques
We first examined the response to four doses of J-113397 (0.01,
0.03, 0.1 and 1 mg/kg) in two stable parkinsonian animals (data not
shown). From 0.03 to 1 mg/kg we did not observe any beneficial
effect on either parkinsonian score or MAP platform performance; at
Fig. 5. J-113397 (0.1–3 mg/kg, i.m.) modulated motor activity in naïve
nonhuman primates. Motor performance was evaluated in the Movement
Analysis Panel (MAP) test. Average time in seconds to retrieve a treat in the
straight rod (panel A) test was significantly improved in 2 animals at the higher
dose of J-113397 tested, but at this dose the other 2 animals showed side effects
(distractibility, scratching and “wet dog” shakes) and failed to perform. These 2
animals were subsequently tested in the platform (easier) task (panel B) of the
MAP test in which they performed significantly worse at the high dose.
⁎pb0.05; different from saline (ANOVA followed by PLSD test).
Fig. 6. Effect of J-113397 onmotor symptoms inMPTP-treated primates. Panel
A. Effect of J-113397 (0.01mg/kg) and L-DOPA (30mg/kg) on the global PRS
score. The average improvement over the baseline score (n=2–3 pharmaco-
logical tests for each compound) is shown for each animal. The improvement
after J-113397 administration (∼19±3%) was more moderate than that
achieved with L-DOPA (∼46±3%, Fisher PLSD p=0.001). Comparative
analysis of the pharmacological effects of L-DOPA and J-113397 on par-
kinsonian symptoms (panel B) showed that all symptoms improved more with
L-DOPA except for hypokinesia.
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similar to the effect of high doses of J-113397 observed in 6-OHDA
rats (30 mg/kg, Morari and Marti, unpublished observation) and did
not perform the reaching test. No major side effects were observed at
0.03 mg/kg but one animal did not test and the other did not show any
improvement in the reaching task. With the lower dose (0.01 mg/kg)
both animals showed an improvement in the MAP platform reaching
task and therefore we selected this dose for the rest of the experiments.
Both J-113397 (0.01 mg/kg) and L-DOPA (30 mg/kg) induced
a significant benefit in parkinsonian scores in the 4 animals (F2,9 =
13.5, pb0.01; Fig. 6A). The overall improvement after J-113397
administration (~19±3%, p = 0.015) was more moderate than that
achieved with L-DOPA (~46±3%, p = 0.001). Although as a group,
the difference between L-DOPA and J-113397 improvement in
global PRS score did not reach significance (p = 0.07), only in one
animal (Mf25) was the response to both drugs not significantly
different (Fig. 6A). There was no significant effect of the baseline
PRS score (i.e. severity of the parkinsonian signs) on the response to
either drug. We further analysed the therapeutic effect on parkin-
sonian symptoms (Fig. 6B). The largest improvement induced by
J-113397 (~30%) was observed on hypokinesia and the L-DOPA
effect on this particular symptom was not significantly different from
J-113397. All other symptoms (rigidity, tremor and bradykinesia)
improved significantly more with L-DOPA (Fig. 6B).Finally, we evaluated the performance of the parkinsonian animals
in the MAP test (Fig. 7). MPTP induced a significant increase in the
time needed to complete the platform task in 3 out of 4 animals (Mf23,
Mf25 andMf30). These animals showed a significant improvement in
the time to retrieve treats from the platform with L-DOPA and one of
them had also a significant improvement in performance after
J-113397 (Fig. 7).
Discussion
The most important finding of the present study is that the NOP
receptor antagonist J-113397 reversed motor disabilities in MPTP-
treated mice and nonhuman primates. These data reinforce the
view that endogenous N/OFQ plays a role in motor symptoms in
parkinsonism across species. Moreover, the efficacy of J-113397 in
some MPTP-treated primates raises the possibility of a therapeutic
effect of NOP receptor antagonists in PD patients, although the
unusual dual action of J-113397 calls for evaluation of other (more
selective?) NOP antagonists.
Role of endogenous N/OFQ in modulation of locomotion under
physiological conditions
Motor impairment has been one of the main biological effects
observed after intracerebroventricular injection of N/OFQ in rodents.
Fig. 7. Effect of J-113397 on the MAP test in MPTP-treated primates. MPTP induced a significant increase in the time needed to complete the platform task
(animals were unable to perform the straight rod task) in 3 out of 4 animals (Mf23, Mf25 andMf30). In these animals L-DOPA improvement on task performance
was significant. Only one of them (Mf23) showed a significant improvement in response to J-113397. ⁎pb0.05; different from post-MPTP performance
(ANOVA followed by PLSD test). #pb0.05; different from J-113397 (ANOVA followed by PLSD test).
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systemic administration of nonpeptide NOP receptor agonists. (Jenck
et al., 2000; Varty et al., 2005). Reports that lower N/OFQ doses
(pmol) facilitate motor performance in rats (Florin et al., 1996;
Kuzmin et al., 2004) and mice (Sakoori and Murphy, 2004) have also
been published. Although this effect is much milder than the
inhibitory one, and observed in a narrower dose range, it confers to the
N/OFQ dose-response curve a biphasic profile. The finding that J-
113397 dually modulated exercise-induced locomotion in Swiss,
C57BL/6J and NOP+/+ but not NOP−/− mice suggests that
endogenous N/OFQ can both facilitate and inhibit motor activity
through NOP receptor activation. These effects, however, do not
appear to be physiologically equivalent, motor inhibition being
predominant (Marti et al., 2004a). Systemic injection of NOP receptor
antagonists or deletion of the NOP receptor gene failed to affect
spontaneous locomotion (Gavioli et al., 2003; Kuzmin et al., 2004;
Marti et al., 2004a;Rizzi et al., 2007). In linewith this view,wedid not
detectmotor facilitation by J-113397 in the bar test (a static test), while
there was a prominent effect in tests engaging the animals in repetitive
and prolonged movements (i.e. the drag and rotarod test). These data
reinforce the hypothesis that endogenous N/OFQ produces a
functional inhibition during induced motor activity and not at rest.
Indeed, extracellular N/OFQ levels rise during rotarod performance
(Marti et al., 2005).
In line with a previous study (Ko et al., 2006), J-113397 did not
exert motor effects in naïvemacaques up to 1mg/kg.However, higher
doses (3 mg/kg) improved arm speed (straight rod test) in two animals
while the remaining two could not perform the test, looking dis-
tracted and slightly “hallucinated”. Although the inconsistency ofresponse prevents from drawing firm conclusions on the role of
endogenous N/OFQ, the data obtained in two animals are in line with
the view that the peptide plays an inhibitory role on motor activity.
Nevertheless, high doses of J-113397 may also activate sigma recep-
tors (Chiou et al., 2007), causing loss of attention and hallucinations
(Okuyama et al., 1994).
Role of endogenous N/OFQ in modulation of MPTP-induced
parkinsonism
The MPTP-lesioned nonhuman primate (macaque) model repro-
duces many PD motor symptoms faithfully and is used to assess the
therapeutic potential of novel antiparkinsonian drugs (Dauer and
Przedborski, 2003). Conversely, the neurochemical and behavioral
outcomes ofMPTP administration inmice are highly variable, mainly
depending on strain, age, gender, route and protocol of administration
(Sedelis et al., 2001; Meredith and Kang, 2006). Thus, a direct
comparison with data obtained in our model is quite difficult. Never-
theless, we found that mice displayed increased immobility time
(likely reflecting increased akinesia), reduced number of steps (pos-
sibly reflecting increased akinesia, bradykinesia and rigidity) and
overall impaired motor performance (possibly reflecting loss of coor-
dination and overall gait ability) at 7 days after MPTP intoxication.
These data are consistent with that reported by other authors using the
bar (Kato et al., 2004; Watanabe et al., 2008) and the treadmill
(Petzinger et al., 2007) test at 7 days after MPTP administration
(4×20 mg/kg). In the same study, no differences in rotarod perfor-
mance after MPTP intoxication were observed. The discrepancy may
be explained on the basis of technical issues such as rod diameter
437R. Viaro et al. / Neurobiology of Disease 30 (2008) 430–438(3 cm vs 8 cm in ourmodel) and exercise protocol, which appearmore
challenging for mice in our study (from 5 to 35 rpm, for a total of
21 min) compared to the previous one (30 rpm for 200 s; Petzinger
et al., 2007). Actually, the difficulty and duration of motor task appear
crucial to detect changes in rotarod performance. Indeed, Sedelis et al.
(2000) did not find difference in rotarod performance 4 days after
MPTP intoxication (4×15 mg/kg) using a less strenuous protocol
(fixed speed of 12 rpm for 120 s; rod 2.5 cm). It is noteworthy that
motor impairment in our study was DA-dependent since it was
associated with significant (~60%) loss of striatal DA terminals and
was reversed by L-DOPA. In these tests, J-113397 reproduced the
antiparkinsonian action of L-DOPA. Thus, in addition to reversing the
neuroleptic and 6-OHDA-induced parkinsonism (Marti et al., 2004b,
2005, 2007), J-113397 was effective both in acute (mice) and chronic
(macaques) paradigms of MPTP administration, overall suggesting
that endogenous N/OFQ plays a role in experimental parkinsonism
independent of the species and models used. Interestingly, not only
DA loss did not prevent the antiparkinsonian action of J-113397 but it
enhanced sensitivity to J-113397, resulting in a leftward shift of the
dose-response curve. In 6-OHDA hemi-lesioned rats, this phenom-
enon was associated with up-regulation of N/OFQ expression and
release (Marti et al., 2005). In parkinsonian macaques, J-113397 was
less effective than L-DOPA, although it improved hypokinesia com-
parably to L-DOPA, indicating a general depressive effect of endo-
genous N/OFQ on movement. In keeping with this notion, we
reported that exogenous N/OFQ depressed motor cortex excitability
andmotor output in vivo via activation of nigral NOP receptors (Viaro
et al., 2006). From a clinical perspective, however, the narrow the-
rapeutic range is quite disappointing, as the antiparkinsonian effects
of 0.01 mg/kg J-113397 vanished at higher doses, turning into mo-
tor inhibition at 1 mg/kg. The fact that this phenomenon was obser-
ved in mice (in the same dose range) suggests that it is mediated
by NOP receptors. Nevertheless, we cannot elucidate whether this
is a peculiarity of the compound (e.g. kinetics of interaction with
the NOP receptor, brain penetrability) or a “class effect” until other
NOP receptor antagonists, preferably chemically unrelated, have been
tested.
Neurobiological substrates of J-113397 action
Systemic administration of J-113397 in naïve rats increased
rotarod performance and elevated striatal DA release, suggesting
that endogenous DA tonically inhibits nigrostriatal DA trans-
mission (Marti et al., 2004a). This is in line with the findings that
exogenous N/OFQ inhibited activity of nigral DA cells, an effect
associated with hypolocomotion (Marti et al., 2004a). Thus, it can be
proposed that the antiparkinsonian action of J-113397 is mediated by
blockade of inhibitory NOP receptors expressed on residual nigral
DA cells resulting in increased DA transmission. However, NOP
receptor antagonists are effective also under conditions of DA
depletion and DA receptor blockade (Marti et al., 2004b; Marti et al.,
2005) suggesting that endogenous N/OFQ causes motor depressant
responses also via non-DA mechanisms. Indeed, NOP receptors are
also present on serotonergic, GABAergic and glutamatergic terminals
in SN (M. Morari and M. Marti, personal communication). In par-
ticular, we found that the antiakinetic effect of J-113397 was
associated with increased GABA and reduced GLU release in the
SNr, leading to an impairment of nigrothalamic GABAergic tran-
smission and, possibly, thalamic disinhibition (Marti et al., 2007).
Within this frame, motor inhibitory actions of J-113397 could be
attributed to an excessive or more prolonged degree of NOP receptorblockade or to blockade of different subsets of NOP receptors
(Kuzmin et al., 2004) (facilitating or inhibitingmotor activity) located
either along the same or different motor pathways. The fact that motor
facilitation induced by exogenous N/OFQ was blocked by haloper-
idol or DA depletion (Florin et al., 1996; Kuzmin et al., 2004)
suggests the involvement of the same mesencephalic DA areas that
mediate locomotion.
Concluding remarks
TheNOP receptor antagonist J-113397 produced a dose-dependent
effect (facilitation at low doses and inhibition at high) of motor
activity in naïve andMPTP-induced parkinsonianmice and nonhuman
primates. This is consistent with the notion that endogenous N/OFQ
is predominantly involved in motor inhibition, particularly during
exercise-induced activity. Although the dual action of J-113397 in
parkinsonian primates needs to be further characterized, our data
support the view that NOP receptor is a new target in the therapy of
PD.
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Suppression of activity in the forelimb motor cortex
temporarily enlarges forelimb representation
in the homotopic cortex in adult rats
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Abstract
After forelimb motor cortex (FMC) damage, the unaffected homotopic motor cortex showed plastic changes. The present
experiments were designed to clarify the electrophysiological nature of these interhemispheric effects. To this end, the output
reorganization of the FMC was investigated after homotopic area activity was suppressed in adult rats. FMC output was compared
after lidocaine-induced inactivation (L-group) or quinolinic acid-induced lesion (Q-group) of the contralateral homotopic cortex. In the
Q-group of animals, FMC mapping was performed, respectively, 3 days (Q3D group) and 2 weeks (Q2W group) after cortical lesion.
In each animal, FMC output was assessed by mapping movements induced by intracortical microstimulation (ICMS) in both
hemispheres (hemisphere ipsilateral and contralateral to injections). The findings demonstrated that in the L-group, the size of
forelimb representation was 42.2% higher than in the control group (P < 0.0001). The percentage of dual forelimb–vibrissa
movement sites significantly increased over the controls (P < 0.0005). The dual-movement sites occupied a strip of the map along
the rostrocaudal border between the forelimb and vibrissa representations. This form of interhemispheric diaschisis had completely
reversed, with the recovery of the baseline map, 3 days after the lesion in the contralateral FMC. This restored forelimb map showed
no ICMS-induced changes 2 weeks after the lesion in the contralateral FMC. The present results suggest that the FMCs in the two
hemispheres interact continuously through predominantly inhibitory influences that preserve the forelimb representation and the
border vs. vibrissa representation.
Introduction
The mammal primary motor cortex contains a somatotopic represen-
tation of the major subdivision of the body musculature, and
predominantly controls the limb muscles on the contralateral side of
the body (Porter & Lemon, 1993). However, increasing evidence
suggests that the primary motor cortex is also involved in controlling
the ipsilateral upper limb movements (Tanji et al., 1988; Wassermann
et al., 1994; Chen et al., 1997, 2003; Donchin et al., 1998; Ziemann
et al., 1999; Steinberg et al., 2002; Cisek et al., 2003). More
speciﬁcally, it controls the timing of ipsilateral upper limb muscle
recruitment in goal-directed and precision grip movements (Yarosh
et al., 2004; Davare et al., 2007).
Studies using focal ischemic or cortical injury within the forelimb
motor cortex (FMC) in rats have reported substantial plastic time-
related events within the undamaged contralateral forelimb motor
cortex (cFMC). These studies have reported dendritic and synaptic
growth within the undamaged motor cortex (Jones & Schallert, 1992,
1994; Biernaskie & Corbett, 2001) as well as axonal sprouting that
runs from the undamaged motor cortex to subcortical motor structures
(Kartje-Tillotson et al., 1985, 1986; Napieralski et al., 1996;
Papadopoulos et al., 2002; Emerick et al., 2003). The reorganized
cFMC in the undamaged hemisphere (i.e. ipsilateral to the affected
forelimb) substantially contributes to recovery of skilled forelimb
movement (Biernaskie et al., 2005).
Although all these studies corroborate the view that the ipsilateral
forelimb motor cortex (iFMC) participates in the control of forelimb
movement under normal conditions as well as after cortical injury, its
precise involvement in preserving the baseline map in the homotopic
cortex of the contralateral hemisphere is still poorly understood.
A previous study in the rat has proposed that the ipsilateral vibrissa
motor cortex (VMC) plays a crucial role in preserving the baseline
map through either a facilitatory or an inhibitory transcallosal
inﬂuence on the contralateral VMC (Maggiolini et al., 2007). In
particular, this paper supports the view that facilitatory transcallosal
input preserves the normal size, shape and excitability of the VMC,
whereas callosal-driven inhibition plays a crucial role in deﬁning the
boundary between vibrissa and forelimb representations.
The present study was designed to measure the effects that iFMC
inactivation and lesion have on the cFMC. The ﬁnal aim of the present
and previous experiments (Maggiolini et al., 2007) was to compare the
interhemispheric diaschisis and its recovery in time between the
forelimb and vibrissa motor systems. This comparison is important,
because it could shed light on differences in the mechanisms of
interhemispheric interaction between these two motor systems, which
present different degrees of lateralization (Brosamle & Schwab, 1997;
Hattox et al., 2002).
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For the experiments described here, unilateral FMC inactivation and
lesion were performed in one hemisphere, and intracortical microsti-
mulation (ICMS)-induced maps of both hemispheres were used to
quantitatively evaluate plastic changes in the FMC following motor
disconnection. This assumes that, after iFMC disconnection, changes
in the shaping and size of the forelimb representation, and in its
current threshold, reﬂect the adaptive changes in cortical circuits
within the disconnected cFMC.
Materials and methods
Overview of the experimental plan
Experiments were carried out on 27 Wistar albino rats, weighing 270–
300 g. Animals were reared in a 12-h light ⁄ dark cycle, with food and
water available ad libitum. The experimental plan was designed in
compliance with Italian law regarding the care and use of experimental
animals (DL116 ⁄ 92) and was approved by the Italian Ministry of
Health. For all experimental procedures, rats were anaesthetized
initially with intraperitoneal ketamine-HCl (50 mg ⁄ kg). For the
duration of the experiment, anesthesia was maintained by supplemen-
tary ketamine injections so as to achieve long-latency and sluggish
hindlimb withdrawal upon pinching of the hindfoot. Under anesthesia,
the body temperature was maintained at 36–38 C with a heat lamp.
All animals were maintained with unlimited access to food and water
presurgery and postsurgery.
The general procedures were as follows. First, seven animals
underwent FMC inactivation by lidocaine injection (L-group) in one
hemisphere followed by mapping of M1 movement in both hemi-
spheres (ipsilateral and contralateral hemispheres: hemispheres ipsi-
lateral and contralateral to the injection, respectively). Second, another
group of 10 animals underwent FMC lesion by quinolinic acid
injection (Q-group) in one hemisphere followed by mapping of M1
movement in both hemispheres (ipsilateral and contralateral hemi-
spheres: hemispheres ipsilateral and contralateral to the lesion,
respectively). In the Q-group of animals, M1 mapping was performed
3 days (Q3D group, ﬁve rats) or 2 weeks (Q2W group, ﬁve rats) after
cortical lesion. Third, ﬁve animals (sham group) underwent three
injections of saline into the FMC in one hemisphere followed by
mapping of M1 movement in both hemispheres (ipsilateral and
contralateral hemispheres: hemispheres ipsilateral and contralateral to
the saline injections, respectively). Finally, in ﬁve animals, both
hemispheres were mapped as reference for normal M1 mapping
(control group: right and left hemispheres).
The control and experimental groups were matched for gender
(three males and two females), age (13–17 weeks), weight (270–300 g
at the time of the mapping procedure), and housing condition.
Lidocaine inactivation of the FMC
In these experiments, before M1 mapping, using a Hamilton syringe, a
total of 12 lL of 3% lidocaine was injected at three sites within the
FMC of one hemisphere [stereotaxic coordinates vs. the bregma: (1)
anteroposterior (AP) +1, lateral (L) 3 mm; (2) AP +2, L 3.5 mm; (3)
AP +3, L 3.5 mm]. Under surgical stereomicroscopy, the microsyringe
needle was lowered into the selected site 1 mm below the pial surface,
the lidocaine was slowly injected (4 lL ⁄min) and, to prevent it from
oozing out, the needle was only withdrawn 3–4 min later. For the
duration of the experiment, cortical inactivation was maintained by
supplementary injections of lidocaine (one or two times for each
animal) at the same sites when the forelimb movement at these sites
was ICMS-evoked at the highest current used under the present
experimental condition (60 lA). The injected sites were remapped
every 30 min to conﬁrm that sites were inactivated, and ICMS began
10 min after injections.
Quinolinic lesion of the FMC
For the M1 lesion, two holes were drilled into the skull over the frontal
cortex of one hemisphere at the stereotaxic coordinate relative to the
bregma: AP +1.5, L 3.5 mm, and AP +3, L 3.5 mm. Injection of 1 lL
of 60 mm quinolinic acid (Cambridge Research Biochemical, Bill-
ingham, UK) dissolved in saline were delivered through a 1-lL
Hamilton syringe into each site at a depth of 1 mm below the top of
the cortex. Each injection was made gradually over a 4-min period,
and the needle was left in situ for another 4 min before being
withdrawn. After injections, the skin was closed using 6-0 surgical
sutures, and the wound was cleansed with an antibiotic solution
(Rifamicina SV, Lepetit, Milan, Italy).
Intracortical stimulation mapping
In each animal, the movements evoked by ICMS in the frontal
agranular cortex were mapped in both hemispheres. In the sham group,
L-group and Q-group, the contralateral hemisphere M1 was mapped
ﬁrst, and then the ipsilateral hemisphere M1. The anesthetized animal
was placed in a Kopf stereotaxic apparatus, and a large craniotomy was
performed over the frontal cortex of both hemispheres. The mapping
procedure was similar to the one described by Donoghue & Wise
(1982) and Sanes et al. (1990), and detailed elsewhere (Franchi, 2000).
Brieﬂy, the dura remained intact and was kept moist with a 0.9% saline
solution. The electrode penetrations were regularly spaced out over a
500-lm grid. Alteration in the coordinate grid, up to 50 lm, was
sometimes necessary to prevent the electrode from penetrating the
surface blood vessels. These adjustments in the coordinate grid were
not reported in the reconstructing maps. When the adjustment was over
50 lm, the penetration at this site was not performed. Glass-insulated
tungsten electrodes (0.6–1 MW impedance at 1 kHz) were used for
stimulation. The electrode was lowered perpendicularly into the cortex
to a depth of 1.5 mm below the cortical surface, and adjusted by
±200 lm so as to evoke movement at the lowest threshold. In
preliminary experiments, this depth was found to correspond to layer V
of the frontal agranular cortex (Franchi, 2000).
Monophasic cathodal pulses (30-ms train duration at 300 Hz, 200-
ls pulse duration) of a maximum of 60 lA were passed through the
electrode with a minimum interval of 2.5 s. Two observers were
required to detect movement and determine threshold. One observed
the movement without knowledge of the actual current intensity and
was unaware of which group the particular rat belonged to. The other
observer changed the level of the current. Starting with a 60-lA
current, intensity was decreased in 5-lA steps until the movement was
no longer evoked; then the intensity was increased to a level at which
approximately 50% of the stimulations elicited movement. This level
deﬁned the current threshold. If no movements or twitches were
evoked with 60 lA, the site was recorded as negative (ineffective
site). Mapping was initiated at a high current because the initial
polysynaptic recruitment of remote neurons optimizes the detection of
movements in this 500-lm-step grid mapping. Body parts activated by
ICMS were identiﬁed by visual inspection and ⁄ or muscle palpation.
When eye movement was observed, the current threshold was
determined under an optical microscope. A normal component of
the output organization of rat M1 is the presence of some sites along
the border region between the forelimb and vibrissa representations
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from which movement of both body parts can be evoked simulta-
neously. At such sites, both movements were recorded for that position
regardless of the individual thresholds (which were determined
separately for each). Hereafter, such movements are indicated as
‘threshold movement’ and ‘over-threshold movement’, respectively,
according to the value of the individual threshold. In some sites along
the border region between the forelimb and vibrissa representations,
both movements can be evoked simultaneously at the current
threshold level (dual forelimb–vibrissa movement site; Figs 2A and
5A). These sites have been referred to as forelimb sites when forelimb
representation size has been analysed. Forelimb movements evoked by
threshold current typically consisted of brief twitches of the elbow or
shoulder (proximal limb movement), wrist and digit (distal limb
movement), or simultaneous twitches of both muscle groups. Fore-
limbs and hindlimbs were approximately halfway between ﬂexion and
extension, and were alternately ﬂexed and extended, particularly at the
representational borders.
Histology and lesions reconstruction
At the end of the experimental procedure, the animals were
anaesthetized (ketamine, 100 mg ⁄ kg) and perfused transcardially.
The brains were then removed, postﬁxed, and transferred to a 30%
sucrose solution until they sank. They were then sectioned coronally
into 50-lm-thick slices. Sections were stained with thionine and
captured using a computer-interfaced light microscopy workstation
with a high-resolution digital camera (Fig. 1A). For each section and
hemisphere, the total cerebral cortex lesion was obtained using
contour tracing software (Adobe System, Mountain View, CA, USA).
The lesion extent and placement were reconstructed onto schematic
templates of cortical coronal sections. Reconstructions within lesion
groups were then overlaid onto one template, and outer boundaries
and shared regions of damage were outlined (Fig. 1B).
Map construction and data analysis
Using a dedicated plotting program (written with the Lab View
Development System; see Acknowledgements), an on-line grid map
was constructed by labeling electrode penetrations according to the
distance (in millimeters) from the bregma. At a current intensity of
60 lA or less, threshold values were recorded on a sheet scrolling
below the map grid. This procedure breaks down the cortical surface
into a square grid where each movement threshold point is the center
of a 500-lm-wide square. In each hemisphere, vibrissa and forelimb
movements were mapped in order to determine the extent and location
of these representations. Map borders were deﬁned as the midpoint
between sites with different movement thresholds. If a site eliciting a
Fig. 1. (A) Representative photomicrographs of typical quinolonic acid-
induced lesion of the forelimb motor cortex (FMC) as viewed in Nissl-stained
coronal sections. Broken lines deﬁne the boundaries of cortical areas according
to Brecht et al. (2004). (B) Nissl-stained coronal section of caudal part of the
quinolinic acid lesion, showing conﬁnement of the lesion to S1. AGl, agranular
lateral area; AGm, agranular medial area; CG1, cingulated area 1; S1, primary
somatosensory cortex. (C) Reconstructions of the extent and placement of
unilateral FMC lesions in the quinolinic acid-induced lesion group of rats with
smaller and larger lesions. The regions in light gray indicate the largest extent
of all combined lesions, and the areas in black are the regions of damage
common to all lesions. Numbers to the left indicate approximate anteroposterior
coordinates in millimeters relative to the bregma.
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movement was ﬂanked by a site that showed no movement upon
stimulation of up to 60 lA, the borderline for the represented
movement was set at 250 lm from the movement site. Penetrations
not performed in correspondence to large vessels were not taken into
account in the calculations. This procedure presents several potential
sources of variability that could affect the accuracy of the conﬁgu-
ration and size of movement representations. To reduce the effect of
experimental sources of variability, similar mapping density was
maintained across all animals. The cortex medial to the vibrissa
representation was not explored less than 1 mm lateral from the
midline. In normal animals, the cortex medial to the vibrissa
representation was occupied by a small representation of eye
movement (Hall & Lindholm, 1974; Donoghue & Wise, 1982;
Guandalini, 1998) and by a thin strip of cortex where ICMS evoked
miosis (Gioanni & Lamarche, 1985; Guandalini, 2003). In any case,
the eye, pupillar movements and ineffective sites formed the basis for
delineating the medial border of the vibrissa representation. The
sample of eye and miosis sites in each hemisphere was too small, and
these sites have been collectively referred to as ‘eye sites’.
In most experimental hemispheres, there is no clear border between
rostrally and laterally situated forelimb sites (Fig. 3), so that, in
computation of the forelimb sites, no distinction is made between the
sites in the rostral and caudal forelimb area.
There is previous evidence that the forelimb representation shares
the longest, common border with the vibrissa representation and that
the position of the forelimb–vibrissa border can change under a variety
of peripheral (Donoghue et al., 1990; Sanes et al., 1990; Franchi,
2000, 2002) and central (Maggiolini et al., 2007) manipulations. In
this light, for each group of hemispheres, a quantitative evaluation of
the forelimb-vibrissa border conﬁguration was obtained by comparing
mediolateral (ML) frequency distributions of sites eliciting vibrissa
and forelimb movements from 2 to 3 mm from the midline (see
Results). To this end, in each hemisphere, penetrations were divided
into 0.5-mm-wide bins into which all sites eliciting movement were
grouped, irrespective of their AP coordinates. For each bin – starting
2 mm from the midline and extending 3 mm laterally – the number of
vibrissa and forelimb sites were tallied and converted to frequency by
expressing data as a percentage of the total number of sites for each
movement.
To determine whether any changes in representational movements
were related to changes inmovement-evoking thresholds, the thresholds
for each movement were determined for each group of hemispheres. For
each group of hemispheres, a threshold analysis of forelimb movement
sites ﬁner than those that emerged within the contralateral M1 was
obtained by comparing ML threshold distributions.
Within-group comparisons were determined using the paired t-test.
Between-group comparisons were determined using one-way anova
and the chi-square test. Post hoc comparisons of groups were
performed when appropriate, using the Scheffe´ test for contrasts.
A probability value of less than 0.05 was considered to be statistically
signiﬁcant. Data are presented as means ± SD.
Results
The mean number of penetrations required to explore the motor region
corresponding to the vibrissa and forelimb representations in each
hemisphere on this 500-lm sampling grid was 65.9 ± 7. Both
hemispheres in each rat were studied, and a threshold-evoked
movement map was derived from each hemisphere (Figs 2–4). In
presenting the results, we ﬁrst evaluate interhemispheric variation in
the forelimb motor representation using data from the control and
sham groups. Next, we present the results testing the effects on the
FMC after the inactivation (L-group) and the lesion (Q-group) of the
homotopic area in the contralateral hemisphere.
Right vs. left hemisphere in the control and sham groups of
animals
In the control hemispheres, the size, shape and location of the forelimb
representation conformed to previous descriptions of the rat M1, and
included the presence of two distinct forelimb areas (caudal and rostral
forelimb area; Fig. 2A) (Donoghue & Wise, 1982; Sievert & Neafsey,
1986). Because, in the experimental animals, the inactivation of
forelimb representation includes both caudal and rostral areas, there
was no distinction between the sites in the rostral and caudal forelimb
areas when forelimb data were analysed. The forelimb motor
representation was rostral and slightly medial to the representation
of the forelimb in S1. In all presented maps, the most caudolateral
forelimb sites overlapped the forelimb representation in S1. The
vibrissa representation was situated medially to the forelimb repre-
sentation at the same AP coordinates. Along the border between the
forelimb and vibrissa representations, both movements could occa-
sionally be evoked simultaneously at the current threshold level (dual
forelimb–vibrissa movement site; Figs 2A and B, and 5A and B). The
hindlimb representation delimited the posterior boundary of the
vibrissa and forelimb representations. In the frontal cortex strip
situated medially to the vibrissa representation, miosis – or, less
commonly, eye movement – was induced under the chosen stimulation
conditions (Hall & Lindholm, 1974; Gioanni & Lamarche, 1985;
Guandalini, 2003). Ineffective sites formed the basis for delineating
the rostral M1 border. Statistical comparison between the right and left
hemispheres of the control group of animals showed no signiﬁcant
difference: (i) in the mean size of the forelimb movement represen-
tation (Figs 2A, 5A and 6A; right hemisphere, mean number of sites
18.0 ± 1.4, mean size 4.5 ± 0.3 mm2, range 4.25–5.0 mm2; left
hemisphere, mean number of sites 17.6 ± 3.2, mean size
4.4 ± 0.8 mm2, range 3.25–5.25.0 mm2, P > 0.8); (ii) in the mean
size of the vibrissa movement representation (Fig. 2A and Table 1;
right hemisphere, mean number of sites 16.4 ± 0.9; left hemisphere,
mean number of sites 16.6 ± 3.2, P > 0.8); and (iii) in the percentage
of dual movement sites (right hemisphere, mean number of sites
0.6 ± 0.5, mean percentage 1.47 ± 1.3%, range 0–2.7%; left hemi-
sphere, mean number of sites 0.8 ± 0.4, mean percentage 2.1 ± 1.2%,
range 0–2.8%, P > 0.4). Expressed as a percentage of the total size
of the forelimb cortex, the mean percentage of forelimb cortex
coding for dual movement did not differ between the right and left
hemispheres (right vs. left hemisphere: 3.4% vs. 4.6%, P > 0.6).
Similarly, no signiﬁcant differences in evoked movement thresholds
were found between the right and left hemispheres in the control
group of animals (eye, P > 0.8; vibrissa, P > 0.7; forelimb, P > 0.8;
hindlimb, P > 0.6). The fact that there were no statistical differ-
ences between the right and left hemispheres in the control group of
animals ensured that, in the absence of manipulation, sources of
variability between the right and left hemispheres were minor and not
signiﬁcant.
Statistical comparison between hemispheres in the control vs.
sham groups of animals showed no signiﬁcant differences: (i) in the
mean size of the forelimb and vibrissa movement representations
(Fig. 2A vs. Fig. 2B; Fig. 6A; P > 0.3); (ii) in the percentage of
dual movement sites (P > 0.9); and (iii) in evoked movement
thresholds (eye, P > 0.4; vibrissa, P > 0.8; forelimb, P > 0.7;
hindlimb, P > 0.5). The fact that there were no statistical differences
between the control and sham groups of animals conﬁrmed that
the intracortical injection of saline did not induce changes in the
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motor representation in either the ipsilateral or the contralateral
hemisphere.
Estimating the area of lidocaine-induced inactivation
in the ipsilateral hemisphere
Shortly after topically applying lidocaine into the iFMC, mapping
revealed that forelimb movement was evoked in only a few sites
(Fig. 3A and B; Fig. 6A; mean number of sites 5.4 ± 4.9; mean size
1.3 ± 0.47 mm2; range 0.5–2 mm2; control group vs. L-group
ipsilateral hemispheres, P < 0.0002), because most of the cortical
sites corresponding to the forelimb region were not excitable.
Figure 3A and B shows, in the ipsilateral hemispheres, the residual
forelimb sites localized at the border between the forelimb and vibrissa
representations. The threshold currents required to evoke forelimb
movement were greater in these sites than those obtained in controls,
although they failed to reach signiﬁcance (control group vs. L-group
Fig. 2. (A) The top scheme provides an example of representation of the movements evoked at threshold current levels in the right and left hemispheres in the
control group of rats. The microelectrode was sequentially introduced to a depth of 1500 lm. Interpenetration distances were 500 lm. In these M1 mapping
schemes, frontal poles are at the bottom. In the anteroposterior (AP) coordinate, 0 corresponds to the bregma, and in the mediolateral (ML) coordinate, 0 corresponds
to the midline; numbers indicate rostral or caudal distance from the bregma or lateral distance from the midline. Movement evoked at one point is indicated by
symbols: double symbol, dual movement at threshold current level; absence of symbol (within or at the border of the maps), penetration not performed due to the
presence of a large vessel. (B) The bottom scheme shows a surface view map for the sham group of rats. In the ipsilateral hemisphere, a symbol set in a square frame
corresponds to the site of the saline injection. Note that the intracortical injection of saline did not induce changes in the motor representation in either the ipsilateral
or contralateral hemisphere.
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ipsilateral hemispheres: 20.9 ± 1.2 lA vs. 27.02 ± 7 lA, range 19.4–
22.3 vs. 19.3–38.0, P > 0.08). Thus, in the ipsilateral hemisphere, the
forelimb sites were reduced by 69.1% vs. the controls, and excitability
was reduced in ﬁve out of seven hemispheres.
Statistical comparison between control group and L-group ipsilat-
eral hemispheres showed that the lidocaine injected within the
forelimb representation did not reduce the size (Fig. 3A and B;
Table 1; control group vs. L-group ipsilateral hemispheres, P > 0.7)
and excitability (Table 2; control group vs. L-group ipsilateral
hemispheres, P > 0.05) of the vibrissa representation. Thus, the
ipsilateral hemispheres only showed limited vibrissa site involvement
at the border with the FMC (see ipsilateral hemispheres in Fig. 3A
and B).
Lidocaine-induced changes in the contralateral hemisphere
The comparison between control group and L-group contralateral
hemispheres showed an increase in the size of the forelimb
representation in all L-group animals (Fig. 2A vs. Fig. 3A and B;
Fig. 6A). The size of the forelimb representation in the L-group
was 38.8% higher than those of the control group (L-group contra-
lateral hemispheres, mean size 6.25 ± 0.6 mm2, range 5.5–7.25 mm2;
A
B
Fig. 3. The top (A) and bottom (B) schemes show two examples of surface view maps in the lidocaine-induced inactivation group of rats. In the ipsilateral
hemisphere, symbols set in a square frame correspond to the lidocaine injection sites. Note that, in the ipsilateral hemisphere, the majority of cortical
sites corresponding to the forelimb region are not excitable. The contralateral hemisphere shows: (i) enlargement of the forelimb representation; (ii) increase
in the number of dual movement sites: sites where the vibrissa and forelimb movements were evoked at threshold current level. AP, anteroposterior; ML,
mediolateral.
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control group vs. L-group, P < 0.0002). In contrast, the size of the
vibrissa representation in the L-group was 15.5% smaller than in the
control group (Table 1; control group vs. L-group, P > 0.1).
Expansion of the forelimb representation was due to increases in
the areas of both the distal and proximal forelimb movement
representations (Fig. 6B; control group vs. L-group, P < 0.01);
however, the ratio of the distal forelimb representation to the
proximal forelimb representation decreased when L-group contralat-
eral hemispheres were compared to the controls (control group vs.
L-group: 4.9 ± 1.6 vs. 3.1 ± 1.3, range 3.2–7.5 vs. 1.4–5.2, P =
0.07). Thus, there was an increase in the representation of proximal
vs. distal forelimb movement in the L-group, although it failed to
reach signiﬁcance, due to the small sample size and the large
variation between L-group contralateral hemispheres. Figure 3A and
B shows that the forelimb area expands laterally towards the cortex
sites that overlap sites that were not excitable in control maps. The
number of cortical sites from which forelimb movement could be
elicited at 4 and 4.5 mm from the ML coordinate increased in
L-group contralateral hemispheres (mean sites in control group vs.
L-group: 2.6 ± 1.4 vs. 5.3 ± 2.7, range 1–4 vs. 2–10, P = 0.064).
Furthermore, in all L-group contralateral hemispheres, there is strong
evidence that the forelimb movement shifted towards medial sites
Fig. 4. Examples of bilateral maps from rats 3 days (A) and 2 weeks (B) after quinolinic acid (Quin.) injection. In the ipsilateral hemisphere, the symbol set in a
square frame corresponds to the injection site. Note that, in all groups, the ipsilateral hemisphere shows that most of the cortical sites corresponding to the forelimb
region are not excitable. The contralateral hemisphere in the 3Ds group and 2Ws group shows a pattern of movement representation similar to that found in the
control group. AP, anteroposterior; ML, mediolateral.
Suppression of activity in the forelimb motor cortex 2739
ª The Authors (2008). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 27, 2733–2746
where vibrissa movement was elicited (Fig. 2A vs. Fig. 3A and B).
To quantitatively assess this spatial aspect of L-group maps, and to
avoid interindividual biases related to differences in the motor map
size and ML position, we expressed forelimb sites as a fraction of the
number of movement sites from 2 to 3 mm from the midline in the
control group vs. L-group. This cut-off was applied because, from 2
to 3 mm to the midline, the cortex corresponded to the forelimb–
vibrissa border in both control group and L-group contralateral
hemispheres (Fig. 2A and Fig. 3A and B). After comparison of
percentages between the control group and L-group, a signiﬁcant
increase in the percentage of forelimb sites was found in the L-group
(control group vs. L-group: 46.85 ± 5.22% vs. 67.01 ± 5.24%, range
42.8–54.5% vs. 58.3–70.5%, P < 0.0005). To determine the effect
that homotopic cortex inactivation has on dual movement sites, the
occurrence of the dual movement site was expressed as a percentage
of the total number of movement sites 2–3 mm from the midline. In
the L-group contralateral hemispheres, the percentage of dual sites
was 22.3 ± 8.1% and was signiﬁcantly higher than in the control
group (P < 0.0005). It is of interest to note that this value was
similar to the increase in the percentage of forelimb sites from 2 to
Fig. 5. Overview of the location, size and topographic overlapping of the forelimb (gray area) and dual vibrissa–forelimb movement sites (unbroken line) in control,
sham, lidocaine-induced inactivation group (L-group), Q3D group and Q2W group contralateral hemispheres. These are schematic composite maps overlaying
the forelimb sites and the dual vibrissa–forelimb sites in all rats in each group. Note that, in the L-group, the dual site composite map is larger than the control
group composite map, and it encompasses most of the medial region of the forelimb representation. In contrast, in both the Q3D and Q2W groups, the cumulative
map of dual movement sites encompasses cortical territory similar to that in the control and sham groups. Quin., quinolinic acid; AP, anteroposterior; ML,
mediolateral.
2740 E. Maggiolini et al.
ª The Authors (2008). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 27, 2733–2746
3 mm from the midline (22.3% vs. 21.7%) and was 66.6% of the
forelimb representation size that enlarged in the contralateral L-group
hemispheres (Fig. 6C). Thus, we can conclude that forelimb
movement expands as dual sites at the border with the vibrissa
representation, and that the dual site region occupies a strip of the
map along the rostrocaudal border between the forelimb and vibrissa
representations (Fig. 5C).
The threshold currents required to evoke forelimb movement in
L-group contralateral hemispheres were similar to those in the controls
(control group vs. L-group: 21.3 ± 1.9 lA vs. 21.1 ± 1.8 lA,
P > 0.9). To analyse the spatial aspect of excitability in the enlarged
forelimb representation, the current required to evoke forelimb
movement was plotted vs. distance to the midline, irrespective of
the AP coordinates. In comparing the control group and the L-group,
Fig. 6. Across-group comparison of the forelimb size. To compare data between diagrams, all the bars represent mean size values in mm2 (+SD). (A) In each group,
bars show the size of the forelimb representation in the right or contralateral hemispheres and in the left or ipsilateral hemisphere for the control and experimental
groups, respectively. Note that, in all experimental groups, the right bar value is far below what it is in the controls (P < 0.05, Scheffe` test) and there is no difference
in this value between experimental groups (P > 0.05, anova). In the lidocaine-induced inactivation group (L-group), the value of the left bar was signiﬁcantly
greater than in the control group (*P < 0.05, Scheffe` test), whereas in the other experimental groups, the left bar value is similar to that found in the controls
(P > 0.05, Scheffe` test). (B) The diagram shows the distal and proximal forelimb movement representation size in the control, sham and experimental groups of rats.
The gray bar shows the size of the forelimb representation where distal forelimb movement is evoked at threshold current level (+SD). The open bar shows the size of
the forelimb representation where the proximal forelimb movement is evoked at threshold current level (+SD). For each bar, the cumulative value is that of the left
bar in diagrams A. Note that, in the L-group, the value of the open bar was signiﬁcantly greater than in the control group (*P < 0.05, Scheffe` test). In the other
experimental groups, the open bar value is similar to that found in the controls (P > 0.05, Scheffe` test). (C) The diagram shows the size of the single (black bar) and
dual forelimb sites (open bar) in control, sham and experimental groups of rats. For each bar, the cumulative value is that of the left bar in diagrams A. Note that, in
the L-group, the value of the open bar was signiﬁcantly greater than in the control group (*P < 0.05, Scheffe` test). In the other experimental groups, the open bar
value is similar to that found in the controls (P > 0.05, Scheffe` test).
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this analysis showed that there was no difference in threshold across
the ML plane (control group vs. L-group: 3 mm ML coordinate,
18.7 ± 2.6 lA vs. 20.6 ± 4.7 lA; 2.5 mm ML coordinate, 21.08 ±
3.1 lA vs. 17.4 ± 3.1 lA; 2 mm ML coordinate, 15.8 ± 1.4 lA vs.
17.2 ± 5.7 lA, P > 0.3). To quantify changes in excitability needed to
evoke forelimb movement in dual movement sites, we compared the
current needed to evoke suprathreshold forelimb movement in vibrissa
sites from 2 to 3 mm from the midline in the control group with the
current needed to evoke forelimb movement in dual sites in the
L-group. Expressed as a percentage of current required to evoke
forelimb movement in those sites where vibrissa movement was
evoked at threshold current in the controls, the current for evoking
forelimb movement decreased by 47.5% in dual movement sites in the
L-group (control group vs. L-group: 26.4 ± 2.4 lAvs. 17.9 ± 6.4 lA,
P > 0.003).
Estimating the area of quinolinic acid-induced lesion
in the ipsilateral hemisphere
Lesions were localized after thionine staining, and photographed to
show the relationship between the lesion and the histological borders
of the lateral agranular cortex of M1. The histological result from one
animal is illustrated in Fig. 1A, and is representative of all the cases
studied. Figure 1A and B shows that the borders of the lesions are
nearly co-extensive with the lateral agranular cortex where forelimb
movements are represented (Brecht et al., 2004). Lesion reconstruc-
tions based on thionine staining revealed that all lesions produced
damage to the lateral agranular cortex (Fig. 1C). In all Q-group
ipsilateral hemispheres, the vast majority of cortical sites lateral to
2.5 mm from the midline were not excitable (Fig. 4). In general, in the
Q-group ipsilateral hemispheres, the average number of forelimb sites
was reduced by 68.75% as compared to the controls (mean number of
sites 5.5 ± 1.5, range 3–8 sites; control group vs. Q-group ipsilateral
hemispheres, P < 0.00001) and, in these residual sites, excitability
was reduced by 19.7% (control group vs. Q-group: P < 0.004).
Comparison of the control group and Q-group ipsilateral hemispheres
showed no statistical difference in the percentage of vibrissa
movement sites (mean number of sites in control group vs. Q-group
ipsilateral hemispheres 38.5 ± 3.95% vs. 37.0 ± 3.7%, range 33.3–
43.2% vs. 30.0–40.4%, P > 0.5). Hence the threshold values needed
to evoke vibrissa movement were also not signiﬁcantly different from
those for the control group (control group vs. Q-group ipsilateral
hemispheres: P > 0.8). Thus, the lesion of the FMC does not
substantially change the size and excitability of the vibrissa movement
representation.
Statistical comparison between ipsilateral hemispheres in the
Q-group of animals showed no signiﬁcant difference in the percent-
ages of vibrissa and forelimb movement sites (vibrissa, P > 0.4;
forelimb, P > 0.1) and in evoked movement thresholds (vibrissa,
P > 0.9; forelimb, P > 0.2; hindlimb, P > 0.2). The fact that there
were no statistical differences between Q-group ipsilateral hemi-
spheres is evidence that the movement representation in M1 found at
3 days after lesion had not changed by 2 weeks after lesion.
Quinolinic acid-induced changes in the contralateral
hemisphere
Three days after lesion of the FMC in the ipsilateral hemisphere, there
was no statistical difference in the size and excitability of the cFMC
when compared with control values (mean size 4.7 ± 0.5 mm2, range
4–5.25 mm2, P > 0.7; Figs 4A and 6A; mean excitability
21.7 ± 2.2 lA, range 19.1–23.6 lA, P > 0.7). Similarly, there was
no difference between the control and Q3D cFMCs in the percentage
of dual movement sites and their localization (control group vs. Q3D
group: mean number of sites 0.6 ± 0.5 vs. 1.0 ± 1.2, mean percentage
1.47 ± 1.3% vs. 2.4 ± 3.0, range 0–2.7% vs. 0–7.5, P > 0.7; Fig. 5A
vs. Fig. 5D; Fig. 6C). Thus, we conclude that, under the present
experimental conditions, the plastic changes in the cFMC seen after
inactivation are evidence of recovery to baseline value at 3 days after
lesion.
No comparisons between the Q3D and Q2W groups of animals
showed any signiﬁcant difference in the mean of values and in the
range of values: forelimb representation size (Fig. 4A vs. Fig. 4B;
Fig. 6A; Q3D group vs. Q2W group, mean size 4.7 ± 0.5 vs.
4.6 ± 0.45 mm2, range 4–5.25 vs. 4–5, P > 0.8), dual movement site
percentage (Fig. 6C; Q3D group vs. Q2W group, mean 2.4 ± 3.0% vs.
2.4 ± 0.2%, range 0–2.7% vs. 0–2.6%, P > 0.7) and localization
(Fig. 5D vs. Fig. 5E), vibrissa representation size (Fig. 4A vs. Fig. 4B;
Table 1; Q3D group vs. Q2W group, P > 0.4), and evoked movement
thresholds [Q3D group vs. Q2W group: vibrissa (Table 2), P > 0.7;
forelimb, 21.7 ± 2.2 lA vs. 23.1 ± 3.1 lA, P > 0.2]. Thus, the
normal cFMC output seen at 3 days after the iFMC lesion showed
no sign of changes at 2 weeks after iFMC lesion.
Discussion
The aim of the present study was to investigate the contribution of the
iFMC to movement representation in the cFMC. The results
demonstrate a substantial increase in the contralateral forelimb
representation, as assessed by ICMS, after the iFMC had been
inactivated. This suggests that the iFMC may play a crucial role in
shaping the motor representation, most likely through a trancallosal
effect on the cFMC. The present data show that this form of
Table 1. Size of vibrissae representation in each hemisphere
Groups
Vibrissae representation (mm2)
Left or ipsilateral
hemisphere
Right or contralateral
hemisphere
Control 4.1 ± 0.8 (3.00–4.75) 4.1 ± 0.2 (3.75–4.25)
Sham 3.7 ± 1.0 (2.25–4.75) 3.6 ± 0.5 (3.00–4.25)
Lidocaine 3.9 ± 1.1 (2.25–5.25) 3.4 ± 0.9 (2.75–4.25)
Q3D 4.5 ± 0.4 (4.25–5.25) 3.6 ± 0.7 (3.00–4.75)
Q2W 4.4 ± 0.7 (3.75–5.75) 4.0 ± 0.6 (3.25–4.75)
Data are presented as mean ± SD (with range in parentheses). Note that there
was no statistical intergroup difference in the vibrissae movement size.
Table 2. Threshold currents for vibrissae movement
Groups
Threshold current (lA)
Left or ipsilateral
hemisphere
Right or contralateral
hemisphere
Control 20.9 ± 0.8 (19.6–21.8) 21.4 ± 0.9 (20.0–22.3)
Sham 21.8 ± 1.8 (19.5–23.8) 20.4 ± 0.6 (20.3–28.8)
Lidocaine 24.2 ± 3.3 (20.3–28.8) 19.4 ± 2.8 (15.5–23.0)
Q3D 22.1 ± 2.5 (19.4–23.8) 20.2 ± 1.3 (19.0–24.6)
Q2W 21.6 ± 0.7 (21.0–22.3) 21.0 ± 1.2 (18.3–22.1)
Data are presented as mean ± SD (with range in parentheses). Note that there
was no statistical intergroup difference in the vibrissae movement threshold.
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interhemispheric diaschisis was completely reversed, with recovery of
the baseline map, 3 days after the lesion in the iFMC. This restored
forelimb map showed no ICMS-induced changes 2 weeks after the
iFMC lesion. It is also important to stress that this form of
interhemispheric diachisis proved very different in nature from the
interhemispheric diachisis after inactivation and lesion in the VMC
described in the previous study (Maggiolini et al., 2007).
Interpretation of motor map changes in the cFMC after iFMC
inactivation and lesion
For these investigations, cortical inactivation and lesion were
produced, respectively, by injecting lidocaine and quinolinic acid.
As shown in the previous study (Maggiolini et al., 2007), the
advantage of these methods is that they are non-invasive and produce
lesions with good reproducibility in terms of size, and a good, sharp
boundary between affected motor representations and surrounding
motor regions.
In the lidocaine experiments, the level of inactivation was assessed
by reviewing injected site responses every 30 min to check for
changes in excitability as mapping progressed, and the interpretation
of the changes in the contralateral hemisphere is based on the
preserved inactivation of the injected sites.
The present study is limited by the fact that experiments with
lidocaine were performed without remapping M1 in either hemisphere
after lidocaine washout. A map-and-then-remap design would require
several hours, and the cortical state could change over such long
experimental sections. Nevertheless, the lack of information on
recovery after lidocaine washout raises a potential question about
the timing of M1 recovery after reversible inactivation of the
homologous cortex.
The transcallosal output from the primary motor cortex (M1) has
been investigated in humans using transcranial magnetic stimulation
(TMS). TMS experiments have demonstrated that transcallosal output
inhibits contralateral M1 (Wassermann et al., 1991; Ferbert et al.,
1992; Meyer et al., 1995; Gerloff et al., 1998) . TMS was performed
by placing a coil tangentially to the scalp at a ﬁxed site over M1
(referred to as a ‘motor hot spot’) and recording motor-evoked
potential and electromyographic activity over arm muscles. The
inhibitory effects of transcallosal output were measured either as a
period of silence in electromyographic activity or as motor-evoked
potential amplitude inhibition by a TMS pulse over M1 of the
contralateral hemisphere (Rothwell et al., 1991; Meyer et al., 1995;
Boroojerdi et al., 1996).
The present study touches on the issue of short-term vs. long-term
effects of contralateral input elimination in the cerebral cortex in an
animal model. The standard ICMS was carried out to map movement
representations in the rat M1. The inhibitory effects of transcallosal
output were measured: (i) as changes in the size and shape of the
forelimb representation; (ii) as changes in the border and overlapping
between the vibrissa and forelimb representations; and (iii) as changes
in the type of movements evoked at both stimulation current threshold
and over-threshold levels.
It is important to point out that the area of the cortex deﬁned as the
forelimb and vibrissae motor cortex is highly dependent upon the
methods used during mapping. In any experiment, the baseline maps
reported depend on the technique used (Donoghue & Wise, 1982;
Gioanni & Lamarche, 1985; Castro-Alamancos & Borrel, 1995; Kleim
et al., 1998; Franchi, 2000; Haiss & Schwarz, 2006; Ramanathan
et al., 2006). Moreover, in all ICMS-induced maps, the amount of
overlapping between different movements is directly related to the
intensity of the stimulus relative to threshold. To avoid biases, in all
hemispheres the vibrissae–forelimb overlapping was measured in the
threshold current-derived map. In all the present control and sham
animals, the topography of movement representations and the amount
of vibrissa–forelimb overlapping are consistent with those of previous
experiments using similar stimulation parameters (Maggiolini et al.,
2007).
The primary ﬁnding of the study is that, after inactivation of the
iFMC, the cFMC exhibits a substantial increase in the cortex area
from which forelimb movement can be elicited at the threshold
stimulation current. Then the cFMC undergoes some rapid functional
changes due to the inactivation of the iFMC. This functional change
facilitates the ability to elicit forelimb movements from cortex sites
that would have not previously produced forelimb movements in
response to similar stimulation. In all maps, forelimb movement
expanded medially within the lateral part of the vibrissa represen-
tation, so that all maps showed a larger than normal cortical area
where vibrissa and forelimb movements overlapped the same cortical
territory.
There is substantial evidence that, via the corpus callosum, each M1
exerts a reciprocal inﬂuence on homotopical representations in the
opposite hemisphere (Jenny, 1979; Spidalieri & Guandalini, 1983;
Gould et al., 1986; Ferbert et al., 1992; Chapman et al., 1998). In the
present study, lidocaine inactivation of the iFMC most likely interfered
with short-term transcallosal inﬂuences between FMCs. If this is the
case, changes in the cortical topography could be explained by a loss
of interhemispheric inhibitory inﬂuence between the FMCs of the two
hemispheres. Indeed, by producing iFMC inactivation, we probably
impede the transcallosal inhibitory inﬂuence that is normally exerted
by the iFMC on the opposite hemisphere, leading to a release of the
transcallosal inhibition exerted on the cFMC. This interpretation of
trancallosal modulation between the bilateral FMCs in rat is in good
agreement with the transcallosal modulation between the bilateral
hand motor cortices, as investigated by TMS in humans. TMS
experiments have shown that transcallosal inhibition between hand
motor representations is more prominent than facilitation (Ferbert
et al., 1992; Ugawa et al., 1993; Meyer et al., 1995; Hanajima et al.,
2001). The interhemispheric inhibitory interactions differ between
homologous arm muscle representations in relation to a proximal–
distal gradient (Shon et al., 2003) or according to the role that each
arm muscle plays in functional movement synergies (Harris-Love
et al., 2007).
The equivalent ICMS current required to elicit forelimb movement
in the control group and L-group of rats indicates that the suppression
of transcallosal inhibition did not alter the basic threshold within the
normal forelimb representation but did give rise to a normal-strength
functional connection between new forelimb sites and the forelimb
motor neuron pool. In some other situations, an alteration in forelimb
size can be detected, even when there is no change in motor threshold
(Teskey et al., 2002).
The recovery in cFMC size – returning to the size found in the
control hemisphere 3 days after iFMC lesion – suggests a rapid
adaptive plastic change as a consequence of the rebalancing of
excitability that does not depend on the lesion in the contralateral
hemisphere. This form of short-lived diaschisis could be explained by
a process of rapid recovery of the excitability of inhibitory interneu-
rons so that the cFMC could rapidly be reshaped to the baseline value
(Fig. 7). Corticocortical input to the disconnected FMC from SI and
SII and thalamocortical activity could both regulate the rate of
recovery of inhibitory interneuron excitability.
After a cortical lesion, alterations in dendritic and synaptic
morphology (Jones et al., 1996; Jones, 1999) and sprouting of axons
(Emerick et al., 2003) could affect the activity (Rema & Ebner, 2003)
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and the ICMS-derived map of the contralateral cortex (Emerick et al.,
2003; Maggiolini et al., 2007). All these long-term plastic changes –
which could affect the ICMS-derived forelimb map – have proved to
be highly dependent on the level of rehabilitative training (Jones &
Schallert, 1994; Jones, 1999). Thus, it is not surprising that, in the
present experiment, 2 weeks after iFMC lesion, the cFMC proved
similar to the controls. However, an alternative possibility is that a
subtle, altered excitatory–inhibitory balance in the cFMC might not be
sensitive to the ICMS as used in the present experiments.
Comparison between vibrissa–interhemispheric and
forelimb–interhemispheric diaschisis
To compare the results from this and previous (Maggiolini et al.,
2007) experiments, we can assume that the neurons in the hemisphere
opposite the site of inactivation would detect the inactivation as a
sudden reduction in activity arising from commissural inputs (Li et al.,
2005).
The distinctive feature of the short-term vibrissa–interhemispheric
diaschisis was shrinkage in the representation size with reduced
excitability of the VMC, whereas the distinctive feature of the
forelimb–interhemispheric diaschisis was enlarged representation
without any change in baseline excitability. Therefore, we conclude
that the VMC and FMC of the two hemispheres continuously
interact, respectively, through prominent excitatory and inhibitory
inﬂuences.
It has proved difﬁcult to explain the observed loss of excitability in
the VMC vs. the normal excitability in the FMC after inactivation of
the homologous M1 region. The main reason could be that the FMC
has fewer homotopical callosal connections than the VMC; moreover,
in the FMC, most callosal projections may not be directly linked to
corticospinal forelimb motorneurons (Fig. 7). These differences in
interhemispheric connectivity could also explain why the recovery of
diachisis after FMC lesion was faster than the recovery after VMC
lesion.
It should be noted that, in both vibrissa–interhemispheric and
forelimb–interhemispheric diaschisis, the forelimb movement expands
within the lateral part of the vibrissae representation. Therefore, we
propose that the changes in the border between the VMC and FMC,
which occur in both forms of diachisis, may be explained by a
callosal-driven downregulation in the activity of inhibitory interneu-
rons linked selectively to forelimb motor neurons (Fig. 7).
Interpretation of the motor map changes in relation
to movement pattern
ICMS-derived maps of movement representation in M1 are essentially
static, and reﬂect the strength of corticospinal connections within the
conditions of the experiment. The present and previous (Maggiolini
et al., 2007) studies suggest that the ipsilateral M1 plays a signiﬁcant
role in shaping motor representation in the contralateral M1, allowing
changes in the border and overlapping between forelimb and vibrissa
Fig. 7. Proposed circuit model depicting transmission of interhemispheric information of callosal neurons to vibrissa and forelimb neurons at the border between
vibrissa and forelimb representations. Axon collaterals provide direct synaptic excitatory connections between callosal afferents and inhibitory interneurons.
Inhibitory interneurons at the border of the vibrissa–forelimb representation are well positioned to modulate callosal input onto forelimb motorneurons. Either
forelimb motor cortex (FMC) (gray area) inactivation or vibrissa motor cortex (VMC) inactivation causes the forelimb representation to expand within the vibrissa
representation, so that it moves in medially. CC, corpus callosum; ICMS, stimulating electrode.
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movement representations. Taken together, these data are not consis-
tent with the idea that the vibrissa–forelimb overlapping is simply due
to overlapping of the stimuli. The vibrissae–forelimb overlapping
appears to be a real feature of rat motor cortex organization after
interhemispheric transient disconnection. Amassian et al. (1995)
suggested that representation overlapping is part of the neural
substrate for the motor control of different muscles during natural
complex movements. In humans, interhemispheric mechanisms are
thought to play a crucial role in motor control by ensuring correct
timing of the synergic recruitment of the set of muscles (Devanne
et al., 2002, 2006; Holdfer & Miller, 2002). In rats, the ﬁnal
interpretation of the present and previous data could be that the
interhemispheric activity between vibrissae and forelimb M1 could
promote synergic activity among vibrissa and forelimb muscles or, in
contrast, could separate forelimb and vibrissa movement representa-
tions into constituent muscles according to different types of
movement that reﬂect animal behavior. Then, the interhemispheric
activity could promote differences in the synergic recruitment of
vibrissa and forelimb muscles in complex movements such as bringing
to the mouth, grooming, or snifﬁng during explorative behavior.
Future studies will be needed to conﬁrm or reject this interpretation of
present ICMS-based results.
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Nociceptin/Orphanin FQ Modulates Motor Behavior and
Primary Motor Cortex Output Through Receptors Located in
Substantia Nigra Reticulata
Matteo Marti1,3,5, Riccardo Viaro1,2,3,5, Remo Guerrini3,4, Gianfranco Franchi2,3 and Michele Morari*,1,3
1Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, Ferrara, Italy; 2Department of Biomedical
Sciences and Advanced Therapies, Section of Human Physiology, University of Ferrara, Ferrara, Italy; 3Center for Neuroscience and Istituto
Nazionale di Neuroscienze, University of Ferrara, Ferrara, Italy; 4Department of Pharmaceutical Sciences and Biotechnology Center; University of
Ferrara, Ferrara, Italy
This study was set to investigate whether motor effects of nociceptin/orphanin FQ (N/OFQ) can be related to changes in primary motor
cortex output. N/OFQ injected i.c.v. biphasically modulated motor performance, low doses being facilitating and higher ones inhibitory.
These effects were counteracted by the N/OFQ receptor antagonist [Nphe1 Arg14,Lys15]N/OFQ-NH2 (UFP-101) confirming the
specificity of N/OFQ action. However, UFP-101 alone facilitated motor performance, suggesting that endogenous N/OFQ inhibits motor
function. N/OFQ and UFP-101 injected into the substantia nigra reticulata but not motor cortex replicated these effects, suggesting
motor responses were mediated by subcortical circuits involving the basal ganglia. Intracortical microstimulation technique showed that
i.c.v. N/OFQ also biphasically modulated motor cortex excitability and movement representation. Low N/OFQ doses caused a leftward
shift of threshold distribution curve in the forelimb area without affecting the number of effective sites. Conversely, high N/OFQ doses
increased unresponsive and reduced excitable (movement) sites in vibrissa but not forelimb area. However, increased threshold currents
and rightward shift of threshold distribution curve were observed in both areas, suggesting an overall inhibitory effect on cortical motor
output. UFP-101 alone evoked effects similar to low N/OFQ doses, suggesting tonic inhibitory control over forelimb movement by
endogenous N/OFQ. As shown in behavioral experiments, these effects were replicated by intranigral, but not intracortical, N/OFQ or
UFP-101 injections. We conclude that N/OFQ receptors located in the substantia nigra reticulata mediate N/OFQ biphasic control over
motor behavior, possibly through changes of primary motor cortex output.
Neuropsychopharmacology (2009) 34, 341–355; doi:10.1038/npp.2008.56; published online 16 April 2008
Keywords: bar test; drag test; intracortical microstimulation; rotarod test; speed test; UFP-101
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INTRODUCTION
Nociceptin/orphanin FQ (N/OFQ) is an endogenous neuro-
peptide that activates a G-protein-coupled receptor termed
NOP. NOP receptors are widely represented in cortical and
subcortical motor areas (Darland et al, 1998; Neal et al,
1999) and are involved in motor control. Both NOP receptor
stimulation and blockade affects motor function. In
particular, i.c.v. injections of N/OFQ or systemic adminis-
tration of Ro 64–6198 (a synthetic NOP receptor agonist)
facilitated spontaneous locomotion at low doses (Florin
et al, 1996; Jenck et al, 1997; Higgins et al, 2001; Kuzmin
et al, 2004) and inhibited it at higher ones (Reinscheid et al,
1995; Devine et al, 1996; Rizzi et al, 2001; Higgins et al,
2001; Kuzmin et al, 2004). NOP receptor agonists also
inhibited exercise-induced locomotion (as in the rotarod
test) although in a monophasic way (Jenck et al, 2000;
Higgins et al, 2001; Marti et al, 2004a). In contrast,
pharmacological blockade (or genetic deletion) of the
NOP receptor did not affect spontaneous locomotion but
increased exercise-induced motor activity (Marti et al,
2004a). Therefore, it has been proposed that endogenous N/
OFQ acts as a physiological constraint of motor function,
being its action more relevant under conditions of motor
activation rather than at rest (Marti et al, 2004a). The
neurobiological substrate(s) underlying motor actions of
exogenous and endogenous N/OFQ have been investigated.
The N/OFQ-induced hypolocomotion has been related to
inhibition of mesencephalic mesoaccumbal (Murphy and
Maidment, 1999) and/or nigrostriatal (Marti et al, 2004a)
DA neurons. Consistently, injections of the NOP receptor
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antagonist [Nphe1 Arg14,Lys15]N/OFQ-NH2 (UFP-101) in
substantia nigra reticulata (SNr) elevated rotarod perfor-
mance and striatal DA release (Marti et al, 2004a). Evidence
that also the hyperlocomotive response induced by i.c.v. N/
OFQ is DA-dependent has been presented (Florin et al,
1996; Kuzmin et al, 2004), although the area involved has
not been identified. Endogenous N/OFQ, however, appears
to cause motor depressant responses also via non-DAergic
mechanisms. Indeed, SNr injections of UFP-101 or systemic
administration of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydro-
xymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimida-
zol-2-one (J-113397) improved motor performance not
only in naive but also DA-depleted (6-OHDA hemilesioned)
or haloperidol-treated rats (Marti et al, 2004b, 2005). In
particular, the antiakinetic effect of J-113397 in 6-OHDA
hemilesioned rats was associated with reduction of ni-
grothalamic GABAergic transmission and, possibly, thala-
mic disinhibition (Marti et al, 2007). SNr is the major
output nucleus of the basal ganglia. It conveys the motor
information generated in the cerebral cortex and processed
in the striatum to the thalamus and then back to the motor
cortex, forming a functional loop which regulates move-
ment initiation and execution (ie the so-called ‘cortico-basal
ganglia-thalamo-cortical’ loop; Albin et al, 1989; Alexander
and Crutcher, 1990). On this basis, pharmacological
treatments (Marti et al, 2004b) or pathological conditions
(Marti et al, 2005) that alter N/OFQergic transmission in
SNr are likely to interfere with the activity of the ‘cortico-
basal ganglia-thalamo-cortical’ loop and, as a consequence,
with processing of motor information at the cortical level.
The present study was therefore undertaken to test whether
changes in motor behavior produced by activation of central
NOP receptors could be associated with changes in motor
cortex output. Motor activity has been evaluated in awake
rats by means of a battery of behavioral tests involving
different motor parameters (ie time to initiate and execute a
movement, coordination, and equilibrium). Primary motor
cortex (M1) excitability and movement representation
(defining motor output) has been investigated in anesthetized
rats by intracortical microstimulation (ICMS). This technique
allows to excite corticofugal neurons and produce repetitive
neuronal discharges, which result in the summation of
excitatory synaptic potentials in motoneurons and muscle
activity. The role of central NOP receptors in modulation of
motor behavior and M1 output has been investigated first by
injecting N/OFQ in lateral cerebral ventricle (LCV). UFP-101
has been used to test the specificity of the N/OFQ action and
to investigate the influence of endogenous N/OFQ. Finally,
the role exerted by NOP receptors located in M1 and SNr has
been elucidated by intracortical (layer V) or intranigral
injections of N/OFQ and UFP-101.
MATERIALS AND METHODS
Male Sprague–Dawley rats (300–350 g; Stefano Morini,
Reggio Emilia, Italy) were kept under regular lighting
conditions (12 h light/dark cycle) and given food and water
ad libitum. The experimental protocols performed in the
present study were approved by Ethical Committee of the
University of Ferrara and adequate measures were taken to
minimize animal pain and discomfort.
Microinjection Technique
A guide cannula (outer diameter 0.55 mm, inner diameter
0.35 mm) was stereotaxically implanted under isoflurane
anesthesia (1.4% in air delivered at 1.2 ml/min) 1 mm above
the right or left LCV, M1 or SNr, according to the following
coordinates from bregma: LCV, AP 0.9, ML ±1.4, VD 2;
M1, AP + 2, ML ±2, VD 0.5; SNr, AP 5.5, ML ±2.2, VD
7.3; nose bar positioned at –2.5 (Paxinos and Watson,
1982). The cannula was secured to the skull by acrylic dental
cement and metallic screws. A stainless steel obturator
(outer diameter 0.30 mm) was left in place inside the guide.
After a 7-day recovery period, each rat was opportunely
handled and trained before behavioral tests. The day of the
experiment, the obturator was removed and saline or
pharmacological treatments were injected (volume 0.5 ml)
through a stainless-steel injector (outer diameter 0.30 mm;
inner diameter 0.15 mm) protruding 1 mm from the cannula
tip. At the end of each experiment the placement of the
probes was verified by microscopic examination and the
rats in which the probes were not correctly positioned were
discarded from the study.
Behavioral Studies
Different behavioral tests were used to collect complemen-
tary information on different motor parameters in rats.
Bar test. Originally developed to quantify morphine-
induced catalepsy (Kuschinsky and Hornykiewicz, 1972),
this test measures the ability of the rat to respond to an
externally imposed static posture. Also known as the
catalepsy test (for a review see Sanberg et al, 1988), it can
be used to quantify akinesia (ie time to initiate a movement)
also under conditions that are not characterized by
increased muscle tone (ie rigidity) as in the cataleptic/
catatonic state. The rat was placed gently on a table and
forepaws were placed alternatively on blocks of increasing
heights (3, 6 and 9 cm). The time (in sec) that each paw
spent on the block (ie the immobility time) was recorded
(cutoff time of 20 s). Akinesia was calculated as total time
spent on the different blocks.
Drag test. Modification of the ‘wheelbarrow test’ (Schallert
et al, 1979), this test measures the ability of the rat to
balance its body posture with forelimbs in response to an
externally imposed dynamic stimulus (backward dragging;
Marti et al, 2005). It gives information regarding the time to
initiate and execute (bradykinesia) a movement. The rat was
gently handled from the tail leaving the forepaws on the
table, and was dragged backwards at a constant speed
(about 20 cm/s) for a fixed distance (100 cm). The number
of steps made by each paw were recorded. Five to seven
determinations were collected for each rat.
Speed test. These tests essentially measure rat speed in an
open field. The rat was allowed to habituate in a square
arena (150 150 cm) for 5 min then elevated 3 cm about the
ground (by holding its tail) and finally positioned in the
centre of the arena. When the animal touched the floor it
started running. Behavior was scored online using the
‘correct walking’ criteria (see Bouwman et al, 2005). Data
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acquisition was stopped when the rat changed its accelera-
tion, velocity or direction. Run speed was calculated as
distance traveled (cm/s).
Rotarod test. The fixed-speed rotarod test (Rozas et al,
1997) measures different motor parameters such as motor
coordination, gait ability, balance, muscle tone and
motivation to run. It was employed according to a
previously described protocol (Marti et al, 2004a) which
allowed to detect both facilitating and inhibitory drug
effects. Briefly, rats were tested in a control session at 4
increasing speeds (30, 35, 40 and 45 r.p.m.; 180 s each),
causing a progressive decrement of performance to B40%
of the maximal response (ie the experimental cutoff time).
Other two sessions were repeated 10 and 60 min after drug
injection, and drug effect expressed as percent of control
performance (total time spent on the rod).
Since pharmacological treatment may induce turning in
rats, rotational behavior was measured after saline, N/OFQ
or UFP-101 treatment. Rats were left to habituate in circular
bowls for 20 min before the beginning of the test.
Contralateral or ipsilateral turns (ie turns in the same or
opposite direction to the injection side) were counted every
5 min, from 15 min before to 90 min after injection.
ICMS
Anesthesia was induced by ketamine hydrochloride (50 mg/
kg i.p.) and maintained by supplementary ketamine
injections (i.m.) throughout the experiment, such that
long-latency, sluggish hindlimb withdrawal was achieved
with severe pinching of the hind-foot. The body tempera-
ture was maintained at 36–381C with a heat lamp. The
animal was placed in a Kopf stereotaxic apparatus and a
large craniotomy was performed over the frontal cortex of
one side. The dura remained intact, and was kept moist with
a 0.9% saline solution. Drug injections (0.01 or 10 nmol N/
OFQ, 10 nmol UFP-101, dissolved in 0.5 ml of saline) were
performed in the left or right LCV (AP¼0.8 mm;
ML¼±1.5 mm; VD¼3.5 mm below the pial surface),
layer V of central M1 (AP¼ 2–3 mm and ML¼ 2.5–3 mm;
VD¼1.5 mm) and SNr (AP¼5.5 mm; ML¼±2.2 mm;
VD¼7.6 mm). Drugs were slowly injected and, to prevent
the substance from refluxing, the needle was withdrawn
from the cortex 120 s later.
In each animal, the movements evoked by ICMS in the
frontal agranular cortex were mapped starting 10 min after
injection. When drugs were injected in LCV and SNr, the
mapping procedure was similar to that described by
Donoghue and Wise (1982) and detailed elsewhere (Franchi,
2000a). Briefly, the electrode penetrations were regularly
spaced out over a 500 mm grid. Glass-insulated tungsten
microelectrodes (0.6–1.2 MO impedance at 1 kHz), were
used for stimulation. The electrode was lowered perpendi-
cularly to the cortical surface down to layer V of the frontal
agranular cortex (1.5 mm; Franchi, 2000a). Monophasic
cathodal pulses (200 ms duration, 30 ms trains at 300 Hz) of
a maximum of 60 mA were passed through the electrode
with a minimum interval of 2.5 s. Two observers were
required for movement detection and threshold determina-
tion. Starting with a current of 60 mA, intensity was
decreased in 5mA steps until the movement was no longer
evoked; then the intensity was increased to a level at which
B50% of the stimulation elicited movement. This level
defined current threshold. If no movements or twitches
were evoked with 60 mA, the site was recorded as negative.
When a movement was observed in two or more body parts,
current thresholds were determined for each component.
Body parts activated by ICMS were identified by visual
inspection and/or muscle palpation. The terms ‘forelimb
movement’ and ‘hindlimb movement’ refer collectively to
proximal and distal joint movements. When drugs were
injected in M1 the procedure was as above, but electrode
penetrations were orthogonally spaced out over 200, 400
and 800 mm from injection site. Although the direct current
spread is confined to 250 mm from the stimulating electrode,
the current can transynaptically activate a wider area of
cortex (Jankowska et al, 1975). Then, the ICMS applied at
different distances to the site of injection ensures a
thorough analysis of drug effect. For each set of experiments
(injections in LCV, M1, SNr) appropriate controls were run
in parallel: five rats were mapped with the cortex untouched
(control group) and the other five received a 0.5 ml injection
of saline on the correspondent site (sham group).
At the end of the experimental procedures, animals were
perfused transcardially with saline and then with 4%
paraformaldehyde solution. Brains were removed, post-
fixed, sectioned coronally into 50 mm thick slices and then
stained with thionine to verify needle and microelectrode
positions.
Data Presentation and Statistical Analysis
Motor performance in the bar, drag and speed tests was
expressed in absolute values (sec, number of steps, cm/s,
respectively) whereas motor performance in the rotarod test
as percentage±SEM of the control session. Statistical
analysis was performed by one-way repeated measure
(RM) ANOVA followed by contrast analysis to determine
group differences. In case a significant time treatment
interaction was found, the sequentially rejective Bonferroni
test was used to determine specific differences (ie at the
single time-point level) between groups. Drug interaction
was studied experimentally according to a 2 2 factorial
design and data analyzed with conventional two-way
ANOVA, factor one being N/OFQ and factor two UFP-101.
ICMS data were presented as mean±SEM. Inter-group
comparisons were determined using one-way ANOVA and
w2 test presented in a two-way contingency table (2 2). P-
values o0.05 were considered to be statistically significant.
Drugs
N/OFQ and UFP-101 were prepared at the University of
Ferrara, as previously described (Guerrini et al, 2000).
RESULTS
Behavioral Studies
I.c.v. injections of nop receptor ligands. To investigate the
role of central NOP receptors in modulation of motor
activity, N/OFQ was injected i.c.v. (in LCV). UFP-101 was
also administered to test the specificity of N/OFQ action and
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to investigate the role of endogenous N/OFQ. Saline
injections did not affect motor activity. Indeed, immobility
time, number of steps, speed and rotarod performance
were similar in saline-injected (0.6±0.2 s, 13.2±0.3,
67.4±2.1 cm/s and 1021±27 s, respectively) and control
(0.8±0.3 s, 12.9±0.8, 68.6±6.3 cm/s and 1064±18 s, res-
pectively) rats. As i.c.v. injection of saline, N/OFQ and
UFP-101 did not induce forepaw motor asymmetry, results
obtained at the contralateral and the ipsilateral forepaw in
the bar and drag test were pooled together.
N/OFQ.
(i) Bar test: RM ANOVA on the immobility time in the
bar test (Figure 1a) showed a significant effect of treat-
ment (F4,28¼ 503.91, po0.0001) time (F1,4¼ 24.85,
po0.0001) and a significant time treatment interac-
tion (F4,29¼ 11.86, po0.0001). Post hoc analysis
revealed that 0.1 nmol N/OFQ evoked a modest and
transient elevation of immobility time (ie caused
akinesia) compared to saline while 1 and 10 nmol N/
OFQ evoked a more robust and prolonged response,
detectable 60 min after injection. No change in
immobility time was elicited by 0.01 nmol N/OFQ.
(ii) Drag test: RM ANOVA on the number of steps in the
drag test (Figure 1b) showed a significant effect of
treatment (F4,28¼ 102.07, po0.0001), time (F1,4¼
59.13, po0.0001) and a significant time treatment
interaction (F4,29¼ 23.60, po0.0001). Post hoc analysis
revealed that N/OFQ evoked a biphasic response,
namely facilitation at 0.01 nmol and inhibition at
higher doses (0.1–10 nmol). Both facilitation and
inhibition were detected after 60 min.
(iii) Speed test: RM ANOVA on speed values (Figure 1c)
showed a significant effect of treatment (F4,28¼ 182.51,
po0.0001), time (F1,4¼ 7.15, p¼ 0.012) and a signifi-
cant time treatment interaction (F4,29¼ 5.18, p¼ 0.002).
Post hoc analysis revealed that, as in the drag test,
N/OFQ evoked a biphasic response, improving
speed at 0.01 nmol and inhibiting it at higher doses
(0.1–10 nmol). Both effects were long-lasting.
(iv) Rotarod test: RM ANOVA on rotarod values
(Figure 1d) showed a significant effect of treatment
(F4,28¼ 4980.92, po0.0001) but not time (F1,4¼ 0.005,
p¼ 0.94) and a non significant time treatment
interaction (F4,29¼ 0.61, p¼ 0.66). Post hoc analysis
revealed that N/OFQ improved rotarod performance at
0.01 nmol and impaired it at higher doses.
UFP-101.
(i) Bar test: RM ANOVA showed a significant effect of
treatment (F3,18¼ 8.94, p¼ 0.0007), time (F1,3¼ 6.96,
p¼ 0.014) and a non significant time treatment
interaction (F3,24¼ 0.94, p¼ 0.43). UFP-101 caused a
reduction of immobility time at 10 nmol (Figure 1e).
(ii) Drag test: RM ANOVA showed a significant effect of
treatment (F3,18¼ 69.29, po0.0001) but not time
Figure 1 Effect of i.c.v. injection of N/OFQ or UFP-101 on motor activity. N/OFQ (0.01–10 nmol) or UFP-101 (0.1–10 nmol) were injected in the lateral
cerebral ventricle and motor activity evaluated in the bar (panels a, e), drag (panels b, f), speed (panels c, g) and rotarod (panels d, h) tests. Each experiment
consisted of three different sessions: a control session followed by other two sessions performed 10 and 60 min after saline, N/OFQ or UFP-101 injection
(see Materials and Methods). In the bar, drag and speed test data are expressed as absolute values (sec, steps, and cm/s, respectively) whereas in the rotarod
test as percentages of motor activity in the control session. Data are means±SEM of 7–9 determinations per group. *po0.05 and **po0.01 significantly
different from saline.
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(F1,3¼ 0.01, p¼ 0.93) and a significant time treat-
ment interaction (F3,24¼ 4.69, p¼ 0.01). UFP-101
elevated the number of steps at 10 nmol (Figure 1f).
The effect of 10 nmol UFP-110 was also detected
60 min after injection.
(iii) Speed test: RM ANOVA showed a significant effect of
treatment (F3,18¼ 81.03, po0.0001), but not time
(F1,3¼ 0.69, p¼ 0.41) and a non significant time-
treatment interaction (F3,24¼ 1.63, p¼ 0.20). UFP-101
induced long-lasting increase in speed at 10 nmol
(Figure 1g).
(iv) Rotarod test: RM ANOVA showed a significant effect
of treatment (F3,18¼ 18.70, po0.0001), time (F1,3¼
4.80, p¼ 0.022) and a significant time treatment
interaction (F3,24¼ 11.71, po0.0001). UFP-101 im-
proved the rotarod performance at 1 and 10 nmol
(Figure 1h). The effect of 1 nmol UFP-101 was
transient whereas that produced by the higher dose
was prolonged.
Co-injection of N/OFQ and UFP-101. To investigate the
selectivity of N/OFQ action, co-injections of low and high
N/OFQ and UFP-101 doses (1:10 ratio) were performed. We
first tested the specificity of 0.01 nmol N/OFQ by challen-
ging it with 0.1 nmol UFP-101 (Figure 2).
RM ANOVA in the drag test (Figure 2a), showed a
significant effect of treatment (F3,18¼ 57.87, po0.0001), but
not time (F1,3¼ 1.15, p¼ 0.29) and a non significant
time treatment interaction (F3,24¼ 0.04, p¼ 0.98). N/OFQ
elevated the number of steps and UFP-101, ineffective alone,
prevented this effect. RM ANOVA on speed values
(Figure 2b) revealed a significant effect of treatment
(F3,18¼ 19.34, po0.0001) and time (F1,3¼ 6.45, p¼ 0.017)
but not a significant interaction between the two
(F3,24¼ 1.44, p¼ 0.25). N/OFQ increased rat speed and
UFP-101, ineffective alone, prevented this effect. RM
ANOVA on rotarod values (Figure 2c) revealed a significant
effect of treatment (F3,18¼ 66.09, po0.0001), but not time
(F1,3¼ 0.02, p¼ 0.88) and a non significant time treatment
interaction (F3,24¼ 0.22, p¼ 0.87). N/OFQ elevated rotarod
performance while UFP-101, ineffective alone, prevented
N/OFQ action.
We then tested the specificity of high N/OFQ doses by
challenging 1 nmol N/OFQ with 10 nmol UFP-101 (Figure 3).
RM ANOVA on the bar test (Figure 3a) revealed a
significant effect of treatment (F3,18¼ 276.13, po0.0001),
time (F1,3¼ 27.19, po0.0001) and a significant time treat-
ment interaction (F3,24¼ 34.45, po0.0001). N/OFQ elevated
immobility time while UFP-101, ineffective alone, prevented
this effect. In the drag test (Figure 3b), a significant effect of
treatment (F3,18¼ 107,13, po0.0001), time (F1,3¼ 12.33,
po0.0017) and a significant time treatment interaction
(F3,24¼ 9.14, p¼ 0.0003) were found. N/OFQ reduced the
number of steps while UFP-101 increased it. The combina-
tion of the two was the sum of their effects, that is, no
change with respect to saline-treated animals. In the speed
test (Figure 3c), a significant effect of treatment
(F3,18¼ 94.71, po0.0001), but not time (F1,3¼ 1.47,
p¼ 0.23) and a non significant time treatment interaction
(F3,24¼ 1.77, p¼ 0.18) were observed. N/OFQ reduced,
whereas UFP-101 increased speed. Again, combination of
the two caused no change in speed when compared to
saline-treated animals. Finally, RM ANOVA on the rotarod
(Figure 3d) showed a significant effect of treatment
(F3,18¼ 164.02, po0.0001), but not time (F1,3¼ 0.14,
p¼ 0.70) and a non significant time treatment interaction
(F3,24¼ 0.04, p¼ 0.97). N/OFQ reduced rotarod perfor-
mance and UFP-101 improved it. Co-application of N/
OFQ and UFP-101 caused a slight increase in performance
compared to saline-treated rats.
Turning behavior: LCV injection of N/OFQ or UFP-101
did not induce turning behavior in the range of doses tested.
M1 injections of NOP receptor ligands. To investigate the
localization of NOP receptors involved in motor actions
elicited by i.c.v. N/OFQ and UFP-101, intracortical injec-
Figure 2 Effect of i.c.v. co-injection of low doses of N/OFQ and UFP-101 on motor activity. N/OFQ (0.01 nmol) and UFP-101 (0.1 nmol) were co-
injected in the lateral cerebral ventricle and motor activity evaluated in the drag (panel a), speed (panel b) and rotarod (panel c) test. Each experiment
consisted of three different sessions: a control session followed by other two sessions performed 10 and 60 min after saline, N/OFQ or UFP-101 injection
(see Materials and Methods). In the drag and speed test data are expressed as absolute values (steps, and cm/s, respectively) whereas in the rotarod test as
percentages of motor activity in the control session. Data are means±SEM of seven determinations per group. **po0.01 significantly different from saline.
}}po0.01 significantly different from N/OFQ.
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tions (layer V of M1) were first made. Saline, N/OFQ (0.01–
10 nmol) or UFP-101 (10 nmol) failed to affect rat perfor-
mance in the bar, drag, speed and rotarod test (Figure S1).
SNr injections of nop receptor ligands. On the basis of our
previous finding that NOP receptors located in the SNr
modulate rotarod performance in rats (Marti et al, 2004a)
we investigated whether motor effects induced by i.c.v. N/
OFQ and UFP-101 could be reproduced by SNr injections.
Since injections were made unilaterally, motor activity was
evaluated separately at the ipsilateral and contralateral paw.
N/OFQ.
(i) Bar test: Saline did not affect the immobility time
at the contralateral (0.9±0.3 s) and ipsilateral
(1.0±0.3 s) forepaw compared to control rats
(1.1±0.3 s). RM ANOVA on the immobility time at
the contralateral paw in the bar test (Figure 4a and b)
showed a significant effect of treatment (F4,24¼ 80.13,
po0.0001), time (F1,4¼ 11.36, p¼ 0.002) and a sig-
nificant time treatment interaction (F4,30¼ 3.36,
p¼ 0.021). N/OFQ increased the immobility time
dose-dependently and in a prolonged way, being
active yet at 0.1 nmol. Qualitatively similar data were
obtained at the ipsilateral paw.
(ii) Drag test: Saline did not modify the number of steps
made by the contralateral (11.9±0.4) and ipsilateral
(12.3±0.6) paw compared to control (11.6±0.5) rats.
In the drag test (Figure 4c and d), RM ANOVA at
the contralateral paw disclosed a significant effect
of treatment (F4,24¼ 92.03, po0.0001), time (F1,4¼
11.77, p¼ 0.0017) and a significant time treatment
interaction (F4,30¼ 5.16, p¼ 0.0027). N/OFQ elevated
the number of steps at 0.01 nmol but reduced them in
the 0.1–10 nmol range. Conversely, RM ANOVA at the
ipsilateral paw showed a significant effect of treatment
(F4,24¼ 26.35, po0.0001), but not time (F1,4¼ 0.27,
p¼ 0.60) and a non significant time treatment
interaction (F4,30¼ 0.48, p¼ 0.88). N/OFQ dose-
dependently reduced the number of steps, the
threshold inhibitory dose being 1 nmol.
(iii) Speed test: Saline did not affect rat speed (66.7±1.1
and 68.6±6.3 cm/s, respectively, for the saline-treated
and control rats). Analysis of speed values (Figure 4e)
revealed a significant effect of treatment
(F4,24¼ 136.15, po0.0001), time (F1,4¼ 6.35,
p¼ 0.017) and a significant time treatment interac-
tion (F4,30¼ 12.37, po0.0001). N/OFQ biphasically
modulated rat speed, low doses (0.01 nmol) being
facilitatory and higher ones (0.1–10 nmol) inhibitory.
UFP-101.
(i) Bar test: RM ANOVA on the immobility time did not
reveal significant effects of UFP-101 at the contral-
ateral and ipsilateral paws (Figure S2).
(ii) Drag test: RM ANOVA at the contralateral paw (Figure
4f and g) revealed a significant effect of treatment
(F3,18¼ 30.22, po0.0001) but not time (F1,3¼ 1.38,
p¼ 0.25) and a non significant time treatment
interaction (F3,24¼ 0.66, p¼ 0.58). UFP-101 (1 and
10 nmol) elevated the number of steps at both 10 and
60 min post injection time. Conversely, RM ANOVA
did not reveal any effect of UFP-101 on stepping
activity at the ipsilateral paw.
(iii) Speed test: RM ANOVA on speed values (Figure 4h)
showed a significant effect of treatment (F3,18¼ 58.87,
po0.0001), but not time (F1,4¼ 0.48, p¼ 0.49) and a
non significant time treatment interaction
(F4,30¼ 0.95, p¼ 0.43). UFP-101 (1 and 10 nmol)
consistently elevated speed at 10 and 60 min after
injection.
Co-injection of N/OFQ and UFP-101. To investigate the
selectivity of N/OFQ action in SNr, co-injections of low and
high N/OFQ and UFP-101 doses (1:10 ratio) were performed
(Figure 5).
In the drag test (Figure 5a), conventional two-way
ANOVA showed a main effect of N/OFQ (F1,24¼ 14.72,
p¼ 0.0008), UFP-101 (F1,24¼ 22.00, p¼ 0.0001) and a
significant N/OFQUFP-101 interaction (F1,24¼ 11.63,
p¼ 0.0023). N/OFQ (0.01 nmol) elevated the number of
steps and UFP-101 (0.1 nmol), ineffective alone, prevented
this increase. Likewise, in the speed test (Figure 5b),
Figure 3 Effect of i.c.v. co-injection of high doses of N/OFQ and UFP-
101 on motor activity. N/OFQ (1 nmol) and UFP-101 (10 nmol) were co-
injected in the lateral cerebral ventricle and motor activity evaluated in the
bar (panel a), drag (panel b), speed (panel c) and rotarod (panel d) test.
Each experiment consisted of three different sessions: a control session
followed by other two sessions performed 10 and 60 min after saline or
UFP-101 injection (see Materials and Methods). In the bar, drag and
speed test data are expressed as absolute values (sec, steps, and cm/s,
respectively) whereas in the rotarod test as percentages of motor
activity in the first session. Data are means±SEM of seven determi-
nations per group. *po0.05, **po0.01 significantly different from
saline. }po0.05, }}po0.01 significantly different from N/OFQ. #po0.05,
##po0.01 significantly different from UFP-101.
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ANOVA showed a main effect of N/OFQ (F1,24¼ 32.45,
po0.0001), UFP-101 (F1,24¼ 21.72, po0.0001) and a
significant N/OFQUFP-101 interaction (F1,24¼ 33.71,
po0.0001). N/OFQ elevated rat speed, and UFP-101,
ineffective alone, prevented its effect.
UFP-101 (10 nmol) was also challenged against N/OFQ
(1 nmol). In the bar test (Figure 5c), ANOVA showed a main
effect of N/OFQ (F1,24¼ 82.79, po0.0001), UFP-101
(F1,24¼ 83.78, po0.0001) and a significant N/OFQUFP-
101 interaction (F1,24¼ 80.45, po0.0001) at the contralateral
paw. N/OFQ increased immobility time and UFP-101,
ineffective alone, prevented this effect. Similar results were
obtained at the ipsilateral paw. In the drag test (Figure 5d),
ANOVA revealed a main effect of N/OFQ (F1,24¼ 140.84,
po0.0001), UFP-101 (F1,24¼ 128.00, po0.0001) and a
significant N/OFQUFP-101 interaction (F1,24¼ 11.57,
p¼ 0.0023) at the contralateral paw. N/OFQ reduced the
number of steps, UFP-101 increased it and the combination
of the two did not result in significant changes compared to
saline-treated animals. At the ipsilateral paw, a main effect
of N/OFQ (F1,24¼ 7.91, p¼ 0.0096) but not UFP-101
(F1,24¼ 1.01, p¼ 0.32) and a non significant N/OFQ
UFP-101 interaction (F1,24¼ 2.59, p¼ 0.12) were found.
N/OFQ reduced the number of steps and UFP-101,
ineffective alone, prevented this effect. Finally, ANOVA
on speed values (Figure 5e) showed a main effect of
N/OFQ (F1,24¼ 22.63, po0.0001), UFP-101 (F1,24¼ 68.86,
p¼ 0.0001) and a non significant N/OFQUFP-101 inter-
action (F1,24¼ 4.03, p¼ 0.056). N/OFQ reduced speed, UFP-
101 increased it and their combination resulted in a
stimulation not different from that evoked by UFP-101
alone.
ICMS
Since NOP receptor stimulation or blockade affected motor
activity, the hypothesis was tested that manipulation of
central NOP receptors could change output from M1.
I.c.v. injections of NOP receptor ligands. Examination of
M1 maps (examples are given in Figure 6) revealed several
changes in movement representation in the 10 nmol N/OFQ
group (Figure 6e). Contiguous unresponsive sites were
consistently observed within M1 after i.c.v. injection of
10 nmol N/OFQ. To quantitatively assess these changes, the
percentage of both unresponsive and responsive sites
(movement sites in the vibrissa and forelimb areas) was
calculated within the total site population (Figure 7a).
ANOVA revealed changes in movement representation
after injection of NOP receptor ligands (F14,74¼ 10.45,
po0.0001). N/OFQ 10 nmol doubled the percentage of
unresponsive sites. This effect was associated with a
significant decrease (B49%) in movement sites in the
vibrissa representation and no change in excitable sites in
Figure 4 Effect of intranigral injections of N/OFQ or UFP-101 on motor activity. N/OFQ (0.01–10 nmol) or UFP-101 (0.1–10 nmol) were injected in SNr
and motor activity evaluated in the bar (panels a–b), drag (panels c–d, f–g) and speed (panels e–h) test. Motor activity in the bar and drag test was evaluated
separately at the paws ipsilateral and contralateral to the injection side. Motor activity in the speed test was calculated as distance traveled. Each experiment
consisted of three different sessions: a control session followed by other two sessions performed 10 and 60 min after saline, N/OFQ or UFP-101 injection
(see Materials and Methods). In the bar, drag and speed test data are expressed as absolute values (sec, steps, and cm/s, respectively) whereas in the rotarod
test as percentages of motor activity in the control session. Data are means±SEM of seven determinations per group. *po0.05 and **po0.01 significantly
different from saline.
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forelimb representation. ANOVA revealed that NOP recep-
tor ligands significantly affected movement thresholds
(F9,49¼ 31.40, po0.0001; Figure 7b). N/OFQ (10 nmol)
increased threshold currents in both vibrissa and forelimb
representations (B55 and B47%, respectively) whereas
both N/OFQ (0.01 nmol) and UFP-101 (10 nmol) reduced
them (B17 and B33%), although only in forelimb
representation. The differences in excitability appeared in
more detail by looking at the distribution of vibrissa and
forelimb movement thresholds. N/OFQ (10 nmol) caused a
significant increase in the percentage of those sites where
higher currents were necessary to evoke vibrissa (Figure 7c;
w2¼ 59.37 po0.01) and forelimb (Figure 7d; w2¼ 40.84,
po0.01) movements (2 2, 35 mA as dividing point).
Conversely, N/OFQ (0.01 nmol) and UFP-101 (10 nmol)
did not change the distribution of thresholds in the vibrissa
but caused a significant leftward shift of the distribution
curve in the forelimb representation (N/OFQ 0.01 nmol:
w2¼ 21.26, po0.01; UFP-101 10 nmol: w2¼ 41.67 po0.01,
2 2, 20 mA as a dividing point). InB40% of sites, currents
Figure 5 Effect of intranigral co-injection of N/OFQ and UFP-101 on
motor activity. N/OFQ and UFP-101 were co-injected at low (0.01 and
0.1 nmol, respectively; panels a–b) and high (1 and 10 nmol, respectively;
panels c–e) doses in substantia nigra pars reticulata (SNr) and motor
activity evaluated, at 10 min post-injection time, in the drag (panel a, d),
speed (panels b, e) and bar (panel c) test. Motor activity in the bar and drag
test was evaluated separately at the paws ipsilateral and contralateral to the
injection side. Motor activity in the speed test was calculated as distance
traveled. In the bar, drag and speed test data are expressed as absolute
values (sec, steps, and cm/s, respectively) and are means±SEM of seven
determinations per group. *po0.05, **po0.01 significantly different from
saline. }}po0.01 significantly different from N/OFQ.
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Figure 6 Effect of i.c.v. injection of N/OFQ and UFP-101 on primary
motor cortex output. Representative primary motor cortex maps of
movements evoked at threshold current levels in the vibrissa and forelimb
areas. A schematic of rat brain showing vibrissa and forelimb areas (right)
and reporting a coordinate grid (left) is represented (panel a). The maps
relative to control rats (panel b) and rats injected with saline (panel c),
N/OFQ (0.01 nmol; panel d), N/OFQ (10 nmol; panel e) and UFP-101
(10 nmol; panel f) in the lateral cerebral ventricle are also shown. The
microelectrode was sequentially introduced to a depth of 1500 mm.
Interpenetration distances were 500 mm. In these mapping schemes, frontal
poles are at the bottom. Zero corresponds to bregma; numbers indicate
rostral or caudal distance from the bregma or lateral distance from the mid-
line. Movement evoked at one point is indicated by symbols and threshold
range by the different grey scale. Absence of symbol (within or at the
border of the maps) indicates that penetration was not performed due to
presence of a large vessel. In panel e, the presence of dark symbols and
unresponsive sites is worth noting.
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lower than 20 mA were usually necessary to evoke forelimb
movement.
M1 injections of NOP receptor ligands. To investigate
whether NOP receptors located in M1 modulated local
excitability, injections of NOP receptor ligands in the layer
V of M1 were made (examples are given in Figure 8).
ANOVA on threshold currents considered as a whole or at
each level away from the injection site (Figure S3) revealed
no significant changes in all treated group compared to
saline.
SNr injections of NOP receptor ligands. Intranigral
injections of NOP receptor ligands were performed to
investigate whether NOP receptors located in SNr affected
motor excitability. ANOVA on M1 maps derived in SNr
(representative examples given in Figure 9) revealed that
NOP receptor ligands modulated the numbers of responsive
and unresponsive sites (F14,74¼ 12.09, po0.0001; Figure
10a). N/OFQ (10 nmol) was ineffective in the vibrissa area
but increased (B121%) the number of unresponsive sites
and simultaneously reduced (B60%) the number of
excitable sites in the forelimb representation. ANOVA also
revealed that NOP receptor ligands modulated threshold
currents (F9,49¼ 13.71, po0.0001; Figure 10b). N/OFQ
(10 nmol) enhanced the mean threshold values in the
vibrissa (B29%) and forelimb (B58%) areas. Moreover,
UFP-101 (10 nmol) reduced (B44%) threshold currents
selectively in the forelimb. A slight inhibition (B15%) was
also observed with 0.01 nmol N/OFQ in the forelimb area,
which however, did not reach the level of significance.
Statistical analysis on threshold distribution showed that N/
OFQ 10 nmol shifted to the right the distribution in
both vibrissa (Figure 10c, w2¼ 20.99, po0.01) and
forelimb (Figure 10d, w2¼ 53.27, po0.01) evoked-move-
ment (2 2, 35 mA as a dividing point). Conversely, N/OFQ
(0.01 nmol) and UFP-101 (10 nmol) caused a significant
leftward shift in the threshold distribution in forelimb
representation (N/OFQ 0.01 nmol w2¼ 9.89 po0.01;
UFP-101 10 nmol: w2¼ 62.80 po0.01, 2 2, 20 mA as a
dividing point).
DISCUSSION
Exogenous N/OFQ produced a dose-dependent, biphasic
regulation of motor performance in rats. Inhibition was
predominant since it was quantitatively larger and detected
in a wider dose-range than facilitation. Conversely, UFP-101
monotonically facilitated motor activity suggesting an
inhibitory role for endogenous N/OFQ in motor control.
NOP receptor ligands produced changes in M1 output,
which were consistent with their motor effects. Thus,
exogenous N/OFQ biphasically regulated motor cortex
excitability, low doses being facilitatory and higher ones
inhibitory. Conversely, UFP-101 increased motor cortex
excitability (in the forelimb area), suggesting that endogen-
ous N/OFQ tonically inhibits forelimb movement. Both
behavioral and electrophysiological effects were evoked by
i.c.v. and intranigral, but not intracortical, drug injections,
overall suggesting that subcortical NOP receptors regulate
motor behavior and motor cortex output via modulation of
cortical afferents.
Motor impairment has been consistently reported as one
of the main biological effects induced by central NOP
Figure 7 Effect of i.c.v. injection of N/OFQ and UFP-101 on primary motor cortex output. N/OFQ (0.01 and 10 nmol) and UFP-101 (10 nmol) were
injected in the lateral cerebral ventricle, and the percentage of unresponsive and excitable sites in the vibrissa and forelimb areas (panel a) or average
thresholds currents required to evoke vibrissa and forelimb movements (panel b) were measured. Threshold current distribution is also shown (panels c–d).
The percentage of other movement sites (neck, jaw, eye and hindlimb) are not shown because these movements were not extensively explored. Note that
N/OFQ (10 nmol) significantly shifted to the right both vibrissa and forelimb threshold distributions whereas N/OFQ (0.01 nmol) and UFP-101 (10 nmol)
significantly shifted to the left the forelimb threshold distribution. Data are means±SEM of five determinations per group. *po0.05, **po0.01 significantly
different from control.
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receptor stimulation in rodents. N/OFQ given i.c.v.
(Reinscheid et al, 1995; Devine et al, 1996; Nishi et al,
1997; Rizzi et al, 2001; Higgins et al, 2001; Kuzmin et al,
2004) or Ro 64–6198 given systemically (Jenck et al, 2000;
Higgins et al, 2001; Varty et al, 2005) depressed both
spontaneous and exercise-induced locomotion. Fairly high
doses of N/OFQ (1–30 nmol) or Ro 64–6198 (10 mg/Kg)
were required to depress motor activity. These doses,
although selective for the NOP receptor (Nishi et al, 1997;
Noda et al, 1998; Higgins et al, 2001), may induce
hypolocomotion and catalepsy by affecting not only motor
but also vestibular and cardiovascular functions (Sulaiman
et al, 1999; Kapusta et al, 1999). The battery of comple-
mentary behavioral tests used in the present study provides
information on the state of activation of the basal ganglia-
thalamo-cortical circuit. Indeed, modulation of the time to
initiate and to execute a movement, as in the bar and drag
test, primarily engage the basal ganglia (Hauber, 1998).
Walking activity (as on the rotarod) also engages the
dorsolateral striatum, as shown by biochemical (Brown and
Sharp, 1995; Holschneider et al, 2003) and neurochemical
(Bergquist et al, 2003; Petzinger et al, 2007) evidence.
Although the cerebellar-thalamo-cortical circuit is also
activated during rotarod performance, its role in motor
control predominates (over the basal ganglia-thalamo-
cortical circuit) when training period is prolonged to
several weeks (Holschneider et al, 2007).
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Figure 8 Intracortical injections of N/OFQ and UFP-101. Examples of
cross-shaped grids showing injection and stimulation sites in control rats
(panel b) or rats injected with saline (panel c), N/OFQ (0.01 and 10 nmol;
panels d and e), and UFP-101 (10 nmol; panel f) in primary motor cortex. A
schematic of rat brain showing vibrissa and forelimb areas (right) and
reporting a coordinate grid (left) is also represented (panel a). For each
stimulation site, a letter indicates the type of ICMS-evoked movement and
the corresponding number the threshold current (in mA) required to evoke
it. Note that threshold values in control and saline groups overlap with
those of N/OFQ and UFP-101 groups.
Hindlimb
Vibrissa
Neck
Eye/Miosis
Unresponsive
site
Jaw/Tongue
Forelimb
10-20 µA 
25-40 µA 
45-60 µA 
Movement
Threshold
ML Coordinate (mm)
A
P 
Co
or
di
na
te
 (m
m)
-1
0 1 2 3 4 5
ML Coordinate (mm)
0 1 2 3 4 5
ML Coordinate (mm)
0 1 2 3 4 5
ML Coordinate (mm)
0 1 2 3 4 5
ML Coordinate (mm)
0 1 2 3 4 5
0
1
2
3
4
5
A
P 
Co
or
di
na
te
 (m
m)
-1
0
1
2
3
4
5
A
P 
Co
or
di
na
te
 (m
m)
-1
0
1
2
3
4
5
A
P 
Co
or
di
na
te
 (m
m)
-1
0
1
2
3
4
5
A
P 
Co
or
di
na
te
 (m
m)
-1
0
1
2
3
4
5
Control
Saline
N/OFQ  10 nmol
N/OFQ  0.01 nmol
UFP-101 10 nmol
Figure 9 Effect of intranigral injection of N/OFQ and UFP-101 on
primary motor cortex output. Representative primary motor cortex maps
of movements evoked at threshold current levels in the vibrissa and
forelimb areas. A schematic of rat brain showing vibrissa and forelimb areas
(right) and reporting a coordinate grid (left) is represented (panel a). The
maps relative to control rats (panel b) and rats injected with saline (panel
c), N/OFQ (0.01 nmol; panel d), N/OFQ (10 nmol; panel e) and UFP-101
(10 nmol; panel f) in substantia nigra reticulata are also shown. The
microelectrode was sequentially introduced to a depth of 1500 mm.
Interpenetration distances were 500 mm. In these mapping schemes, frontal
poles are at the bottom. Zero corresponds to bregma; numbers indicate
rostral or caudal distance from the bregma or lateral distance from the mid-
line. Movement evoked at one point is indicated by symbols and threshold
range by the different grey scale. Absence of symbol (within or at the
border of the maps) indicates that penetration was not performed due to
presence of a large vessel. In panel e, the presence of dark symbols and
unresponsive sites is worth noting.
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These tests allowed to clearly demonstrate that lower
doses of i.c.v. N/OFQ (0.1–1 nmol) inhibited motor behavior
by inducing akinesia and bradykinesia, by slowing the time
to initiate and to execute a movement. The specificity of
these effects is also confirmed by reports that these doses of
N/OFQ did not affect other motor parameters such as
righting reflex (Devine et al, 1996) or muscle strength
(Jenck et al, 1997) and tone (Devine et al, 1996; Marti et al,
2004a). Moreover, akinesia and bradykinesia, were repli-
cated by N/OFQ injections in SNr, the motor output of basal
ganglia. This confirms and extends our previous studies in
naive (Marti et al, 2004a) and 6-OHDA hemilesioned (Marti
et al, 2005) rats, further endorsing the view that nigral NOP
receptors are modulators of specific motor patterns.
Inhibition of locomotion was not the only effect induced
by central NOP receptor stimulation since very low doses of
N/OFQ (0.01 nmol) produced mild but significant facilita-
tion. In previous studies, i.c.v. injection of 0.01–0.5 nmol
N/OFQ (Florin et al, 1996; Jenck et al, 1997; Kuzmin et al,
2004; Sakoori and Murphy, 2004) or systemic administra-
tion of intermediate doses of Ro 64–6198 (3–6 mg/Kg,
Higgins et al, 2001) facilitated spontaneous locomotion in
rodents. This facilitation was previously related to the well-
known anxiolytic effect of NOP receptor agonists (Jenck
et al, 1997). However, the present study points out that the
0.01 nmol N/OFQ-induced facilitation is a specific motor
effect. Indeed, i.c.v. N/OFQ enhanced not only rat speed and
rotarod performance but also stepping activity. Moreover,
facilitation in the drag and speed test was replicated by
stimulation of NOP receptors in the SNr, suggesting
activation of motor pathways. To confirm this view, the
contralateral limb was selectively affected in the drag test. In
fact, we have previously reported that SNr injections of
0.01 nmol N/OFQ did not affect rotarod performance (Marti
et al, 2004a). The most parsimonious explanation is that the
improvements in stepping activity and run speed induced
by unilateral SNr N/OFQ injections are too mild to affect
exercise-induced locomotion as in the rotarod test.
Despite the fact that exogenous N/OFQ evoked both
motor facilitation and inhibition, the latter effect appeared
predominant. This is in line with the finding that
endogenous N/OFQ physiologically inhibits movement.
Indeed, UFP-101, given i.c.v. or injected in SNr, facilitated
stepping activity, run speed and rotarod performance (see
Marti et al, 2004a, for the effect of UFP-101 injections in SNr
on rotarod performance). Consistently, deletion of the NOP
receptor gene resulted in enhanced rotarod performance
(Marti et al, 2004a). It is noteworthy that motor activation
was induced by doses of UFP-101 (1 nmol i.c.v.) that were
found ineffective in modulating spontaneous locomotion
(Kuzmin et al, 2004; Gavioli et al, 2003; Rizzi et al, 2007;
Sakoori and Murphy, 2008), pain (Calo` et al, 2002, 2005;
Rizzi et al, 2006) or depression (Gavioli et al, 2003). This
finding strengthens the view that exercise-induced move-
ment is the most sensitive biological parameter influenced
by endogenous N/OFQ, possibly due to phasic release of
N/OFQ under motor activation (Marti et al, 2005). This view
is not contradicted by the finding that UFP-101 10 nmol
improved motor performance also under static conditions
(ie reduced the immobility time in the bar test). Indeed, this
facilitation was not consistent across groups. This may
possibly be due to experimental reasons. Indeed, changes in
immobility time below 1 s (which is about the time required
to withdraw the paw from the blocks) approach the limits of
sensitivity of the method (ie the reaction time of the
operator). It is therefore possible that slight changes in
Figure 10 Effect of intranigral injection of N/OFQ and UFP-101 on primary motor cortex output. N/OFQ (0.01 and 10 nmol) and UFP-101 (10 nmol)
were injected in substantia nigra reticulata, and the percentage of unresponsive and excitable sites in the vibrissa and forelimb areas (panel a) or the
thresholds currents required to evoke vibrissa and forelimb movements (panel b) were measured. Threshold current distribution is also shown (panels c–d).
The percentage of other movement sites (neck, jaw, eye and hindlimb) are not shown because these movements were not extensively explored. Note that
N/OFQ (10 nmol) significantly shifted to the right both vibrissa and forelimb distributions whereas N/OFQ (0.01 nmol) and UFP-101 (10 nmol) significantly
shifted to the left the forelimb distribution. Data are means±SEM of five determinations per group. *po0.05, **po0.01 significantly different from control.
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basal activity across different groups of animals may alter
the possibility to detect a significant response to UFP-101.
Overall, the data obtained with N/OFQ and UFP-101 suggest
that exogenous N/OFQ is capable of activating facilitatory
and inhibitory motor pathways while endogenous N/OFQ
tonically interacts only with the inhibitory ones. Whether
these effects are mediated by different receptor subtypes
(Marti et al, 2003, Kuzmin et al, 2004) or receptor located
along different and functional opposing pathways remains a
matter of conjecture.
Changes in motor behavior observed after stimulation
and blockade of NOP receptors in awake rats were in line
with changes in motor output observed in anesthetized rats
by using ICMS in layer V of M1. Indeed, the efferent
neurons located in this area are most intensively involved in
movement control (Beloozerova et al, 2003). ICMS in layer
V elicits movement via direct stimulation of corticofugal
and/or intracortical neurons (Jankowska et al, 1975),
resulting in summation of excitatory synaptic potentials in
motoneurons and muscle activity. Thus, movement repre-
sentation, as assessed by ICMS, is a measure of the output
function of the motor cortex. Moreover, it has proven to be
highly sensitive to a variety of neural manipulations that
influence the balance between excitatory and inhibitory
circuits within M1 (Sanes et al, 1990; Hess and Donoghue,
1994; Huntley, 1997; Nudo and Milliken, 1996; Franchi,
2000b).
NOP receptors are widely expressed in cortical areas
(particularly in layers III–VI; Neal et al, 1999), where they
can modulate local neurotransmission both at the pre-
synaptic (Sbrenna et al, 2000; Marti et al, 2003) and post-
synaptic (Siniscalchi et al, 2002; Bianchi et al, 2004) level.
However, neither motor output nor behavior was affected
by M1 injections of NOP receptor ligands. This indicates
that cortical NOP receptors were not involved in local
modulation of the normal balance between excitatory and
inhibitory circuits or that they did not change the
excitability of cortico-fugal neurons belonging to the main
subcortical output systems, namely the cortico-spinal, the
cortico-pontine, the cortico-striatal and the cortico-thala-
mic system. Conversely, the fact that SNr injections of
N/OFQ and UFP-101 affect motor cortex excitability
suggests that the main influence on M1 cortical circuits is
due to changes in cortical inputs. M1 receives inputs related
to locomotion primarily from the ventrolateral thalamus,
and in the absence of this input, the locomotion-related
modulation of cortical activity nearly vanishes (Beloozerova
and Sirota, 1998). Therefore, a candidate mechanism
capable of altering the cortical excitability after injection
of NOP receptor ligands might be the modulation of
thalamic excitatory input to M1.
Neurobiological Substrates of N/OFQ Actions
Changes in DA transmission may underlie motor effects
induced by N/OFQ. Indeed, stimulation of NOP receptors
expressed on nigral DA neurons (Norton et al, 2002;
Maidment et al, 2002) hyperpolarized DA cells and reduced
their firing activity (Marti et al, 2004a). Moreover, motor
inhibition induced by intranigral injections of N/OFQ was
associated with reduced nigrostriatal DA transmission in
vivo (Marti et al, 2004a). Disruption of motor cortex activity
was also associated with motor impairment. M1 receives
inputs from basal ganglia circuits that are known to be
severely disrupted by striatal DA deficiency (Steiner and
Kitai, 2000; Orieux et al, 2002; Parr-Brownlie and Hyland,
2005). In haloperidol-treated cats, the activity of the motor
thalamus was found to be reduced and the afferent
pathways to M1, that influence the segmental apparatus of
the spinal cord, inhibited (Voloshin et al, 1994). Moreover,
haloperidol-induced motor impairment in rats was asso-
ciated with reduced baseline firing rate, bursting activity
and movement-related firing in cortical neurons (Parr-
Brownlie and Hyland, 2005). The finding that high N/OFQ
doses injected in SNr inhibited motor behavior and cortical
motor output, possibly via inhibition of DA transmission, is
consistent with an inhibitory effect of N/OFQ on thalamo-
cortical transmission. Indeed, reduction of thalamo-cortical
inputs leaves the motor cortex functionally deactivated
(Wichmann and DeLong, 1993; Obeso et al, 2000; Boraud
et al, 2002; Rolland et al, 2007). Evidence that endogenous
N/OFQ in SNr also modulates thalamo-cortical projections,
although possibly via non-DA mechanisms, has been
obtained in the 6-hydroxydopamine hemilesioned rat model
of Parkinson’s disease. Indeed, NOP receptor antagonists
elevated GABA and reduced GLU release in the lesioned
SNr, which was associated with reduced nigro-thalamic
GABA transmission and attenuation of akinesia at the
parkinsonian limb (Marti et al, 2007). This finding suggests
that endogenous N/OFQ in SNr tonically inhibits thalamic
activity. Interestingly, the electrophysiological data indicate
that this tonic activity affects forelimb but not vibrissa
motor representations. The main reason of this difference
may be the nature of vibrissa and forelimb motor systems
which involve different cortico-basal ganglia motor circuits
(Hoover et al, 2003; Miyachi et al, 2006).
It proves more difficult to explain the enhanced motor
cortex excitability and motor facilitation induced by low
N/OFQ doses. Motor facilitation was prevented by D1 and
D2 receptor antagonists (Florin et al, 1996) or catechola-
mine depletion (Kuzmin et al, 2004). It is possible that a low
degree of NOP receptor stimulation reduces dendritic DA
release in SN. This would remove the inhibitory feedback
mediated by somatodendritic D2 autoreceptors (Cragg and
Greenfield, 1997; Bustos et al, 2004) and result in a
facilitation of rat locomotion (Bergquist et al, 2003).
Alternatively, as shown for classical opioids (Johnson and
North, 1992), low N/OFQ doses may preferentially inhibit
GABA interneurons leading to disinhibition of nigral DA
neurons (Cobb and Abercrombie, 2002).
Concluding Remarks
A careful analysis of motor behavior using a battery of
complementary tests, has demonstrated that exogenous
N/OFQ dose-dependently facilitates and inhibits motor
behavior while endogenous N/OFQ regulates movement in
an inhibitory way. Although we cannot exclude the
possibility that other areas also mediate N/OFQ motor
effects (eg the VTA and spontaneous locomotion), these
data indicate that NOP receptors in SNr mediate specific
motor programs such as time to initiate and execute a
movement. The present study also demonstrates for the first
time that exogenous NOP receptor ligands and endogenous
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N/OFQ regulate motor cortex excitability in a way, which is
consistent with their motor actions. Although the neuro-
biological substrates remain to be investigated, the present
study suggests that changes in cortical output and behavior
are mainly operated by subcortical NOP receptors located in
SNr through modulation of the ‘cortico-basal ganglia-
thalamo-cortical’ loop.
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J-113397Motor activity of mice acutely treated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,5,6-tetrahy-
dropyridine (MPTP) was monitored for 6 days using behavioral tests which provide complementary
information on motor function: the bar, reaction time, drag, stair climbing, grip, rotarod and footprinting
tests. These tests consistently disclosed a prolonged motor impairment characterized by akinesia,
bradykinesia, speed reduction, loss of coordination and gait patterns. This impairment was associated
with ∼60% loss of striatal dopamine terminals, as revealed by tyrosine hydroxylase immunohistochemistry,
and was attenuated by dopaminergic drugs. Indeed, the dopamine precursor, L-dopa (1–10 mg/kg), and the
D3/D2 receptor agonist pramipexole (0.0001–0.001 mg/kg) promoted stepping activity in the drag test (a
test for akinesia/bradykinesia). The novel nociceptin/orphanin FQ receptor (NOP) antagonist 1-[1-
(cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-benzi-
midazol-2-one (Trap-101, 0.001–0.1 mg/kg), an analogue of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxy-
methyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397), also promoted stepping and
synergistically or additively (depending on test) attenuated parkinsonism when combined to dopamine
agonists. High doses of L-dopa (100 mg/kg), pramipexole (0.1 mg/kg), Trap-101 and J-113397 (1 mg/kg),
however, failed to modulate stepping, worsening immobility time and/or rotarod performance. Low doses
of amisulpride (0.1 mg/kg) reversed motor inhibition induced by L-dopa and J-113397, suggesting
involvement of D2/D3 receptors. This study brings further evidence for a dopamine-dependent motor
phenotype in MPTP-treated mice reinforcing the view that this model can be predictive of symptomatic
antiparkinsonian activity provided the appropriate test is used. Moreover, it offers mechanistic
interpretation to clinical reports of paradoxical worsening of parkinsonism following L-dopa. Finally, it
conﬁrms that NOP receptor antagonists may be proven effective in reversing parkinsonism when
administered alone or in combination with dopamine agonists.and Clinical Medicine, Section
Mortara 17-19, 44100 Ferrara,
l rights reserved.
ual motor response to L-dopa and nociceptin
traeted mice: Paradoxical..., Exp. Neurol. (20© 2010 Elsevier Inc. All rights reserved.Introduction
The pathological hallmark of Parkinson's disease (PD) is the
death of pigmented dopamine (DA) neurons in substantia nigra
compacta (SNc), which triggers a slow onset of motor symptoms
such as akinesia/bradykinesia, rigidity, resting tremor and gait/
postural abnormalities. Neurodegeneration models have been
developed to understand the physiopathological mechanisms
underlying PD (Dauer and Przedborski, 2003; Meredith and Kang,
2006). A commonly used neurotoxin is 1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine (MPTP; Langston et al., 1983), which isconverted by monoamine oxidase B (MAO-B) to 1-methyl-4-
phenylpyridinium ion (MPP+). This metabolite enters DA cells and
inhibits mitochondrial complex I, generating oxidative stress and
cell death (Przedborski et al., 2000). Although MPTP-treated
nonhuman primates represent the reference PD model, the MPTP-
treated mouse is commonly used to investigate the neurotoxicity
pathways underlying PD and test the neuroprotective potential of
antiparkinsonian drugs. Nonetheless, this model has failed to
reproduce the motor impairment seen in PD patients or consistently
replicate the phenotype observed in other parkinsonism models.
Indeed, mice treated with MPTP can display no change in motor
behavior (Miller et al., 1991; Itzhak et al., 1999), transient (Nishi et
al., 1991; Sedelis et al., 2000) or sustained (Fredriksson et al., 1994;
Haobam et al., 2005) motor impairment, and even hyperlocomotion
(Colotla et al., 1990; Chia et al., 1996). Though this variability could
be attributed to precise experimental factors (Sedelis et al., 2001;/orphanin FQ receptor antagonists in 1-methyl-4-
10), doi:10.1016/j.expneurol.2010.01.014
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ARTICLE IN PRESSJackson-Lewis and Przedborski, 2007), it has prevented the MPTP
model from being used to screen for symptomatic antiparkinsonian
drugs, essentially limiting its applications to neurotoxicity studies.
We have recently developed a battery of behavioral tests which can
be used in a sequence to collect complementary information on
motor function: the bar, drag and rotarod tests. These tests allowed
us to disclose symptomatic effects of L-dopa in 6-hydroxydopamine
(6-OHDA) hemilesioned rats (Marti et al., 2005, 2007) and MPTP-
treated mice (Viaro et al., 2008), although in that study only a
single dose of L-dopa was investigated. To further validate this
approach, a more thorough phenotypic characterization of MPTP-
treated mice and evaluation of their motor responses to classical
and potential antiparkinsonian drugs was attempted in the present
study. Mice were evaluated daily for 6 days after acute MPTP
treatment using a broad range of behavioral tests including not only
the bar, drag and rotarod but also the reaction time, grip, stair
climbing and footprinting tests. Since a parkinsonian-like phenotype
emerged from this analysis, we investigated its DA-dependence by
measuring striatal tyrosine hydroxylase (TH) density and motor
responses to the DA precursor L-dopa and the D3/D2 receptor
agonist pramipexole. Moreover, we tested the novel nociceptin/
orphanin FQ (N/OFQ) receptor (NOP) antagonist 1-(1-Cyclooctyl-
methyl-5-hydroxymethyl-1,2,3,6-tetrahydro-pyridin-4-yl)-3-ethyl-
1,3-dihydro-benzoimidazol-2-one (Trap-101), a structural analogue
of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-
ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397), administered
alone and in combination with DA agonists. These tests revealed
dual motor responses, facilitation being observed at low doses and
inhibition (or loss of response) at higher ones. Since pramipexole is
known to depress motor activity via D2 (auto)receptors (Mierau
and Schingnitz, 1992; Maj et al., 1997; Siuciak and Fujiawara, 2004),
we studied whether amisulpride was able to prevent motor
inhibition. Indeed, a preferential binding to D2 autoreceptors was
observed at low amisulpride doses (Scatton et al., 1997; Perrault et
al., 1997; Schoemaker et al., 1997).
Materials and methods
Animals
Young adult (8 weeks old) male C57BL/6J mice (20–25 g; S.Pietro
al Natisone, Harlan, Italy) were used for this study. Animals were
housed four for cage, with free access to food and water, and kept
under environmentally controlled conditions (12-h light/dark cycle
with light on between 07:00 and 19:00). This study was compliant
with the European Council Directive of 24 November 1986 (86/609/
EEC), and approved by the Ethical Committee of the University of
Ferrara and Italian Ministry of Health (license n. 94/2007B). Adequate
measures were taken to minimize animal pain as well as the number
of animals used.
Experimental design
Prior to pharmacological testing, mice were handled for 1 week by
the same operator to reduce stress, and trained daily for an additional
week in the behavioral tests until their motor performance became
reproducible. The ﬁrst set of experiments (experiment #1) was aimed
at the analysis of behavioral phenotype of MPTP-treated mice.
Animals were injected with MPTP (4×20 mg/kg, i.p., 90 min apart)
and their motor activity assessed daily for 6 days (beginning 24 h after
toxin administration) by a battery of behavioral tests, namely the bar,
reaction time, drag, stair climbing, grip, rotarod and footprinting tests.
These tests were performed starting at 09.00 in a ﬁxed sequence (as
listed). Animals were then sacriﬁced, their brain removed and
processed for TH immunohistochemistry to quantify the degree of
striatal denervation.Please cite this article as: Viaro, R., et al., Dual motor response to L-dop
phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,The second set of experiments (experiment #2) was aimed at
studying the DA-dependence of motor deﬁcit, and mice responsive-
ness to classical and potential antiparkinsonian compounds. Three
tests only were used for these experiments: the bar, drag and rotarod
tests. Mice were treated with MPTP as above and drug testing was
performed 7 days later. DA agonists (L-dopa and pramipexole) and
Trap-101 were administered systemically (i.p.) over a wide dose
range. L-Dopawas associatedwith benserazide (4:1 ratio). After dose–
response curves were obtained, low doses (subthreshold or threshold
depending on test) of Trap-101, L-dopa and pramipexole were also
tested in combination. Appropriate controls (saline, benserazide
25 mg/kg) were run in parallel. These experiments revealed that
high doses of DA agonists and Trap-101 were either ineffective or
caused mild inhibition. The same phenomenon was previously
reported for J-113397 (Viaro et al., 2008). Therefore, the D2/D3
antagonist amisulpride was tested alone or in combination with L-
dopa, pramipexole and J-113397 (20 min pre-treatment), to inves-
tigate whether D2/D3 receptors were involved. The three tests were
performed in a sequence (bar, drag and rotarod) before (control
session) and after (10 and 60 min) drug injections.
Behavioral motor studies
Bar test
This test, also known as the catalepsy test (Sanberg et al., 1988),
measures the ability of the animal to respond to an externally
imposed static posture. Each mouse was placed gently on a table and
the right and left forepaws were placed alternatively on blocks of
increasing heights (1.5, 3 and 6 cm). The immobility time (in seconds)
of each forepaw on the block was recorded (cut-off time 20 s/step,
60 s maximum). Akinesia was calculated as total time spent on the
blocks (mean between the two forepaws).
Reaction time test
This test measures motor reactivity of the animal in an open ﬁeld.
Mice were allowed to habituate to the center of a square arena
(150×150 cm) for 5min, then elevated 3 cm above the surface (lifting
from the tail), and ﬁnally left to fall. When the animal touched the
ﬂoor, the latency time for the ﬁrst forelimb movement was recorded.
Drag test
This test (modiﬁcation of the “wheelbarrow” test; Schallert et al.,
1979), measures the ability of the animal to balance its body posture
using forelimbs in response to an externally imposed dynamic
stimulus (backward dragging; Marti et al., 2005). Each mouse was
gently lifted from the tail (allowing the forepaws on the table) and
dragged backwards at a constant speed (about 20 cm/s) for a ﬁxed
distance (100 cm). The number of touches made by each forepawwas
counted by two separate observers (mean between the two
forepaws).
Stair climbing test
This test (modiﬁcation of the SCA test; Kumar and Sehgal, 2007)
analyzed themotivation and themotor skill during a climb-walk. Each
mouse was positioned on the ﬁrst step (2 cm height, 2 cm long, 5 cm
wide) of a 45°-sloping staircase. At the top of the staircase a food
pellet was lodged in a small dark goal box. The time needed for
climbing 20 consecutive steps (50 cm) was recorded and the average
speed calculated (cm/s). Steps made at the beginning and the end of
the climb were excluded because of velocity changes or obvious
acceleration/deceleration.
Grip test
This test was used to evaluate the skeletalmuscle strength inmice
(Meyer et al., 1979). The grip-strength apparatus (ZP-50N, IMADA,
Japan) is comprised of a wire grid (5×5 cm) connected to ana and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
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ARTICLE IN PRESSisometric force transducer (dynamometer). In the grip-strength test
mice were held by their tails and allowed to grasp the grid with their
forepaws. The mice were then gently pulled backward by the tail
until the grid was released. The average force exerted by the mouse
before losing grip was recorded. The mean of 10 measurements for
each animal was calculated and the mean average force was
determined. The skeletal muscle strength in mice was expressed in
grams force (gf) and was recorded and processed by IMADA ZP-
Recorder software.
Rotarod test
This test analyzes the ability of the mouse to run on a rotating
cylinder (diameter 8 cm) and provides information on different
motor parameters such as coordination, gait, balance, muscle tone
and motivation to run (Rozas et al., 1997). The ﬁxed-speed rotarod
test was employed according to a previously described protocol
(Marti et al., 2004; Viaro et al., 2008). Brieﬂy, mice were tested at
stepwise increasing speeds (usually from 5 to 45 rpm for naïve and
from 5 to 35 rpm for MPTP-treated mice; 180 s each step) and time
spent on the rod calculated (in seconds). In experiment #2, a
shorter protocol was used to allow measurement of drug effect at
two different time-points. This protocol was speciﬁcally developed
to measure both facilitatory and inhibitory drug effects on rotarod
performance (Marti et al., 2004). After obtaining reproducible motor
performance during training, mice were tested over a narrower
speed window (usually from 20 to 35 rpm, stepwise, 180 s each
step) which was found to cause a progressive decrement of
performance to ∼40% of the maximal response (i.e. the experimen-
tal cut-off time). Drug effect was then calculated by comparing the
performances (time on rod) over these narrow speed windows,
before and after drug treatment.
Footprinting test
This test provides information on gait patterns (Klapdor et al.,
1997). Mice paws were marked with ink and gait patterns (stride
length and width, foot angle, overlap, speed) analyzed after walkingFig. 1. MPTP-treatment induced abnormalities of gait and posture in mice. (A–E) Systemi
increased the stride width of hindlimbs (in millimeters; B), the distance of matching (in mill
centimeters per second; E). (F) Complete set of parameters in the footprints of a saline (left
6 days) MPTP-treatment. Data are means±SEM of 10 determinations per group. ⁎pb0.0
sequentially rejective Bonferroni's test for multiple comparisons).
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phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,over a sheet of paper (Fig. 1F). The apparatus was composed of a white
runway (5 cm wide, 70 cm long, with borders of 10 cm height)
arranged to lead out into a dark goal box (20×20×30 cm). The
parameters were measured by wetting forepaws and hindpaws with
commercially available pencil nontoxic ink (the paws were painted
with different colored inks) and allowing the mice to trot on a strip of
paper (5 cm wide, 70 cm long) onto the runway. Pawprints made at
the beginning and the end of the run were excluded because of
velocity changes or obvious acceleration/deceleration. Stride length is
the average distance (in millimeters) of forward movement between
each forepaw and hindpaw footprint. Stride width is the average
lateral distance (in millimeters) between opposite left and right
forepaw and opposite left and right hindpaw. This was determined by
measuring the perpendicular distance of a given step to a line
connecting its opposite preceding and succeeding steps. Foot angle is
the angle of hindpaw (in degrees) with respect to main direction. This
was determined by measuring the amplitude of angle between the
direction of run and each direction of the hindpaw (line starting at
center of paw to the third ﬁnger). Placement of paws is the footprint
overlap (in millimeters) and is calculated by measuring the distance
between the center of the forepaw footprint and the ipsilateral
hindpaw footprint, taken from successive steps. Speed of run (in
centimeters/second), was calculated by the ratio between the length
of runway and time spent along the runway. After the run, animals
were placed in a cage ﬁlled with 0.5 cmwarmwater for 1 min in order
to wash off the dye.
Histological evaluation
Mice were deeply anesthetized (ketamine 85 mg/kg, xylazine
15mg/kg, i.p.), transcardially perfusedwith phosphate-buffered saline
(PBS; 20 mM, pH 7.4, at room temperature) and ﬁxed with cold 4%
paraformaldheyde in PBS. Brains were removed, post-ﬁxed in the
ﬁxative overnight and transferred to 20% sucrose solution in PBS for
cryoprotection. Serial coronal sections of 30 μm thickness were made
using a freezing microtome. Every second section in the striatum wasc administration of MPTP reduced the stride length of hindlimbs (in millimeters; A),
imeters; C) and the angle of hindpaws (in degrees; D) and reduced the speed of run (in
) and MPTP-treated mouse (right). All tests were performed before and after (daily for
5, ⁎⁎pb0.01 different from saline (RM ANOVA followed by contrast analysis and the
a and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
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ARTICLE IN PRESSselected from the region spanning from bregma −0.8 to +1.3, and
processed for TH immunohistochemistry. Sections were rinsed three
times in PBS and incubated for 15min in 3% H2O2 and 10%methanol in
PBS to block the endogenous peroxidase activity. After washing in PBS,
the sections were preincubated in blocking serum (5% normal horse
serumand 0.3% TritonX 100 in PBS) for 60min, followedby incubation
in anti-TH mouse monoclonal antibody solution (1:2000, Chemicon,
Temecula, CA) for 16 h at room temperature. The sections were then
rinsed in PBS and incubated for 1 h in biotinylated horse anti-mouse
IgG secondary antibody (1:200; Vector Laboratories, Burlingame, CA).
After rinsing, sections were incubated with avidin–biotin–peroxidase
complex (Vector Laboratories) for 30 min at room temperature. After
rinsing with PBS, immunoreactivity was visualized by incubating the
sections in a solution containing 0.05% 3,3-diaminobenzidine (DAB) in
0.013% H2O2 in PBS for about 1 min. The sections were rinsed in PBS,
mounted on gelatine-coated slides, driedwith ethanol and xylene, and
coverslipped with mounting medium. The sections were viewed with
a Zeiss Axioskop (Carl Zeiss, Germany). Sections were acquired
(AxioCam ICc3, Carl Zeiss) at ﬁve antero-posterior (AP) levels
(−0.10, +0.20, +0.50, +0.80, +1.10 mm) and TH-immunoreactive
ﬁber density analyzed using ImageJ software (Wayne Rasband; NIH,
USA). For each animal, optical density was calculated as the mean of
the ﬁve striatal levels and corrected for non-speciﬁc background,
measured in the corpus callosum.
Drugs
Benserazide, L-dopa and MPTP were purchased from Sigma
Chemical Company (St. Louis, MO, USA). Amisulpride and domper-
idone were purchased from Tocris Bioscience (Bristol, UK). Pramipex-
ole was purchased from McTony Bio and Chem (Vancouver, Canada).
J-113397 and Trap-101 were synthesized in the laboratories of the
Department of Pharmaceutical Chemistry at the University of Ferrara.
All drugs were freshly dissolved in saline just prior to use and the
volume injected was 10 μl/g body weight.
Data presentation and statistical analysis
Data are expressed as means±SEM of 10 (experiment #1) or 6–
8 (experiment #2) determinations per group. Motor performance in
the behavioral tests has been indicated in absolute values (experi-
ment #1) or as percentage of the control session (i.e. the session
performed before treatment, which represents the internal control for
each mouse; experiments #2). Statistical analysis was performed by
two-way repeated measure (RM) ANOVA, implemented on a
spreadsheet. In the case these tests yielded a signiﬁcant F score,
post-hoc analysis was performed by contrast analysis to determine
group differences and the sequentially rejective Bonferroni test was
used to determine speciﬁc differences (i.e. at the single time-point
level) between groups. To compare TH density the Student's t-test
was performed. P values b0.05 were considered to be statistically
signiﬁcant.
Results
MPTP induced long-lasting motor deﬁcits (experiment #1)
MPTP administration induced a variety of acute behavioral
changes observed unsystematically, such as muscular hypotonia,
piloerection, elevated bowed stiff tail (i.e. Straub tail), increased
respiration (i.e. hyperpnea). These phenomena appeared imme-
diately after the ﬁrst injection and vanished within 16 h. About
30% of MPTP-treated mice died within 24 h after toxin
administration. Body weight of surviving MPTP-treated mice did
not change with respect to vehicle-injected mice over time (data
not shown).Please cite this article as: Viaro, R., et al., Dual motor response to L-dop
phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,MPTP treatment caused akinesia and bradykinesia
Acute MPTP treatment increased the immobility and reaction
times, and decreased the number of steps, the climbing speed, the
pulling force and the time spent on the rod. Motor impairment was
usually maximal at D1 after MPTP and, despite a tendency to subside
over time, it was still evident after 6 days.
Bar test
RM ANOVA on bar test values (Fig. 2A) showed a signiﬁcant effect
of treatment (F1,9=43.92, pb0.0001), but not time (F6,6=1.00,
p=0.50) and a signiﬁcant time×treatment interaction (F6,108=
12.30, p=0.0038). Post hoc analysis revealed thatMPTP increased the
immobility time, which was maximal at D1 after MPTP and subsided
from D4 onward. At 6 days after MPTP, mice were still akinetic.
Reaction time test
RM ANOVA on reaction time test values (Fig. 2B) showed a
signiﬁcant effect of treatment (F1,9=33.02, pb0.0001), but not time
(F6,6=1.10, p=0.46) and a nonsigniﬁcant time×treatment interac-
tion (F6,108=3.38, p=0.08). Post hoc analysis revealed that MPTP
caused a marked loss of reactivity that was substantially unchanged
from D1 through D6.
Drag test
RM ANOVA on stepping values (Fig. 2C) showed a signiﬁcant
effect of treatment (F1,9=95.48, pb0.001), but not time (F6,6=
1.01, p=0.50), and a signiﬁcant time×treatment interaction
(F6,108=10.99, pb0.001). Post hoc analysis revealed thatMPTP caused
a decrease in stepping activity. The effect was maximal at D1 and D2
(∼60%) and still detectable, albeit attenuated (∼15%), at D6.
Stair climbing test
RM ANOVA on climbing test values (Fig. 2D) showed a signiﬁcant
effect of treatment (F1,9=69.83, pb0.001), but not time (F6,6=0.93,
p=0.53), and a signiﬁcant time×treatment interaction (F6,108=5.22,
p=0.032). Post hoc analysis revealed that MPTP caused a marked
impairment of climbing speed at D1 (∼70%) which tended to revert
back over time (∼40% at D6).
Grip test
RM ANOVA on force values (Fig. 2E) showed a signiﬁcant effect of
treatment (F1,9=18.41, p=0.002), but not time (F6,6=2.02, p=
0.21), and a nonsigniﬁcant time×treatment interaction (F6,108=2.59,
p=0.14). Post hoc analysis revealed that MPTP caused a maximal
reduction of pulling force in the D1–D4 range. After 6 days, however,
the pulling force was normalized.
Rotarod test
RM ANOVA on time-on-rod values (Fig. 2F) showed a signiﬁcant
effect of treatment (F1,9=13.57, p=0.005), but not time (F6,6=0.97,
p=0.52), and a signiﬁcant time×treatment interaction (F6,108=
10.48, p=0.0058). Post hoc analysis revealed that MPTP caused a
maximal ∼65% impairment of the rotarod performance at D1. In the
following days, attenuation of motor impairment settled to ∼30%.
MPTP treatment caused abnormalities in gait and posture
In addition to akinesia and bradykinesia, MPTP caused long lasting
loss of gait ability and correct posture, as shown by reductions in
stride length and speed, increases in stride width and angle of paw,
and mismatch of paw placement.
Stride length
RM ANOVA on stride length values (Fig. 1A) showed a signiﬁcant
effect of treatment (F1,9=14.18, p=0.0045), but not timea and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
Exp. Neurol. (2010), doi:10.1016/j.expneurol.2010.01.014
Fig. 2.MPTP-treatment induced akinesia and bradykinesia in mice. (A–F) Systemic administration of MPTP increased the immobility and reaction time (in seconds; bar and reaction
time tests; A, B) and decreased the number of steps (drag test; C), the climbing speed (stair climbing test; cm/s; D), the pulling force (grip test; gram force; E) and the time spent on
the rod (in seconds, rotarod test; F). All tests were performed before and after (daily for 6 days) MPTP-treatment. Data are means±SEM of 10 determinations per group. ⁎pb0.05,
⁎⁎pb0.01 different from saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni's test for multiple comparisons).
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ARTICLE IN PRESS(F6,6=1.74, p=0.26), and a signiﬁcant time×treatment interaction
(F6,108=7.97, p=0.012). Post hoc analysis revealed that MPTP caused
a slight reduction (∼16%) of hindpaw stride length. A parallel
impairment was detectable by measuring forepaw stride length
(data not shown).
Stride width
RM ANOVA on stride width values (Fig. 1B) showed a
signiﬁcant effect of treatment (F1,9=60.38, pb0.001), but not
time (F6,6=2.46, p=0.14), and a nonsigniﬁcant time×treatment
interaction (F6,108=2.57, p=0.14). Post hoc analysis revealed that
MPTP caused a long lasting increase (∼20%) of hindpaw stride
width.
Overlap
RM ANOVA on overlap values (Fig.1C) showed a signiﬁcant effect
of treatment (F1,9=19.79, p=0.002), but not time (F6,6=0.94, p=
0.54) and a nonsigniﬁcant time×treatment interaction (F6,108=3.81,
p=0.064). Post hoc analysis revealed thatMPTP caused amismatch in
the overlap of the ipsilateral paw that showed a tendency to recover
over time.Fig. 3.MPTP-treatment reduced the tyrosine hydroxylase (TH)-positive (TH+) ﬁber density in
and MPTP-treated (B) mouse. (C) Optical density of TH+ ﬁbers in the striatum. Data are mean
Please cite this article as: Viaro, R., et al., Dual motor response to L-dop
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RM ANOVA on placement angle values (Fig. 1D) showed a
signiﬁcant effect of treatment (F1,9=36.06, pb0.001), but not time
(F6,6=1.56, p=0.30), and a nonsigniﬁcant time×treatment interac-
tion (F6,108=3.04, p=0.10). Post hoc analysis revealed that MPTP
caused a stable increase in the angle amplitude between hindpaws
and the main direction.
Speed
RM ANOVA on speed values (Fig. 1E) showed a signiﬁcant effect of
treatment (F1,9=29.09, pb0.001), but not time (F6,6=0.47, p=
0.81), and a signiﬁcant time×treatment interaction (F6,108=4.83,
p=0.039). Post hoc analysis revealed that MPTP caused a marked
decrease of running speed, which was almost halved with respect to
saline-treated animals.
MPTP induced loss of TH staining in the striatum
Seven days after treatment, MPTP-treated mice displayed partial
(∼60%) bilateral loss of TH-positive DA terminals compared to
vehicle-injected mice (Figs. 3A–C).the mouse striatum. (A–B) Photomicrographs of TH+ ﬁbers in the striatum of a saline (A)
s±SEM of 10 determinations per group. ⁎⁎pb0.01 different from saline (Student's t-test).
a and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
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To investigate whether the MPTP-induced phenotype was gener-
ated by DA deﬁciency, the ability of DA agonists (i.e. L-dopa and
pramipexole) to attenuate motor deﬁcit was investigated. The novel
NOP receptor antagonist Trap-101 was also tested since this
compound was found effective in promoting movement in 6-OHDA
hemilesioned rats (Marti et al., 2008). Animals were challenged in the
bar, drag and rotarod test only.
L-Dopa
L-Dopa dually modulated motor performance, causing motor
facilitation at low doses (1–10 mg/kg) and inhibition (or no effect)
at higher ones (100 mg/kg).
Bar test
RM ANOVA on bar test values (Fig. 4A) showed a signiﬁcant effect
of treatment (F4,28=25.27, pb0.001) but not time (F1,4=0.03, p=
0.86) and a nonsigniﬁcant time×treatment interaction (F4,29=0.40,
p=0.80). Post hoc analysis revealed that L-dopa caused dual and
prolonged changes of immobility time, namely a reduction at 10 mg/
kg and an increase at 100 mg/kg.
Drag test
RMANOVA on drag test values (Fig. 4B) showed a signiﬁcant effect
of treatment (F4,28=12.45, pb0.001), but not time (F1,4=0.02, p=
0.87) and a nonsigniﬁcant time×treatment interaction (F4,29=1.16,
p=0.34). Post hoc analysis revealed that L-dopa elevated the number
of steps at 1 and 10mg/kg, being ineffective at higher doses. The effect
of 1 mg/kg was transient whereas that produced by 10 mg/kg was
detected also 60 min after injection.Fig. 4. Dopamine agonists attenuated parkinsonian symptoms inMPTP-treated mice. (A–F) S
kg, i.p.) affected the immobility time in the bar test (A, D), the number of steps in the drag tes
at 7 days after MPTP administration, before (control session) and after (10 and 60min) drug i
percentage of the control session. ⁎pb0.05, ⁎⁎pb0.01 different from saline (RM ANOVA fol
comparisons).
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RM ANOVA on rotarod test values (Fig. 4C) showed a signiﬁcant
effect of treatment (F4,28=133.25, pb0.0001) but not time (F1,4=
0.14, p=0.71) and a nonsigniﬁcant time×treatment interaction
(F4,29=0.19, p=0.94). Post hoc analysis revealed that L-dopa
increased motor performance at 10 mg/kg and reduced it at
100 mg/kg. These effects were long lasting.
Since L-dopa was administered in combination with benserazide
(ratio 4:1), benserazide alone was tested at the highest does (25 mg/
kg). Benserazide did not affect motor performance with respect to
saline (data not shown).
Pramipexole
Different from L-dopa, pramipexole effects were strictly dependent
on dose and test used. Low doses (0.0001–0.001 mg/kg) promoted
performance in the drag test but did not affect that in the bar and
rotarod test. Conversely, higher doses (0.01–0.1 mg/kg) caused
inhibition in the bar and rotarod test being mildly effective or inef-
fective in the drag test.
Bar test
RM ANOVA on bar test values (Fig. 4D) showed a signiﬁcant effect of
treatment (F4,24=5.18, p=0.003) and time (F1,4=6.05, p=0.019) but
not a signiﬁcant time×treatment interaction (F4,32=1.32, p= 0.28).
Post hocanalysis revealed that pramipexole0.01and0.1mg/kg increased
the immobility time, although the effect of the lower dose appeared
only 60 min after injection. Lower pramipexole doses were ineffective.
Drag test
RM ANOVA on drag test values (Fig. 4E) showed a signiﬁcant effect
of treatment (F4,24=10.25, p=0.0001), but not time (F1,4=0.22,ystemic administration of L-dopa (0.1–100 mg/kg, i.p.) or pramipexole (0.0001–0.1 mg/
t (B, E) and the time spent on the rod in the rotarod test (C, F). All tests were performed
njection. Data aremeans±SEM of 7–8 determinations per group andwere calculated as
lowed by contrast analysis and the sequentially rejective Bonferroni's test for multiple
a and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
Exp. Neurol. (2010), doi:10.1016/j.expneurol.2010.01.014
7R. Viaro et al. / Experimental Neurology xxx (2010) xxx–xxx
ARTICLE IN PRESSp=0.63) and a nonsigniﬁcant time×treatment interaction (F4,32=
1.39, p=0.25). Post hoc analysis revealed that pramipexole elevated
the number of steps in the 0.0001–0.01 mg/kg dose range but was
ineffective at higher doses (0.1 mg/kg). Only the facilitation induced
by 0.001 mg/kg was long lasting.
Rotarod test
RM ANOVA on rotarod test values (Fig. 4F) showed a signiﬁcant
effect of treatment (F4,24=13.04, pb0.001) and time (F1,4=6.76,
p=0.014) but not a signiﬁcant time× treatment interaction
(F4,32=1.47, p=0.23). Post hoc analysis revealed that pramipexole
was ineffective up to 0.001 mg/kg while it impaired motor
performance at 0.01 and 0.1 mg/kg.
Trap-101
Similar to pramipexole, Trap-101 caused motor changes that were
dependent on dose and test used. Low doses (0.001–0.1 mg/kg)
facilitated motor activity in the bar and drag test being ineffective in
the rotarod test. Higher doses caused (mild) inhibition of rotarod
performance being otherwise ineffective.
Bar test
RM ANOVA on bar test values (Fig. 5A) showed a signiﬁcant effect
of treatment (F4,24=7.96, p=0.0003), time (F1,4=15.18, p=
0.0005) and a nonsigniﬁcant time×treatment interaction (F4,32=
1.26, p=0.31). Post hoc analysis revealed that Trap-101 caused a
transient reduction of immobility time at 0.01 and 0.1 mg/kg but was
ineffective at 1 mg/kg.
Drag test
RMANOVA on drag test values (Fig. 5B) showed a signiﬁcant effect
of treatment (F4,24=10.44, pb0.0001), but not time (F1,4=0.92, p=
0.34) and a nonsigniﬁcant time×treatment interaction (F4,32=2.06,
p=0.11). Post hoc analysis revealed that Trap-101 elevated the
number of steps in the 0.001–0.1 mg/kg dose range, being ineffective
at 1 mg/kg. Only the facilitation induced by Trap-101 0.1 mg/kg was
detected at 60 min after injection.
Rotarod test
RM ANOVA on rotarod test values (Fig. 5C) showed a signiﬁcant
effect of treatment (F4,24=3.47, p=0.022) but not time (F1,4=1.87,
p=0.18) and a nonsigniﬁcant time× treatment interaction
(F4,32=0.86, p=0.49). Post hoc analysis revealed that Trap-101 was
ineffective up to 0.1 mg/kg and transiently reduced rotarod
performance at 1 mg/kg.Fig. 5. Trap-101 attenuated parkinsonian symptoms in MPTP-treated mice. (A–C) Systemic a
test (A), the number of steps in the drag test (B) and the time spent on the rod in the rotarod
session) and after (10 and 60 min) drug injection. Data are means±SEM of 7–8 determin
⁎⁎pb0.01 different from saline (RM ANOVA followed by contrast analysis and the sequenti
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We previously demonstrated (Marti et al., 2007, 2008) that co-
administration of L-dopa and J-113397 or Trap-101 produced additive
attenuation of parkinsonism in 6-OHDA hemilesioned rats. Therefore,
we ﬁrst tested whether low doses of L-dopa (1 mg/kg) and Trap-101
(0.001 mg/kg) could synergistically or additively attenuate parkin-
sonism in MPTP-treated mice. Indeed, synergistic interaction was
observed in the bar test (where both compounds were ineffective
alone) whereas additive interaction were observed in the drag test
(where both compounds were effective alone). No interaction was
observed in the rotarod test.
Bar test
RM ANOVA on bar test values (Fig. 6A) showed a signiﬁcant effect
of treatment (F3,18=3.27, p=0.045), time (F1,3=8.52, p=0.007)
and a nonsigniﬁcant time×treatment interaction (F3,26=0.78,
p=0.51). Post hoc analysis revealed that L-dopa and Trap-101 alone
were ineffective whereas their combination reduced the immobility
time. This effect was observed only at 10 min after injection.
Drag test
RMANOVA on drag test values (Fig. 6B) showed a signiﬁcant effect
of treatment (F3,18=12.24, pb0.001), but not time (F1,3=3.23,
p=0.083) and a nonsigniﬁcant time× treatment interaction
(F3,26=1.73, p=0.18). Post hoc analysis at 10 min after injection
revealed that L-dopa and Trap-101 slightly increased the number of
steps, their combination producing an additive effect. The combina-
tion effect was even more evident at 60 min, since both compounds
were ineffective alone.
Rotarod test
No change in rotarod performance was observed after adminis-
tration of low doses of L-dopa and Trap-101, either alone or in
combination (Fig. 6C).
We then co-administered low doses of pramipexole (0.0001 mg/
kg) and Trap-101 (0.001mg/kg). Additive interaction was observed in
the drag test, the combination being otherwise ineffective.
Bar test
No change in immobility time was observed after administration
of pramipexole and Trap-101, alone or in combination (Fig. 6D).
Drag test
RM ANOVA on drag test values (Fig. 6E) showed a signiﬁcant effect
of treatment (F3,18=7.69, p=0.002), but not time (F1,3=0.88,dministration of Trap-101 (0.001–1 mg/kg, i.p.) affected the immobility time in the bar
test (C). All tests were performed at 7 days after MPTP administration, before (control
ations per group and were calculated as percentage of the control session. ⁎pb0.05,
ally rejective Bonferroni's test for multiple comparisons).
a and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
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Fig. 6. Combination of L-dopa and pramipexole with Trap-101 synergistically or additively attenuated parkinsonian symptoms in MPTP-treated mice. (A–C) Combined
administration of L-dopa (1 mg/kg, i.p.) and Trap-101 (0.001 mg/kg, i.p.) affected the immobility time in the bar test (A) and the number of steps in the drag test (B) but not the time
spent on the rod in the rotarod test (C). (D–F) Combined administration of pramipexole (0.0001mg/kg, i.p.) and Trap-101 (0.001mg/kg, i.p.) affected only the number of steps in the
drag test (E) but not the immobility time in the bar test (D) and the time spent on the rod in the rotarod test (F). All tests were performed at 7 days after MPTP administration, before
(control session) and after (10 and 60min) drug injection. Data aremeans±SEM of 7–8 determinations per group andwere calculated as percentage of the control session. ⁎pb0.05,
⁎⁎pb0.01 different from saline; °pb0.05 different from L-dopa; #pb0.05 different from Trap-101 (RM ANOVA followed by contrast analysis and the sequentially rejective
Bonferroni's test for multiple comparisons).
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ARTICLE IN PRESSp=0.35) and a nonsigniﬁcant time×treatment interaction (F3,26=
0.53, p=0.66). Post hoc analysis at 10 min revealed that pramipexole
and Trap-101 transiently elevated the number of steps, while their
combinationproduced agreater (additive) and sustained improvement.
Rotarod test
No change in rotarod performance was observed after adminis-
tration of subthreshold doses of pramipexole and Trap-101, either
alone or in combination (Fig. 6F).
Amisulpride prevented hypomotility induced by L-dopa and NOP
receptor antagonist
Pramipexole is known to depress motor activity (Mierau and
Schingnitz, 1992; Maj et al., 1997; Siuciak and Fujiawara, 2004), likely
via stimulation of presynaptic D2S (short isoform) autoreceptors
(Usiello et al., 2000; Vallone et al., 2000). We therefore tested the
hypothesis that motor inhibition induced by L-dopa and pramipexole
could be reversed by theD2/D3 receptor antagonist amisulpride. Indeed,
this antagonist preferentially binds to D2 autoreceptors at low doses
(Scatton et al., 1997; Perrault et al., 1997; Schoemaker et al., 1997). To
investigate the DA-dependence of the motor inhibition produced by
NOP receptor blockade, we used J-113397 instead of Trap-101 since,
differently from Trap-101, J-113397 caused marked motor inhibition
also in the bar test (Viaro et al., 2008). The effect of amisulpride alone
was ﬁrst assessed in a dose-ﬁnding study. Amisulpride caused
consistent motor inhibition in the three tests at 0.5 and 5 mg/kg.
Bar test
RM ANOVA on bar test values (Fig. 7A) showed a signiﬁcant effect
of treatment (F3,15=31.30, pb0.001) but not time (F1,3=0.01, p=
0.97), and a nonsigniﬁcant time×treatment interaction (F3,20=0.37,Please cite this article as: Viaro, R., et al., Dual motor response to L-dop
phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,p=0.77). Post hoc analysis revealed that amisulpride caused a
prolonged increase of immobility time at the highest dose tested
(5 mg/kg).
Drag test
RMANOVA on drag test values (Fig. 7B) showed a signiﬁcant effect
of treatment (F3,15=13.24, pb0.001), but not time (F1,3=3.55, p=
0.07) and a nonsigniﬁcant time×treatment interaction (F3,20=0.42,
p=0.74). Post hoc analysis revealed that amisulpride caused a
prolonged reduction in stepping activity at 5 mg/kg.
Rotarod test
RM ANOVA on rotarod test values (Fig. 7C) showed a signiﬁcant
effect of treatment (F3,15=19.03, pb0.001) but not time (F1,3=1.17,
p=0.29) and a nonsigniﬁcant time×treatment interaction (F3,20=
0.62, p=0.62). Post hoc analysis revealed that amisulpride caused
sustained motor impairment at 0.5 and 5 mg/kg, which could be
detected also at 60 min after injection.
Based on these preliminary ﬁndings we selected an ineffective dose
of amisulpride (0.1 mg/kg) and challenged it with motor inhibiting
doses of L-dopa (100 mg/kg), pramipexole (0.1 mg/kg) or J-113397
(1 mg/kg). The outcome of the interaction was dependent on com-
pound and test used. Essentially, amisulpride prevented (or reversed
into facilitation) motor inhibition induced by L-dopa and J-113397 in
the bar and rotarod test, being ineffective against pramipexole.
Moreover, in the presence of amisulpride, high (ineffective) doses of
J-113397 were able to increase stepping activity in the drag test.
Bar test
RM ANOVA on bar test values (Fig. 7D) showed a signiﬁcant effect
of treatment (F7,35=24.13, pb0.001), but not time (F1,7=1.10, p=
0.29) and a nonsigniﬁcant time×treatment interaction (F7,40=1.03,a and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
Exp. Neurol. (2010), doi:10.1016/j.expneurol.2010.01.014
Fig. 7. Amisulpride prevented motor inhibition induced by high doses of L-dopa and J-113397 but not pramipexole in MPTP-treated mice. (A–C) Systemic administration of
amisulpride (0.1–5mg/kg, i.p.) increased the immobility time in the bar test (A), reduced the number of steps in the drag test (B) and the time spent on the rod in the rotarod test (C).
(D–F) Twenty minute pretreatment with amisulpride (0.1 mg/kg, i.p.) differentially affected motor inhibition induced by L-dopa (100 mg/kg, i.p.) and J-113397 (1 mg/kg, i.p.) in the
bar (D), drag (E) and rotarod (F) test but was ineffective against hypomotility induced by pramipexole (0.1 mg/kg; i.p.). (A–F) All tests were performed at 7 days after MPTP
administration, before (control session) and after (10 and 60 min) L-dopa, pramipexole and J-113397 administration. When amisulpride were tested alone, behavioral testing was
performed 30 and 80 min after administration. Data are means±SEM of six determinations per group and were calculated as percentage of the control session. ⁎pb0.05, ⁎⁎pb0.01
different from saline; °pb0.05, °°pb0.01 different from amisulpride alone (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferroni's test for multiple
comparisons).
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ARTICLE IN PRESSp=0.43). Post hoc analysis revealed that motor inhibition caused by
L-dopa (100 mg/kg) and J-113397 (1 mg/kg) was reversed into
facilitation in the presence of amisulpride. Conversely, amisulpride
did not prevent the effect of pramipexole.
Drag test
RM ANOVA on drag test values (Fig. 7E) showed a signiﬁcant effect
of treatment (F7,35=11.25, pb0.001), but not time (F1,7=0.02, p=
0.89) and a nonsigniﬁcant time×treatment interaction (F7,40=0.15,
p=0.99). Post hoc analysis revealed that L-dopa and pramipexole
were ineffective either alone or in combination with amisulpride.Fig. 8.Motor inhibition induced by pramipexole was insensitive to domperidone inMPTP-tre
attenuate motor inhibition caused by pramipexole (0.1 mg/kg, i.p.) in the bar (A), drag (B) an
(control session) and after (10 and 60min) pramipexole administration.When domperidone
Data are means±SEM of six determinations per group and were calculated as percentage o
contrast analysis and the sequentially rejective Bonferroni's test for multiple comparisons)
Please cite this article as: Viaro, R., et al., Dual motor response to L-dop
phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,Conversely, J-113397, ineffective alone, caused a prolonged increase
in stepping activity in the presence of amisulpride.
Rotarod test
RM ANOVA on rotarod test values (Fig. 7F) showed a signiﬁcant
effect of treatment (F7,35=15.64, pb0.001) but not time (F1,7=0.01,
p=0.99) and a nonsigniﬁcant time×treatment interaction (F7,40=
1.14, p=0.36). Post hoc analysis revealed that motor impairment
caused by L-dopa (100mg/kg) and J-113397 (1mg/kg) was prevented
by amisulpride. However, amisulpride failed to attenuate the
impairment in rotarod performance induced by pramipexole.atedmice. (A–C) Twentyminute pretreatment with domperidone (5mg/kg, i.p.) did not
d rotarod (C) test. All tests were performed at 7 days after MPTP administration, before
was tested alone, behavioral testing was performed 30 and 80min after administration.
f the control session. ⁎pb0.05, ⁎⁎pb0.01 different from saline (RM ANOVA followed by
.
a and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
Exp. Neurol. (2010), doi:10.1016/j.expneurol.2010.01.014
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ARTICLE IN PRESSWe ﬁnally tested whether the pramipexole-induced hypolocomo-
tion had a peripheral origin. The peripheral DA receptor antagonist
domperidone (5 mg/kg) alone failed to affect the immobility time
(Fig. 8A), number of steps (Fig. 8B) or rotarod performance (Fig. 8C)
and was not able to counteract the inhibitory effect of pramipexole.
Discussion
Motor phenotype in MPTP-treated mice
The use of a broad range of motor tasks allowed for the collection
of information on different motor parameters in MPTP-treated mice
such as the time required to initiate (akinesia) and execute
(bradykinesia) a movement, muscle strength, gait patterns and
coordinated motor performance in freely moving or exercise-driven
conditions. These tests showed that the MPTP-induced bilateral
partial (∼60%) lesions of striatal DA terminals was associated with
an increase of immobility and reaction time, a reduction of stepping
activity, climbing speed, time on rod and muscle strength, as well as
gait abnormalities such as reduced stride length and increased stride
width. Consistent with the evidence that loss of nigral DA cells and
striatal DA terminal is maximal at 2 and 7 days after MPTP,
respectively (Sundström et al., 1988), motor deﬁcits were maximal
the day following MPTP administration and subsided 3–4 days
afterward, being still detectable a week later. These observations are
in line with studies reporting reduced performance in the bar (Kato et
al., 2004; Watanabe et al., 2008) and treadmill (Petzinger et al., 2007)
tests as well as gait abnormalities in the footprinting test (Tillerson et
al., 2002) at 7 days after MPTP intoxication. The evidence of a
parkinsonian-like phenotype at 7 days after intoxication was further
conﬁrmed by positive response to DA agonists.
Response to DA agonists
L-Dopa (1–10mg/kg) attenuatedMPTP-inducedmotor impairment
in the bar, drag and rotarod tests. Consistently, L-dopa (15–20 mg/kg)
attenuated hypoactivity (Fredriksson et al., 1990; Sundström et al.,
1990) and gait abnormalities (Tillerson et al., 2002) in mice at 7 days
afterMPTP administration. These data also conﬁrmpreviousﬁndings in
6-OHDAhemilesioned rats (Marti et al., 2005, 2007) though L-dopawas
overall more potent (effective yet at 0.1mg/kg) possibly due to greater
striatal denervation in this model (∼95%). Motor testing however
disclosedparadoxical effects of L-dopa, highdoses causing exacerbation
of parkinsonism. This is the ﬁrst evidence for a dual motor response to
L-dopa in a model of parkinsonism. Nonetheless, opposite dose-
dependent effects of L-dopa on sleep have been detected in MPTP-
treated mice (Laloux et al., 2008), and a biphasic effect on pain
(hyperalgesia followed by antinociception) was described in naïve rats
at high L-dopa doses (Paalzow, 1992). Interestingly, antinociception
was reversed by the D2 receptor antagonist sulpiride and the cate-
cholamine depletor alpha-methyl-p-tyrosine, suggesting its depen-
dence on presynaptic mechanisms.
Extending previous ﬁndings in 6-OHDA hemilesioned or reserpi-
nized rats, reserpinized mice and MPTP-treated non human primates
(Mierau and Schingnitz, 1992; Maj et al., 1997), pramipexole exerted
symptomatic antiparkinsonian effects in MPTP-treated mice by pro-
moting stepping in the drag test. This effect was observed at very low
doses (0.0001–0.001mg/kg) but vanishedathigherones (0.1mg/kg). In
fact, overt motor inhibition in the bar and rotarod tests emerged at this
dose. As for L-dopa, this dual response has not been previously reported
for pramipexole. Nonetheless, a dual effect of DA receptor agonists
cabergoline and bromocriptine on spontaneous locomotion in mice
made hypoactive with MPTP has been described, low doses being
facilitatory and higher ones inhibitory (Archer et al., 2003).
A possible explanation of the dual motor responses of pramipexole
(and L-dopa) calls for a different contribution of D2 pre- andPlease cite this article as: Viaro, R., et al., Dual motor response to L-dop
phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,postsynaptic receptors. Indeed, pramipexole (0.001–1 mg/kg) causes
hypolocomotion in naïve mice via stimulation of D2 autoreceptors
(Mierau and Schingnitz, 1992; Maj et al., 1997, Siuciak and Fujiawara,
2004) of the D2S isoform (Usiello et al., 2000; Vallone et al., 2000).
However, under parkinsonian conditions, DA deafferentation causes
compensatory supersensitvity in striatal postsynaptic D2 receptors,
which allows DA agonists to promote movement (Seeman, 2007)
outweighing the negative contribution of D2 autoreceptors. Since
compensatory increase in striatal D2 receptor binding has been
detected at 7 days after MPTP (Smith et al., 1997), it may be
speculated that the increased stepping activity observed with low
doses of pramipexole and L-dopa is mediated by stimulation of striatal
postsynaptic D2 receptors while the hypokinesia induced by higher
doses reﬂects progressive recruitment of D2 autoreceptors, leading to
reduction in DA release. This possibility may be further underpinned
by experiments with amisulpride. Amisulpride is an atypical neuro-
leptic reported to inhibit D2 autoreceptors at low doses and block
postsynaptic D2 receptors at higher ones (Scatton et al., 1997; Perrault
et al., 1997; Schoemaker et al., 1997). Indeed, amisulpride caused
overt motor impairment in MPTP-treated mice, an effect reported for
other D2 receptor antagonists in this model (Weihmuller et al., 1990),
and related to the blockade of D2L (long isoform) postsynaptic striatal
receptors (Wang et al., 2000). However, at lower doses, per se
ineffective on motor activity, amisulpride prevented the motor
inhibition induced by L-dopa. This may suggest that high L-dopa
doses not only activate D2 postsynaptic receptors but also D2
autoreceptors, leading to a reduction of neurosecretion and ﬁring
activity at DA pathways. Consistent with this view, low doses of L-
dopa elevated striatal DA levels in reserpinized rats while higher ones
(100 mg/kg) were ineffective (Fisher et al., 2000). In this context,
reversal of L-dopa motor inhibition into facilitation (bar test) by
amisulpride may be explained on the basis of a removal of D2
autoreceptor inhibition leading to disclosure of a D2 postsynaptic
facilitation. The possibility that high L-dopa doses cause hypolocomo-
tion by recruiting populations of amisulpride-sensitive postsynaptic
receptors should also be considered. Amisulpride is a D2/D3 receptor
selective antagonist with high afﬁnity at 5-HT2B and 5-HT7A receptors
(Schoemaker et al., 1997; Abbas et al., 2009). The involvement of 5-HT
receptors in L-dopa hypolocomotion appears remote in view of the fact
that 5-HT2 receptors stimulate locomotion whereas 5-HT7 receptors
do not inﬂuence it (Millan et al., 2003; Clemett et al., 1998). However,
D3 receptors have been shown to inhibit locomotion (Sautel et al.,
1995; Pritchard et al., 2007; Mela et al., 2010). It should also be
considered that amisulpride displays some limbic selectivity (Schoe-
maker et al., 1997), suggesting that L-dopa hypolocomotion may be
due to impact on subpopulations of “normosensitive” D2 receptors
located in (extrastriatal) areas in which DA transmission has been less
impacted by MPTP.
The failure of amisulpride in preventing pramipexole-induced
hypolocomotion remains puzzling. One possible reason could be a
suboptimal antagonist/agonist dose ratio, in view of the poor brain
penetrability of amisulpride (Assié et al., 2006) and the different
mechanisms of action of L-dopa and pramipexole. L-Dopa replenishes
DA stores, favoring synaptic DA release via activity-dependent
mechanisms and activation of a full set of DA receptors (D1–D5)
while pramipexole is a D3/D2 selective agonist with preferential action
on extrasynaptic (Pickel et al., 2002) D2 autoreceptors (Mierau and
Schingnitz, 1992). Moreover, differently from pramipexole, L-dopa
may also operate those populations of D2 receptors whose activity is
enabled by D1 receptor coupling (Clark and White, 1987).
Response to NOP receptor antagonists
The novel NOP receptor antagonist Trap-101 is a J-113397
derivative with 3-fold lower selectivity and potency at recombinant
NOP receptors but comparable activity at native NOP receptors, anda and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-
Exp. Neurol. (2010), doi:10.1016/j.expneurol.2010.01.014
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al., 2006). Consistently, Trap-101 and J-113397 attenuated parkinson-
ism and enhanced the antiparkinsonian action of L-dopa in 6-OHDA
hemilesioned rats through blockade of NOP receptors located in SNr
and overinhibition of nigro-thalamic transmission (Marti et al., 2007,
2008). The present study demonstrates that Trap-101 also shares with
J-113397 (Viaro et al., 2008) the ability to improve parkinsonism in
MPTP-treated mice. In addition, Trap-101 synergistically or additively
(depending on test) attenuated MPTP-induced akinesia/bradykinesia
when combined with L-dopa and pramipexole. The antiparkinsonian
action of Trap-101 appeared at much lower doses (0.001–0.1 mg/kg)
than those effective in promotingmovement naïvemice (1–10mg/kg;
Marti et al., 2008), suggesting that MPTP caused a leftward shift of the
Trap-101 dose–response curve. Increased sensitivity to J-113397 was
previously observed in both 6-OHDA hemilesioned rats (Marti et al.,
2005, 2008) and MPTP mice and nonhuman primates (Viaro et al.,
2008) and may be related to up-regulation of N/OFQ transmission
following DA depletion (Marti et al., 2005; Di Benedetto et al., 2009).
A major concern regarding possible clinical use of NOP receptor
antagonists was that high doses of J-113397 caused motor inhibition
in MPTP-treated mice and nonhuman primates (Viaro et al., 2008).
The present study sheds some light on this phenomenon. Indeed, as
for L-dopa, amisulpride reversed the pro-akinetic effect of J-113397
and prevented its inhibition of rotarod performance. In addition, it
disclosed a J-113397-mediated facilitation in the drag test. This
suggests that motor inhibition induced by NOP receptor antagonists is
mediated by endogenous DA. Consistently, NOP receptor antagonists
were capable of increasing striatal DA release in naïve rats, revealing a
tonic inhibitory inﬂuence of endogenous N/OFQ over nigro-striatal DA
transmission (Marti et al., 2004). In mice, however, there is no ﬁrm
evidence that NOP receptor blockade elevates striatal DA release.
Indeed, UFP-101 (a peptide NOP receptor antagonist) elevated
accumbal DA levels but via NOP-independent mechanisms (Koizumi
et al., 2004). Nonetheless, the possibility that NOP receptor blockade
elevates DA levels in other motor areas cannot be ruled out.
Concluding remarks
Motor phenotype of mice acutely treated with MPTP was
monitored daily using a broad range of behavioral tests. Speciﬁcally,
the drag test (a test for akinesia/bradykinesia) revealed that MPTP-
induced motor deﬁcit was attenuated by classical antiparkinsonian
drugs such as L-dopa and pramipexole. This test appeared most
predictive of antiparkinsonian activity and suitable to screen for novel
antiparkinsonian drugs (also) in the MPTP model. Possibly relevant
from a clinical perspective, the present study provides evidence that L-
dopa can cause paradoxical worsening of motor performances at high
doses. Responsiveness to L-dopa and DA agonists is a diagnostic
criterion for idiopathic PD.However, reports that L-dopa canexacerbate
symptoms, especially in those patients suffering from parkinsonism,
have been published (Wiener et al., 1978; Jenkins and Pearce, 1992;
Merello and Lees, 1992; Cicarelli et al., 2002). This phenomenonmaybe
clinically underestimated and contribute to motor ﬂuctuations (Nutt
et al., 1988). Although various mechanism(s) have been put forward,
the present study suggests that low doses of a D2/D3 receptor
antagonist, possibly acting on D2 (auto)receptors, can reverse it.
Finally, NOP receptor antagonists were conﬁrmed in their ability to
attenuate MPTP-induced parkinsonism, also providing additive/
synergistic symptomatic beneﬁt when given in combination with
DA agonists. The strong analogies between motor responses to NOP
receptor antagonists in 6-OHDA lesioned rats (Marti et al., 2005,
2007, 2008) and MPTP-treated mice (Viaro et al., 2008, present
data) strengthen the pathogenic contribution of N/OFQ across species
and experimental models of parkinsonism, endorsing the view
that NOP receptor antagonists may represent a promising therapeutic
approach to PD.Please cite this article as: Viaro, R., et al., Dual motor response to L-dop
phenyl-1,2,5,6-tetrahydropyridine (MPTP) traeted mice: Paradoxical...,Acknowledgments
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Abbreviations: 
5-HT, 5-hydroxytryptamine (serotonin); DA, dopamine; ED50, median effective dose; GBR12783, 
(1-[2-(diphenylmethoxy)ethyl]4-(3-phenyl-2-(propenyl)-piperazine); N/OFQ, nociceptin/orphanin 
FQ; NOP, nociceptin opioid receptor; NOP-/-, nociceptin opioid receptor knockout; NOP+/+ 
nociceptin opioid receptor wild-type; J-113397, 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-
4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; PPX, pramipexole; S33084, (3aR, 9bS)-
N-[4-(8-cyano-1,3a,4,9b-tetrahydro-3H-benzopyrano[3,4-c]pyrrole-2-yl)-butyl]-(4-phenyl) 
benzamide; SB-277011-A, (trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-
yl)ethyl]cyclohexyl]-4-quinolininecarboxamide); SCH23390, 7-chloro-8-hydroxy-1-phenyl-2,3,4,5-
tetrahydro-1H-3-benzazepine; SNr, substantia nigra reticulata; Trap-101, 1-[1-(cyclooctylmethyl)-
1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 
UFP-101, [Nphe1,Arg14,Lys15]N/OFQ-NH2. 
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Summary 
Background and purpose: Nociceptin/orphanin FQ (N/OFQ) reduces dopamine release in rat 
mesencephalic areas while antagonists at the N/OFQ receptor (NOP) elevate it. We therefore 
investigated the contribution of endogenous dopamine in motor actions of NOP receptor 
ligands in naïve mice. 
Experimental approach: The motor profiles of N/OFQ and NOP receptor antagonists 
[Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101), 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-
4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and 1-[1-
(cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-
benzimidazol-2-one (Trap-101) were characterized using behavioral tests providing 
complementary information on motor function. NOP receptor knockout mice were used to 
confirm the specificity of motor responses. D1/D5 (SCH23390), D2/D3 (raclopride, 
amisulpride) and D3 (S33084) dopamine receptor antagonists, the dopamine precursor L-dopa 
and the D3/D2 receptor agonist pramipexole were used to unravel the specific contribution of 
dopamine receptor subtypes. A preparation of striatal synaptosomes preloaded with [3H]-
dopamine was employed to study presynaptic effects of L-dopa and pramipexole. 
Key results: Both NOP receptor antagonists and N/OFQ facilitated motor activity at low doses 
and inhibited it at higher ones, being ineffective in NOP receptor knockout mice. Motor 
facilitation was selectively prevented by raclopride while motor inhibition (induced by NOP 
receptor antagonists) by amisulpride. Amisulpride also prevented hypolocomotion induced by 
L-dopa and pramipexole. Pramipexole and L-dopa caused inhibition and facilitation of K+-
evoked synaptosomal [3H]-dopamine release, which were reversed by amisulpride and 
SCH23390, respectively. 
Conclusions and implications: Motor responses to NOP receptor antagonists in naïve mice are 
dopamine-dependent and mediated by D2 postsynaptic (facilitation) and D2 presynaptic 
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autoreceptors (inhibition). L-dopa can stimulate D1/D5 dopamine receptors in vitro prior to 
dopamine conversion. 
 
Key words: dopamine receptors, J-113397, L-dopa, motor activity, nociceptin/orphanin FQ, 
pramipexole, synaptosomes, Trap-101, UFP-101. 
Page 5 of 47
British Pharmacological Society
British Journal of Pharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 5 
Introduction 
Nociceptin/orphanin FQ (N/OFQ; Meunier et al., 1995; Reinscheid et al., 1995) is a neuropeptide 
belonging to the opioid family, and the endogenous ligand of the N/OFQ peptide (NOP) receptor. 
The N/OFQ-NOP receptor system shares with classical opioid systems the ability to modulate a 
number of central functions such as pain, reward, mood, and locomotion (Mogil and Pasternak, 
2001) and the NOP receptor is an emerging target with broad therapeutic potential (Lambert, 2008), 
including movement disorders (Marti et al., 2005). Endogenous N/OFQ exerts a physiologically 
inhibitory control over motor function (Marti et al., 2004; 2008). Indeed, NOP receptor selective 
antagonists such as [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101; Calò et al., 2002), 1-[(3R,4R)-1-
cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-
113397 or Compound B; Kawamoto et al., 1999) and its achiral analogue 1-[1-(cyclooctylmethyl)-
1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one 
(Trap-101; Trapella et al., 2006) increased stepping activity, run speed and rotarod performance in 
naïve rats (Marti et al., 2004; 2008, 2009). J-113397 and Trap-101 also elevated motor performance 
in naïve mice (Viaro et al., 2008; Marti et al., 2008), while J-113397 increased arm movement 
speed in nonhuman primates (Viaro et al., 2008). The view of N/OFQ as a physiological constraint 
over motor activity was also corroborated by the finding that NOP receptor knockout (NOP-/-) mice 
had greater stepping activity and rotarod performance than wild-type mice (Marti et al., 2004, 2005; 
Viaro et al., 2008). Recent data, however, suggested that endogenous N/OFQ may play a more 
complex role in motor control. Indeed, J-113397 and Trap-101 facilitated motor activity at low 
doses and impaired it at higher ones through NOP receptor blockade in naïve rodents (Viaro et al., 
2008; Marti et al., 2008). A similar dual response was also reported after i.c.v. administration of 
N/OFQ, low doses facilitating (Florin et al., 1996; Jenck et al., 1997; Higgins et al., 2001; Kuzmin 
et al., 2004, Marti et al., 2009) and higher ones inhibiting (Reinscheid et al., 1995; Devine et al., 
1996; Rizzi et al., 2001; Higgins et al., 2001; Kuzmin et al., 2004; Marti et al., 2009) spontaneous 
locomotion. Importantly, we found that N/OFQ-induced motor facilitation was a true motor 
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response (Marti et al., 2009) and not a result of an anxiolytic effect of N/OFQ as previously thought 
(Florin et al., 1996; Jenck et al., 1997). In fact, motor improvement induced by low N/OFQ doses 
given i.c.v. or injected into substantia nigra reticulata (SNr) was associated with enhanced motor 
cortex excitability and motor output, while motor impairment induced by higher N/OFQ doses was 
accompanied by opposite electrophysiological changes (Marti et al., 2009). Interestingly, NOP 
receptor antagonists replicated the electrophysiological and behavioral changes induced by low 
N/OFQ doses, overall suggesting that i) dual motor responses to NOP receptor ligands are mediated 
by NOP receptors in SNr and ii) NOP receptor antagonists and N/OFQ (at low doses) activate 
common pathways. 
Evidence that mesencephalic dopamine (DA) neurons transduce motor actions of NOP receptor 
ligands has been presented. Indeed, N/OFQ and NOP receptor antagonists, given systemically or 
into SNr, inhibited and facilitated DA release in dorsal striatum, respectively (Marti et al., 2004). 
Moreover, N/OFQ inhibited DA release in limbic striatum (Murphy et al., 1999; Narayanan et al., 
2004) while J-113397 elevated it, although via NOP-unrelated mechanisms (Koizumi et al., 2004). 
Finally, even the hyperlocomotive response to N/OFQ was reported to be DA-dependent (Florin et 
al., 1996; Kuzmin et al., 2004). 
In the present study, we investigated the role of endogenous DA in motor actions of NOP receptor 
ligands in mice. The motor profile of chemically unrelated NOP receptor antagonists, namely UFP-
101 (peptide), J-113397 and Trap-101 (nonpeptides), was evaluated by using a battery of previously 
validated behavioral tests (the bar, drag and rotarod tests; Marti et al., 2004, 2005, 2008, 2009; 
Viaro et al., 2008) providing complementary information on akinesia, bradykinesia and gait ability. 
The effect of i.c.v. administration of N/OFQ was also investigated. NOP-/- mice were used to 
confirm the specificity of the motor responses of NOP receptor ligands. To unravel the specific 
contribution of DA receptor subtypes, D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 
selective (S33084) receptor antagonists were tested alone and in combination with NOP receptor 
ligands. Since a specific role for D2 receptors emerged from these experiments, the motor responses 
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to the DA precursor, L-dopa, and the DA agonist pramipexole (PPX) were also analyzed. Finally, 
the presynaptic effects of PPX and L-dopa were more specifically investigated in a preparation of 
striatal synaptosomes preloaded with [3H]-DA. 
 
Methods 
Animals 
Young adult (8 weeks old) male C57BL/6J mice (20-25 g; Harlan, Italy, S.Pietro al Natisone) and 
CD1/C57BL6J/129 NOP+/+ and NOP-/- mice (20-25 g; Ferrara vivarium; Nishi et al., 1997) were 
housed with free access to food and water and kept under environmentally controlled conditions 
(12-h light/dark cycle with light on between 07:00 and 19:00). The experimental protocols were 
approved by the Italian Ministry of Health (license n. 94/2007B) and Ethical Committee of the 
University of Ferrara. Adequate measures were taken to minimize animal pain and discomfort. 
Experimental design 
Prior to pharmacological testing, mice were handled for 1 week by the same operator to reduce 
stress, and trained daily for an additional week on the behavioral tests until their motor performance 
became reproducible. Motor activity was assessed by a battery of previously validated behavioral 
tests specific for different motor abilities: the bar, drag and rotarod test (Marti et al., 2004, 2005, 
2008, 2009; Viaro et al., 2008). On the day of experiment, drugs were administered systemically 
(i.p.). N/OFQ and UFP-101 were injected in the lateral cerebral ventricle (i.c.v.). L-dopa was 
administered in combination with benserazide (4:1 ratio). The three tests were repeated in a fixed 
sequence (bar, drag and rotarod) before (control session) and after (10 and 60 min) drug injection. 
When DA receptor antagonists were used, motor analysis was performed 30 and 80 min after 
injection to match time of administration in the interaction studies (i.e. 20 min before NOP receptor 
antagonists or DA receptor agonists).  
Since in most cases we did not observe differences in motor responses between the first (10 or 30 
min) and the second time point (60 or 80 min) evaluated after drug administration, for the sake of 
Page 8 of 47
British Pharmacological Society
British Journal of Pharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 8 
clarity, drug effects as 10 or 30 min were presented in figures 1 through 10 while effects at 60 or 80 
min as supplementary material (Fig S1). 
Microinjection technique 
The injections in the lateral cerebral ventricle were given according to the procedure described by 
Laursen and Belknap (1986). Briefly, the syringe was held at an approximate 45° angle to the skull. 
Bregma was found by lightly rubbing the point of the needle over the skull until the suture was felt. 
Once found, care was taken to maintain the approximate 45° angle and the needle was inserted 
about 2 mm lateral to the midline. The skull is relatively thin at this point, so only mild pressure 
was required to insert and remove the needle. Drugs were slowly injected (0.5 µl in about 5 sec) and 
to prevent the substance from refluxing, the needle was withdrawn from the skull 5 sec later. 
Behavioral studies 
Bar test. Originally developed to quantify morphine-induced catalepsy (Kuschinsky and 
Hornykiewicz, 1972), this test measures the ability of the mouse to respond to an externally 
imposed static posture. Also known as the catalepsy test (for a review see Sanberg et al., 1988), it 
can be used to quantify akinesia (i.e. time to initiate a movement) also under conditions that are not 
characterized by increased muscle tone (i.e rigidity) as in the cataleptic/catatonic state. The mouse 
was placed gently on a table and forepaws were placed alternatively on blocks of increasing heights 
(1.5, 3 and 6 cm). The time (in sec) that each paw spent on the block (i.e. the immobility time) was 
recorded (cut-off time of 20 sec). Akinesia was calculated as total time spent on the different 
blocks. 
Drag test. Modification of the “wheelbarrow test” (Schallert et al., 1979), this test measures the 
ability of the animal to balance its body posture with forelimbs in response to an externally imposed 
dynamic stimulus (backward dragging; Marti et al., 2005). It gives information regarding the time 
to initiate and execute (bradykinesia) a movement. The animal was gently lifted from the tail 
leaving the forepaws on the table, and was dragged backwards at a constant speed (about 20 
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cm/sec) for a fixed distance (100 cm). The number of steps made by each paw were recorded by 
two separate observers. Five to seven determinations were collected for each animal.  
Rotarod test. The fixed-speed rotarod test (Rozas et al., 1997) measures different motor parameters 
such as motor coordination, gait ability, balance, muscle tone and motivation to run. It was 
employed according to a previously described protocol (Marti et al., 2004), in which mice were 
tested at stepwise increasing speeds (from 5 to 50 rpm; 180 sec each). 
Synaptosome preparation and [3H]-DA analysis 
To minimize pain and discomfort, mice were decapitated under light ether anesthesia and the 
striatum was quickly excised to prepare synaptosomes, as previously described (Morari et al., 
1998). Briefly, striata were homogenized in ice-cold 0.32 M sucrose buffer at pH 7.4 then 
centrifuged for 10 min at 2,500 gmax (4°C). The supernatant was then centrifuged for 20 min at 
9,500 gmax (4°C) with the synaptosomal pellet being resuspended in oxygenated (95% O2, 5% CO2) 
Krebs solution (mM: NaCl 118.5, KCl 4.7, CaCl2 1.2, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, 
glucose 10) containing ascorbic acid (0.05 mM) and disodium EDTA (0.03 mM). Synaptosomes 
were pre-loaded with [3H]-DA by incubation in medium containing 50 nM [3H]-DA (specific 
activity 27.8 Ci/mmol, NEN DuPont, Boston, MA, USA.) for 25 min. 
One milliliter aliquots of the suspension (~0.35 mg protein) were slowly injected into nylon syringe 
filters (outer diameter 13 mm, 0.45 µM pore size, internal volume of about 100 µl; MSI, Westporo, 
MA, USA) which were then connected to a peristaltic pump. Filters were maintained at 36.5 °C in a 
thermostatic bath and superfused at a flow rate of 0.4 ml/min with a pre-oxygenated Krebs solution. 
Under these experimental conditions, spontaneous [3H]-DA efflux was essentially unaffected by 
reuptake. Sample collection (every 3 min) was initiated after a 20 min period of filter washout. The 
effect of drugs was evaluated on both spontaneous and K+-stimulated neurotransmitter outflow. In 
this case, drugs were added to the perfusion medium 6 (agonist) or 9 (antagonist) min before a 10 
mM KCl pulse (120 sec) and maintained until the end of the experiment. [3H]-DA levels in the 
samples were measured by liquid scintillation spectrophotometry. Sample superfusate (1.2 
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ml/sample) and filter retained (dissolved with 1 ml of 1 M NaOH followed by 1 M HCl) were 
opportunely mixed with Ultima Gold XR scintillation fluid (Packard Instruments B.V., Groningen, 
The Netherlands) and radioactivity was determined by a Beckman LS 1800 β-spectrophotometer. 
Data presentation and statistical analysis 
Data are expressed as means ± SEM of 6-8 determinations per group. Motor performance in the 
behavioral tests has been expressed as percentage of the control session (i.e. the session performed 
before treatment, which represents the internal control for each mouse). Statistical analysis was 
routinely (Fig 1-11) performed (CoStat 6.3, CoHort Software, Monterey, CA, USA) by two-way 
repeated measure ANOVA on percent values. In the case these tests yielded a significant F score, 
post-hoc analysis was performed by contrast analysis to determine group differences followed by 
the sequentially rejective Bonferroni test to determine specific differences (i.e. at the single time-
point level) between groups. Data obtained in synaptosomes were treated by one-way ANOVA on 
percent (Fig. 11A-B) or area-under-the curve (AUC; Fig. 12A-C) values followed by the Newman-
Keuls test. ANOVA values have been presented as supplemental material (Fig. S2). P values <0.05 
were considered to be statistically significant.  
Materials 
Benserazide, L-dopa methyl ester and L-dopa free-base were purchased from Sigma (St. Louis, 
MO, USA). Amisulpride, domperidone, GBR12783, raclopride and SCH23390 were purchased 
from Tocris (Bristol, UK). PPX was purchased from McTony Bio&Chem (Vancouver, Canada). 
S33084 was provided by Institut de Recherches Servier (Croissy-sur-Seine, France). J-113397, 
N/OFQ, Trap-101 and UFP-101 were synthesized in the laboratories of Department of 
Pharmaceutical Chemistry at the University of Ferrara. All drugs were freshly dissolved in the 
vehicle just prior to use. For in vivo experiments, the volume injected was 10 µl/g body weight 
(systemic administration) or 0.5 µl (i.c.v. administration). 
 
Results 
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NOP receptor antagonists dually modulated motor activity 
The motor profiles of three NOP receptor antagonists were investigated in C57BL/6J mice by using 
static and dynamic tests providing complementary information on motor parameters: the bar, drag 
and rotarod tests. The non peptide antagonist J-113397 and its achiral analogue Trap-101 were 
administered systemically while the peptide antagonist UFP-101 was given i.c.v. Basal activity in 
absolute values was 0.8 ± 0.1 sec (immobility time in the bar test), 16.5 ± 0.9 steps (drag test) and 
937.9 ± 62.1 sec (time on rod). Motor activity was not different at the right and left paw so data 
were pooled together. 
J-113397 did not affect the immobility time in the bar test up to 1 mg/Kg and increased it at 10 
mg/Kg (Fig. 1A). J-113397 caused a biphasic regulation of stepping activity in the drag test (Fig. 
1B) and overall gait ability in the rotarod test (Fig. 1C). In both tests, facilitation was observed at 
0.3 and 1 mg/Kg and reduction at 10 mg/Kg. Trap-101 did not affect the immobility time at any of 
the doses tested (Fig. 1D). However, Trap-101 biphasically modulated motor activity in the drag 
and rotarod test, increasing the number of steps (Fig. 1E) and time on rod (Fig. 1F) at 10 mg/Kg and 
reducing them at 30 mg/Kg. UFP-101 increased the immobility time at 30 nmol (Fig. 1G) and 
caused dual responses in the drag (Fig. 1H) and rotarod test (Fig. 1I), namely facilitation at 1 and 3 
nmol and marked inhibition at 30 nmol. Differently from non peptide antagonists, the effects of 
UFP-101 were detected also at 60 min after injection (Fig. S1.1). 
Dopamine receptor antagonists differentially modulate motor actions of NOP receptor 
antagonists 
We previously reported that NOP receptor antagonists elevate striatal DA release in rats, suggesting 
that endogenous N/OFQ tonically inhibits nigro-striatal DA transmission (Marti et al., 2004). We 
therefore employed selective DA receptor antagonists to unravel the contribution of endogenous 
DA to motor actions of NOP receptor antagonists. The D1/D5 receptor antagonist SCH23390, the 
D2/D3 receptor antagonists raclopride and amisulpride, and the D3 selective receptor antagonist 
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S33084 were tested alone and in combination with motor facilitating or inhibiting doses of NOP 
receptor antagonists. 
Raclopride dose-dependently inhibited motor performance, as shown by an increase in immobility 
time (Fig. 2A) and reduction in both the number of steps (Fig. 2B) and time on rod (Fig. 2C). These 
effects were evoked at 0.1 and 0.3 mg/Kg and observed both 30 and 80 min (Fig. S1.2) after 
administration. Amisulpride partially replicated motor inhibiting action of raclopride, causing a 
prolonged increase in immobility time (Fig. 2D) and inhibition of rotarod performance (Fig. 2F) at 
the highest dose tested (15 mg/Kg). Delayed impairment of rotarod performance was observed also 
at 5 mg/Kg (Fig. S1.2). Different from raclopride, amisulpiride did not affect stepping activity in 
the drag test (Fig. 2E). SCH23390 produced consistent motor inhibition in the three tests (Fig. 3). 
Increased immobility time (Fig. 3A), reduced stepping activity (Fig. 3B) and rotarod performance 
(Fig. 3C) were observed at 0.01 and 0.03 mg/Kg. The effects in the bar and drag tests were 
prolonged (Fig. S1.3), while those in the rotarod were detected only 30 min after injection. S33084 
did not produce marked changes in motor activity (Fig. 3D-F), the only effect observed being mild 
inhibition of stepping at 0.64 mg/Kg (Fig. 3E). 
To disclose the role of endogenous DA, we challenged NOP receptor antagonists with doses of DA 
receptor antagonists per se ineffective on motor activity. The effect of DA receptor antagonists on 
motor facilitation was first investigated. Raclopride (0.03 mg/Kg) prevented the increase in stepping 
activity (Fig. 4B) and rotarod performance (Fig. 4C) induced by J-113397 (0.3 mg/Kg), Trap-101 
(0.3 mg/Kg) and UFP-101 (3 nmol, see also Fig. S1.4). Conversely, amisulpride (0.5 mg/Kg), 
SCH23390 (0.003 mg/Kg) and S33084 (0.16 mg/Kg) were ineffective (Fig. 4E-F). 
Differently from facilitation, motor inhibition caused by J-113397 (10 mg/Kg), Trap-101 (30 
mg/Kg) and UFP-101 (30 nmol) in the bar (Fig. 5A), drag (Fig. 5B) and rotarod test (Fig. 5C) was 
prevented by amisulpride while raclopride was ineffective (Fig. 5D-F). It is noteworthy that 
individual doses of J-113397 and Trap-101 which caused inhibition of stepping activity in the drag 
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test induced significant stimulation in the presence of amisulpride (Figs. 5B and S1.5). A similar 
reversal of action was observed for J-113397 on rotarod performance (Fig. 5C). 
Raclopride prevented motor facilitation induced by N/OFQ 
The data collected thus far indicate that the dual action profile of NOP antagonists is mediated by 
endogenous DA acting on populations of D2 receptors differently sensitive to amisulpride and 
raclopride. Previous studies in mice have reported that N/OFQ given i.c.v. stimulates spontaneous 
locomotion through DA-dependent mechanisms (Florin et al., 1996; Kuzmin et al., 2004). We 
therefore investigated the role of D2 receptors in motor facilitation induced by N/OFQ in the bar, 
drag and rotarod tests. 
N/OFQ produced different effects on motor activity depending on the dose and motor task used. In 
particular, N/OFQ monotonically increased immobility time (Fig. 6A) and dually regulated both 
stepping activity (Fig. 6B) and rotarod performance (Fig. 6C). The effects were also detected after 
60 min from administration (Fig. S1.6). Motor facilitation in the drag and rotarod tests was 
observed at 0.01 nmol while motor inhibition predominated at higher doses (0.1-10 nmol) in all 
tests. Increases in stepping activity and rotarod performance induced by 0.01 nmol N/OFQ were 
prevented by raclopride (Fig. 6E-F and S1.6). 
UFP-101 and N/OFQ modulated motor activity in NOP+/+ mice being ineffective in NOP-/- 
mice 
To test the specificity of NOP receptor ligands, motor facilitating and inhibitory doses of UFP-101 
and N/OFQ were challenged in NOP+/+ and NOP-/- mice. Low doses of UFP-101 (3 nmol) and 
N/OFQ (0.01 nmol) did not affect immobility time (Fig 7A) but facilitated stepping activity (Fig. 
7B) and rotarod performance (Fig. 7C) in NOP+/+ mice. Higher doses of UFP-101 (30 nmol) and 
N/OFQ (10 nmol) elevated immobility time and inhibited stepping and rotarod performance (Fig. 
7A-C). These effects were detectable also at 60 min after treatment (Fig. S1.7). No major difference 
was observed between C57BL/6J and NOP+/+ mice in terms of sensitivity to N/OFQ or duration of 
the response. Conversely, UFP-101 and N/OFQ were not effective in NOP-/- mice at any of the 
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doses tested, suggesting that the dual responses they evoked in NOP+/+ mice relied on the 
interaction (blockade and stimulation, respectively) with NOP receptors. 
Dopamine receptor antagonists prevented motor inhibition induced by L-dopa and PPX 
To strengthen the role of D2 receptors in motor control, we first analyzed motor responses to the 
DA precursor, L-dopa (in combination with benserazide), and the D3/D2 agonist PPX. 
L-dopa inhibited motor activity at the highest dose tested (100 mg/Kg), elevating immobility time 
(Fig. 8A) and reducing both stepping activity (Fig. 8B) and rotarod performance (Fig. 8C). Impaired 
rotarod performance was also detected at the lower 10 mg/Kg dose. Similar to L-dopa, PPX evoked 
a marked increase in immobility time (Fig. 8D) and rotarod performance (Fig. 8F) at 0.1 and 1 
mg/Kg. Stepping activity, however, was minimally and transiently reduced only at the highest PPX 
dose tested (1 mg/Kg; Fig. 8E). These effects were also observed at 60 min post-injections time 
(Fig. S1.8). 
Since motor inhibition was the only effect detected following DA agonists, amisulpride and 
raclopride were used to demonstrate the involvement of D2/D3 receptors. Amisulpride consistently 
prevented motor inhibition induced by high doses of L-dopa (100 mg/Kg) in the bar, drag and 
rotarod tests (Figs. 9A-C and S1.9). Conversely, it modulated the effects of PPX depending on the 
test and agonist dose used. Thus, amisulpride prevented the increase in immobility time induced by 
0.1 mg/Kg PPX (Fig. 9A) but failed to attenuate the impairment in rotarod performance induced by 
the same dose (Fig. 9C). Amisulpride also did not affect motor inhibition induced by the higher 
PPX dose (1 mg/Kg) in the bar and drag tests (Fig. 9A-B) but slightly attenuated impairment in 
rotarod performance (Fig. 9C). On the other hand, raclopride did not prevent motor inhibition 
induced by PPX on the rotarod (Fig. 9F) and even worsened the inhibition of immobility time (Fig. 
9D) and stepping activity (Figs. 9E and S1.9) induced by PPX in the bar and drag tests, 
respectively. Since PPX is a potent D3 receptor agonist, we investigated whether motor inhibition 
could be mediated by D3 receptors (Figs. 10 and S1.10). Not only did S33084 not prevent motor 
inhibition induced by both doses of PPX in the three tests (Fig. 10A-C) but it even worsened 
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impairment of stepping activity induced by the PPX 1 mg/Kg in the drag test (Fig. 10B). Likewise, 
S33084 enhanced inhibition of stepping activity induced by 100 mg/Kg L-dopa (Figs. 10B and 
S1.10) leaving unaffected its motor responses in the bar (Fig. 10A) and rotarod (Fig. 10C) tests. A 
combination of S33084, amisulpride and raclopride failed to attenuate PPX-induced inhibition (data 
not shown). We finally investigated whether peripheral D2-like receptors could contribute to motor 
inhibition induced by PPX, e.g. by inducing hypotension. The peripheral non selective D2 receptor 
antagonist domperidone (5 mg/Kg; Figs. 10D-F and S1.10) did not affect motor activity alone and 
also failed to prevent the effect of 0.1 mg/Kg PPX. 
L-dopa and PPX oppositely modulated [3H]-DA release in striatal synaptosomes 
Previous in vivo data suggest that motor inhibitory actions of L-dopa and PPX rely on an 
interaction with presynaptic D2 autoreceptors. We therefore analyzed the effects of L-dopa (free-
base) and PPX in a preparation of striatal synaptosomes preloaded with [3H]-DA (Fig 11-12). This 
would also demonstrate whether L-dopa might have biological activity per se or if its effects are due 
to its conversion to DA. Basal synaptosomal [3H]-DA efflux was 0.021 ± 0.001 pmol mg prot-1 min-
1
 (n=68) and corresponded to a fractional release of 6.79 ± 0.15 %. A 2 minute pulse of KCl 10 mM 
evoked a tritium overflow of 0.006 ± 0.001 pmol mg prot-1 min-1 (n=24) which was attenuated by 
~70 % in the absence of Ca++ (Fig. 11A). PPX (100 nM) decreases [3H]-DA overflow (~51 %) and 
this effects was prevented by pre-treatment with amisulpride (100 nM), ineffective per se (Fig. 
11A). Conversely, L-dopa (1 µM) doubled [3H]-DA overflow (Fig. 11B). This effect was prevented 
by SCH23390 (100 nM) but not by the DA transporter blocker GBR12783 (300 nM; Fig 11B). 
Neither compound affected the K+-evoked tritium overflow. L-dopa (1-100 µM) also increased in a 
dose-dependent manner tritium efflux (Fig. 12A). GBR12783 (300 nM) prevented the response to 
10 µM L-dopa (Fig. 12B) and attenuated that of 100 µM L-dopa (Fig. 12C), while SCH23390 (1 
µM) was ineffective. GBR12783 and SCH23390 did not affect spontaneous tritium efflux at the 
doses tested. 
 
Page 16 of 47
British Pharmacological Society
British Journal of Pharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 16 
Discussion 
DA receptor ligands and motor activity 
The role of endogenous DA in the modulation of motor activity has been largely investigated using 
DA selective antagonists, DA lesioning techniques and DA receptor knockout mice (Clark and 
White, 1997; Millan et al., 2004; Scatton et al., 1997; Vallone et al., 2000). In keeping with these 
studies, raclopride and amisulpride dose-dependently increased akinesia (bar test) and bradykinesia 
(drag test), and impaired overall gait abilities (rotarod test), likely through the blockade of striatal 
D2L (long isoform) postsynaptic receptors (Wang et al., 2000). D3 receptors appear to be 
minimally involved in tonic regulation of motor activity in naïve animals since S33084 alone did 
not produce marked changes in motor performance. Consistently, S33084 (Millan et al., 2000, 
2004) or another D3 receptor selective antagonist (SB-277011-A; Reavill et al., 2000) failed to alter 
spontaneous locomotion. Mimicking D2/D3 receptor antagonists, SCH23390 induced dose-
dependent motor impairment (Clark and White, 1997). Disruption of cooperative D1-D2 receptor 
interaction at the postsynaptic level (Clark and White, 1997) or blockade of D2-independent D1 
receptor pathways (Usiello et al., 2000) may underlie this effect. The major role played by D2 
receptors in movement control was further confirmed with DA receptor agonists. In fact, PPX 
caused monotonic motor inhibition in the 0.01-1 mg/Kg dose-range, as previously reported (Mierau 
and Schingnitz, 1992; Siuciak and Fujiawara, 2004). It has been proposed (Usiello et al., 2000; 
Vallone et al., 2000) that such hypomotility is mediated by central (domperidone-insensitive) DA 
receptors, possibly presynaptic D2S (short isoform) receptors, via reduced striatal DA release 
(Carter and Müller, 1991). L-dopa replicated the PPX-induced hypomotility, suggesting that not 
only in DA-depleted but also in naïve animals endogenous DA newly formed from L-dopa 
decarboxylation can be incorporated in releasable vesicular pools and exert receptor-mediated 
central biological effects. The finding that L-dopa and PPX-induced motor inhibition was 
counteracted by amisulpride further strengthened the role of D2 autoreceptors, although PPX effects 
(particularly on rotarod performance) appeared poorly sensitive to amisulpride. This may be due to 
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the different levels of DA receptor occupancy required to induce the biological response and/or to 
the different spectrum of DA receptors activated by the two agonists. Additional mechanisms not 
involving classical D2 receptors may also be recruited by PPX to inhibit rotarod performance. As a 
possibility, we could speculate involvement of pharmacologically distinct receptor entities such 
D2/D3 heterodimers (Maggio et al., 2003). Interestingly, although D3 receptors appear not to be 
tonically activated, they markedly contributed to motor responses to PPX and L-dopa. Indeed, 
S33084 worsened inhibition of stepping activity induced by both agonists in the drag test, 
suggesting that D3 receptors play a specific role in facilitation of movement initiation and 
execution. The worsening of PPX-induced motor inhibition observed in the presence of raclopride 
may also rely on the high affinity of this compound for the D3 receptor. Alternatively, the opposite 
modulation of the PPX response exerted by raclopride (enhancement) and amisulpride (attenuation) 
may be due to blockade of different D2 receptor subpopulations, namely post- and presynaptic. In 
fact, amisulpride given systemically was reported to inhibit D2 autoreceptors at low doses (ED50 3.7 
mg/Kg) and block postsynaptic D2 receptors, thereby causing akinesia and catalepsy, at higher ones 
(ED50 ~60 mg/Kg; Scatton et al., 1997). Nonetheless, different from raclopride (Roth et al., 1994), 
amisulpride also blocks 5-HT2B and 5-HT7A receptors with high affinity (Schoemaker et al., 1997; 
Abbas et al., 2009). However, the involvement of 5-HT receptors in PPX and L-Dopa 
hypolocomotion action appears remote in view of the fact that 5-HT2 receptors stimulate 
locomotion whereas 5-HT7 receptors do not influence it (Millan et al., 2003; Clemett et al., 1998). 
The possibility that high doses of L-dopa activate D2 autoreceptors may be further corroborated by 
the bell-shaped profile of L-dopa on striatal DA release in reserpinized rats, low doses being 
stimulatory and higher ones (100 mg/Kg) ineffective (Fisher et al., 2000).   
An important finding of the present study is that L-dopa modulated [3H]-DA release from a 
preparation of nerve terminals (synaptosomes). Expectedly, the synaptosomal K+-evoked tritium 
overflow was largely Ca++-dependent, thus exocitotic in nature (Marti et al., 2003), and was 
inhibited by PPX via activation of amisulpride-sensitive D2 receptors. Indeed, striatal D2 receptors 
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mainly serve as autoreceptors (Stamford et al., 1991; Kennedy et al., 1992). Unexpectedly however, 
L-dopa elevated tritium overflow via SCH23390-sensitve D1/D5 receptors. D1 receptors are indeed 
expressed by striatal nerve terminals (Hersch et al., 1995) and their activation leads to a SCH23390-
sensitive rise in synaptosomal Ca++ levels (Wu et al., 2006). Although D1 presynaptic receptors are 
mainly heteroreceptors and expressed by cholinergic and GABAergic terminals, D1 receptors also 
co-localize with tyrosine hydroxylase, suggesting a role as autoreceptors (Wu et al., 2006). In 
addition to vesicular [3H]-DA release, L-dopa also increased spontaneous tritium efflux at higher 
concentrations, through different mechanisms. Indeed, spontaneous [3H]-DA efflux is Ca++-
insensitive (Marti et al., 2003) mainly reflecting non vesicular release. The finding that GBR12783 
prevented L-dopa action, suggests that L-dopa is uptaken by the DA transporter, causing reversal of 
its action and promoting tritium efflux. The ineffectiveness of GBR12783 alone relies on 
superfusion conditions, since continuous removal of the neurotransmitter from the perfusion 
medium minimizes the role of uptake. Despite the evidence that L-dopa can have biological activity 
and stimulate presynaptic D1/D5 receptors in vitro, motor inhibition induced by high doses was 
mediated by D2/D3 receptors, suggesting that in vivo, its actions are mediated by endogenous DA. 
Although not operative in naïve mice however, this facilitatory control may become important in 
Parkinson’s disease, where storage capability of DA nerve terminals is compromised and D1 
receptor transmission up-regulated. Under these conditions, direct stimulation of D1/D5 presynaptic 
(even postsynaptic) receptors may contribute to L-dopa sensitization and development of dyskinesia 
(Bezard et al., 2001).  
NOP receptor ligands and motor activity 
We previously reported that UFP-101 microinjections in rat SNr (Marti et al., 2004) or systemic 
administrations of J-113397 (Viaro et al., 2008) and Trap-101 (Marti et al., 2008) in naïve rodents 
facilitated motor activity at low doses and inhibited it at higher ones. The present study confirms 
that dual motor response is indeed a consequence of progressive central NOP receptor blockade, 
further demonstrating the involvement of endogenous DA. Motor facilitation induced by NOP 
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receptor antagonists was raclopride-sensitive but amisulpride-insensitive, suggesting that NOP 
receptor blockade can ultimately lead to postsynaptic D2L receptor activation. Indeed, J-113397 
elevated striatal DA release via blockade of an inhibitory N/OFQ tone on nigral DA neurons (Marti 
et al., 2004), although in rats this effect was observed at higher doses (3 mg/Kg) than those 
facilitating motor activity in mice. J-113397 (10 mg/Kg) also elevated DA release in the mouse 
nucleus accumbens although in a NOP-independent manner (Koizumi et al., 2004). Motor 
facilitation induced by low N/OFQ doses was also raclopride-sensitive. This extends previous 
findings that N/OFQ-induced facilitation was prevented by haloperidol (Florin et al., 1996) or by 
lesioning the DA system (Kuzmin et al., 2004), further suggesting that low doses of N/OFQ and 
NOP antagonists activate common pathways. To support this view, both 0.01 nmol N/OFQ or 0.1 
nmol UFP 101 injected into SNr evoked motor activation associated with increases in excitability 
and output from motor cortex (Marti et al., 2009), likely via inhibition of nigro-thalamic output 
neurons and thalamic disinhibition (Deniau and Chevalier, 1985). At present, however, evidence 
that N/OFQ stimulates nigral efferent DA pathways is still lacking. Rather, exogenous N/OFQ 
inhibits the activity of nigro-striatal (Marti et al., 2004) and meso-accumbal (Murphy and 
Maidment, 1999) DA neurons, an effect related to N/OFQ induced hypolocomotion (Marti et al., 
2004; Murphy and Maidment, 1999; Narayanan et al., 2004). Contrary to facilitation, motor 
inhibition induced by NOP antagonists was amisulpride-sensitive and raclopride-insensitive, 
suggesting that high doses of NOP receptor antagonists cause excessive DA release leading to 
stimulation of negative feedback mechanisms via D2 autoreceptors. Indeed, motor inhibition was 
reversed into facilitation in the presence of amisulpride. Consistently, motor impairment induced by 
high Trap-101 doses in naïve rats was turned into motor facilitation after striatal DA depletion 
(Marti et al., 2008).  
Conclusions 
NOP receptor antagonists evoked dual motor responses in mice. Motor facilitation was raclopride-
sensitive and amisulpride-insensitive while the opposite was true for motor inhibition. Raclopride 
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also blocked motor facilitation induced by N/OFQ whereas amisulpride attenuated motor 
impairment induced by PPX and L-dopa, suggesting that facilitation and inhibition are mediated by 
different populations of D2 receptors, likely postsynaptic and presynaptic (autoreceptors), 
respectively. D1/5 and D3 receptors do not contribute to motor responses to NOP receptor ligands. 
However, D3 receptors shape motor responses to both PPX and L-Dopa, opposing their D2 
autoreceptor-mediated inhibitory actions in a test specific for movement initiation and execution. 
Moreover, D1/D5 receptors mediate presynaptic facilitatory actions of L-dopa on DA release 
occurring prior to its conversion to DA. This finding may be clinically relevant as D1/D5 receptor 
stimulation underlie L-dopa-induced dyskinesia during Parkinson’s disease therapy (Obeso et al., 
2000). In conclusion, the present study demonstrates the involvement of endogenous DA in motor 
action of NOP receptor antagonists in naïve mice, suggesting that the dual motor response can be 
shaped by pharmacological manipulations of D2 pre- or postsynaptic receptors, or be influenced by 
physio-pathological changes of their expression. Further studies are warranted to investigate the 
dopaminergic component of the dual motor response to NOP receptor antagonists in DA-depleted 
rodents (Viaro et al., 2008), in view of the proposed clinical application as antiparkinsonian agents 
(Marti et al., 2005, 2007). 
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Figures and Legends 
 
Figure 1. NOP receptor antagonists dually modulated motor activity in mice. Systemic (i.p.) 
administration of J-113397 (0.1-10 mg/Kg) and Trap-101 (0.1-30 mg/Kg), or i.c.v. injection of 
UFP-101 (0.1-30 nmol) produced motor facilitation or inhibition depending on dose. Motor activity 
has been evaluated as immobility time in the bar test (A, D, G), number of steps in the drag test (B, 
E, H) and time spent on the rod in the rotarod test (C, F, I). All tests were performed before 
(control session) and after (10 and 60 min) drug administration. Data (collected 10 min after 
treatment) are means ± SEM of 6 determinations per group and were expressed as percentage of the 
control session. Data collected 60 min after treatment have been presented as supplementary 
material (Fig. S1.1). *p<0.05, **p<0.01 different from saline (RM ANOVA followed by contrast 
analysis and the sequentially rejective Bonferrroni’s test for multiple comparisons). 
 
Figure 2. D2/D3 receptor antagonists decreased motor activity in mice. Systemic (i.p.) 
administration of raclopride (0.03-0.3 mg/Kg) and amisulpride (0.5-15 mg/Kg) increased 
immobility time in the bar test (A, D) and reduced time spent on the rod in the rotarod test (C, F). 
Raclopride also reduced the number of steps in the drag test (B), amisulpride being ineffective (E). 
All tests were performed before (control session) and after (30 and 80 min) drug administration. 
Data (collected 30 min after treatment) are means ± SEM of 6 determinations per group and were 
calculated as percentage of the control session. Data collected 80 min after treatment have been 
presented as supplementary material (Fig. S1.2). *p<0.05, **p<0.01 different from saline (RM 
ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test for multiple 
comparisons). 
 
Figure 3. D1/D5 and D3 receptor selective antagonists differentially affected motor activity in 
mice. Systemic (i.p.) administration of the D1/D5 selective antagonist SCH23390 (0.003-0.03 
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mg/Kg) increased immobility time in the bar test (A), reducing both the number of steps in the drag 
test (B) and time spent on the rod in the rotarod test (C). Systemic (i.p.) administration of the D3 
receptor selective antagonist S33084 (0.04-0.64 mg/Kg) did not affect immobility time (D) and time 
spent on the rod (F), slightly reducing the number of steps (E). All tests were performed before 
(control session) and after (30 and 80 min) drug administration. Data (collected 30 min after 
treatment) are means ± SEM of 6 determinations per group and were calculated as percentage of the 
control session. Data collected 80 min after treatment have been presented as supplementary 
material (Fig. S1.3). *p<0.05, **p<0.01 different from saline (RM ANOVA followed by contrast 
analysis and the sequentially rejective Bonferrroni’s test for multiple comparisons). 
 
Figure 4. Facilitation of motor activity induced by NOP receptor antagonists was selectively 
prevented by raclopride. Pretreatment (20 min in advance) with raclopride (0.03 mg/Kg, i.p.) 
prevented motor facilitation induced by low doses of J-113397 (0.3 mg/Kg, i.p.), Trap-101 (10 
mg/Kg, i.p.) and UFP-101 (3 nmol, i.c.v.) in the drag (B) and rotarod (C) tests. Raclopride and NOP 
receptor antagonists did not affect immobility time in the bar test (A). Pretreatment with 
amisulpride (0.5 mg/Kg, i.p.), S33084 (0.16 mg/Kg, i.p.) and SCH23390 (0.003 mg/Kg, i.p.) did not 
affect motor facilitation induced by J-113397 (0.3 mg/Kg, i.p.) in the drag (E) and rotarod (F) tests. 
Amisulpride, S33084, SCH23390 and J-113397 (alone or in combination) did not affect immobility 
time in the bar test (D). All tests were performed before (control session) and after (10 and 60 min) 
NOP receptor antagonist administration. When DA receptor antagonists were tested alone, 
behavioral testing was performed 30 and 80 min after drug administration. Data (collected 10 min 
after treatment) are means ± SEM of 6 determinations per group and were calculated as percentage 
of the control session. Data collected 60 min after treatment have been presented as supplementary 
material (Fig. S1.4). *p<0.05, **p<0.01 different from saline; °p<0.05, °°p<0.01 different from the 
same group in the absence of raclopride or J-113397 (RM ANOVA followed by contrast analysis 
and the sequentially rejective Bonferrroni’s test for multiple comparisons). 
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Figure 5. Inhibition of motor activity induced by NOP receptor antagonists was selectively 
prevented by amisulpride. Pretreatment (20 min in advance) with amisulpride (0.5 mg/Kg) reduced 
motor inhibition caused by high doses of J-113397 (10 mg/Kg, i.p.), Trap-101 (30 mg/Kg, i.p.) and 
UFP-101 (30 nmol, i.c.v) in the bar (A), drag (B) and rotarod (C) tests. Conversely, pretreatment 
with raclopride (0.03 mg/Kg, i.p.) was ineffective (D-F). All tests were performed before (control 
session) and after (10 and 60 min) NOP receptor antagonist administration. When DA receptor 
antagonists were tested alone, behavioral testing was performed 30 and 80 min after drug 
administration. Data (collected 10 min after treatment) are means ± SEM of 6 determinations per 
group and were expressed as percentage of the control session. Data collected 60 min after 
treatment have been presented as supplementary material (Fig. S1.5). *p<0.05, **p<0.01 different 
from saline; °p<0.05, °°p<0.01 different from the same group in the absence of amisulpride (RM 
ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test for multiple 
comparisons). 
 
Figure 6. Nociceptin/orphanin FQ (N/OFQ) dually modulated motor activity in mice. I.c.v. 
injections of N/OFQ (0.01-10 nmol) produced motor facilitation or inhibition in the drag (B) and 
rotarod (C) tests depending on dose. Only motor inhibition was observed in the bar test (A). 
Pretreatment (20 min in advance) with raclopride (0.03 mg/Kg, i.p.) prevented increases in the 
number of steps (E) and time on rod (F) induced by low doses of N/OFQ (0.01 nmol, i.c.v.). Low 
doses of N/OFQ, alone or in combination with raclopride, did not affect immobility time in the bar 
test (D). All tests were performed before (control session) and after (10 and 60 min) N/OFQ 
injection. When raclopride was tested alone, behavior was assessed 30 and 80 min after drug 
administration. Data (collected 10 min after treatment) are means ± SEM of 6 determinations per 
group and were calculated as percentage of the control session. Data collected 60 min after 
treatment have been presented as supplementary material (Fig. S1.6). *p<0.05, **p<0.01 different 
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from saline (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s 
test for multiple comparisons). 
 
Figure 7. Specificity of action of UFP-101 and nociceptin/orphanin FQ (N/OFQ). I.c.v. injections 
of UFP-101 (3 and 30 nmol, respectively) and N/OFQ (0.01 and 10 nmol, respectively) 
differentially affected immobility time in the bar test (A), number of steps in the drag test (B) and 
time spent on the rod in the rotarod test (C) in NOP+/+ mice, being ineffective in NOP-/- mice. All 
tests were performed before (control session) and 10 min and 60 min after N/OFQ and UFP-101 
injection. Data (collected 10 min after treatment) are means ± SEM of 6 determinations per group 
and were calculated as percentage of the control session. Data collected 60 min after treatment have 
been presented as supplementary material (Fig. S1.7). **p<0.01 different from saline (RM ANOVA 
followed by contrast analysis and the sequentially rejective Bonferrroni’s test for multiple 
comparisons). 
 
Figure 8. DA receptor agonists decreased motor activity in mice. Systemic administration of L-
dopa (1-100 mg/Kg combined with benserazide 4:1 ratio, i.p.) and pramipexole (PPX; 0.0001-1 
mg/Kg, i.p.) increased immobility time in the bar test (A, D), and reduced both the number of steps 
in the drag test (B, E) and time spent on the rod in the rotarod test (C, F). All tests were performed 
before (control session) and after (10 and 60 min) drug administration. Data (collected 10 min after 
treatment) are means ± SEM of 6 determinations per group and were calculated as percentage of the 
control session. Data collected 60 min after treatment have been presented as supplementary 
material (Fig. S1.8). *p<0.05, **p<0.01 different from saline (RM ANOVA followed by contrast 
analysis and the sequentially rejective Bonferrroni’s test for multiple comparisons). 
 
Figure 9. Amisulpride differentially affected motor inhibition induced by L-dopa and pramipexole 
(PPX). Pretreatment (20 min in advance) with amisulpride (0.5 mg/Kg) differentially affected motor 
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inhibition induced by L-dopa (100 mg/Kg plus benserazide 25 mg/Kg) and PPX (0.1 and 1 mg/Kg, 
i.p.) in the bar (A), drag (B) and rotarod (C) tests. Amisulpiride consistently counteracted the effect 
of L-dopa in the three test but was partially effective against PPX, only prevented the increase in 
immobility time induced by PPX 0.1 mg/Kg in the bar test (A) and attenuated impairment in rotarod 
performance induced by PPX 1 mg/Kg (C). Pretreatment with raclopride (0.03 mg/Kg, i.p.) did not 
attenuate motor inhibition induced by L-dopa and PPX and even worsened it (D-F). All tests were 
performed before (control session) and after (10 and 60 min) L-dopa and PPX administration. When 
DA receptor antagonists were tested alone, behavioral testing was performed 30 and 80 min after 
drug administration. Data (collected 10 min after treatment) are means ± SEM of 6 determinations 
per group and were calculated as percentage of the control session. Data collected 60 min after 
treatment have been presented as supplementary material (Fig. S1.9). *p<0.05, **p<0.01 different 
from saline; °p<0.05, °°p<0.01 different from the same group in the absence of amisulpride or 
raclopride (RM ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s 
test for multiple comparisons). 
 
Figure 10. Motor inhibition induced by L-dopa or pramipexole (PPX) was insensitive to the D3 
selective receptor antagonist S33084 or the peripheral non selective DA receptor antagonist 
domperidone. Pretreatment (20 min in advance) with S33084 (0.16 mg/Kg, i.p.; A-C) or 
domperidone (5 mg/Kg, i.p.; D-F) did not attenuate motor inhibition caused by L-dopa (100 mg/Kg 
plus benserazide 25 mg/Kg; i.p.) and PPX (0.1 and 1 mg/Kg) in the bar (A, D), drag (B, E) and 
rotarod (C, F) test. S33084 alone even increased the inhibition of stepping activity induced by both 
DA receptor agonists in the drag test (B). All tests were performed before (control session) and after 
(10 and 60 min) DA receptor agonist administration. When DA receptor antagonists were tested 
alone, behavioral testing was performed 30 and 80 min after drug administration. Data (collected 10 
min after treatment) are means ± SEM of 6 determinations per group and were calculated as 
percentage of the control session. Data collected 60 min after treatment have been presented as 
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supplementary material (Fig. S1.10). *p<0.05, **p<0.01 different from saline; °p<0.05, °°p<0.01 
different from the same group in the absence of S33084; #p<0.05 different from PPX 1 mg/Kg (RM 
ANOVA followed by contrast analysis and the sequentially rejective Bonferrroni’s test for multiple 
comparisons). 
 
Figure 11. Pramipexole (PPX) and L-dopa oppositely modulated K+-evoked DA release from 
synaptosomes. PPX (100 nM) inhibited (A) while L-dopa (1 µM) elevated (B) the [3H]-DA 
overflow evoked by a 2 min pulse of 10 mM KCl from a preparation of striatal synaptosomes in 
superfusion. The inhibition induced by PPX was prevented by the D2-like receptor antagonist 
amisulpride (A) while the stimulation induced by L-dopa was prevented by the D1-like receptor 
antagonist SCH23390 (B). PPX and L-dopa were administered 6 min prior to KCl whereas 
antagonists 3 min before agonists. Data are means ± SEM of 8 determinations per group and were 
expressed as percentage of control (i.e. the K+-evoked tritium overflow). *p<0.05, **p<0.01 
different from control (ANOVA followed by the Newman-Keuls test). 
 
Figure 12. L-dopa increased spontaneous tritium efflux from synaptosomes. L-dopa (1-100 µM) 
elevated spontaneous tritium efflux from a preparation of striatal synaptosomes in superfusion pre-
loaded with [3H]-DA (A). The dopamine transporter blocker GBR12783 but not the D1-like 
selective antagonist SCH23390 prevented the elevation of tritium efflux induced by the lower L-
dopa concentration (10 µM; B) and attenuated that induced by the higher L-dopa concentration (100 
µM; C). GBR12783 and SCH23390 were given 3 min prior to L-dopa and maintained until the end 
of experiments. Data are means ± SEM of 6 determinations per group and were expressed as 
percentage of basal tritium efflux (calculated as the mean between the two samples before L-dopa). 
*p<0.05, **p<0.01 different from washout; °°p<0.01 different from L-dopa alone (ANOVA 
followed by the Newman-Keuls test performed on AUC values). 
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